"","nct_id","...1","study_type","phase","start_date","completion_date","official_title","enrollment","agency_class","classification","White_percent","Black_percent","POC_percent","Black_POC_percent","female_percent","total_sex","start_year","end_year","years_passed","countries","vi","Countries_name","funding","start_year_binary","id","name","drugs","opioids","N_total","White_N","Black_N","POC_N","Black_POC_N","phase_binary","pain_type","special_population","Black_percent_2","multiple_locations","Location_Black_Percent","Location_Black_N","Nature","kids_2","Nature_2","female_2","veterans_2","Mean_Trips","Mean_Vehicles","Mean_Cost","Mean_Black_highschool","Mean_Black_bachelor","Mean_Computer","Mean_Internet","Mean_insurance","Mean_uninsured","Black_diff","Median_Black_Income","state","body_count","Mean_body_count","Mean_hours_work_Black","Mean_weeks_unemployed_black_2","Median_weeks_unemployed_black_2","Mean_housing_units","Mean_homeowner_rates","Mean_poverty_rates","bi_year","diverse_index","Mean_Religious","State_politics","N_binary","Mean_total_bachelor","acute_2","chronic_2","cancer_2","N_total_quartile","start_year_quartile","Location_Black_Percent_quartile","Mean_Trips_quartile","Mean_Vehicles_quartile","Mean_Cost_quartile","Mean_Black_highschool_quartile","Mean_Black_bachelor_quartile","Mean_Computer_quartile","Mean_Internet_quartile","Mean_insurance_quartile","Median_Black_Income_quartile","Mean_body_count_quartile","Mean_weeks_unemployed_black_2_quartile","Mean_housing_units_quartile","Mean_homeowner_rates_quartile","Mean_poverty_rates_quartile","Mean_Religious_quartile","Mean_Computer_Overtime","Mean_Internet_Overtime","Mean_Highschool_Overtime","Mean_Bachelor_Overtime","Mean_Employment_Overtime","Mean_Homeownership_Overtime","Mean_Housing_Overtime","Mean_Insurance_Overtime","Mean_MedianIncome_Overtime","Mean_body_Overtime","Mean_Population_Overtime","Mean_Poverty_Overtime","Mean_Transport_Overtime","Mean_Computer_Overtime_quartile","Mean_Internet_Overtime_quartile","Mean_Highschool_Overtime_quartile","Mean_Bachelor_Overtime_quartile","Mean_Employment_Overtime_quartile","Mean_Homeownership_Overtime_quartile","Mean_Housing_Overtime_quartile","Mean_Insurance_Overtime_quartile","Mean_MedianIncome_Overtime_quartile","Mean_body_Overtime_quartile","Mean_Population_Overtime_quartile","Mean_Poverty_Overtime_quartile","Mean_Transport_Overtime_quartile","elderly_2","Mean_Total_Population_Overtime","special_population_2"
"1","NCT00000409",1,"Interventional","Phase 4",2000-03-31,2015-04-30,"Spine Patient Outcomes Research Trial (SPORT): A Multicenter Randomized Trial for Degenerative Spondylolisthesis (DS) With Spinal Stenosis (SpS) at L4/L5 Level.",304,"Other",NA,84,10,6,16,68,NA,2000,2015,15,"North America",0,"United States","Non-Industry","Earlier 2013",5063240,"Decompressive laminectomy, Non-surgical treatments, Fusion--Instrumented, Fusion-Non-instrumented",0,"Non-opioids",601,506,61,34,95,"Late Phase","chronic",NA,10.1497504159734,"yes",0.112672727272727,1411554.90909091,"Mixed","non-kids","Non-Government","non-female","non-veterans",46.1950944377122,9491.76923076923,22.5239989320072,85.1428186047976,21.6627493713192,91.6375450192019,85.8863905765359,92.5076923076923,7.49230769230769,"0",43465.5384615385,"California,California,Georgia,Illinois,Maine,Michigan,Missouri,Nebraska,New Hampshire,New York,New York,Ohio,Pennsylvania","808,808,542,532,4,277,318,33,1,292,292,368,308",352.538461538462,38.4769230769231,25.5818181818182,11.5272727272727,5843604.84615385,64.5903846153846,11.6,"Before","0",0.501538461538462,"Mixed","large",33.1525596066752,"non-acute","chronic","non-cancer","3","0","1","3","2","1","0","1","1","2","2","2","2","2","2","1","1","1",57.5,51.1,76.0962277965154,16.1923076923077,60.3846153846154,67.9596153846154,1572049.30769231,88.4676552774953,43751.8461538462,14.9090909090909,1505526.23076923,10.5307692307692,8.97066031691119,"0","0","0","0","3","2","0","2","0","1","1","0","1","non-elderly",10.7292185429287,"general"
"2","NCT00058968",7,"Interventional","Phase 3",2002-10-31,2005-03-31,"Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy",660,"Industry",NA,85,3,12,15,44,NA,2002,2005,3,"North America",0,"United States","Industry","Earlier 2013",5056530,"Duloxetine hydrochloride, placebo",1,"Non-opioids",1024,876,36,112,118,"Late Phase","chronic",NA,3.515625,"no",0.1607,3359030,NA,"non-kids",NA,"non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before",NA,0.54,"R","large",30.4516559104648,"non-acute","chronic","non-cancer","3","0","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",61.1,55.7,83.3,25.7,61.8,72.4,278099,84.3769657370662,38024,16,2875804,12.6,10.0831815208954,"0","0","0","3","3","3","0","1","0","1","3","1","2","non-elderly",15.261658159499,"general"
"3","NCT00109772",11,"Interventional","Phase 2",2005-02-28,2008-04-30,"A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1",184,"Industry",NA,93,4,3,7,80,NA,2005,2008,3,"North America",0,"United States","Industry","Earlier 2013",5051162,"lenalidomide, Placebo",1,"Non-opioids",180,167,7,6,13,"Early Phase","chronic",NA,3.88888888888889,"yes",0.116117647058824,1459593.47058824,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",36.4901881207334,8142.03703703704,21.4749889198862,87.0674953486894,23.3349035726517,91.9238501819311,85.8741418198264,91.6777777777778,8.32222222222222,"0",44074.1111111111,"Arizona,California,California,Florida,Illinois,Illinois,Iowa,Maryland,Massachusetts,Massachusetts,Minnesota,Missouri,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Texas,Texas,Virginia,Washington","60,808,808,620,532,532,34,269,45,45,71,318,292,292,264,264,264,264,368,18,308,308,308,624,624,249,79",321.037037037037,38.8592592592593,24.66,11.432,5971038,64.1425925925926,11.762962962963,"Before",NA,0.534074074074074,"Mixed","small",34.1290094213051,"non-acute","chronic","non-cancer","2","1","1","3","2","1","2","2","2","2","1","2","2","2","2","1","1","1",82.2444444444444,67.9814814814815,85.7185185185185,28.5740740740741,58.2444444444444,68.6259259259259,2474237.51851852,86.4755679188859,47408.5185185185,13.5769230769231,1532010.92592593,12.137037037037,9.34920292760804,"1","0","2","3","2","2","1","1","0","1","1","1","2","non-elderly",12.0281700754906,"general"
"4","NCT00118430",12,"Interventional","Phase 4",2004-09-30,2008-08-31,"Stepped Care for Affective Disorders and Musculoskeletal Pain",500,"Other","United States",58,38,4,42,52,500,2004,2008,4,"North America",0,"United States","Non-Industry","Earlier 2013",5050511,"Stepped Care, Antidepressants, Usual Care",1,"Non-opioids",500,291,191,18,209,"Late Phase","chronic",NA,38.2,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","non-veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"Before","0",0.54,"R","large",26.882966396292,"non-acute","chronic","non-cancer","3","0","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",74.7,65.8,87.2,21.1,57.9,74.95,5099041,87.6053884529897,42329,4,578506,11.6,8.67182330071009,"0","0","2","2","2","3","2","2","0","0","0","0","1","non-elderly",8.9129530132787,"general"
"5","NCT00127413",14,"Interventional",NA,2004-09-30,2010-09-30,"Integrated Treatment for Chronic Pain and PTSD",42,"U.S. Fed","United States",60,31,9,40,19,42,2004,2010,6,"North America",0,"United States","Non-Industry","Earlier 2013",5049840,"Cognitive Behavioral Therapy - Pain, Cognitive Behavioral Therapy-Integrated, Cognitive Processing Therapy - PTSD, Treat as Usual",0,"Non-opioids",42,25,13,4,17,NA,"chronic","veterans",30.952380952381,"no",0.0763,522357,"GOVERNMENT","non-kids","Government","non-female","veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"Before","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","1","0","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",85.8,76.3,86.9,36.7,58.9,63.375,2263742,90.2213332592313,52019,1,410795,9.3,9.2587366295912,"1","2","2","3","3","1","0","2","1","0","0","0","2","non-elderly",6.26474130787064,"veterans"
"6","NCT00129480",15,"Interventional",NA,2006-01-31,2010-07-31,"Improving the Treatment of Chronic Pain in Primary Care",401,"U.S. Fed","United States",89,2,9,11,8,401,2006,2010,4,"North America",0,"United States","Non-Industry","Earlier 2013",5049688,"Assistance with Pain treatment",0,"Non-opioids",401,357,7,37,44,NA,"chronic",NA,1.74563591022444,"no",0.0191,78679,"GOVERNMENT","non-kids","Government","non-female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"0",41773,"Oregon","18",18,38.7,NA,NA,1808465,62.375,10.6,"Before","0",0.48,"D","large",34.2300108729167,"non-acute","chronic","non-cancer","3","1","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.73945683684397,"general"
"7","NCT00142519",16,"Interventional","Phase 2",2005-03-31,2018-07-31,"Translational Studies in Analgesic Pharmacology: Analgesic Synergy in Clinical Pain. A Phase 2 Study Comparing a Single Dose of a 1:1 Combination of Methadone and Morphine With Morphine Alone in Patients With Post-operative Pain.",50,"Other","United States",92,4,4,8,0,50,2005,2018,13,"North America",0,"United States","Non-Industry","Earlier 2013",5048698,"Methadone, methadone and morphine",1,"Opioids",50,46,2,2,4,"Early Phase","acute",NA,4,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","1","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.7,30.4,55.2,55.925,849932,87.9470878655293,47176,12,2792447,14.5,6.33298278377812,"0","0","2","3","1","0","0","2","0","1","3","2","0","non-elderly",14.3997846978615,"general"
"8","NCT00159679",17,"Interventional","Phase 4",2004-09-30,2005-10-31,"A 13 Week, Double-Blind, Placebo-Controlled Phase 4 Trial of Pregabalin (CI-1008, 600 mg/Day) for Relief of Pain in Subjects With Painful Diabetic Peripheral Neuropathy",167,"Industry",NA,74,12,14,26,38,NA,2004,2005,1,"North America",0,"United States","Industry","Earlier 2013",5047408,"Pregabalin",1,"Non-opioids",167,123,21,23,44,"Late Phase","chronic",NA,12.5748502994012,"yes",0.114769230769231,1536789.76923077,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",37.7506213646743,9609.43333333333,23.9816091014856,87.1976694719104,23.1574860288768,92.4619294098517,85.9340741187136,89.38,10.62,"1",44836.6,"Arkansas,California,California,California,Colorado,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Massachusetts,Nebraska,Nebraska,Nevada,New Jersey,New Jersey,New Jersey,New York,New York,New York,North Carolina,Ohio,Pennsylvania,Texas,Texas,Texas,Texas,Texas","106,808,808,808,52,620,620,620,620,620,620,620,45,33,33,80,243,243,243,292,292,292,264,368,308,624,624,624,624,624",425.933333333333,39.18,24.0103448275862,10.6586206896552,7628457.63333333,62.6033333333333,12.3166666666667,"Before",NA,0.543666666666667,"Mixed","small",33.1354261499811,"non-acute","chronic","non-cancer","2","0","1","3","2","2","2","2","2","2","0","2","3","2","2","1","2","1",81.4466666666667,67.6533333333333,84.4833333333333,27.7866666666667,57.8433333333333,67.2791666666667,1733025.16666667,83.8017650566403,44607.7333333333,13.3666666666667,1968820.83333333,12.4733333333333,9.0799741479767,"0","0","1","3","2","2","0","1","0","1","2","1","1","non-elderly",11.6442890157394,"general"
"9","NCT00178178",18,"Interventional",NA,2005-03-31,2007-11-30,"A Placebo Controlled, Prospective, Randomized Clinical Investigation of the Efficacy of Continuous Infusion Regional Anesthetic on Postoperative Pain Following Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions",96,"Other","United States",94,4,2,6,28,96,2005,2007,2,"North America",0,"United States","Non-Industry","Earlier 2013",5046010,"Breg Pain Care 3000 Catheter, Bupivicaine 0.5%, Placebo",1,"Non-opioids",96,90,4,2,6,NA,"acute",NA,4.16666666666667,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.7,30.4,55.2,55.925,849932,87.9470878655293,47176,12,2792447,14.5,6.33298278377812,"0","0","2","3","1","0","0","2","0","1","3","2","0","non-elderly",14.3997846978615,"general"
"10","NCT00179348",19,"Interventional",NA,2001-02-08,2016-07-20,"Evaluation of a Yoga-Based Cancer Rehabilitation Program",399,"NIH",NA,23,43,34,77,100,NA,2001,2016,15,"North America",0,"United States","Non-Industry","Earlier 2013",5045923,"Quality-of-Life Assessment, Yoga",0,"Non-opioids",128,30,55,43,98,NA,"cancer",NA,42.96875,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"non-acute","non-chronic","cancer","2","0","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",54.9,50.1,83.2,28.9,53.9,55.925,796510,86.0883620940299,42114,9,2792447,14.2,6.33298278377812,"0","0","0","3","1","0","0","1","0","1","3","2","0","non-elderly",14.3997846978615,"general"
"11","NCT00234286",23,"Interventional",NA,2005-08-31,2013-09-30,"Intervention to Improve Care at Life's End in VA Medical Centers",78,"U.S. Fed",NA,65,35,0,35,2,NA,2005,2013,8,"North America",0,"United States","Non-Industry","Earlier 2013",5041819,"Comfort care education intervention",0,"Non-opioids",6066,3528,1876,932,2808,NA,"pallative",NA,30.9264754368612,"no",0.2664,1299050,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.62507069982056,900,22.6392183673469,83.3613868714217,17.195147573548,87.6352559797239,80.1686731141783,90.3,9.7,"1",33928,"Alabama","278",278,39.1,20.7,12.4,2284847,70.725,16,"Before","0",0.77,"R","large",25.3013815767412,"non-acute","non-chronic","non-cancer","3","1","3","0","0","1","0","0","0","0","1","0","1","0","0","3","3","3",75,55.3,80.9,19.8,52.9,76.575,125458161,85.973564767092,37150,10,1256566,16.7,6.81114958575696,"0","0","0","2","1","3","3","1","0","1","1","3","0","non-elderly",26.2588871163301,"general"
"12","NCT00269321",24,"Interventional","Phase 2",2003-10-31,2008-03-31,"Randomized Clinical Trial of Chiropractic Manual Therapy Plus Home Exercise, Supervised Exercise Plus Home Exercise and Home Exercise Alone For Individuals 65 and Over With Chronic Mechanical Low Back Pain",240,"Other",NA,96,2,2,4,51,NA,2003,2008,5,"North America",0,"United States","Non-Industry","Earlier 2013",5039196,"Chiropractic Manual treatment + home exercise (procedure+behavior), Supervised rehabilitative exercise+home exercise, Home exercise",0,"Non-opioids",247,232,6,9,15,"Early Phase","chronic","elderly",2.42914979757085,"no",0.0641,356515,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"0",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"Before","0",0.49,"R","small",37.1630582351401,"non-acute","chronic","non-cancer","3","0","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",68,61.7,92.3,32.5,66.4,76.525,4385565,91.2776146292948,52823,4,268406,7.4,7.83802073605776,"0","0","3","3","3","3","1","3","2","0","0","0","1","elderly",5.05417106668494,"elderly"
"13","NCT00293020",27,"Interventional","Phase 3",2006-02-28,2008-06-30,"An Open Label, Long-term Treatment Evaluation of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy",244,"Industry","United States",86,9,5,14,53,243,2006,2008,2,"North America",0,"United States","Industry","Earlier 2013",5037428,"BEMA Fentanyl",1,"Opioids",243,209,23,9,32,"Late Phase","cancer",NA,9.46502057613169,"no",0.1213,3428210,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before","0",0.64,"R","small",30.2773131098502,"non-acute","non-chronic","cancer","3","1","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,60.3,78.7,25.5,58.6,65.975,2701301,76.1413438202638,43307,24,2904687,16.4,9.43231929885351,"0","0","0","3","2","1","1","0","0","2","3","3","2","non-elderly",11.5004707188636,"general"
"14","NCT00293033",28,"Interventional","Phase 3",2006-02-28,2007-04-30,"A Double-blind, Placebo Controlled Evaluation of the Efficacy, Safety and Tolerability of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects",152,"Industry","United States",87,8,5,13,56,151,2006,2007,1,"North America",0,"United States","Industry","Earlier 2013",5037427,"BEMAâ„¢, Placebo",1,"Opioids",151,131,12,8,20,"Late Phase","cancer",NA,7.94701986754967,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"Before","0",0.65,"R","small",31.8954262899941,"non-acute","non-chronic","cancer","2","1","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",79.1,61.2,84.2,25.6,60,70.175,7970267,82.5999306198871,39797,13,2023810,13.8,8.40197402658067,"0","0","1","3","3","3","3","0","0","1","2","2","1","non-elderly",21.1661112132563,"general"
"15","NCT00305058",31,"Interventional","Phase 2/Phase 3",2005-07-31,2007-03-31,"A Randomized Clinical Trial Comparing Intravenous Morphine and Intravenous Hydromorphone in the Treatment of Adult ED Patients With Moderate to Severe Pain",194,"Other","United States",25,27,48,75,70,183,2005,2007,2,"North America",0,"United States","Non-Industry","Earlier 2013",5036531,"Morphine, Hydromorphone",1,"Opioids",183,45,49,89,138,"Early Phase","acute","elderly",26.775956284153,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.7,30.4,55.2,55.925,849932,87.9470878655293,47176,12,2792447,14.5,6.33298278377812,"0","0","2","3","1","0","0","2","0","1","3","2","0","elderly",14.3997846978615,"elderly"
"16","NCT00305110",32,"Interventional","Phase 2",2006-01-31,2006-10-31,"Safety and Speed of Onset of a Fixed Dose of Intravenous Hydromorphone in the Treatment of Adult Patients Presenting to the Emergency Department With Acute Severe Pain",298,"Other","United States",6,32,62,94,62,269,2006,2006,0,"North America",0,"United States","Non-Industry","Earlier 2013",5036527,"2 mg IV hydromorphone",1,"Opioids",269,16,85,168,253,"Early Phase","acute",NA,31.5985130111524,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","3","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.1,32.2,54.9,55.65,867425,86.6167945291493,48222,12,2792447,14,6.33298278377812,"0","0","1","3","1","0","0","1","0","1","3","2","0","non-elderly",14.3997846978615,"general"
"17","NCT00365105",38,"Interventional","Phase 3",2006-07-11,2017-02-27,"Randomized Phase III Trial to Evaluate Radiopharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases From Lung, Breast, and Prostate Cancer",261,"NIH",NA,89,10,1,11,38,NA,2006,2017,11,"North America",0,"United States","Non-Industry","Earlier 2013",5032048,"Calcium, Vitamin D, zoledronic acid, Sm-153, Sr-89",1,"Non-opioids",248,221,25,2,27,"Late Phase","cancer",NA,10.0806451612903,"yes",0.12274375,1016725.09375,"Mixed","non-kids","Non-Government","non-female","non-veterans",27.7185135081166,6772.1768707483,21.7549758128999,86.2005871211055,20.4961545056736,91.3838085347907,85.2716553265647,92.352380952381,7.64761904761905,"0",40127.6870748299,"Alabama,California,California,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Indiana,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Kansas,Kansas,Kentucky,Louisiana,Maine,Maryland,Massachusetts,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Minnesota,Mississippi,Missouri,Missouri,Missouri,Missouri,Montana,Montana,Montana,Montana,Nebraska,New Jersey,New Jersey,New Jersey,New Jersey,New Jersey,New Mexico,New York,New York,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Dakota,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,Utah,Utah,Utah,Utah,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Wisconsin,Wisconsin,Wisconsin","278,808,808,808,808,808,808,808,620,620,620,620,620,620,620,620,620,620,620,620,542,542,532,532,532,532,532,532,532,532,532,144,144,144,34,34,34,34,34,34,34,60,60,76,341,4,269,45,45,277,277,277,277,277,277,277,277,277,277,277,71,208,318,318,318,318,1,1,1,1,33,243,243,243,243,243,8,292,292,292,292,292,292,292,264,264,264,1,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,140,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,229,229,14,14,14,14,79,79,79,79,79,79,79,96,96,96",307.082191780822,38.6979591836735,23.03046875,10.26328125,5207932.87142857,66.7367346938776,11.7170068027211,"Before","0",0.540136054421769,"Mixed","small",31.8723281366547,"non-acute","non-chronic","cancer","3","1","2","2","2","1","1","0","1","1","2","1","2","1","1","2","1","1",81.6884353741497,68.0340136054422,87.5972789115646,27.1877551020408,58.4673469387755,70.7680272108844,2825424.1292517,87.1113371137699,48457.2108843537,15.4852941176471,1307838.28571429,11.6408163265306,9.16427557019765,"0","0","2","3","2","3","1","1","1","1","1","0","1","non-elderly",11.0889980406012,"general"
"18","NCT00366444",39,"Interventional","Phase 3",2006-08-31,NA,"Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery",201,"Industry","United States",58,21,21,42,87,201,2006,NA,NA,"North America",0,"United States","Industry","Earlier 2013",5031947,"diclofenac potassium (XP21L), Placebo",1,"Non-opioids",201,117,42,42,84,"Late Phase","acute",NA,20.8955223880597,"yes",0.120125,1385177.25,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",25.7694176097515,10687.6666666667,22.7849768101125,89.6869710520722,26.0387478617464,93.5200297942983,88.2460582616348,92.85,7.15,"1",53192,"California,California,Maryland,Maryland,Pennsylvania,Utah","808,808,269,269,308,14",412.666666666667,38.85,22.98,11.16,6756575.5,64.7083333333333,9.76666666666667,"Before",NA,0.538333333333333,"Mixed","small",36.1783244698464,"acute","non-chronic","non-cancer","2","1","1","2","3","2","3","3","3","3","2","3","3","1","2","1","0","1",84.7833333333333,70.7833333333333,85.7833333333333,30.7666666666667,60.5666666666667,68.7041666666667,2486894.66666667,85.3262119166404,56846.5,30,1503020,10.3,12.4549494479509,"1","1","2","3","3","2","1","1","2","3","1","0","3","non-elderly",13.4952289967633,"general"
"19","NCT00371462",42,"Interventional",NA,2007-10-31,2011-09-30,"PDA+: A Personal Digital Assistant for Obesity Treatment",70,"U.S. Fed","United States",75,25,0,25,14,69,2007,2011,4,"North America",0,"United States","Non-Industry","Earlier 2013",5031566,"Use of PDA + support to reduce weight and pain, MOVE! level 2 group weight loss counseling",0,"Non-opioids",69,52,17,NA,17,NA,"chronic","veterans",24.6376811594203,"no",0.142,1813590,"GOVERNMENT","non-kids","Government","non-female","veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"1",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"Before",NA,0.51,"D","small",35.1771599850269,"non-acute","chronic","non-cancer","1","1","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",79.9,69.3,87.2843,19.2183,54.9,69.425,644649,87.0462612138163,52506,26,1838731,10,6.03837995473793,"0","1","2","1","1","2","0","1","1","3","2","0","0","non-elderly",14.3168047504798,"veterans"
"20","NCT00375934",44,"Interventional","Phase 3",2006-09-30,NA,"Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery",200,"Industry","United States",62,12,26,38,86,200,2006,NA,NA,"North America",0,"United States","Industry","Earlier 2013",5031229,"diclofenac potassium (XP21L), Placebo",1,"Non-opioids",200,123,23,54,77,"Late Phase","acute",NA,11.5,"yes",0.0666,1732529.5,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.4933089248452,8174.75,25.0390616372518,89.6038447629376,24.4407925936124,93.4209794345584,86.0974368905825,83.775,16.225,"1",45367,"Texas,Texas,Texas,Utah","624,624,624,14",471.5,39.975,26.5,9.3,8745895,64.775,12.25,"Before",NA,0.64,"R","small",31.469207469329,"acute","non-chronic","non-cancer","2","1","0","1","2","3","3","2","3","2","0","2","3","3","3","1","2","3",81.725,63.925,81.825,25.875,61.525,67.86875,4363360.75,77.9331789460277,46137.25,24,2185192.5,14.625,10.1615273569215,"0","0","0","3","3","2","1","0","0","2","3","2","2","non-elderly",8.86584735044741,"general"
"21","NCT00386243",48,"Interventional",NA,2007-12-31,2012-09-30,"Evaluation of Stepped Care for Chronic Pain in Iraqi/Afghanistan Veterans",242,"U.S. Fed","United States",76,13,11,24,12,NA,2007,2012,5,"North America",0,"United States","Non-Industry","Earlier 2013",5030449,"Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics",1,"Opioids",241,185,31,25,56,NA,"chronic","veterans",12.8630705394191,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"Before","0",0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","3","1","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",74.7,65.8,87.1877,14.6486,58.7,73.825,5253354,88.9526287517301,47453,3,578506,11.8,8.67182330071009,"0","0","2","0","2","3","2","2","0","0","0","1","1","non-elderly",8.9129530132787,"veterans"
"22","NCT00387010",NA,"Interventional","Phase 3",2006-12-31,2007-10-31,"A 4-week Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Chronic Pain",218,"Industry",NA,NA,NA,NA,NA,NA,NA,2006,NA,NA,"North America",NA,"United States","Industry",NA,5030393,NA,NA,"Opioids",218,208,7,NA,3,"Late Phase","chronic",NA,3.21100917431193,"yes",0.12819,1302697.45,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",23.5578398232234,7804.33333333333,23.9822914350176,87.2995810663026,21.9987627672152,92.1469260813933,85.4553585590083,90.269696969697,9.73030303030303,"0",42606.5151515152,"Alabama,Arizona,California,California,California,California,California,Colorado,Connecticut,Florida,Florida,Florida,Florida,Georgia,Illinois,Illinois,Indiana,Indiana,Indiana,Kansas,Louisiana,Montana,Nevada,Nevada,New York,Oregon,Pennsylvania,Pennsylvania,South Carolina,Tennessee,Texas,Texas,Utah","278,60,808,808,808,808,808,52,41,620,620,620,620,542,532,532,144,144,144,60,341,1,80,80,292,18,308,308,229,201,624,624,14",368.757575757576,38.930303030303,22.6655172413793,11.8103448275862,6091555.15151515,64.1795454545454,12.4484848484848,"Before",NA,0.550909090909091,"Mixed","small",31.4363701537521,"non-acute","chronic","non-cancer","2","1","2","2","2","2","2","1","2","1","1","1","2","1","2","1","2","2",81.2515151515152,67.0575757575758,85.2454545454545,26.8939393939394,59.0606060606061,68.8681818181818,6207631.15151515,83.6569952261765,48074.0606060606,19.3,1466418.06060606,12.0575757575758,9.38588503043864,"0","0","1","3","3","2","2","0","0","2","1","1","2","non-elderly",11.4507956754622,"general"
"23","NCT00399490",49,"Interventional","Phase 2",2006-09-30,2008-02-29,"Open-Label, Multiple-Dose Study Of The Safety And Efficacy Of RN624 In Adults With Pain Due To Osteoarthritis Of The Knee",281,"Industry",NA,89,5,6,11,61,NA,2006,2008,2,"North America",0,"United States","Industry","Earlier 2013",5029455,"RN624 (PF-04383119)",1,"Non-opioids",281,251,15,15,30,"Early Phase","chronic",NA,5.33807829181495,"yes",0.110178260869565,1150074.56521739,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.82581548766,6666.44444444444,22.5001968556038,87.764220704173,22.9682806516865,91.8711051753559,85.2279048906707,89.9333333333333,10.0666666666667,"0",44660.5833333333,"Alabama,Alabama,Arizona,California,California,California,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Hawaii,Idaho,Indiana,Kentucky,Maryland,Massachusetts,Missouri,Nebraska,New Mexico,New York,North Carolina,North Carolina,Ohio,Pennsylvania,Tennessee,Tennessee,Texas,Texas,Texas,Texas,Texas,Utah,Virginia,Washington","278,278,60,808,808,808,41,41,620,620,620,620,2,1,144,76,269,45,318,33,8,292,264,264,368,308,201,201,624,624,624,624,624,14,249,79",329.388888888889,38.9694444444444,22.80625,12.31875,5776831.02777778,65.0277777777778,12.5222222222222,"Before",NA,0.57,"Mixed","small",31.9810711150023,"non-acute","chronic","non-cancer","3","1","1","1","2","1","2","2","2","1","1","2","2","1","2","1","2","2",81.0527777777778,66.0888888888889,84.6888888888889,27.3722222222222,60.3027777777778,69.0951388888889,9143361.08333333,83.9904663820951,47942.75,15.46875,1478761.16666667,12.4805555555556,9.98602262684911,"0","0","1","3","3","2","3","1","0","1","1","1","2","non-elderly",11.6269277915789,"general"
"24","NCT00408876",50,"Interventional","Phase 3",2006-12-31,2007-11-30,"Protocol F1J-MC-HMEO Duloxetine Versus Placebo in the Treatment of Chronic Low Back Pain",404,"Industry","Argentina",80,8,12,20,57,404,2006,2007,1,"North America",0,"United States","Industry","Earlier 2013",5028749,"Duloxetine, Placebo",1,"Non-opioids",404,322,33,49,82,"Late Phase","chronic",NA,8.16831683168317,"yes",0.1607,3359030,NA,"non-kids",NA,"non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida,Florida,Florida,Florida","620,620,620,620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before",NA,0.54,"R","large",30.4516559104648,"non-acute","chronic","non-cancer","3","1","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",81.4,69.5,86.7,27.2,61.8,72.425,289098,79.7230375339534,45676,16,2875804,11.5,10.0831815208954,"0","1","2","3","3","3","0","0","0","1","3","0","2","non-elderly",15.261658159499,"general"
"25","NCT00414466",53,"Interventional","Phase 2",2006-12-31,2010-08-31,"A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.",254,"Industry","United States",93,4,3,7,57,NA,2006,2010,4,"North America",0,"United States","Industry","Earlier 2013",5028334,"Intraspinal Gabapentin",1,"Non-opioids",170,159,7,4,11,"Early Phase","chronic",NA,4.11764705882353,"yes",0.126654545454545,1653889.54545455,"Mixed","non-kids","Non-Government","non-female","non-veterans",30.4484748257782,7110,22.4549666529519,86.4601166889267,22.800176707936,92.1955403265871,85.3844510551937,90.5785714285714,9.42142857142857,"0",41174.1428571429,"Arkansas,California,Florida,Louisiana,Minnesota,Minnesota,New York,North Carolina,Oregon,Oregon,Pennsylvania,Texas,Texas,Utah","106,808,620,341,71,71,292,264,18,18,308,624,624,14",298.5,38.9214285714286,22.7636363636364,10.3818181818182,5619752.78571429,64.45,12.3357142857143,"Before",NA,0.567142857142857,"Mixed","small",32.2701127439726,"non-acute","chronic","non-cancer","2","1","2","2","2","1","1","1","2","1","1","1","2","1","2","1","2","2",81.8071428571428,67.2428571428571,85.75,27.3714285714286,58.3,69.0482142857143,3112494.5,83.2067697781326,47063,16.4545454545455,1398906.71428571,12.8285714285714,10.4101999352459,"1","0","2","3","2","2","1","0","0","1","1","1","2","non-elderly",10.8717331244471,"general"
"26","NCT00415597",54,"Interventional","Phase 3",2006-12-31,2008-03-31,"A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain",467,"Industry",NA,88,9,3,12,52,NA,2006,2008,2,"North America",0,"United States","Industry","Earlier 2013",5028251,"ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)",1,"Opioids",465,410,41,14,55,"Late Phase","chronic",NA,8.81720430107527,"yes",0.126064285714286,1245259.17857143,NA,"non-kids",NA,"non-female","non-veterans",19.5122464267562,6505.68965517241,23.5798651614432,87.0187610804934,21.8796559435718,91.9886546144393,85.134135397272,89.6775862068965,10.3224137931034,"0",42256.6896551724,"Alabama,Arizona,Arizona,Arizona,Arizona,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Illinois,Illinois,Indiana,Iowa,Louisiana,Massachusetts,Massachusetts,Michigan,Missouri,Missouri,Montana,Nebraska,Nevada,Nevada,Nevada,New Jersey,New Mexico,New York,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Oklahoma,Oregon,Pennsylvania,South Carolina,Tennessee,Tennessee,Texas,Texas,Texas,Texas,Utah,Virginia","278,60,60,60,60,808,808,808,808,808,620,620,620,620,620,620,620,620,620,542,542,542,532,532,144,34,341,45,45,277,318,318,1,33,80,80,80,243,8,292,264,264,264,368,368,368,140,18,308,229,201,201,624,624,624,624,14,249",360.672413793103,39.0396551724138,22.2754716981132,10.7075471698113,5863582.54385965,64.8206896551724,12.8637931034483,"Before","0",0.565344827586207,"Mixed","large",31.1959577683716,"non-acute","chronic","non-cancer","3","1","2","1","2","2","2","1","2","1","0","1","2","1","2","1","3","2",81.1551724137931,66.401724137931,85.1724137931034,26.6206896551724,59.8827586206897,69.4172413793103,4302010.13793103,83.1871089249631,47172.3965517241,16.6111111111111,1557089.51724138,12.5137931034483,8.8404093076982,"0","0","1","3","3","2","1","0","0","2","1","1","1","non-elderly",12.4925004746745,"general"
"27","NCT00416715",NA,"Interventional","Phase 2",2006-10-31,2010-05-31,"A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara® )",100,"Other",NA,NA,NA,NA,NA,NA,NA,2006,NA,NA,"North America",NA,"United States","Non-Industry",NA,5028166,NA,NA,"Non-opioids",100,87,2,11,13,"Early Phase","cancer","female",2,"no",0.038,281683,"GOVERNMENT","non-kids","Government","female","non-veterans",36.3274444869134,9176,31.6889445945946,89.9549312007655,27.2652644054344,94.6878709316023,90.128095190568,93.4,6.6,"0",52742,"Washington","79",79,40.1,19.5,7.1,3195004,63.75,10.3,"Before","0",0.45,"D","small",36.6505101649993,"non-acute","non-chronic","cancer","2","1","0","3","2","3","3","3","3","3","2","3","0","0","1","1","0","0",89.6,75.7,91.1,31.4,61.9,66.675,3249588,88.52519612909,54723,1,229359,8,13.486176059384,"3","2","3","3","3","2","1","2","2","0","0","0","3","non-elderly",3.40068405407906,"female"
"28","NCT00434343",58,"Interventional",NA,2006-11-30,2007-11-30,"A Pilot Feasibility Study of Physical Therapy for the Treatment of Urologic Pelvic Pain Syndromes",48,"NIH",NA,87,4,9,13,51,NA,2006,2007,1,"North America",0,"United States","Non-Industry","Earlier 2013",5026840,"Physical Therapy",0,"Non-opioids",47,41,2,4,6,NA,"chronic",NA,4.25531914893617,"yes",0.115475,1727050,"Mixed","non-kids","Non-Government","non-female","non-veterans",28.1605160418622,11008.4,22.1206223320592,87.2043742297165,21.3133403103691,91.8934444102828,85.8639587023935,93.02,6.98,"0",39492.6,"California,Illinois,Illinois,Michigan,Ohio","808,532,532,277,368",503.4,38.4,30.54,12.34,7000989.6,65.275,11.62,"Before","0",0.524,"Mixed","small",32.6244423438741,"non-acute","chronic","non-cancer","1","1","1","2","3","1","2","1","2","2","2","1","3","3","2","2","1","1",80.66,67.82,86.76,28.32,55.54,70.075,1118952.4,87.0929588807969,49441.6,27.4,1719628.8,11.76,8.50583672205376,"0","0","2","3","2","3","0","1","1","3","2","1","1","non-elderly",12.0754989964802,"general"
"29","NCT00448110",60,"Interventional","Phase 3",2006-05-31,2007-11-30,"Randomized, Double-Blind, Active- and Placebo-Controlled Study of the Efficacy and Safety of Repeated Dosing of DIC075V Relative To Parenteral Ketorolac and Placebo in Patients With Acute Post-Op Pain After Abdominal or Pelvic Surgery",331,"Industry",NA,77,9,14,23,81,NA,2006,2007,1,"North America",0,"United States","Industry","Earlier 2013",5025777,"Intravenous Diclofenac (DIC075V), Intravenous Ketorolac, placebo",1,"Non-opioids",331,255,31,45,76,"Late Phase","acute",NA,9.36555891238671,"yes",0.1268625,1634942,"Mixed","non-kids","Non-Government","non-female","non-veterans",10.0088474958985,6955.28571428571,23.3873665682753,86.4844770850387,21.5740450984876,91.2157901786657,83.547642164209,88.6,11.4,"0",40829,"Alabama,Alabama,Alabama,Alabama,Arkansas,California,California,Florida,North Carolina,North Dakota,Texas,Texas,Texas,Utah","278,278,278,278,106,808,808,620,264,1,624,624,624,14",400.357142857143,39.4357142857143,23.075,10.925,6360469.07142857,64.9553571428571,13.7214285714286,"Before",NA,0.645714285714286,"Mixed","large",29.3008277592252,"acute","non-chronic","non-cancer","3","1","2","1","2","2","1","1","1","0","0","1","2","1","2","1","3","3",79.3,62.1071428571429,82.8142857142857,24.7714285714286,58.8428571428571,69.3053571428571,38898901,81.9809232452656,43612.2857142857,20.1666666666667,1674661.78571429,13.8928571428571,10.4523374078496,"0","0","0","3","2","2","3","0","0","2","2","2","2","non-elderly",14.674436052304,"general"
"30","NCT00458510",61,"Interventional","Phase 3",2007-01-31,2012-07-31,"An Open-Label Study Investigating Long-Term Safety and Tolerability of Fentanyl Citrate Nasal Spray in the Treatment of BTCP in Subjects Taking Regular Opioid Therapy",403,"Industry",NA,50,4,46,50,48,NA,2007,2012,5,"North America",0,"United States","Industry","Earlier 2013",5024992,"Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)",1,"Opioids",171,85,7,79,86,"Late Phase","cancer",NA,4.09356725146199,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before","0",NA,NA,"small",NA,"non-acute","non-chronic","cancer","2","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"31","NCT00465647",NA,"Interventional","Phase 4",2007-04-30,2010-04-30,"A Multi-center, Open-label, Dose Titration Study Pharmacokinetics/Pharmacodynamics, Safety, and Efficacy of Hydromorphone Oral Solution in Subjects From 28 Days to 16 Years of Age, Who Require Opioid Analgesics for Postoperative Pain",116,"Industry",NA,NA,NA,NA,NA,NA,NA,2007,NA,NA,"North America",NA,"United States","Industry",NA,5024463,NA,NA,"Opioids",116,82,23,11,34,"Late Phase","acute",NA,19.8275862068966,"yes",0.11324,1460259.8,"Mixed","non-kids","Non-Government","non-female","non-veterans",12.9527673226782,7790.28571428571,22.1471652915221,87.6373836712099,22.0957201641908,92.0260549632559,85.1399862735875,89.2142857142857,10.7857142857143,"1",42752.2142857143,"Arkansas,California,California,Colorado,Connecticut,Florida,Iowa,Missouri,North Carolina,North Carolina,Ohio,Texas,Texas,Texas","106,808,808,52,41,620,34,318,264,264,368,624,624,624",396.785714285714,38.9357142857143,24.825,12.7916666666667,7321756.61538462,63.8642857142857,12.5785714285714,"Before","0",0.576428571428571,"Mixed","small",31.8457366281229,"acute","non-chronic","non-cancer","2","1","1","1","2","1","2","1","2","1","0","1","2","2","2","1","2","2",80.5714285714286,65.0571428571428,85.0755428571428,17.8689714285714,59.5714285714286,68.0553571428571,3561082.14285714,83.298520290009,49466.8571428571,23.5833333333333,1651214.21428571,13.2428571428571,9.6492653857047,"0","0","1","1","3","2","1","0","1","2","1","1","2","non-elderly",11.3801246080623,"general"
"32","NCT00471445",62,"Interventional","Phase 3",2007-10-31,2013-11-30,"Assessment of Topical Treatment Response With Amitriptyline and Ketamine: Combination Trial in Chemotherapy Peripheral Neuropathy (ATTRACT-CPN)",462,"Other","United States",88,8,4,12,71,458,2007,2013,6,"North America",0,"United States","Non-Industry","Earlier 2013",5024026,"ketamine/amitriptyline NP-H cream, placebo",1,"Non-opioids",458,405,38,15,53,"Late Phase","cancer",NA,8.29694323144105,"yes",0.105991666666667,946139,"Mixed","non-kids","Non-Government","non-female","non-veterans",45.2665514048183,6677.52941176471,23.9128097611725,86.8452675495052,22.1173754214588,92.0291343337793,85.6816293968557,92.5235294117647,7.47647058823529,"0",42509.2352941177,"Hawaii,Illinois,Illinois,Illinois,Kansas,Michigan,Minnesota,Nevada,New York,New York,North Carolina,Oregon,South Carolina,South Carolina,Washington,Washington,Wisconsin","2,532,532,532,60,277,71,80,292,292,264,18,229,229,79,79,96",215.529411764706,38.5764705882353,26.5266666666667,11.6333333333333,3739939.17647059,64.5602941176471,11.2647058823529,"Before","1",0.521176470588235,"Mixed","large",33.196995176779,"non-acute","non-chronic","cancer","3","1","1","3","2","2","2","1","2","2","2","1","1","3","1","1","1","1",82.5058823529412,68.4882352941176,87.6455764705882,18.3699705882353,58.6176470588235,67.7088235294118,2066280.05882353,87.4942890023426,51707.2352941177,9.66666666666667,1095019.29411765,11.5235294117647,8.07983961885484,"1","0","2","1","2","2","0","1","1","1","1","0","1","non-elderly",11.5961148243222,"general"
"33","NCT00489411",66,"Interventional","Phase 3",2008-04-30,2013-03-31,"A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated With Chemotherapy-Induced Peripheral Neuropathy",231,"Other","United States",81,14,5,19,63,NA,2008,2013,5,"North America",0,"United States","Non-Industry","Earlier 2013",5022678,"duloxetine hydrochloride, placebo",1,"Non-opioids",220,178,31,11,42,"Late Phase","cancer",NA,14.0909090909091,"yes",0.112610810810811,936224.783783784,"Mixed","non-kids","Non-Government","non-female","non-veterans",25.7657277784678,6821.02947368421,21.3606525359965,86.2036258756496,20.9257382634339,91.678981230456,85.5650716764179,92.5549473684211,7.44505263157895,"1",40407.0168421053,"California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Connecticut,Connecticut,Delaware,Delaware,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Hawaii,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kentucky,Kentucky,Maine,Maryland,Maryland,Maryland,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nevada,Nevada,New Hampshire,New Hampshire,New Hampshire,New Hampshire,New Hampshire,New Hampshire,New Jersey,New Jersey,New Jersey,New Jersey,New Jersey,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Dakota,Texas,Virginia,Virginia,Virginia,Virginia,Virginia,West Virginia,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin","808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,41,41,31,31,620,620,620,620,620,620,620,542,542,542,542,542,542,542,542,542,542,542,542,542,2,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,76,76,4,269,269,269,45,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,318,318,318,318,318,318,318,318,318,318,318,318,318,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,33,33,33,33,33,80,80,1,1,1,1,1,1,243,243,243,243,243,292,292,292,292,292,292,292,292,292,292,292,292,292,292,292,292,264,264,264,264,264,264,264,264,264,264,264,1,1,1,1,1,1,1,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,18,308,308,308,308,308,308,308,308,308,308,308,308,308,229,229,229,229,229,229,229,229,229,229,229,1,624,249,249,249,249,249,18,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96",300.371549893843,38.5488421052632,23.59025,10.58125,4952610.1790393,65.8432105263158,11.2218947368421,"Before","0",0.5253911205074,"Mixed","small",32.6973072509277,"non-acute","non-chronic","cancer","3","1","1","2","2","1","1","1","1","2","2","1","2","1","1","2","1","1",81.7802105263158,74.4353684210526,87.810816,18.2808677894737,57.3461052631579,68.8666315789474,2494507.50105263,87.3237962479445,51277.0863157895,15.7368421052632,1153358.64842105,12.4067368421053,8.336186194023,"0","1","2","1","2","2","1","1","1","1","1","1","1","non-elderly",10.2882329592099,"general"
"34","NCT00490919",67,"Interventional","Phase 3",2007-06-30,2008-10-31,"Multi-center, Randomized, Double-blind, Placebo-controlled With Open Label run-in Study Assessing Efficacy, Tolerability, Safety of BTDS 10 or 20 Compared to Placebo in Opioid-naïve Subjects With Moderate to Severe, Chronic Low Back Pain",539,"Industry",NA,70,22,8,30,55,NA,2007,2008,1,"North America",0,"United States","Industry","Earlier 2013",5022562,"Buprenorphine transdermal system, Placebo",1,"Opioids",541,381,120,40,160,"Late Phase","chronic",NA,22.181146025878,"yes",0.126641379310345,1122163,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",20.3224094498939,6721.06976744186,22.8711529141053,86.886534015266,22.0090108744129,91.8684345144038,84.9892516738828,89.8313953488372,10.1686046511628,"1",42414.8953488372,"Alabama,Alabama,Arizona,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,Colorado,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Georgia,Hawaii,Idaho,Indiana,Kansas,Kansas,Louisiana,Louisiana,Louisiana,Louisiana,Massachusetts,Massachusetts,Massachusetts,Michigan,Mississippi,Missouri,Missouri,Missouri,Missouri,Nevada,Nevada,New Mexico,New York,New York,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Rhode Island,South Carolina,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Virginia","278,278,60,60,60,60,808,808,808,808,808,808,808,808,52,41,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,542,2,1,144,60,60,341,341,341,341,45,45,45,277,208,318,318,318,318,80,80,8,292,292,264,264,264,368,368,368,368,368,140,18,18,308,308,308,308,308,7,229,624,624,624,624,624,624,14,249",381.96511627907,38.9593023255814,22.2443037974684,10.9696202531646,6088820.41860465,64.7851744186047,13.1581395348837,"Before",NA,0.563255813953488,"Mixed","large",31.3157692715999,"non-acute","chronic","non-cancer","3","1","2","2","2","2","2","1","2","1","1","1","2","1","2","1","3","2",81.2058139534884,66.5779069767442,85.5295779069767,17.2643918604651,59.5302325581395,68.6645348837209,5264481.62790698,84.1379609642263,48709.3953488372,20.2435897435897,1647358.59302326,12.9581395348837,9.42462601822013,"0","0","1","0","3","2","2","1","1","2","1","1","2","non-elderly",13.3023683010394,"general"
"35","NCT00503984",69,"Interventional","Phase 1/Phase 2",2007-05-31,2015-06-30,"A Phase I/II Study of Azacitidine (Vidaza), Docetaxel and Prednisone for Patients With Hormone Refractory Metastatic Prostate Cancer Previously Treated With a Taxotere Containing Regimen.",22,"Other","United States",77,23,0,23,0,22,2007,2015,8,"North America",0,"United States","Non-Industry","Earlier 2013",5021579,"Azacitidine, Docetaxel, Prednisone, GADD45Î± methylation and expression analysis, Pegfilgrastim, Filgrastim",1,"Non-opioids",22,17,5,NA,5,"Early Phase","cancer",NA,22.7272727272727,"no",0.1607,3359030,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"1",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before","0",0.54,"R","small",30.4516559104648,"non-acute","non-chronic","cancer","0","1","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",81.4,69.5,85.9484,16.5154,62.1,71.75,291766,80.2292335435013,45794,31,2875804,12.5,10.0831815208954,"0","1","2","0","3","3","0","0","0","3","3","1","2","non-elderly",15.261658159499,"general"
"36","NCT00507026",71,"Interventional","Phase 3",2007-07-31,2009-01-31,"Randomized, Double-Blind, Active-and Placebo-Controlled Study of the Analgesic Efficacy and Safety of Repeated Dosing of DIC075V Versus Parenteral Ketorolac and Placebo in Acute Post-Operative Pain After Elective Orthopedic Surgery",277,"Industry",NA,86,10,4,14,66,NA,2007,2009,2,"North America",0,"United States","Industry","Earlier 2013",5021351,"IV Diclofenac, IV ketorolac, Placebo",1,"Non-opioids",1289,1107,126,56,182,"Late Phase","acute",NA,9.77501939487975,"yes",0.132275,1833526.25,"Mixed","non-kids","Non-Government","non-female","non-veterans",14.0114261317068,7476.75,21.958708872119,87.3931717121265,21.5614845226299,91.3116640256885,84.5378865117417,89.525,10.475,"0",41939.625,"Alabama,Arizona,California,Florida,Kentucky,North Carolina,Pennsylvania,Texas","278,60,808,620,76,264,308,624",379.75,38.825,21.1,10.3375,6646391,65.45,13.8875,"Before",NA,0.5975,"Mixed","large",29.8612659557541,"acute","non-chronic","non-cancer","3","1","2","1","2","1","2","1","1","0","0","1","2","0","2","2","3","3",79.925,63.5125,84.150925,16.34785,57.75,69.4875,18085582.5,83.7162062397652,46051.25,20.125,1640145.875,13.9875,8.99949172964955,"0","0","1","0","2","2","3","0","0","2","1","2","1","non-elderly",12.7409377756583,"general"
"37","NCT00522041",74,"Interventional","Phase 3",2007-08-31,2008-07-31,"A Randomized. Double-blind, Placebo-controlled, Multi-national Study to Determine the Effect of Cellegesic Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With a Chronic Anal Fissure",248,"Industry",NA,79,15,6,21,47,NA,2007,2008,1,"North America",0,"United States","Industry","Earlier 2013",5020218,"Cellegesic, Placebo",1,"Non-opioids",247,195,37,15,52,"Late Phase","chronic",NA,14.9797570850202,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before","0",NA,NA,"small",NA,"non-acute","chronic","non-cancer","3","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"38","NCT00526903",75,"Interventional","Phase 2",2009-01-31,2014-03-31,"Recurrent Abdominal Pain in Children",168,"NIH",NA,60,13,27,40,57,NA,2009,2014,5,"North America",0,"United States","Non-Industry","Earlier 2013",5019852,"Elimination Diet",0,"Non-opioids",84,51,11,22,33,"Early Phase","chronic","kids",13.0952380952381,"no",0.1213,3428210,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","1","1","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,65.5,81.0773,17.7566,56.6,65.35,2801999,74.4968474593154,47475,25,2904687,17.3,9.43231929885351,"0","0","0","1","2","1","1","0","0","2","3","3","2","non-elderly",11.5004707188636,"kids"
"39","NCT00530803",76,"Interventional","Phase 2",2007-06-30,2009-01-31,"The Efficacy of the Eutectic Mixture of Local Anesthetics (EMLA) Cream Versus the Synera Patch for Pain Reduction During Venipuncture in Children",100,"Other","United States",11,23,66,89,60,100,2007,2009,2,"North America",0,"United States","Non-Industry","Earlier 2013",5019555,"EMLA Cream, Synera Patch",1,"Non-opioids",100,11,23,66,89,"Early Phase","acute","kids",23,"no",0.1566,3065470,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.0733,18.8331,55.7,55.9,881499,87.7477251256719,48944,9,2792447,14.5,6.33298278377812,"0","0","1","1","2","0","0","2","1","1","3","2","0","non-elderly",14.3997846978615,"kids"
"40","NCT00558870",77,"Interventional","Phase 2",2007-11-30,2015-01-31,"Role of Methadone As Co-Opioid Analgesic in Cancer Patients",5,"Other","United States",75,25,0,25,100,4,2007,2015,8,"North America",0,"United States","Non-Industry","Earlier 2013",5017452,"Morphine, Methadone",1,"Opioids",4,3,1,0,1,"Early Phase","cancer",NA,25,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before","1",0.64,"R","small",30.2773131098502,"non-acute","non-chronic","cancer","0","1","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,60.3,81.0773,17.7566,60,66.05,2746081,75.2596993455451,46053,38,2904687,16.5,9.43231929885351,"0","0","0","1","3","1","1","0","0","3","3","3","2","non-elderly",11.5004707188636,"general"
"41","NCT00561652",78,"Interventional",NA,2008-04-30,2009-07-31,"Education/Exercise and Chiropractic for Chronic Back Pain",30,"U.S. Fed","United States",90,0,10,10,13,30,2008,2009,1,"North America",0,"United States","Non-Industry","Earlier 2013",5017242,"Education & Exercise, Chiropractic treatment (plus Education & Exercise)",0,"Non-opioids",30,27,0,3,3,NA,"chronic","veterans",0,"no",0.0641,356515,"GOVERNMENT","non-kids","Government","non-female","veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"0",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"Before","0",0.49,"R","small",37.1630582351401,"non-acute","chronic","non-cancer","0","1","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",84.6,77.8,92.1251,21.8476,63.6,73.1,4537500,91.7742716828385,54925,4,268406,9.9,7.83802073605776,"1","2","3","2","3","3","2","3","2","0","0","0","1","non-elderly",5.05417106668494,"veterans"
"42","NCT00593281",79,"Interventional","Phase 3",2006-01-31,2006-10-31,"INcreased Flow Utilizing Subcutaneously Enabled Morphine (INFUSE-Morphine) With and Without Human Recombinant Hyaluronidase (HYLENEX) and Intravenously",13,"Industry",NA,92,8,0,8,62,NA,2006,2006,0,"North America",0,"United States","Industry","Earlier 2013",5014885,"Hylenex",1,"Opioids",13,12,1,NA,1,"Late Phase","pallative",NA,7.69230769230769,"yes",0.0579,2274110,"Mixed","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California,California","808,808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before","0",0.49,"D","small",34.3650287791398,"non-acute","non-chronic","non-cancer","0","1","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",83.6,69,80.8,29.8,55.3,60.15,1277319,82.1951768303908,55319,49,2154356,12.2,14.2617707647834,"1","0","0","3","1","0","0","0","2","3","2","1","3","non-elderly",5.76811979363611,"general"
"43","NCT00594516",80,"Interventional","Phase 3",2007-12-31,2008-05-31,"A Randomized, Double-Blind, 2-Period, Crossover Study to Establish the Dose Equivalence and Direct Conversion Between Immediate Release (IR) and Extended-Release (ER) CG5503 in Subjects With Moderate-to-Severe, Chronic Low Back Pain",117,"Industry",NA,75,15,10,25,51,NA,2007,2008,1,"North America",0,"United States","Industry","Earlier 2013",5014790,"tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR)",1,"Opioids",116,90,14,12,26,"Late Phase","chronic",NA,12.0689655172414,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before",NA,NA,NA,"small",NA,"non-acute","chronic","non-cancer","2","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"44","NCT00602420",81,"Interventional","Phase 3",2008-06-30,2012-03-31,"Prevention of Pegfilgrastim-Induced Bone Pain (PIBP): A Phase III Double-Blind Placebo-Controlled Clinical Trial",510,"Other","United States",89,6,5,11,86,510,2008,2012,4,"North America",0,"United States","Non-Industry","Earlier 2013",5014202,"naproxen, placebo",1,"Non-opioids",510,455,33,22,55,"Late Phase","cancer",NA,6.47058823529412,"yes",0.116716666666667,1095959,"Mixed","non-kids","Non-Government","non-female","non-veterans",30.6968632546426,5624.125,22.3720940158799,86.516006640519,21.1512154794492,91.6082137854377,85.2755005438277,92.55625,7.44375,"0",41013.4375,"Hawaii,Illinois,Illinois,Kansas,Michigan,Minnesota,Missouri,New York,North Carolina,Ohio,Ohio,South Carolina,South Carolina,Washington,Washington,Wisconsin","2,532,532,60,277,71,318,292,264,368,368,229,229,79,79,96",237.25,38.65625,23.96,10.24,3748593.1875,66.575,11.46875,"Before","0",0.5425,"Mixed","large",32.5043695540638,"non-acute","non-chronic","cancer","3","1","1","2","1","1","1","1","1","1","2","1","1","2","1","2","1","1",81.76875,74.025,88.04830625,18.03491875,57.125,68.9296875,2082502.625,88.0754552104312,50168,11.6,1074532.0625,12.34375,8.09394728534991,"0","1","2","1","2","2","0","2","1","1","1","1","1","non-elderly",12.1674712091568,"general"
"45","NCT00613925",83,"Interventional",NA,2008-01-31,2011-01-31,"Comparison of Pain Experienced by Patients Undergoing Endometrial Biopsy by Pipelle and Explora Curette",73,"Other","United States",92,4,4,8,100,NA,2008,2011,3,"North America",0,"United States","Non-Industry","Earlier 2013",5013348,"Pipelle de Cornier, Explora curette",0,"Non-opioids",66,61,3,2,5,NA,"acute","female",4.54545454545455,"yes",0.0191,78679,"Mixed","non-kids","Non-Government","female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"1",41773,"Oregon,Oregon","18,18",18,38.7,NA,NA,1808465,62.375,10.6,"Before","0",0.48,"D","small",34.2300108729167,"acute","non-chronic","non-cancer","1","1","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.73945683684397,"female"
"46","NCT00617097",84,"Interventional","Phase 2/Phase 3",2008-01-31,2009-06-30,"Paracervical Block With Ketorolac and Lidocaine in First Trimester Surgical Abortions",50,"Other","United States",50,30,20,50,100,50,2008,2009,1,"North America",0,"United States","Non-Industry","Earlier 2013",5013115,"lidocaine, ketorolac and lidocaine",1,"Non-opioids",50,25,15,10,25,"Early Phase","acute","female",30,"no",0.0191,78679,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"1",41773,"Oregon","18",18,38.7,NA,NA,1808465,62.375,10.6,"Before",NA,0.48,"D","small",34.2300108729167,"acute","non-chronic","non-cancer","1","1","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.73945683684397,"female"
"47","NCT00618904",85,"Interventional",NA,2005-12-31,2007-09-30,"Clinical Efficacy of Probiotic Bacteria in Subjects With Irritable Bowel Syndrome (IBS), Functional Diarrhea, or Functional Bloating",56,"Other",NA,84,10,6,16,72,NA,2005,2007,2,"North America",0,"United States","Non-Industry","Earlier 2013",5012982,"Probiotics - Lactobacillus and bifidobacterium, Placebo",0,"Non-opioids",57,48,6,3,9,NA,"chronic",NA,10.5263157894737,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"Before","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","1","1","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",79.1,61.2,84,25.3,57.8,70.9,7916683,85.5293484395759,42056,7,2023810,13.1,8.40197402658067,"0","0","0","3","2","3","3","1","0","0","2","1","1","non-elderly",21.1661112132563,"general"
"48","NCT00619866",NA,"Interventional","Phase 2",2008-02-19,2009-08-28,"A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis",155,"Industry",NA,NA,NA,NA,NA,NA,NA,2008,NA,NA,"North America",NA,"United States","Industry",NA,5012908,NA,NA,"Non-opioids",155,126,11,18,29,"Early Phase","acute","female",7.09677419354839,NA,NA,NA,NA,"non-kids",NA,"female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before",NA,NA,NA,"small",NA,"acute","non-chronic","non-cancer","2","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"female"
"49","NCT00619983",86,"Interventional","Phase 4",2008-02-29,2013-05-31,"Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy",22,"Other","United States",68,32,0,32,36,44,2008,2013,5,"North America",0,"United States","Non-Industry","Earlier 2013",5012899,"donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin",1,"Non-opioids",22,15,7,NA,7,"Late Phase","chronic",NA,31.8181818181818,"yes",0.16925,1823475,"Mixed","non-kids","Non-Government","non-female","non-veterans",7.4213003296544,4219.5,22.7052365271226,86.012464611813,19.5060249498133,90.8401145638104,84.265527342628,91.05,8.95,"1",36133,"North Carolina,Ohio","264,368",316,38.55,22.4,9.95,4990406,66.6125,13.45,"Before","0",0.615,"R","small",30.3709322853199,"non-acute","chronic","non-cancer","0","1","3","0","1","2","1","0","0","0","1","0","2","1","1","2","3","3",78.85,70.85,86.60125,16.65355,55.8,70.0875,4186337,86.8155386481701,44932,10.5,1709353.5,13.8,8.14692701809964,"0","1","2","0","2","3","1","1","0","1","2","2","1","non-elderly",16.6288036712825,"general"
"50","NCT00627367",87,"Interventional","Phase 3",2007-12-31,2008-03-31,"A Randomized Controlled Trial Comparing Protocolized Versus Non-protocolized Treatment of Adult ED Patients With Acute Severe Pain",224,"Other","United States",8,27,65,92,65,218,2007,2008,1,"North America",0,"United States","Non-Industry","Earlier 2013",5012343,"Hydromorphone, Nonprotocolized",1,"Opioids",218,17,59,142,201,"Late Phase","acute",NA,27.0642201834862,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.0733,18.8331,55.7,55.9,881499,87.7477251256719,48944,9,2792447,14.5,6.33298278377812,"0","0","1","1","2","0","0","2","1","1","3","2","0","non-elderly",14.3997846978615,"general"
"51","NCT00651924",NA,"Interventional","N/A",2008-12-31,2009-04-30,"Piloting Interactive Voice Response Modules for Chronic Pain Treatment",27,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2008,NA,NA,"North America",NA,"United States","Non-Industry",NA,5010480,NA,NA,"Non-opioids",24,17,6,1,7,NA,"chronic",NA,25,"no",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"Before","0",0.43,"D","small",39.6963200211786,"non-acute","chronic","non-cancer","0","1","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",86.8,82,89.0157,20.5814,61.5,70.7,2186987,90.630228110436,64682,2,335151,8.1,10.6706250487306,"2","3","3","2","3","3","0","2","3","0","0","0","2","non-elderly",9.36942019354931,"general"
"52","NCT00659633",89,"Interventional",NA,2008-12-31,2016-08-31,"The Effect of Intravenous Lidocaine on Allodynia (Carl Koller Grant)",10,"Other","United States",90,10,0,10,70,10,2008,2016,8,"North America",0,"United States","Non-Industry","Earlier 2013",5009896,"lidocaine",1,"Non-opioids",10,9,1,0,1,NA,"acute","healthy",10,"no",0.2664,1299050,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.62507069982056,900,22.6392183673469,83.3613868714217,17.195147573548,87.6352559797239,80.1686731141783,90.3,9.7,"0",33928,"Alabama","278",278,39.1,20.7,12.4,2284847,70.725,16,"Before","0",0.77,"R","small",25.3013815767412,"acute","non-chronic","non-cancer","0","1","3","0","0","1","0","0","0","0","1","0","1","0","0","3","3","3",75,61.7,82.6959,13.8874,54.1,73.025,130522504,88.5193351891897,44476,23,1256566,14.3,6.81114958575696,"0","0","0","0","1","3","3","2","0","2","1","2","0","non-elderly",26.2588871163301,"general"
"53","NCT00660348",90,"Interventional",NA,2008-03-31,2011-03-31,"A Randomized Study of Optimal Pain Management: Standard Pain Control Versus Early Intervention With Intrathecal Therapy in Patients With Advanced Pancreatic Cancer",1,"Other","United States",100,0,0,0,NA,NA,2008,2011,3,"North America",0,"United States","Non-Industry","Earlier 2013",5009841,"morphine sulfate, Medtronic intrathecal pump",1,"Opioids",1,1,0,0,0,NA,"cancer",NA,0,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"Before","0",0.54,"D","small",40.7376904453232,"non-acute","non-chronic","cancer","0","1","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",84.7,78.7,89.018,20.4528,66,70.6,716135,88.602397570159,63711,14,1679719,8.7,10.8327699960329,"1","2","3","2","3","3","0","2","3","1","2","0","2","non-elderly",29.0308369434955,"general"
"54","NCT00674375",91,"Interventional","Phase 3",2008-11-30,2010-01-31,"Can Risk Score Alerts Improve Office Care for Chest Pain?",8000,"Other",NA,64,13,23,36,64,NA,2008,2010,2,"North America",0,"United States","Non-Industry","Earlier 2013",5008773,"Electronic risk alerts",0,"Non-opioids",7083,4570,938,1575,2513,"Late Phase","cardio",NA,13.2429761400536,"yes",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts,Massachusetts","45,45",45,39.3,23.6,13.5,2928732,61.325,9.8,"Before","0",0.33,"D","large",44.4377437165865,"non-acute","non-chronic","non-cancer","3","1","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",85.8,81.7,89.054,22.2431,59.7,65.65,2359193,95.0285261478165,60320,1,410795,11.3,9.2587366295912,"1","3","3","2","3","1","0","3","3","0","0","0","2","non-elderly",6.26474130787064,"general"
"55","NCT00682435",94,"Interventional","Phase 4",2007-08-31,2007-11-30,"Safety and Speed of Onsent of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg in the Treatment of Adult ED Patients With Moderate to Severe Pain",230,"Other","United States",7,29,64,93,65,223,2007,2007,0,"North America",0,"United States","Non-Industry","Earlier 2013",5008165,"Hydromorphone",1,"Opioids",223,15,65,143,208,"Late Phase","acute",NA,29.1479820627803,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","3","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.0733,18.8331,55.7,55.9,881499,87.7477251256719,48944,9,2792447,14.5,6.33298278377812,"0","0","1","1","2","0","0","2","1","1","3","2","0","non-elderly",14.3997846978615,"general"
"56","NCT00686127",95,"Interventional","Phase 4",2003-09-30,2007-12-31,"A Randomized, Double-Blind, Placebo-Controlled Trial (RDBPCT) of the Effectiveness of the Lidocaine Patch in the Management of Neuropathic Pain After Breast Cancer Surgery",21,"Other","United States",52,14,34,48,100,42,2003,2007,4,"North America",0,"United States","Non-Industry","Earlier 2013",5007884,"Lidoderm patch, Placebo patch",1,"Non-opioids",21,11,3,7,10,"Late Phase","cancer",NA,14.2857142857143,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before",NA,0.49,"D","small",34.3650287791398,"non-acute","non-chronic","cancer","0","0","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",66.3,59.6,81.3,31.7,56.3,59.7,1218679,82.7342945717312,49300,39,2154356,13.1,14.2617707647834,"0","0","0","3","2","0","0","0","1","3","2","1","3","non-elderly",5.76811979363611,"general"
"57","NCT00694018",96,"Interventional",NA,2009-05-31,2012-03-31,"Veterans Walk to Beat Back Pain",229,"U.S. Fed","United States",80,11,9,20,12,229,2009,2012,3,"North America",0,"United States","Non-Industry","Earlier 2013",5007288,"Education and standard care, Internet mediated enhanced pedometer intervention",0,"Non-opioids",229,183,24,22,46,NA,"chronic","veterans",10.4803493449782,"no",0.1379,1374310,"GOVERNMENT","non-kids","Government","non-female","veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan","277",277,37.9,23.2,9.1,4629611,73.025,11,"Before","0",0.53,"R","small",29.5564246895313,"non-acute","chronic","non-cancer","3","1","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",81.3,73.8,88.7032,15.7211,43.2,74.5,2801841,87.0208656047818,45994,15,1371429,14,8.29877292639095,"0","1","3","0","0","3","1","1","0","1","1","2","1","non-elderly",13.8842695584969,"veterans"
"58","NCT00694369",NA,"Interventional","Phase 3",2008-06-30,2009-01-31,"A Phase III Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Multiple-Dose Clinical Trial to Study the Efficacy and Safety of MK0663/Etoricoxib 90 and 120 mg, Ibuprofen 600 mg, and Acetaminophen 600 mg/Codeine 60 mg in the Treatment of Patients With Postoperative Dental Pain",588,"Industry",NA,NA,NA,NA,NA,NA,NA,2008,NA,NA,"North America",NA,"United States","Industry",NA,5007261,NA,NA,"Non-opioids",588,532,17,39,56,"Late Phase","acute",NA,2.89115646258503,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before",NA,NA,NA,"large",NA,"acute","non-chronic","non-cancer","3","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"59","NCT00720330",NA,"Interventional","N/A",2008-07-31,2010-02-28,"The Effect of Thoracolumbar Paravertebral Block or Intravenous Lidocaine and Ketamine Versus Standard Care on Acute and Chronic Pain After Inguinal Herniorrhaphy",12,"Other",NA,NA,NA,NA,NA,NA,NA,2008,NA,NA,"North America",NA,"United States","Non-Industry",NA,5005300,NA,NA,"Non-opioids",12,11,1,NA,1,NA,"acute",NA,8.33333333333333,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"Before","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","0","1","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",78.6,72.6,88.3686,15.5867,53,70.775,313209,88.7669774894425,46934,12,1394897,13.7,7.8918800096186,"0","1","2","0","1","3","0","2","0","1","1","1","1","non-elderly",12.0914961293086,"general"
"60","NCT00726388",98,"Interventional","Phase 3",2008-09-30,2009-05-31,"An Open-Label, Multiple-Dose, Multiple-Day, Non-Randomized, Single-Arm Safety Study Of Repeat-Doses Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain",850,"Industry",NA,86,10,4,14,66,NA,2008,2009,1,"North America",0,"United States","Industry","Earlier 2013",5004848,"DIC075V (intravenous diclofenac sodium)",1,"Non-opioids",1289,1107,126,56,182,"Late Phase","acute",NA,9.77501939487975,"yes",0.135835294117647,1436201.05882353,"Mixed","non-kids","Non-Government","non-female","non-veterans",24.6004909424501,8052.73913043478,22.318574461389,87.1101599790912,21.8965660832864,91.2635643247022,84.8242033876422,90.8130434782609,9.18695652173913,"0",42308.0869565217,"Alabama,Alabama,Alabama,Alabama,Alabama,Alabama,Alabama,Arizona,Arizona,Arkansas,California,California,California,California,California,California,California,Colorado,Colorado,Colorado,Connecticut,Florida,Florida,Florida,Florida,Georgia,Indiana,Kansas,Kansas,Louisiana,Montana,New York,New York,Ohio,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Tennessee,Texas,Texas,Texas","278,278,278,278,278,278,278,60,60,106,808,808,808,808,808,808,808,52,52,52,41,620,620,620,620,542,144,60,60,341,1,292,292,368,308,308,308,308,308,308,308,308,201,624,624,624",372.652173913043,38.7152173913043,21.1642857142857,11.0833333333333,6282140.17391304,64.9375,12.9391304347826,"Before",NA,0.575217391304348,"Mixed","large",31.3945284912687,"acute","non-chronic","non-cancer","3","1","2","2","2","1","2","1","1","1","1","1","2","1","2","1","3","2",80.55,71.7239130434783,85.3589847826087,17.299497826087,57.0239130434783,68.1798913043478,22084414.9565217,85.087074509121,49565.0217391304,21,1519118.36956522,13.6130434782609,9.67800878073124,"0","1","1","0","2","2","3","1","1","2","1","1","2","non-elderly",12.7744674860797,"general"
"61","NCT00737737",100,"Interventional","Phase 4",2008-08-31,2014-04-30,"Effects of Chronic Musculoskeletal Pain and Opioidergic Versus Placebo Interventions on Neuroendocrine Function in Men",8,"NIH","United States",75,0,25,25,0,4,2008,2014,6,"North America",0,"United States","Non-Industry","Earlier 2013",5003989,"MS Contin, Placebo",1,"Opioids",4,3,0,1,1,"Late Phase","chronic",NA,0,"no",0.2989,1799090,"GOVERNMENT","non-kids","Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"Before","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","0","1","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",84.7,78.7,89.018,20.4528,66,70.6,716135,88.602397570159,63711,14,1679719,8.7,10.8327699960329,"1","2","3","2","3","3","0","2","3","1","2","0","2","non-elderly",29.0308369434955,"general"
"62","NCT00743730",101,"Interventional",NA,2005-06-30,2010-02-28,"Outcomes And Parent Satisfaction Associated With Parent/Nurse Controlled Analgesia In Pediatric Patients With Developmental Delay",94,"Other","United States",74,16,10,26,42,NA,2005,2010,5,"North America",0,"United States","Non-Industry","Earlier 2013",5003535,"Pain and standard side effect management for PNCA with basal method., Pain and standard side effect management with PNCA without basal, Pain and standard side effect management with IV on an as needed basis method.",0,"Opioids",81,60,13,8,21,NA,"acute","kids",16.0493827160494,"no",0.0641,371200,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"1",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"Before","0",0.45,"R","small",30.1959597752958,"acute","non-chronic","non-cancer","1","1","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",84.2,71.8,90.4,25,57,71.1,868858,91.184536113203,44650,2,344384,10.2,5.85443389695935,"1","1","3","3","2","3","0","3","0","0","0","0","0","non-elderly",6.05132939510076,"kids"
"63","NCT00751400",NA,"Interventional","Phase 3",2008-07-31,2008-11-30,"An Open Label, Actual Use Study in Consumers Taking an Extended-Release Over the Counter NSAID in a Naturalistic Setting",497,"Industry",NA,NA,NA,NA,NA,NA,NA,2008,NA,NA,"North America",NA,"United States","Industry",NA,5002957,NA,NA,"Non-opioids",497,399,56,42,98,"Late Phase","acute",NA,11.2676056338028,"yes",0.0799571428571429,860220.285714286,NA,"non-kids",NA,"non-female","non-veterans",18.1759810032041,6137.29166666667,21.8546160661627,86.9564984963131,23.0718083952306,93.331781907648,87.2855515624695,91.6541666666667,8.34583333333333,"1",42400,"California,California,California,Kansas,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Missouri,Missouri,Missouri,North Carolina,North Carolina,North Carolina,North Carolina,Utah,Utah,Utah,Utah,Utah,Washington,Washington,Washington","808,808,808,60,71,71,71,71,71,318,318,318,264,264,264,264,14,14,14,14,14,79,79,79",214.833333333333,39.1583333333333,19.5789473684211,9.08947368421053,4144946.33333333,67.021875,10.5958333333333,"Before",NA,0.559166666666667,"Mixed","large",34.3257621597777,"acute","non-chronic","non-cancer","3","1","0","1","1","1","2","2","3","2","1","1","1","0","1","2","0","2",84.9583333333333,76.5458333333333,88.318225,19.4747875,61.8333333333333,69.9479166666667,5114741.58333333,87.4666167292555,53581.5,10.6666666666667,790484.958333333,11.2791666666667,10.1502710199095,"1","2","2","2","3","3","2","1","2","1","0","0","2","non-elderly",7.61367154326179,"general"
"64","NCT00801398",106,"Interventional","Phase 3",2009-02-17,2011-04-18,"An Open-Label, Ascending, Two-Part, Single- and Multiple-Dose Evaluation of the Safety, Pharmacokinetics, and Effectiveness of Oxymorphone for Acute Postoperatiave Pain in Pediatric Subjects",58,"Industry","United States",86,10,4,14,66,58,2009,2011,2,"North America",0,"United States","Industry","Earlier 2013",4999211,"Oxymorphone IR",1,"Opioids",58,50,6,2,8,"Late Phase","acute","kids",10.3448275862069,"yes",0.14092,1353875,"Mixed","kids","Non-Government","non-female","non-veterans",64.6040606968112,7155,23.1856749581552,87.8108334873754,22.7945274710477,91.7893095438668,85.3129162177334,91.1909090909091,8.80909090909091,"0",42952.5454545455,"Arkansas,California,Colorado,Florida,Indiana,Pennsylvania,Pennsylvania,Tennessee,Texas,Washington","106,808,52,620,144,308,308,201,624,79",325,39.1909090909091,21.77,10.74,5464451.09090909,63.0954545454545,12.4363636363636,"Before",NA,0.562,"Mixed","small",34.1053602419525,"acute","non-chronic","non-cancer","1","1","2","3","2","2","2","1","1","1","1","1","2","1","2","1","2","2",80.2727272727273,72.5272727272727,86.1784545454545,17.8629545454545,53.7818181818182,66.1931818181818,3059175.36363636,84.0343013697735,48764.2727272727,16.4444444444444,1218414.09090909,14.8,10.6390359763415,"0","1","2","1","1","1","1","1","1","1","1","2","2","non-elderly",13.8467009161063,"kids"
"65","NCT00801983",107,"Interventional",NA,2009-01-31,2013-08-31,"The Effect of Alternative Keyboards on Discomfort and Typing Kinematics",85,"Other","United States",87,10,3,13,92,77,2009,2013,4,"North America",0,"United States","Non-Industry","Earlier 2013",4999167,"Alternative Keyboard",0,"Non-opioids",77,67,8,2,10,NA,"chronic",NA,10.3896103896104,"no",0.1118,1430660,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"Before",NA,0.53,"R","small",31.8196178223866,"non-acute","chronic","non-cancer","1","1","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",82.2,74.3,88.7087,16.44,50.7,72.2,1670383,89.0803440068202,48172,18,1323261,11.1,12.1914636349471,"1","1","3","0","0","3","0","2","0","2","1","0","3","non-elderly",10.4114832611178,"general"
"66","NCT00813488",108,"Interventional","Phase 3",2008-12-31,2010-01-31,"A Double Blind, Active Controlled Crossover Study to Evaluate the Efficacy and Safety of Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain",213,"Industry","United States",90,9,1,10,56,213,2008,2010,2,"North America",0,"United States","Industry","Earlier 2013",4998302,"Fentanyl Buccal Tablet, Immediate release oxycodone",1,"Opioids",213,191,19,3,22,"Late Phase","chronic",NA,8.92018779342723,"yes",0.156286363636364,1417206.31818182,"Mixed","non-kids","Non-Government","non-female","non-veterans",24.282143491359,7224.26,22.7413126447046,86.5675895297069,21.3500361666939,91.5905903289083,84.820745527919,90.53,9.47,"0",41793.44,"Alabama,Alabama,California,California,California,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Illinois,Illinois,Illinois,Indiana,Indiana,Indiana,Kansas,Kentucky,Louisiana,Maryland,Maryland,Michigan,Mississippi,Missouri,Nevada,New York,New York,Ohio,Ohio,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Carolina,Texas,Texas,Utah","278,278,808,808,808,808,808,41,620,620,620,620,620,620,620,542,542,542,542,532,532,532,144,144,144,60,76,341,269,269,277,208,318,80,292,292,368,368,18,308,308,308,308,308,229,229,229,624,624,14",397.96,38.976,23.6770833333333,11.68125,5939641.1,65.638,12.728,"Before",NA,0.5716,"Mixed","small",31.3438716677709,"non-acute","chronic","non-cancer","2","1","2","2","2","2","1","1","1","1","1","1","2","1","2","2","2","2",80.642,72.546,85.637482,17.035042,57.056,69.1355,7348694.34,85.043810604638,49309.36,19.9795918367347,1724991.9,13.332,9.21817963975015,"0","1","1","0","2","2","3","1","1","2","2","1","2","non-elderly",15.5363771818173,"general"
"67","NCT00825370",109,"Interventional","Phase 3",2008-10-31,2009-05-31,"Protocolized vs Discretionary Use of Opioids in Acute Pain",350,"Other","United States",5,27,68,95,61,338,2008,2009,1,"North America",0,"United States","Non-Industry","Earlier 2013",4997402,"Hydromorphone, IV opioid",1,"Opioids",338,16,90,232,322,"Late Phase","acute",NA,26.6272189349112,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","1",0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,76.9,85.0733,18.8331,55.6,54.95,891095,86.6122987104584,50461,13,2792447,14.2,6.33298278377812,"0","2","1","1","2","0","0","1","1","1","3","2","0","non-elderly",14.3997846978615,"general"
"68","NCT00829387",NA,"Interventional","N/A",2010-03-31,2013-12-31,"Cognitive Behavioral Therapy for Diabetic Peripheral Neuropathic Pain",47,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Non-Industry",NA,4997094,NA,NA,"Non-opioids",47,33,12,2,14,NA,"chronic",NA,25.531914893617,"yes",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut,Connecticut","41,41",41,37.4,38.1,43.2,1524992,64.25,9.9,"Before","0",0.43,"D","small",39.6963200211786,"non-acute","chronic","non-cancer","1","2","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",9.36942019354931,"general"
"69","NCT00830596",110,"Interventional",NA,2007-07-31,2012-07-31,"Effect of Spinal Manipulation on Sensorimotor Functions in Back Pain Patients",221,"Other",NA,89,7,4,11,46,NA,2007,2012,5,"North America",0,"United States","Non-Industry","Earlier 2013",4997001,"HVLA-SM, LVVA-SM, Sham Intervention",0,"Non-opioids",221,197,16,8,24,NA,"chronic",NA,7.23981900452489,"no",0.0371,116359,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"Before","0",0.55,"R","small",28.6266618238787,"non-acute","chronic","non-cancer","3","1","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",82.5,68.3,90.9661,17.55,62.6,73.7,2769545,91.1852844108841,48908,1,93041,8.9,6.7023965919847,"1","0","3","0","3","3","1","3","1","0","0","0","0","non-elderly",3.0506416147767,"general"
"70","NCT00861302",111,"Interventional","Phase 1",2008-09-30,2011-11-30,"Evaluating Outcomes and Response Profiles of a Psychological Treatment for People With Chronic Pain",72,"Other",NA,91,6,3,9,79,NA,2008,2011,3,"North America",0,"United States","Non-Industry","Earlier 2013",4994687,"Mind-body emotional awareness program",0,"Non-opioids",72,66,4,2,6,"Early Phase","chronic",NA,5.55555555555556,"no",0.1379,1374310,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan","277",277,37.9,23.2,9.1,4629611,73.025,11,"Before","0",0.53,"R","small",29.5564246895313,"non-acute","chronic","non-cancer","1","1","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",81.3,73.8,88.7032,15.7211,48.7,75.9,2790008,88.538852515108,49788,15,1371429,13,8.29877292639095,"0","1","3","0","0","3","1","2","1","1","1","1","1","non-elderly",13.8842695584969,"general"
"71","NCT00880607",114,"Interventional","Phase 4",2008-12-31,2012-09-30,"The Use of Intraoperative Intrathecal Morphine Versus Epidural Extended Release Morphine for Postoperative Pain Control in Pediatric Patients Undergoing Posterior Spinal Fusion",84,"Other","United States",82,4,14,18,77,71,2008,2012,4,"North America",0,"United States","Non-Industry","Earlier 2013",4993230,"Intrathecal morphine, Extended Release Epidural Morphine",1,"Opioids",71,58,3,10,13,"Late Phase","acute","kids",4.22535211267606,"no",0.0416,233647,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",23.9179698236295,3308,21.2598045977011,90.3840342736655,28.6491314070065,94.6862260297194,89.9455520549368,92,8,"1",51677,"Colorado","52",52,38.2,NA,NA,2464164,64.75,8.9,"Before","0",0.47,"D","small",41.9890895854971,"acute","non-chronic","non-cancer","1","1","0","2","0","1","3","3","3","3","1","3","0",NA,"0","1","0","0",82.1,76.1,90.2304,23.2832,61.9,69,13596788,84.6450363685349,60943,2,189658,11,9.56613444451818,"1","2","3","3","3","2","3","1","3","0","0","0","2","non-elderly",3.75629496990635,"kids"
"72","NCT00895999",118,"Interventional",NA,2007-03-31,2011-12-31,"Psychosocial Treatment for Gynecology Patients With Comorbid Depression and Pain",60,"NIH",NA,16,65,19,84,100,NA,2007,2011,4,"North America",0,"United States","Non-Industry","Earlier 2013",4992065,"Interpersonal Therapy for Pain (IPT-P), Enhanced Support and Connection to Counseling",0,"Non-opioids",61,10,40,11,51,NA,"chronic","female",65.5737704918033,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","1","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,67.8,85.0733,18.8331,55.7,55.9,881499,87.7477251256719,48944,9,2792447,14.5,6.33298278377812,"0","0","1","1","2","0","0","2","1","1","3","2","0","non-elderly",14.3997846978615,"female"
"73","NCT00910208",121,"Interventional",NA,2009-04-30,2010-06-30,"Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department",211,"NIH",NA,6,27,67,94,68,NA,2009,2010,1,"North America",0,"United States","Non-Industry","Earlier 2013",4991030,"Patient-controlled analgesia, morphine",1,"Opioids",206,12,56,138,194,NA,"acute",NA,27.1844660194175,"no",0.1566,3065470,"GOVERNMENT","non-kids","Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,76.9,85.0733,18.8331,51.1,54.375,897343,85.8831174991195,50216,17,2792447,15.8,6.33298278377812,"0","2","1","1","0","0","0","1","1","2","3","3","0","non-elderly",14.3997846978615,"general"
"74","NCT00922220",122,"Interventional","Phase 1",2004-10-31,2008-11-30,"Immediate Effect of Physical Interventions for Low Back Pain",94,"Other",NA,75,20,5,25,28,NA,2004,2008,4,"North America",0,"United States","Non-Industry","Earlier 2013",4990116,"stationary bike, lumbar extension exercise, spinal manipulative therapy",0,"Non-opioids",36,27,7,2,9,"Early Phase","chronic",NA,19.4444444444444,"no",0.1607,3359030,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"1",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before","0",0.54,"R","small",30.4516559104648,"non-acute","chronic","non-cancer","1","0","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",81.4,69.5,85.9,26,59.6,72.4,282303,81.7054239264875,40535,23,2875804,11.6,10.0831815208954,"0","1","2","3","3","3","0","0","0","2","3","0","2","non-elderly",15.261658159499,"general"
"75","NCT00926588",123,"Interventional","Phase 3",2009-10-31,2015-06-30,"Stepped Care to Optimize Pain Care Effectiveness (SCOPE)",250,"U.S. Fed","United States",77,19,4,23,17,250,2009,2015,6,"North America",0,"United States","Non-Industry","Earlier 2013",4989795,"Stepped care",1,"Non-opioids",250,192,48,10,58,"Late Phase","chronic","veterans",19.2,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"Before","0",0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","3","1","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",74.7,69.5,87.1877,14.6486,48.8,72.025,5296355,86.2628216629557,44305,1,578506,16.1,8.67182330071009,"0","1","2","0","0","3","2","1","0","0","0","3","1","non-elderly",8.9129530132787,"veterans"
"76","NCT00933400",124,"Interventional","Phase 4",2009-07-31,2012-04-30,"Randomized Controlled Study of a Rapid ""Rule Out"" Strategy Using CT Coronary Angiogram Versus Traditional Care for Low- to Intermediate-Risk ED Patients With Potential Acute Coronary Syndromes",1365,"Other",NA,38,59,3,62,53,NA,2009,2012,3,"North America",0,"United States","Non-Industry","Earlier 2013",4989282,"CT Coronary Angiography, Traditional, Standard of Care",0,"Non-opioids",1370,523,813,34,847,"Late Phase","cardio",NA,59.3430656934307,"yes",0.1631,1815710,"Mixed","non-kids","Non-Government","non-female","non-veterans",27.047691799876,6808.8,19.1367910416667,87.4427116757555,20.1044265493562,89.889379824684,84.4857845151866,93.1,6.9,"1",38669.6,"North Carolina,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania","264,308,308,308,308",299.2,38.34,19.26,9.56,5535691,68.39,12.02,"Before","0",0.554,"R","large",31.8347795159081,"non-acute","non-chronic","non-cancer","3","1","3","2","2","0","2","0","0","0","2","1","2","0","2","3","2","2",81.58,73.26,87.93374,16.69608,51.6,71.78,2956576.2,87.7013987116896,46918.8,15.8,1463370.8,12.26,11.4335657132738,"0","1","2","0","0","3","1","2","0","1","1","1","3","non-elderly",12.5624088515455,"general"
"77","NCT00945763",125,"Interventional","Phase 2",2009-07-31,2009-11-30,"A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Adaptive Design, Single-Dose Study of Intravenous N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery",230,"Industry",NA,92,1,7,8,67,NA,2009,2009,0,"North America",0,"United States","Industry","Earlier 2013",4988340,"N1539, placebo, N1539, N1539, Motrin",1,"Non-opioids",230,212,1,17,18,"Early Phase","acute",NA,0.434782608695652,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"0",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"Before","0",0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","3","1","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",0.961977245198848,"general"
"78","NCT00946803",127,"Interventional",NA,2009-07-31,2011-01-31,"A Patient-Controlled Cognitive-Behavioral Intervention for Cancer Symptoms",86,"NIH",NA,93,5,2,7,59,NA,2009,2011,2,"North America",0,"United States","Non-Industry","Earlier 2013",4988261,"Patient-Controlled Cognitive-Behavioral Intervention",0,"Non-opioids",86,80,4,2,6,NA,"cancer",NA,4.65116279069767,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"0",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"Before","0",0.45,"R","small",30.1959597752958,"non-acute","non-chronic","cancer","2","1","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",84.2,78.8,90.4802,17.2444,49.2,70.325,882019,91.0677314352593,51237,4,344384,10.8,5.85443389695935,"1","2","3","0","0","3","0","2","1","0","0","0","0","non-elderly",6.05132939510076,"general"
"79","NCT00964886",128,"Interventional","Phase 2",2010-01-31,2015-12-31,"Efficacy of Antidepressants in Chronic Back Pain",142,"U.S. Fed","United States",60,15,25,40,NA,NA,2010,2015,5,"North America",0,"United States","Non-Industry","Earlier 2013",4986897,"cognitive behavioral therapy, desipramine hydrochloride, cognitive behavioral therapy, benztropine mesylate 0.125 mg daily, desipramine hydrochloride",1,"Non-opioids",138,84,21,33,54,"Early Phase","chronic",NA,15.2173913043478,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","2","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",83.6,64.9,81.0994,19.2392,48.6,56.1,13688147,80.617178135,54283,29,2154356,16.3,14.2617707647834,"1","0","0","1","0","0","3","0","2","3","2","3","3","non-elderly",5.76811979363611,"general"
"80","NCT00973973",NA,"Interventional","Phase 2",2009-10-12,2010-09-22,"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 Sodium in Subjects With Endometriosis",137,"Industry",NA,NA,NA,NA,NA,NA,NA,2009,NA,NA,"North America",NA,"United States","Industry",NA,4986209,NA,NA,"Non-opioids",155,126,11,18,29,"Early Phase","acute","female",7.09677419354839,NA,NA,NA,NA,"non-kids",NA,"female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before",NA,NA,NA,"small",NA,"acute","non-chronic","non-cancer","2","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"female"
"81","NCT00985439",133,"Interventional","Phase 2",2009-09-30,2009-12-31,"A Phase 2, Randomized, Double-Blind, Single-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Pain After Surgical Removal of Impacted Third Molars",202,"Industry","United States",93,2,5,7,57,NA,2009,2009,0,"North America",0,"United States","Industry","Earlier 2013",4985353,"Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg, Placebo",1,"Non-opioids",202,188,6,8,14,"Early Phase","acute",NA,2.97029702970297,"no",0.1213,3428210,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before",NA,0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","2","1","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,65.5,81.0773,17.7566,56.6,65.35,2801999,74.4968474593154,47475,25,2904687,17.3,9.43231929885351,"0","0","0","1","2","1","1","0","0","2","3","3","2","non-elderly",11.5004707188636,"general"
"82","NCT00986180",134,"Interventional","Phase 3",2009-09-30,2010-12-31,"A Randomized, Double-Blind, Parallel-Group Study of NUCYNTA (Tapentadol) Immediate Release vs. Oxycodone Immediate Release for the Treatment of Acute Low Back Pain",667,"Industry","UNITED STATES",70,24,6,30,50,NA,2009,2010,1,"North America",0,"United States","Industry","Earlier 2013",4985296,"NUCYNTA, Oxycodone IR",1,"Opioids",585,409,142,34,176,"Late Phase","acute",NA,24.2735042735043,"yes",0.136977777777778,1271208.2962963,NA,"non-kids",NA,"non-female","non-veterans",20.285957299977,7126.67567567568,23.2545455335818,86.6953678457181,21.5217340098254,91.8365839905224,84.9323363683932,89.6567567567567,10.3432432432432,"1",41926.4324324324,"Alabama,Arizona,Arkansas,California,California,California,California,California,California,California,Colorado,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Indiana,Indiana,Kansas,Kentucky,Louisiana,Louisiana,Louisiana,Louisiana,Louisiana,Massachusetts,Massachusetts,Michigan,Missouri,Missouri,Missouri,Nevada,Nevada,New Jersey,New Jersey,New Jersey,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Pennsylvania,Pennsylvania,South Carolina,Tennessee,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Utah,Virginia","278,60,106,808,808,808,808,808,808,808,52,41,620,620,620,620,620,620,620,620,620,620,620,620,542,542,144,144,60,76,341,341,341,341,341,45,45,277,318,318,318,80,80,243,243,243,292,292,264,264,264,264,368,368,368,368,368,368,140,308,308,229,201,624,624,624,624,624,624,624,624,14,14,249",396.743243243243,39.1608108108108,22.9591549295775,10.9380281690141,6352164.0945946,64.7067567567568,13.0824324324324,"Before",NA,0.577297297297297,"Mixed","large",31.2755871191425,"acute","non-chronic","non-cancer","3","1","2","2","2","2","1","1","1","1","0","1","2","1","2","1","3","2",80.5810810810811,72.5324324324324,85.2746256756757,17.2560851351351,53.7567567567568,67.9452702702703,4141711.68918919,82.5130776156129,48730.8513513514,18.9295774647887,1717674.27027027,14.5905405405405,9.05359928782357,"0","1","1","0","1","2","1","0","1","2","2","2","1","non-elderly",13.7920443110232,"general"
"83","NCT01005459",136,"Interventional","Phase 4",2009-08-31,2011-12-12,"Comparison of Spinal Tetracaine With Fentanyl and Epinephrine Versus Bupivacaine With Fentanyl and Epinephrine for Combined Spinal Epidural Labor Analgesia",46,"Other","United States",76,15,9,24,100,46,2009,2011,2,"North America",0,"United States","Non-Industry","Earlier 2013",4983832,"Tetracaine, Bupivacaine",1,"Opioids",46,35,7,4,11,"Late Phase","acute","female",15.2173913043478,"no",0.2144,2200760,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"Before","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","1","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",79.1,69.1,84.8339,17.7204,55.2,70.1,8101349,82.1856175311671,41906,7,2023810,16.9,8.40197402658067,"0","1","1","0","1","3","3","0","0","0","2","3","1","non-elderly",21.1661112132563,"female"
"84","NCT01010633",NA,"Interventional","Phase 3",2009-11-30,2010-08-31,NA,406,"Industry",NA,NA,NA,NA,NA,NA,NA,2009,NA,NA,"North America",NA,"United States","Industry",NA,4983441,NA,NA,"Non-opioids",406,358,36,12,48,"Late Phase","acute",NA,8.86699507389163,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,76.9,85.0733,18.8331,51.1,54.375,897343,85.8831174991195,50216,17,2792447,15.8,6.33298278377812,"0","2","1","1","0","0","0","1","1","2","3","3","0","non-elderly",14.3997846978615,"general"
"85","NCT01011816",NA,"Interventional","Phase 3",2010-03-31,2013-05-31,"A Multicenter, Randomized, Blinded, Saline-Controlled Trial of Resorbable Biologic Disc Augmentation for Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System",220,"Industry",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Industry",NA,4983350,NA,NA,"Non-opioids",220,199,17,4,21,"Late Phase","chronic",NA,7.72727272727273,"yes",0.158114285714286,1625254.28571429,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.5343609773206,9028.3,22.0370907316517,87.27984858289,22.9785245987767,91.8997301687122,85.7552395450745,91.34,8.66,"0",44510.55,"Alabama,Arizona,California,California,California,California,Florida,Illinois,Maryland,Minnesota,Mississippi,North Carolina,Ohio,Ohio,Pennsylvania,Pennsylvania,Texas,Virginia,Virginia,Washington","278,60,808,808,808,808,620,532,269,71,208,264,368,368,308,308,624,249,249,79",404.35,38.9,22.4,10.29,6622829.5,65.0525,12.43,"Before","0",0.5645,"Mixed","small",32.9222582879611,"non-acute","chronic","non-cancer","3","2","3","1","2","1","2","2","2","2","1","2","2","1","2","1","2","2",81.81,65.165,85.6841,17.981395,51.725,66.95125,6271589.75,83.7981162328,50541.5,16.6,1578680.5,14.975,9.93459317420488,"1","0","2","1","0","2","2","0","1","2","1","2","2","non-elderly",13.6825053608392,"general"
"86","NCT01015053",138,"Interventional",NA,2009-11-30,2011-11-30,"Postoperative Pain After Pediatric Umbilical Hernia Repair: a Randomized Clinical Trial of Ultrasound-guided Bilateral Rectus Sheath Blocks Versus Local Anesthetic Infiltration",53,"Other",NA,38,25,37,62,50,NA,2009,2011,2,"North America",0,"United States","Non-Industry","Earlier 2013",4983103,"bilateral ultrasound-guided rectus sheath block, Wound infiltration",0,"Non-opioids",52,20,13,19,32,NA,"acute","kids",25,"yes",0.0763,522357,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts,Massachusetts","45,45",45,39.3,23.6,13.5,2928732,61.325,9.8,"Before","1",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","1","1","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",85.8,81.7,89.054,22.2431,51.5,65.125,2371293,95.6973429902215,59373,3,410795,10.8,9.2587366295912,"1","3","3","2","0","1","1","3","3","0","0","0","2","non-elderly",6.26474130787064,"kids"
"87","NCT01025752",141,"Interventional",NA,2011-05-31,2016-04-30,"IVR-based Cognitive Behavior Therapy for Chronic Low Back",134,"U.S. Fed","United States",64,26,10,36,22,125,2011,2016,5,"North America",0,"United States","Non-Industry","Earlier 2013",4982294,"Face to face cognitive behavior therapy, IVR based cognitive behavioral therapy",0,"Non-opioids",125,80,32,13,45,NA,"chronic",NA,25.6,"no",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After","0",0.43,"D","small",39.6963200211786,"non-acute","chronic","non-cancer","2","2","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",88.3766067526777,84.4,89.0157,20.5814,55.8,70.625,1491803,91.395160279,65415,1,338670,10.1,10.6706250487306,"2","3","3","2","2","3","0","3","3","0","0","0","2","non-elderly",9.45818272303055,"general"
"88","NCT01035047",142,"Interventional",NA,2010-01-31,2012-08-31,"Randomized Investigation of Chest Pain Diagnostic Strategies",105,"Other",NA,63,33,4,37,46,NA,2010,2012,2,"North America",0,"United States","Non-Industry","Earlier 2013",4981588,"Clinical decision unit care, coupled with cardiac MRI",0,"Non-opioids",105,68,35,2,37,NA,"cardio",NA,33.3333333333333,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"Before","0",0.65,"R","small",31.8954262899941,"non-acute","non-chronic","non-cancer","2","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",79.1,62.8,84.8339,17.7204,52.4,69.475,4334128,82.883511837,43830,7,2023810,17.4,8.40197402658067,"0","0","1","0","1","2","1","0","0","0","2","3","1","non-elderly",21.1661112132563,"general"
"89","NCT01055639",NA,"Interventional","Phase 2",2010-02-28,2013-09-30,"Telehealth Therapy for Chronic Pain",126,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Non-Industry",NA,4980074,NA,NA,"Non-opioids",126,71,35,20,55,"Early Phase","chronic",NA,27.7777777777778,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","2","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",83.6,64.9,81.0994,19.2392,48.6,56.1,13688147,80.617178135,54283,29,2154356,16.3,14.2617707647834,"1","0","0","1","0","0","3","0","2","3","2","3","3","non-elderly",5.76811979363611,"general"
"90","NCT01058265",NA,"Interventional","N/A",2009-10-31,2010-12-31,"Effect of an Integrative Medicine Consultation on Outcome for Patients With Pain or Fatigue",47,"Other",NA,NA,NA,NA,NA,NA,NA,2009,NA,NA,"North America",NA,"United States","Non-Industry",NA,4979874,NA,NA,"Non-opioids",47,42,4,1,5,NA,"chronic",NA,8.51063829787234,"no",0.045,317462,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",13.1690644369743,2618,21.9949418181818,89.8384852939726,25.0101131688258,93.3056955655765,86.6387024886614,88.7,11.3,"1",47386,"Arizona","60",60,38.2,10.3,7.8,3075981,65.825,14.4,"Before","0",0.53,"R","small",29.6115954315844,"non-acute","chronic","non-cancer","1","1","0","1","0","1","3","2","3","2","0","2","0","0","1","2","3","1",84.2,74.3,85.7143,17.0129,50.8,68.95,304426,81.0517003068053,45739,1,248863,21.2,6.01721550623265,"1","1","2","0","0","2","0","0","0","0","0","3","0","non-elderly",3.88015598394509,"general"
"91","NCT01064661",144,"Interventional",NA,2010-02-28,2012-02-29,"Physiological Effects of Probiotic Bacteria Lactobacillus Acidophilus NCFM Alone Versus a Combination With Bifidobacterium Lactids - LBi07 in Patients With Mild to Moderate Abdominal Pain/Discomfort and Bloating",22,"Industry",NA,100,0,0,0,100,NA,2010,2012,2,"North America",0,"United States","Industry","Earlier 2013",4979388,"Single probiotic arm of L-NCFM alone, Blend probiotic arm of L-NCFM and B-LBi07",0,"Non-opioids",22,22,0,0,0,NA,"chronic","female",0,NA,NA,NA,NA,"non-kids",NA,"female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before","1",NA,NA,"small",NA,"non-acute","chronic","non-cancer","0","2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"female"
"92","NCT01067144",145,"Interventional","Phase 3",2010-05-31,2016-07-31,"Stanford Accelerated Recovery Trial (START)",422,"Other",NA,74,4,22,26,61,NA,2010,2016,6,"North America",0,"United States","Non-Industry","Earlier 2013",4979199,"Gabapentin, Lorazepam (active control), Placebo (inactive)",1,"Non-opioids",371,275,16,80,96,"Late Phase","chronic",NA,4.31266846361186,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before","0",0.49,"D","large",34.3650287791398,"non-acute","chronic","non-cancer","3","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",83.6,64.9,81.0994,19.2392,48.6,56.1,13688147,80.617178135,54283,29,2154356,16.3,14.2617707647834,"1","0","0","1","0","0","3","0","2","3","2","3","3","non-elderly",5.76811979363611,"general"
"93","NCT01087489",147,"Interventional",NA,2010-04-30,2011-06-30,"Clinical Comparison of Two Anesthetic Preparations for Intravitreal Injection",53,"U.S. Fed","United States",77,6,17,23,4,NA,2010,2011,1,"North America",0,"United States","Non-Industry","Earlier 2013",4977653,"4% lidocaine, 3.5% ophthalmic lidocaine gel",1,"Non-opioids",48,37,3,8,11,NA,"acute",NA,6.25,"no",0.1607,3359030,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before","0",0.54,"R","small",30.4516559104648,"acute","non-chronic","non-cancer","1","2","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",81.4,66.2,85.9484,16.5154,52.5,69.225,8995100,79.306725454,44066,26,2875804,16,10.0831815208954,"0","0","2","0","1","2","3","0","0","3","3","3","2","non-elderly",15.261658159499,"general"
"94","NCT01094301",NA,"Interventional","N/A",2010-04-30,2017-07-25,"A Prospective Multi-Center Pilot Study of the SPR™ System for the Treatment of Post-Stroke Shoulder Pain",28,"Industry",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Industry",NA,4977132,NA,NA,"Non-opioids",28,14,14,NA,14,NA,"chronic",NA,50,"yes",0.151725,2035770,"Mixed","non-kids","Non-Government","non-female","non-veterans",62.4554873981139,9079.5,22.1599043312697,86.0798423265911,20.9422978232161,90.5738724790679,84.6857320833973,92.775,7.225,"1",39845.75,"New York,North Carolina,Ohio,Pennsylvania","292,264,368,308",308,38.45,24.875,11.625,6029455.25,63.6125,12.55,"Before",NA,0.555,"Mixed","small",32.4592026212544,"non-acute","chronic","non-cancer","0","2","2","3","2","1","1","1","0","0","2","1","2","2","2","1","2","2",80.3,64.425,86.746125,17.14505,50.55,66.45625,5787258.25,85.810719723,46952.75,10.5,1883603.75,15.25,8.70457511373112,"0","0","2","0","0","2","2","1","0","1","2","2","1","non-elderly",14.5172188253861,"general"
"95","NCT01094366",150,"Interventional","Phase 4",2010-04-30,2012-11-30,"An Evaluation of the Paracervical Block for Pain Control in First Trimester Surgical Abortion",121,"Other",NA,66.7,5.8,27.5,33.3,100,NA,2010,2012,2,"North America",0,"United States","Non-Industry","Earlier 2013",4977127,"Paracervical Block, Sham Paracervical Block",0,"Non-opioids",120,80,7,33,40,"Late Phase","acute","female",5.83333333333333,"no",0.0191,78679,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"1",41773,"Oregon","18",18,38.7,NA,NA,1808465,62.375,10.6,"Before","0",0.48,"D","small",34.2300108729167,"acute","non-chronic","non-cancer","2","2","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",87,70.5,89.3255,18.3022,47.8,66.25,1677303,83.979927418,50602,2,66777,14.3,14.574172019163,"2","1","3","1","0","1","0","1","1","0","0","2","3","non-elderly",1.73945683684397,"female"
"96","NCT01098747",151,"Interventional","Phase 3",2010-04-30,2010-08-31,"Evaluation Of The Efficacy Of A Novel Ibuprofen Formulation In The Treatment Of Post-Surgical Dental Pain: Study I",335,"Industry",NA,95,1,4,5,51,NA,2010,2010,0,"North America",0,"United States","Industry","Earlier 2013",4976795,"Novel Ibuprofen, Standard Ibuprofen, Standard Ibuprofen, Placebo",1,"Non-opioids",316,301,1,14,15,"Late Phase","acute",NA,0.316455696202532,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Before",NA,NA,NA,"large",NA,"acute","non-chronic","non-cancer","3","2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"97","NCT01115569",152,"Interventional","Phase 3",2010-05-31,2012-01-31,"A Long-Term Open-Label Safety Study of Hydrocodone Bitartrate Controlled-Release Capsules With Flexible Dosing to Treat Subjects With Moderate to Severe Chronic Pain",424,"Industry","United States",81,17,2,19,56,638,2010,2012,2,"North America",0,"United States","Industry","Earlier 2013",4975510,"Hydrocodone Bitartrate",1,"Opioids",638,518,107,13,120,"Late Phase","chronic",NA,16.7711598746081,"yes",0.119853846153846,1157040.34615385,"Mixed","non-kids","Non-Government","non-female","non-veterans",23.0319935383669,6489.5,22.7701385065314,87.489564034591,22.6450210585363,91.8265425084824,85.0368601019059,89.918,10.082,"1",42914.18,"Arizona,Arizona,Arizona,Arkansas,California,California,California,California,Colorado,Connecticut,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Idaho,Illinois,Kansas,Kansas,Louisiana,Louisiana,Massachusetts,Massachusetts,Mississippi,Missouri,Missouri,Montana,New Mexico,New York,New York,North Carolina,Ohio,Ohio,Ohio,Oklahoma,Oklahoma,Pennsylvania,Pennsylvania,Rhode Island,Texas,Texas,Texas,Texas,Texas,Utah,Utah,Virginia,Washington","60,60,60,106,808,808,808,808,52,41,620,620,620,620,542,542,542,1,532,60,60,341,341,45,45,208,318,318,1,8,292,292,264,368,368,368,140,140,308,308,7,624,624,624,624,624,14,14,249,79",326.52,38.876,23.1136363636364,11.6295454545455,5384625.54,64.8795,12.888,"Before",NA,0.5646,"Mixed","large",31.9371778739728,"non-acute","chronic","non-cancer","3","2","1","2","1","2","2","1","1","1","1","1","2","1","2","1","3","2",81.46,64.754,85.801728,17.79124,54.604,66.978,5035132.24,82.96864671186,48391.68,15,1409846.3,15.722,9.16935875174665,"0","0","2","1","1","2","2","0","0","1","1","3","1","non-elderly",11.7838707434404,"general"
"98","NCT01118988",155,"Interventional",NA,2009-12-31,2011-06-30,"Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents",27,"Other",NA,59,11,30,41,70,NA,2009,2011,2,"North America",0,"United States","Non-Industry","Earlier 2013",4975252,"Mentorship",0,"Non-opioids",27,16,3,8,11,NA,"chronic","kids",11.1111111111111,"no",0.0579,2274110,"GOVERNMENT","kids","Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"Before","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","0","1","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",83.6,75.6,81.0994,19.2392,51.8,56.95,1311457,80.6588206536358,56134,41,2154356,15.3,14.2617707647834,"1","2","0","1","0","0","0","0","2","3","2","2","3","non-elderly",5.76811979363611,"kids"
"99","NCT01123382",157,"Interventional",NA,2010-01-31,2013-02-28,"Electrical Stimulation for Hemiplegic Shoulder Pain",25,"Other","United States",44,52,4,56,52,25,2010,2013,3,"North America",0,"United States","Non-Industry","Earlier 2013",4974915,"Intramuscular Electrical Stimulator, Outpatient Therapy",0,"Non-opioids",25,13,11,1,12,NA,"chronic",NA,44,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"Before","1",0.58,"R","small",28.8464382806458,"non-acute","chronic","non-cancer","0","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",78.6,63.5,88.3686,15.5867,50.4,69.75,5128641,86.377182247,45886,12,1394897,15.4,7.8918800096186,"0","0","2","0","0","3","2","1","0","1","1","3","1","non-elderly",12.0914961293086,"general"
"100","NCT01156142",161,"Interventional","Phase 3",2010-12-31,2015-03-02,"A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy",155,"NIH","United States",90,5,5,10,20,NA,2010,2015,5,"North America",0,"United States","Non-Industry","Earlier 2013",4972428,"doxepin hydrochloride, placebo",1,"Non-opioids",140,126,7,7,14,"Late Phase","cancer",NA,5,"yes",0.10279375,982745.9375,"Mixed","non-kids","Non-Government","non-female","non-veterans",10.5736516725359,3473.31666666667,19.8409705601785,84.8946839132884,19.3884096964182,91.3233046772958,85.0482576125724,93.5841666666667,6.41583333333333,"0",35726.1333333333,"Arizona,Connecticut,Florida,Georgia,Idaho,Illinois,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Iowa,Iowa,Iowa,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Virginia,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin","60,41,620,542,1,532,144,144,144,144,144,144,144,144,144,144,144,144,144,34,34,34,45,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,33,33,33,33,33,33,1,1,1,1,1,1,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,249,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96",177.983333333333,38.7991666666667,18.0309090909091,8.53181818181818,3377970.82051282,69.3635416666667,10.6666666666667,"Before","0",0.519416666666667,"Mixed","small",31.1676385406925,"non-acute","non-chronic","cancer","2","2","1","1","1","0","0","0","1","1","2","0","0","0","1","3","0","1",81.635,67.1758333333333,89.5660125,17.6234175,51.2241666666667,71.6141666666667,3218121.96666667,87.819267657875,48943.75,7.75892857142857,769169.833333333,13.3583333333333,8.424873513483,"0","0","3","0","0","3","1","2","1","1","0","1","1","non-elderly",8.88479471566527,"general"
"101","NCT01162304",162,"Interventional","Phase 4",2010-03-31,2013-12-31,"Open-Label Trial Comparing Oxycodone Medications for Effectiveness and Satisfaction (OUTCOMES)",18,"Other","United States",50,11,39,50,61,18,2010,2013,3,"North America",0,"United States","Non-Industry","Earlier 2013",4971960,"Extended Release Oxycodone, Immediate Release Oxycodone",1,"Opioids",18,9,2,7,9,"Late Phase","chronic",NA,11.1111111111111,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,64.3,85.0733,18.8331,51.5,54.45,8115218,84.916585934,49781,6,2792447,16,6.33298278377812,"0","0","1","1","0","0","3","1","1","0","3","3","0","non-elderly",14.3997846978615,"general"
"102","NCT01168986",163,"Interventional","Phase 1/Phase 2",2009-09-30,2015-05-31,"The Effectiveness of a Mechanical Manual Therapy Device in the Treatment of Neck Pain",62,"Other","United States",66,13,21,34,76,62,2009,2015,6,"North America",0,"United States","Non-Industry","Earlier 2013",4971448,"Pulstar Multiple Impulse Therapy, Exercise",0,"Non-opioids",62,41,8,13,21,"Early Phase","chronic",NA,12.9032258064516,"no",0.1607,3359030,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"Before","0",0.54,"R","small",30.4516559104648,"non-acute","chronic","non-cancer","1","1","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",81.4,75,85.9484,16.5154,54.5,70.9,295409,78.288724554533,45631,33,2875804,14.6,10.0831815208954,"0","1","2","0","1","3","0","0","0","3","3","2","2","non-elderly",15.261658159499,"general"
"103","NCT01172600",NA,"Interventional","N/A",2011-01-31,2013-03-31,"Effect of Nitrous Oxide in Treating Neuropathic Pain: A Pilot Study in Chronic Low Back Pain Patients",78,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4971173,NA,NA,"Non-opioids",78,54,24,NA,24,NA,"chronic",NA,30.7692307692308,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","1",0.58,"R","small",28.8464382806458,"non-acute","chronic","non-cancer","1","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,75,88.3686,15.5867,48.5,68.9,5134668,86.316692631,44648,20,1380254,15.1,7.8918800096186,"1","1","2","0","0","2","2","1","0","2","1","2","1","non-elderly",11.9554773337713,"general"
"104","NCT01194466",168,"Interventional",NA,2011-05-15,2012-08-14,"The Influence of TENS on Mucositis Pain and Function in Head and Neck Cancer Patients: A Randomized and Placebo-Controlled Double Blind Clinical Trial",41,"Other","United States",83,5,12,17,17,41,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4969506,"Transcutaneous Electrical Nerve Stimulation (TENS)",0,"Non-opioids",41,34,2,5,7,NA,"cancer",NA,4.8780487804878,"no",0.0371,116359,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"After","0",0.55,"R","small",28.6266618238787,"non-acute","non-chronic","cancer","1","2","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",2.81297543781506,"general"
"105","NCT01210352",NA,"Interventional","Phase 3",2010-12-13,2017-10-06,"An Open-Label, Non-randomized, Multicenter, Ascending Dose by Age, Single- and Multiple-Dose Evaluation of the Effectiveness, Safety, and Tolerability of Oral Liquid Oxymorphone HCl Immediate-Release Oral Liquid for Acute Postoperative Pain in Pediatric Subjects",61,"Industry",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Industry",NA,4968300,NA,NA,"Opioids",61,45,12,4,16,"Late Phase","acute","kids",19.672131147541,"yes",0.1009125,988366.75,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",11.657646395868,3763.75,21.7078143190722,88.3087717741494,21.663420485514,91.1082479884139,83.9079196277558,89.2875,10.7125,"1",40655.875,"Arizona,Arkansas,Colorado,Indiana,Oklahoma,Pennsylvania,Tennessee,Texas","60,106,52,144,140,308,201,624",204.375,39.325,17.7571428571429,10.3428571428571,3955495.5,66.834375,12.8,"Before",NA,0.6,"Mixed","small",29.6345105614775,"acute","non-chronic","non-cancer","1","2","1","1","1","1","2","1","1","0","0","1","0","0","1","2","2","3",78.4875,61.95,85.86965,16.6958,54.0625,68.984375,3653575.375,83.588651133125,46141.125,10.375,878633.625,15.7875,8.76028643742275,"0","0","2","0","1","2","1","0","0","1","1","3","1","non-elderly",9.74420757812919,"kids"
"106","NCT01211340",171,"Interventional",NA,2010-09-30,2015-07-31,"The ACTIVE Intervention to Improve Hospice Care",446,"Other","United States",92,5,3,8,78,446,2010,2015,5,"North America",0,"United States","Non-Industry","Earlier 2013",4968224,"ACTIVE",0,"Non-opioids",446,409,23,14,37,NA,"pallative",NA,5.15695067264574,"yes",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"0",37179,"Missouri,Missouri","318,318",318,40.3,20.9,8.9,2819383,69.05,11.9,"Before","0",0.6,"R","large",29.5879678888084,"non-acute","non-chronic","non-cancer","3","2","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",81.6,61.7,87.7113,16.2926,57.1,71.225,2714627,86.066962903,45817,8,696002,15,6.97619334002276,"0","0","2","0","2","3","1","1","0","1","0","2","0","non-elderly",11.6073246677788,"general"
"107","NCT01211600",172,"Interventional",NA,2010-06-30,2014-12-31,"Cesarean Randomized Control Trial Of Sutures vs. Staples (CROSS)",746,"Other",NA,42,44,14,58,100,NA,2010,2014,4,"North America",0,"United States","Non-Industry","Earlier 2013",4968204,"Staples, Suture",0,"Non-opioids",746,316,325,105,430,NA,"acute","female",43.5656836461126,"yes",0.1095,907038,"Mixed","non-kids","Non-Government","female","non-veterans",21.7121138570998,4501.5,20.7463960252193,87.8360589430054,21.3448632824038,90.9443625043296,86.001249916069,94.15,5.85,"1",43780,"Connecticut,Pennsylvania","41,308",174.5,37.85,27.9,26,3628810,66.7375,10.7,"Before","1",0.48,"Mixed","large",35.7579689217826,"acute","non-chronic","non-cancer","3","2","1","2","1","1","2","1","0","2","3","2","0","3","1","2","0","0",84.5,70.6,88.8622,18.5107,51.85,71.475,3529845.5,88.9351219135,57156,17,829206,10.4,11.4310443418388,"1","1","3","1","0","3","1","2","2","2","0","0","3","non-elderly",9.89045172733356,"female"
"108","NCT01211613",NA,"Interventional","N/A",2010-11-30,2013-10-31,"A Comparison of Chiropractic Manipulation Methods and Standard Medical Care for Low Back Pain",107,"Other",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Non-Industry",NA,4968203,NA,NA,"Non-opioids",107,67,29,11,40,NA,"acute",NA,27.1028037383178,"no",0.1118,1430660,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"1",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"Before","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","2","2","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",82.2,67.1,88.7087,16.44,47.9,72.15,5571046,89.065598874,48314,17,1323261,12.2,12.1914636349471,"1","0","3","0","0","3","2","2","0","2","1","1","3","non-elderly",10.4114832611178,"general"
"109","NCT01221233",175,"Interventional",NA,2011-02-14,2011-11-22,"Lumbar Stabilization Exercises and Neuromuscular Electrical Stimulation: An Investigation of Muscle Size and Function in Older Adults With Chronic Low Back Pain",38,"Other","United States",94,6,0,6,47,34,2011,2011,0,"North America",0,"United States","Non-Industry","Earlier 2013",4967466,"Neuromuscular Electrical Stimulation, Moist Heat",0,"Non-opioids",34,32,2,0,2,NA,"chronic","elderly",5.88235294117647,"no",0.2218,212302,"GOVERNMENT","non-kids","Government","non-female","non-veterans",8.47142851173364,618,34.479,88.7155780965911,22.1477942746097,92.8085358689267,88.4755978154442,93.4,6.6,"0",50361,"Delaware","31",31,38.8,25.1,10.5,443781,73.1,9.6,"After",NA,0.52,"D","small",31.2080137092089,"non-acute","chronic","non-cancer","0","2","3","0","0","3","3","1","2","3","2","3","0","2","0","3","0","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"elderly",20.8868580751487,"elderly"
"110","NCT01223365",NA,"Interventional","Phase 3",2010-10-31,2012-09-30,"A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours in Patients Who Require Opioid Treatment for an Extended Period of Time",330,"Industry",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Industry",NA,4967302,NA,NA,"Opioids",330,260,66,4,70,"Late Phase","chronic",NA,20,"yes",0.137204,1306540.52,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.537120141031,8402.64814814815,23.280701583508,87.6215610937591,22.5814707457852,92.0395167621155,85.3882203552217,89.7703703703704,10.2296296296296,"1",43259.7037037037,"Alabama,California,California,California,California,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Illinois,Indiana,Kansas,Kentucky,Louisiana,Maryland,Massachusetts,Missouri,Missouri,Nebraska,Nevada,New Jersey,New York,North Carolina,Ohio,Ohio,Oklahoma,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Rhode Island,South Carolina,South Carolina,South Carolina,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah","278,808,808,808,808,808,808,808,808,808,620,620,620,620,620,542,542,542,542,532,144,60,76,341,269,45,318,318,33,80,243,292,264,368,368,140,18,18,308,308,308,308,7,229,229,229,624,624,624,624,624,624,624,14",426.907407407407,39.1425925925926,23.1333333333333,10.7196078431373,6806111.14814815,64.162037037037,12.6925925925926,"Before",NA,0.570925925925926,"Mixed","large",31.7991009879116,"non-acute","chronic","non-cancer","3","2","2","2","2","2","2","1","2","1","0","2","3","1","2","1","2","2",81.2203703703704,64.337037037037,84.9511425925926,17.5679925925926,52.9055555555556,66.3856481481481,6369299.11111111,82.3217111711296,48523.5185185185,18.9230769230769,1734621.01851852,15.8203703703704,9.58435649783435,"0","0","1","0","1","1","2","0","1","2","2","3","2","non-elderly",13.1492195548989,"general"
"111","NCT01229449",176,"Interventional","Phase 3",2009-01-31,2009-09-30,"A Double-blind, 5 Parallel-group, Placebo-controlled, Randomised, Single Dose, 3-site Study to Compare the Analgesic Efficacy and Tolerability of a Combination of Ibuprofen 400 mg Plus Paracetamol 1000 mg; a Combination of Ibuprofen 200 mg Plus Paracetamol 500 mg; a Combination of Ibuprofen 400 mg Plus Codeine 25.6 mg (Nurofen Plus®); a Combination of Paracetamol 1000 mg Plus Codeine 30 mg (Panadeine® Extra) in Postoperative Adult Dental Pain Following Third Molar Extraction.",678,"Industry","United States",94,2,4,6,60,678,2009,2009,0,"North America",0,"United States","Industry","Earlier 2013",4966842,"Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen PlusÂ®, PanadeineÂ® Extra, Placebo",1,"Non-opioids",678,635,15,28,43,"Late Phase","acute",NA,2.21238938053097,"no",0.1213,3428210,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before","0",0.64,"R","large",30.2773131098502,"acute","non-chronic","non-cancer","3","1","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,65.5,81.0773,17.7566,56.6,65.35,2801999,74.4968474593154,47475,25,2904687,17.3,9.43231929885351,"0","0","0","1","2","1","1","0","0","2","3","3","2","non-elderly",11.5004707188636,"general"
"112","NCT01236521",NA,"Interventional","N/A",2011-12-31,2015-12-31,"Care Management for the Effective Use of Opioids (CAMEO)",261,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4966321,NA,NA,"Opioids",261,191,54,16,70,NA,"chronic",NA,20.6896551724138,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","non-veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"After","0",0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","3","2","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",85.0256665939072,73.5,87.1877,14.6486,50.2,72.15,2806770,87.974002061,44445,7,580310,15.6,8.67182330071009,"1","1","2","0","0","3","1","2","0","0","0","3","1","non-elderly",8.90466388887269,"general"
"113","NCT01238536",178,"Interventional","Phase 4",2011-04-30,2015-09-30,"Multicenter Randomized Controlled Trial of Epidural Steroid Injections for Spinal Stenosis in Persons 50 and Older",400,"U.S. Fed",NA,69,26,5,31,55,NA,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4966152,"Epidural steroid with local anesthetic injection, Epidural local anesthetic injection, Epidural steroid injection, Epidural local anesthetic injection",1,"Non-opioids",400,276,105,19,124,"Late Phase","chronic","elderly",26.25,"yes",0.0831111111111111,1130122.33333333,"Mixed","non-kids","Non-Government","non-female","non-veterans",25.8951570241135,9119.8,21.9944343768173,88.1654255550224,25.810832100799,93.3292132117186,87.7062699689184,92.28,7.72,"1",47306.7,"California,California,Colorado,Massachusetts,Michigan,Minnesota,Oregon,Texas,Virginia,Washington","808,808,52,45,277,71,18,624,249,79",303.1,38.99,22.125,9.7875,6108189.7,63.6275,10.87,"After","0",0.498,"Mixed","large",36.2506167261952,"non-acute","chronic","non-cancer","3","2","1","2","2","1","2","3","3","3","2","2","2","1","2","1","1","0",89.2692558768206,80.03,87.05118,19.8329,50.86,64.9925,5744637,85.4438270928,55541.4,16.2,1133977.3,13.83,10.8173681034898,"3","2","2","2","0","1","2","1","2","1","1","2","2","elderly",7.61735101463336,"elderly"
"114","NCT01240863",NA,"Interventional","Phase 3",2010-11-30,2011-08-31,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time",391,"Industry",NA,NA,NA,NA,NA,NA,NA,2010,NA,NA,"North America",NA,"United States","Industry",NA,4965978,NA,NA,"Opioids",294,220,69,5,74,"Late Phase","chronic",NA,23.469387755102,"yes",0.130248148148148,1230171.18518519,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.5659219210942,7822.54794520548,23.2006978872957,87.3368792149373,22.0558204151385,92.0491915803071,85.3878646142393,90.0506849315069,9.94931506849315,"1",42482.9178082192,"Alabama,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,Colorado,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Illinois,Illinois,Indiana,Kansas,Kentucky,Kentucky,Louisiana,Louisiana,Maryland,Massachusetts,Missouri,Missouri,Missouri,Nebraska,Nevada,New Jersey,New York,North Carolina,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Rhode Island,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Utah","278,60,60,60,808,808,808,808,808,808,808,808,808,808,808,52,620,620,620,620,620,620,620,620,542,542,542,532,532,144,60,76,76,341,341,269,45,318,318,318,33,80,243,292,264,368,368,368,368,368,368,140,18,18,308,308,308,308,7,229,229,229,229,229,624,624,624,624,624,624,624,14,14",403.150684931507,39.0534246575342,22.6191176470588,10.4705882352941,6461213.54794521,64.7845890410959,12.7917808219178,"Before",NA,0.57041095890411,"Mixed","small",31.4677461320985,"non-acute","chronic","non-cancer","3","2","2","1","2","2","2","1","2","1","1","1","2","1","2","1","2","2",81.0684931506849,64.1890410958904,85.2593712328767,17.3792657534247,52.9178082191781,66.9551369863014,6063867.42465753,82.4807320162877,48197.6438356164,17.5,1604198.73972603,15.8698630136986,9.32694468947896,"0","0","1","0","1","2","2","0","0","2","1","3","2","non-elderly",12.6446188078722,"general"
"115","NCT01248468",179,"Interventional","Phase 4",2010-11-30,2011-03-31,"A Multi-center, Randomized, Double-blind, Parallel-group Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine.",752,"Industry","United States",79,15,6,21,82,752,2010,2011,1,"North America",0,"United States","Industry","Earlier 2013",4965400,"Aspirin, acetaminophen and caffeine, Sumatriptan, Placebo",1,"Non-opioids",752,596,115,41,156,"Late Phase","acute",NA,15.2925531914894,"yes",0.131923076923077,1726934.30769231,NA,"non-kids",NA,"non-female","non-veterans",34.1645850600344,9293.1,22.8274763093853,86.1305196577779,21.6317212352364,92.4208922324526,85.6337283944452,89.915,10.085,"1",42464.45,"California,California,Florida,Florida,Florida,Florida,Florida,Florida,Illinois,Michigan,Missouri,New York,New York,North Carolina,Ohio,South Carolina,Tennessee,Texas,Utah,Washington","808,808,620,620,620,620,620,620,532,277,318,292,292,264,368,229,201,624,14,79",441.3,39.155,24.9263157894737,11.2473684210526,7369638.75,64.48125,12.475,"Before",NA,0.5585,"Mixed","large",31.9308353168236,"acute","non-chronic","non-cancer","3","2","2","3","2","2","1","1","2","2","1","1","3","2","2","1","2","2",81.445,64.93,85.76068,17.433025,52.415,66.91125,6920429.5,82.3560624518,47274,18.4210526315789,1999269.25,15.59,9.55393731697964,"0","0","2","0","1","2","2","0","0","2","2","3","2","non-elderly",13.2690924831673,"general"
"116","NCT01250418",180,"Interventional",NA,2010-08-31,2012-05-31,"A Comparison Between the Correlation of the Bispectral Index Versus Snap Index With the Observer's Assessment of Alertness and Sedation (OAA/S) Scale During a Sedation Regimen With and Without Ketamine",25,"Other","United States",76,20,4,24,100,25,2010,2012,2,"North America",0,"United States","Non-Industry","Earlier 2013",4965252,"Ketamine group",1,"Non-opioids",25,19,5,1,6,NA,"acute",NA,20,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"1",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"Before","1",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","0","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",79.9,65.2,87.2843,19.2183,47.8,68.75,5297593,85.160547725,50728,26,1838731,14.1,6.03837995473793,"0","0","2","1","0","2","2","1","1","3","2","2","0","non-elderly",14.3168047504798,"general"
"117","NCT01270659",182,"Interventional","Phase 3",2011-05-31,2014-10-31,"Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain: The FAIRTOP II Trial",60,"Other","United States",63,32,5,37,43,60,2011,2014,3,"North America",0,"United States","Non-Industry","Earlier 2013",4963701,"Fentanyl, Fentanyl, Oxycodone/acetaminophen, oxycodone/acetaminophen",1,"Opioids",60,38,19,3,22,"Late Phase","acute",NA,31.6666666666667,"no",0.0728,286356,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",2.61575566952378,1418,23.5663274509804,90.6048286733593,19.3788545037197,90.3825205041924,82.2039364279145,85.7,14.3,"1",35296,"Oklahoma","140",140,40.9,26.9,21.5,1749464,68.825,14,"After","0",0.66,"R","small",25.838855282203,"acute","non-chronic","non-cancer","1","2","0","0","0","2","3","0","0","0","0","0","0","3","0","3","3","3",83.650102186435,71.3,86.1069,15.9697,53.7,69.425,1672350,83.107396982,48455,9,272021,13.9,4.78924714468882,"1","1","2","0","1","2","0","0","0","1","0","2","0","non-elderly",7.17448044419265,"general"
"118","NCT01271855",183,"Interventional","Phase 4",2009-07-22,2011-09-29,"CRAMPS Trial: Controlled Randomized Trial Assessing Maternal Post-partum Pain With Suppositories",100,"Other","United States",49,13,38,51,100,100,2009,2011,2,"North America",0,"United States","Non-Industry","Earlier 2013",4963609,"Belladonna and opioid suppository, Glycerin Suppository",1,"Opioids",100,49,13,28,51,"Late Phase","acute","female",13,"yes",0.142,1813590,"Mixed","non-kids","Non-Government","female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois,Illinois","532,532",532,38.4,43,17.1,5388066,65.175,10.9,"Before","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","2","1","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",79.9,74.2,87.2843,19.2183,50.1,69.125,663836,85.795797754321,52870,23,1838731,13.2,6.03837995473793,"0","1","2","1","0","2","0","1","2","2","2","1","0","non-elderly",14.3168047504798,"female"
"119","NCT01280591",185,"Interventional","Phase 3",2010-10-31,2011-02-28,"A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep",712,"Industry",NA,89,4,7,11,56,NA,2010,2011,1,"North America",0,"United States","Industry","Earlier 2013",4962937,"Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111), Naproxen sodium 440 mg (BAYH6689), DPH 50 mg",1,"Non-opioids",712,634,27,51,78,"Late Phase","acute","kids",3.79213483146067,"yes",0.0666,1732529.5,NA,"kids",NA,"non-female","non-veterans",12.9552907511195,5974.5,24.3950849511503,89.2398523990309,23.7788973226473,94.3715405082215,87.4852544562023,85.95,14.05,"0",44162,"Texas,Utah","624,14",319,39.85,26.5,9.3,6208437,67.125,10.8,"Before",NA,0.64,"R","large",32.6611018288079,"acute","non-chronic","non-cancer","3","2","0","1","1","3","3","2","3","3","0","2","2","3","2","2","1","3",84.45,66.4,85.9063,18.925,64.45,68.9125,5489356,80.819257054,51983.5,31,1465698,14.2,10.8907354149896,"1","0","2","1","3","2","2","0","1","3","1","2","3","non-elderly",6.23122398203122,"kids"
"120","NCT01298765",NA,"Interventional","Phase 3",2011-03-31,2012-08-31,"A 52-Week, Open Label, Longterm Treatment Evaluation of the Safety and Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain",302,"Industry",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Industry",NA,4961553,NA,NA,"Opioids",302,237,58,7,65,"Late Phase","chronic",NA,19.205298013245,"yes",0.12285625,1521131.125,NA,"non-kids",NA,"non-female","non-veterans",25.5387987800413,8345.23076923077,23.3161848220044,87.350843225222,22.7685411881263,92.5269883681166,85.8884945633056,89.8,10.2,"1",43544.1923076923,"Alabama,Alabama,Arizona,California,California,California,California,Colorado,Florida,Florida,Florida,Florida,Georgia,Illinois,Indiana,Kansas,Massachusetts,Nevada,New York,North Carolina,North Carolina,Pennsylvania,Texas,Texas,Utah,Utah","278,278,60,808,808,808,808,52,620,620,620,620,542,532,144,60,45,80,292,264,264,308,624,624,14,14",391.807692307692,39.0307692307692,22.895652173913,11.1086956521739,6651033.07692308,63.9653846153846,12.4846153846154,"After","0",0.561153846153846,"Mixed","large",32.3763637637415,"non-acute","chronic","non-cancer","3","2","2","2","2","2","2","1","2","2","1","2","2","1","2","1","2","2",87.4208653254453,77.5692307692308,85.3038730769231,17.9316115384615,53.2115384615385,65.4394230769231,6249358.53846154,83.2645194645,49381.3076923077,24.0434782608696,1679708.80769231,15.1230769230769,9.42393821697526,"2","2","1","1","1","1","2","0","1","2","2","2","2","non-elderly",11.9518911180801,"general"
"121","NCT01301105",186,"Interventional",NA,2005-10-31,2007-04-30,"The Effects of Mindfulness Training on Pain Regulation, Negative Affect, Attention, and Social Stress.",80,"Other",NA,82.5,7,10.5,17.5,82.5,NA,2005,2007,2,"North America",0,"United States","Non-Industry","Earlier 2013",4961375,"Mindfulness Based Stress Reduction (MBSR), Health Enhancement Program (HEP)",0,"Non-opioids",57,47,4,6,10,NA,"acute","healthy",7.01754385964912,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"1",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"Before","0",0.45,"R","small",30.1959597752958,"acute","non-chronic","non-cancer","1","1","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",84.2,71.8,90.4,25,57,71.1,868858,91.184536113203,44650,2,344384,10.2,5.85443389695935,"1","1","3","3","2","3","0","3","0","0","0","0","0","non-elderly",6.05132939510076,"general"
"122","NCT01311895",188,"Interventional","Phase 3",2011-01-31,2011-11-30,"Randomized Clinical Trial Comparing Two Protocols Using IV Hydromorphone",350,"Other","United States",4,28,68,96,63,334,2011,2011,0,"North America",0,"United States","Non-Industry","Earlier 2013",4960559,"H2O, 1+1",1,"Opioids",334,13,92,229,321,"Late Phase","acute",NA,27.5449101796407,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After",NA,0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,79.7,85.0733,18.8331,50.8,53.6,8143255,87.824723438,50636,13,2808414,16,6.33298278377812,"2","2","1","1","0","0","3","2","1","1","3","3","0","non-elderly",14.4278735016142,"general"
"123","NCT01316471",190,"Interventional","Phase 2",2011-05-31,2015-11-30,"Web-MAP 2: Internet Intervention for Adolescents With Chronic Pain",273,"Other",NA,84.8,4.5,10.7,15.2,84.4,NA,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4960216,"Online Behavioral Intervention, Education: Online Patient Education",0,"Non-opioids",228,193,10,25,35,"Early Phase","chronic","kids",4.3859649122807,"no",0.038,281683,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",36.3274444869134,9176,31.6889445945946,89.9549312007655,27.2652644054344,94.6878709316023,90.128095190568,93.4,6.6,"1",52742,"Washington","79",79,40.1,19.5,7.1,3195004,63.75,10.3,"After","0",0.45,"D","small",36.6505101649993,"non-acute","chronic","non-cancer","3","2","0","3","2","3","3","3","3","3","2","3","0","0","1","1","0","0",91.3957683421682,86.1,90.0053,20.0857,51.1,64.2,2909741,85.536365929,56850,1,231498,12.5,13.486176059384,"3","3","3","2","0","1","1","1","2","0","0","1","3","non-elderly",3.38941013212518,"kids"
"124","NCT01324570",NA,"Interventional","Phase 3",2011-07-31,2016-05-31,"An Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Efficacy of Buprenorphine Transdermal System (BTDS) in Children From 7 to 16 Years of Age, Inclusive, Who Require Continuous Opioid Analgesia for Moderate to Severe Pain",41,"Industry",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Industry",NA,4959600,NA,NA,"Opioids",41,21,17,3,20,"Late Phase","chronic","kids",41.4634146341463,"yes",0.17285,1641949.5625,"Mixed","kids","Non-Government","non-female","non-veterans",66.972281437267,9612.45454545455,23.0062099331053,87.2525920133451,23.2523064962619,91.7441227787091,85.4583183597654,91.2090909090909,8.79090909090909,"1",44673.9090909091,"California,California,California,Colorado,Connecticut,Florida,Georgia,Illinois,Kentucky,Louisiana,New Jersey,New York,New York,New York,North Carolina,North Carolina,Pennsylvania,Rhode Island,South Carolina,Texas,Texas","808,808,808,52,41,620,542,532,76,341,243,292,292,292,264,264,308,7,229,624,624",384.142857142857,38.7409090909091,28.4571428571429,14.452380952381,6382675.45454545,61.1818181818182,12.7954545454545,"After",NA,0.554761904761905,"Mixed","small",34.7020020122762,"non-acute","chronic","non-cancer","1","2","3","3","2","2","2","2","1","1","1","2","2","3","2","0","2","2",86.7087386256403,76.1090909090909,84.787,18.4186227272727,51.3090909090909,63.2409090909091,6027791,83.8703841846364,50154.7272727273,22.45,1776087.68181818,15.8409090909091,8.90573501070172,"2","2","1","1","0","1","2","1","1","2","2","3","1","non-elderly",15.6645267257181,"kids"
"125","NCT01325714",NA,"Interventional","Phase 3",2011-05-31,2015-09-30,"Preventing Aggression in Veterans With Dementia",203,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4959512,NA,NA,"Non-opioids",203,94,73,36,106,"Late Phase","chronic","veterans",35.9605911330049,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","2","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,69.5,81.0773,17.7566,56.6,64.325,10077002,76.244536607,49047,33,2942701,17.4,9.43231929885351,"2","1","0","1","2","1","3","0","1","3","3","3","2","non-elderly",11.4614900181233,"veterans"
"126","NCT01327677",NA,"Interventional","Phase 4",2011-05-31,2014-05-31,"Post Craniotomy Analgesia Safety Monitoring With ET CO2",137,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4959363,NA,NA,"Opioids",104,86,12,6,18,"Late Phase","acute",NA,11.5384615384615,"no",0.2989,1799090,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","1",0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","2","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,81.4,89.018,20.4528,60.2,69.7,2386743,86.191573981,68876,15,1696598,9.3,10.8327699960329,"3","3","3","2","3","3","1","1","3","1","2","0","2","non-elderly",29.1097095562694,"general"
"127","NCT01330134",191,"Interventional","Phase 4",2011-02-28,2015-04-30,"Comparison of Two Lidocaine Administration Techniques",481,"Other",NA,59,38,3,41,47,NA,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4959179,"lidocaine, lidocaine",1,"Non-opioids",481,283,184,14,198,"Late Phase","acute",NA,38.2536382536383,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"1",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","large",35.1771599850269,"acute","non-chronic","non-cancer","3","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,78.2,87.2843,19.2183,46.1,68.4,5302784,85.261702238,50637,36,1843317,14.2,6.03837995473793,"2","2","2","1","0","2","2","1","1","3","2","2","0","non-elderly",14.3234120938898,"general"
"128","NCT01330459",192,"Interventional","Phase 4",2011-02-28,2011-10-31,"An Evaluation of Hydrocodone/Acetaminophen for Pain Control in First Trimester Surgical Abortion",121,"Other","United States",79,4,17,21,100,NA,2011,2011,0,"North America",0,"United States","Non-Industry","Earlier 2013",4959156,"Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine",1,"Opioids",121,96,6,19,25,"Late Phase","acute","female",4.95867768595041,"yes",0.0191,78679,"Mixed","non-kids","Non-Government","female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"1",41773,"Oregon,Oregon","18,18",18,38.7,NA,NA,1808465,62.375,10.6,"After","0",0.48,"D","small",34.2300108729167,"acute","non-chronic","non-cancer","2","2","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",90.8657845331328,81.5,89.3255,18.3022,40.7,66.425,1683702,86.21085773,51526,1,66696,14.4,14.574172019163,"3","3","3","1","0","1","0","1","1","0","0","2","3","non-elderly",1.72258338952942,"female"
"129","NCT01334944",193,"Interventional","Phase 4",2011-06-30,2012-10-31,"A Multi-Center, Open-Label, Surveillance Trial To Evaluate The Safety and Efficacy of a Shortened Infusion Time of Intravenous Ibuprofen.",150,"Industry","United States",71,23,6,29,61,150,2011,2012,1,"North America",0,"United States","Industry","Earlier 2013",4958812,"Intravenous ibuprofen",1,"Non-opioids",150,106,34,10,44,"Late Phase","acute",NA,22.6666666666667,"yes",0.147233333333333,1996779.22222222,"Mixed","non-kids","Non-Government","non-female","non-veterans",31.1564096445295,7204.76923076923,22.0281612098326,86.6625814050496,22.3359933687186,91.5582377594114,85.2761100243245,91.3384615384615,8.66153846153846,"1",42224.3076923077,"California,Connecticut,Florida,Georgia,Massachusetts,New York,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Pennsylvania","808,41,620,542,45,292,264,264,264,264,368,368,308",342.153846153846,38.6076923076923,25.2384615384615,14.0076923076923,5882050.15384615,63.7403846153846,12.7538461538462,"After","0",0.553846153846154,"Mixed","small",33.4879844755464,"acute","non-chronic","non-cancer","2","2","2","2","2","1","1","1","1","1","1","1","2","2","2","1","2","2",86.4689748034306,76.2615384615385,86.0942461538462,17.9782230769231,51.2538461538462,66.3288461538462,5584973.30769231,85.6679051392308,49526.0769230769,17.5384615384615,1841941.38461538,14.7153846153846,9.16986259755744,"2","2","2","1","0","1","2","1","1","2","2","2","1","non-elderly",15.4802107818173,"general"
"130","NCT01334957",194,"Interventional","Phase 4",2011-06-30,2013-01-31,"A Multi-Center, Open-Label, Surgical Surveillance Trial To Evaluate The Safety And Efficacy Of A Shortened Infusion Time of Intravenous Ibuprofen",300,"Industry","United States",76,20,4,24,63,300,2011,2013,2,"North America",0,"United States","Industry","Earlier 2013",4958811,"Intravenous ibuprofen",1,"Non-opioids",300,229,60,11,71,"Late Phase","acute",NA,20,"yes",0.159178571428571,1774144.85714286,"Mixed","non-kids","Non-Government","non-female","non-veterans",42.4595804212207,8945.59090909091,22.0107719666021,86.0975603703618,21.6142357277223,91.1568504484368,84.5790339471222,91.2772727272727,8.72272727272727,"1",41088.2727272727,"California,California,Florida,Florida,Illinois,Kansas,Louisiana,Massachusetts,Michigan,Mississippi,New York,New York,New York,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Pennsylvania,Pennsylvania,Tennessee,Texas","808,808,620,620,532,60,341,45,277,208,292,292,292,264,264,264,368,368,308,308,201,624",371.090909090909,38.7363636363636,24.8409090909091,11.5454545454545,6429235.27272727,63.9022727272727,13.0409090909091,"After","0",0.562727272727273,"Mixed","small",32.1101268588147,"acute","non-chronic","non-cancer","3","2","3","3","2","1","1","1","1","0","1","1","2","2","2","1","3","2",85.7286953197602,75.4772727272727,85.5127818181818,17.3772409090909,50.6545454545455,65.7329545454545,6114250.68181818,84.9250511585,47983.4545454545,19.7727272727273,1842813.81818182,15.4318181818182,8.99195064889601,"1","2","1","0","0","1","2","1","0","2","2","3","1","non-elderly",15.0765913096876,"general"
"131","NCT01339117",196,"Interventional",NA,2011-01-31,2017-12-31,"Delivered Dietary Intervention for Children With Irritable Bowel Syndrome",40,"Other",NA,66.6,30.3,3,33.3,67,NA,2011,2017,6,"North America",0,"United States","Non-Industry","Earlier 2013",4958507,"Low fermentable substrate diet, High fermentable substrate diet",0,"Non-opioids",33,22,10,1,11,NA,"chronic","kids",30.3030303030303,"yes",0.1213,3428210,"Mixed","kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas,Texas","624,624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","1",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","0","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,69.5,81.0773,17.7566,56.6,64.325,10077002,76.244536607,49047,33,2942701,17.4,9.43231929885351,"2","1","0","1","2","1","3","0","1","3","3","3","2","non-elderly",11.4614900181233,"kids"
"132","NCT01343927",197,"Interventional",NA,2012-06-30,2014-12-31,"Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations (Back to Health)",320,"NIH",NA,17.8,57.2,25,82.2,63.8,NA,2012,2014,2,"North America",0,"United States","Non-Industry","Earlier 2013",4958139,"Weekly yoga classes, Individual physical therapy treatment, Education",0,"Non-opioids",320,57,183,80,263,NA,"chronic","minority",57.1875,"yes",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts","45,45,45,45,45,45,45,45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","large",44.4377437165865,"non-acute","chronic","non-cancer","3","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,76,89.7075,22.3615,52.4,65.825,2826209,95.861080399,63656,3,425654,11.3,9.2587366295912,"3","2","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.40452569188991,"minority"
"133","NCT01350492",200,"Interventional",NA,2013-04-16,2019-06-18,"Impact of Exercise Training on Pain and Brain Function in Gulf War Veterans",77,"U.S. Fed","United States",93,7,0,7,20,54,2013,2019,6,"North America",0,"United States","Non-Industry","Earlier 2013",4957638,"Resistance Exercise Training",0,"Non-opioids",54,50,4,0,4,NA,"chronic","veterans",7.40740740740741,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"1",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","0",0.45,"R","small",30.1959597752958,"non-acute","chronic","non-cancer","1","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",86.2985410000457,77.8766338411077,78.7659,12.7665,53.3,68.5,2647111,90.9,51726,7,351135,13.5,5.85443389695935,"2","2","0","0","1","2","1","2","1","0","0","1","0","non-elderly",6.11444451429142,"veterans"
"134","NCT01358526",NA,"Interventional","Phase 3",2011-05-31,2012-11-30,"A Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Enriched Study Design to Assess the Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Pain Due to Chronic Low Back Pain Who Require Around-the-clock Opioid Therapy",1095,"Industry",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Industry",NA,4957024,NA,NA,"Opioids",600,462,114,24,138,"Late Phase","chronic",NA,19,"yes",0.121347222222222,1069751.86111111,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",22.6242374747907,8068.32450331126,22.6591766785486,87.0416464137703,22.3707153001198,92.1837218827006,85.5255507161661,90.0986754966887,9.90132450331126,"1",43239.8675496689,"Alabama,Alabama,Alabama,Alabama,Alabama,Arizona,Arizona,Arizona,Arizona,Arizona,Arkansas,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Colorado,Colorado,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Georgia,Idaho,Illinois,Indiana,Indiana,Indiana,Kansas,Kansas,Kentucky,Louisiana,Louisiana,Maryland,Maryland,Massachusetts,Massachusetts,Massachusetts,Michigan,Michigan,Michigan,Missouri,Missouri,Missouri,Nebraska,Nevada,New Jersey,New Jersey,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,North Dakota,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Oklahoma,Oklahoma,Oregon,Oregon,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Rhode Island,South Carolina,South Carolina,South Carolina,South Dakota,South Dakota,Tennessee,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Utah,Utah,Utah,Virginia,Virginia,Virginia,Washington","278,278,278,278,278,60,60,60,60,60,106,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,52,52,41,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,542,542,542,1,532,144,144,144,60,60,76,341,341,269,269,45,45,45,277,277,277,318,318,318,33,80,243,243,292,292,292,292,292,264,264,264,264,1,368,368,368,368,368,368,368,368,368,140,140,140,18,18,18,18,308,308,308,308,308,308,308,7,229,229,229,1,1,201,624,624,624,624,624,624,624,624,624,624,624,14,14,14,14,249,249,249,79",400.072847682119,39.0735099337748,22.6649635036496,10.9627737226277,6607093.33774834,64.4804635761589,12.6264900662252,"After",NA,0.562582781456954,"Mixed","large",31.9175078700229,"non-acute","chronic","non-cancer","3","2","1","2","2","2","2","1","2","1","1","1","2","1","2","1","2","2",87.062217368238,76.7715231788079,85.5642390728477,17.6001079470199,52.2165562913907,66.1144039735099,6228448.69536424,83.3628949470397,49321.5231788079,24.2919708029197,1689292.78807947,15.2496688741722,9.62972727256204,"2","2","1","0","1","1","2","0","1","2","2","2","2","non-elderly",12.3928258499333,"general"
"135","NCT01367249",202,"Interventional","Phase 3",2011-05-31,2011-12-31,"Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for the Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery.",440,"Industry","United States",75,9,16,25,65,440,2011,2011,0,"North America",0,"United States","Industry","Earlier 2013",4956363,"Bromfenac Ophthalmic Solution, Placebo",1,"Non-opioids",440,329,39,72,111,"Late Phase","acute",NA,8.86363636363636,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","large",34.3650287791398,"acute","non-chronic","non-cancer","3","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,76.6,81.0994,19.2392,47.1,55.3,13728423,80.271144403,53367,49,2148618,16.9,14.2617707647834,"3","2","0","1","0","0","3","0","2","3","2","3","3","non-elderly",5.70047494539412,"general"
"136","NCT01369680",204,"Interventional","Phase 1",2011-05-31,2012-10-31,"Oral Ketamine for Control of Chronic Pain in Children",12,"Other","United States",83,8,9,17,75,NA,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4956176,"Ketamine",1,"Non-opioids",12,10,1,1,2,"Early Phase","chronic","kids",8.33333333333333,"no",0.1566,3065470,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,79.7,85.0733,18.8331,50.8,53.6,8143255,87.824723438,50636,13,2808414,16,6.33298278377812,"2","2","1","1","0","0","3","2","1","1","3","3","0","non-elderly",14.4278735016142,"kids"
"137","NCT01377038",205,"Interventional",NA,2011-09-30,2015-07-31,"Central Pain Mechanisms in Osteoarthritis: A Longitudinal Cohort",0,"Other",NA,86.4,6.8,6.8,13.6,54.5,NA,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4955619,"Phenotype assessment",0,"Non-opioids",45,38,3,4,7,NA,"chronic","elderly",6.66666666666667,"no",0.1379,1374310,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan","277",277,37.9,23.2,9.1,4629611,73.025,11,"After","0",0.53,"R","small",29.5564246895313,"non-acute","chronic","non-cancer","1","2","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",86.1674818732829,79.6,88.7032,15.7211,41.9,74.075,4535204,87.537576134,48879,10,1372738,15,8.29877292639095,"1","2","3","0","0","3","2","1","1","1","1","2","1","elderly",13.899473551888,"elderly"
"138","NCT01383317",NA,"Interventional","N/A",2011-06-30,2017-04-30,"Remote Ischemic Preconditioning (RIPC) and Its Effect on the Postoperative Pain Experience Following Intra-abdominal Surgery",64,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4955141,NA,NA,"Non-opioids",64,41,12,11,23,NA,"acute",NA,18.75,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,72,84.8339,17.7204,51.2,68.325,4360685,83.69072238,45206,10,2064166,15.4,8.40197402658067,"1","1","1","0","0","2","1","0","0","1","2","3","1","non-elderly",21.3761421051176,"general"
"139","NCT01384448",206,"Interventional",NA,2011-08-31,2017-02-28,"A Randomized Trial Comparing Coronary CT Angiography and Stress Echocardiography for Evaluation of Low-to-Intermediate Risk Emergency Department Chest Pain Patients",400,"Other",NA,13,32,55,87,42.5,NA,2011,2017,6,"North America",0,"United States","Non-Industry","Earlier 2013",4955054,"Stress Echocardiography, Coronary CT Angiography",0,"Non-opioids",400,51,128,221,349,NA,"cardio",NA,32,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","large",37.275328091991,"non-acute","non-chronic","non-cancer","3","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,79.7,85.0733,18.8331,50.8,53.6,8143255,87.824723438,50636,13,2808414,16,6.33298278377812,"2","2","1","1","0","0","3","2","1","1","3","3","0","non-elderly",14.4278735016142,"general"
"140","NCT01385137",207,"Interventional","Phase 3",2012-02-29,2014-03-31,"S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III",262,"NIH",NA,87,8,5,13,100,NA,2012,2014,2,"North America",0,"United States","Non-Industry","Earlier 2013",4955001,"omega-3 fatty acid, placebo",0,"Non-opioids",249,217,20,12,32,"Late Phase","cancer","female",8.03212851405623,"yes",0.12278,1035624.02857143,"Mixed","non-kids","Non-Government","female","non-veterans",21.4268674839567,8084.15068493151,23.3444359620989,87.8927871396141,22.4786901360152,92.4282082781679,86.1150145022699,91.9020547945206,8.09794520547945,"0",42929.4212328767,"Alabama,Alaska,Alaska,Arkansas,Arkansas,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Colorado,Colorado,Colorado,Connecticut,Florida,Georgia,Georgia,Hawaii,Idaho,Idaho,Idaho,Idaho,Idaho,Idaho,Idaho,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Iowa,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kentucky,Louisiana,Louisiana,Louisiana,Louisiana,Maryland,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Mississippi,Mississippi,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Nebraska,New Mexico,New Mexico,New York,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,Tennessee,Texas,Texas,Texas,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Virginia,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington","278,7,7,106,106,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,52,52,52,41,620,542,542,2,1,1,1,1,1,1,1,532,532,532,532,532,144,144,34,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,76,341,341,341,341,269,45,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,208,208,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,1,1,1,1,1,1,1,1,1,1,33,8,8,292,292,292,292,292,292,264,264,264,264,264,264,264,264,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,18,18,18,18,18,18,18,18,18,18,18,18,18,229,229,229,229,229,229,229,229,229,229,229,229,229,229,201,624,624,624,14,14,14,14,14,14,14,14,14,249,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79",307.917525773196,38.6681506849315,21.8090534979424,9.5082304526749,5342366.83161512,65.2057363013699,11.8486301369863,"After","0",0.539212328767123,"Mixed","small",32.2450734640709,"non-acute","non-chronic","cancer","3","2","2","2","2","2","2","1","2","2","1","1","2","1","2","2","2","1",87.5939604189451,70.163698630137,87.4032359589041,18.2733619863014,52.7582191780822,65.2818493150685,5097258.48630137,85.3901294351849,51816.6917808219,15.5867158671587,1093768.57534247,14.5873287671233,10.0091444809618,"2","1","2","1","1","1","2","1","1","1","1","2","2","non-elderly",9.42905985514144,"female"
"141","NCT01400139",210,"Interventional","Phase 3",2011-07-31,2013-10-31,"An Open-label, Multicenter Study to Assess the Long -Term Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain",922,"Industry",NA,82,15,3,18,51,NA,2011,2013,2,"North America",0,"United States","Industry","Earlier 2013",4953857,"Hydrocodone bitartrate q24h film-coated tablets",1,"Opioids",922,761,141,20,161,"Late Phase","chronic",NA,15.29284164859,"yes",0.122909677419355,1161133.03225806,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",25.5640896170542,8078.22448979592,22.9683848900125,86.989432805968,21.9934392000792,91.982832881407,85.2385472312806,89.6744897959184,10.3255102040816,"1",42933.612244898,"Alabama,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Illinois,Indiana,Indiana,Iowa,Kansas,Kentucky,Kentucky,Louisiana,Massachusetts,Massachusetts,Michigan,Missouri,Missouri,Missouri,Missouri,Nebraska,Nevada,Nevada,New Jersey,New Jersey,New Mexico,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Oklahoma,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Carolina,South Dakota,Tennessee,Tennessee,Tennessee,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Utah,Virginia,Washington,Washington","278,60,60,60,808,808,808,808,808,808,808,808,808,808,808,41,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,532,144,144,34,60,76,76,341,45,45,277,318,318,318,318,33,80,80,243,243,8,292,292,292,292,292,264,264,264,264,368,368,368,368,140,308,308,308,308,308,229,229,229,1,201,201,201,624,624,624,624,624,624,624,624,624,624,624,14,14,249,79,79",396.387755102041,39.1510204081633,22.9333333333333,10.9258064516129,6710935.94845361,64.4066326530612,12.7755102040816,"After",NA,0.56734693877551,"Mixed","large",31.5933474483522,"non-acute","chronic","non-cancer","3","2","2","2","2","2","2","1","2","1","0","1","2","1","2","1","2","2",86.7060883800242,75.8612244897959,85.2913336734694,17.4060663265306,52.6285714285714,66.0012755102041,6247228.68367347,83.0838840565204,48615.5918367347,23.5777777777778,1746222.2755102,15.4734693877551,9.26080023369984,"2","2","1","0","1","1","2","0","1","2","2","3","2","non-elderly",12.4694241761515,"general"
"142","NCT01402570",211,"Interventional",NA,2011-08-31,2013-07-31,"Oral Glutathione and Health Outcomes Among Persons With Post-Polio Syndrome",20,"Other","United States",90,10,0,10,NA,NA,2011,2013,2,"North America",0,"United States","Non-Industry","Earlier 2013",4953671,"Glutathione",0,"Non-opioids",20,18,2,0,2,NA,"chronic",NA,10,"no",0.1379,1374310,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan","277",277,37.9,23.2,9.1,4629611,73.025,11,"After","0",0.53,"R","small",29.5564246895313,"non-acute","chronic","non-cancer","0","2","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",86.1674818732829,79.6,88.7032,15.7211,41.9,74.075,4535204,87.537576134,48879,10,1372738,15,8.29877292639095,"1","2","3","0","0","3","2","1","1","1","1","2","1","non-elderly",13.899473551888,"general"
"143","NCT01411995",212,"Interventional",NA,2011-08-31,2011-12-31,"Randomized Controlled Trial of Cervical Lidocaine for Intrauterine Device Insertion Pain",200,"Other","United States",53,38,9,47,100,199,2011,2011,0,"North America",0,"United States","Non-Industry","Earlier 2013",4952950,"2% lidocaine gel, Water based lubricant",1,"Non-opioids",199,105,75,19,94,NA,"acute","female",37.6884422110553,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"acute","non-chronic","non-cancer","2","2","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,72.4,87.7113,16.2926,55,71.15,2719902,85.123648431,45774,16,684018,15.4,6.97619334002276,"1","1","2","0","1","3","1","1","0","1","0","3","0","non-elderly",11.3800283761193,"female"
"144","NCT01419314",NA,"Interventional","N/A",2011-08-31,2012-06-30,"Lower Extremity Splinting to Manage Pain and Sleep Disturbances Associated With HIV/AIDS Related Peripheral Neuropathy",46,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4952398,NA,NA,"Non-opioids",45,15,24,6,30,NA,"chronic",NA,53.3333333333333,"no",0.1213,3428210,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","1","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,69.5,81.0773,17.7566,56.6,64.325,10077002,76.244536607,49047,33,2942701,17.4,9.43231929885351,"2","1","0","1","2","1","3","0","1","3","3","3","2","non-elderly",11.4614900181233,"general"
"145","NCT01429285",215,"Interventional","Phase 4",2009-07-31,2012-06-30,"Safety and Efficacy of Intravenous Hydromorphone Using Incremental Doses of 0.5 mg in Elderly ED Patients With Acute Severe Pain",350,"Other","United States",10,25,65,90,67,319,2009,2012,3,"North America",0,"United States","Non-Industry","Earlier 2013",4951637,"Hydromorphone, Usual care",1,"Opioids",319,31,79,209,288,"Late Phase","acute","elderly",24.7648902821317,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before",NA,0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","1","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,76.9,85.0733,18.8331,51.1,54.375,897343,85.8831174991195,50216,17,2792447,15.8,6.33298278377812,"0","2","1","1","0","0","0","1","1","2","3","3","0","elderly",14.3997846978615,"elderly"
"146","NCT01429298",216,"Interventional","Phase 4",2010-03-31,2010-11-30,"Randomized Clinical Trial Comparing Intravenous Hydromorphone to Usual Care",350,"Other","United States",7,24,69,93,59,325,2010,2010,0,"North America",0,"United States","Non-Industry","Earlier 2013",4951636,"Hydromorphone, Usual care",1,"Opioids",325,22,79,224,303,"Late Phase","acute",NA,24.3076923076923,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"Before",NA,0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",81.3,64.3,85.0733,18.8331,51.5,54.45,8115218,84.916585934,49781,6,2792447,16,6.33298278377812,"0","0","1","1","0","0","3","1","1","0","3","3","0","non-elderly",14.3997846978615,"general"
"147","NCT01438203",217,"Interventional","Phase 2",2011-02-28,2012-02-29,"Early Use of Thrust Manipulation Versus Non-Thrust Manipulation: A Randomized Clinical Trial",149,"Other",NA,91.4,2,6.6,8.6,53,NA,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4950958,"Thrust manipulation, Non-thrust manipulation",0,"Non-opioids",149,136,3,8,11,"Early Phase","chronic",NA,2.01342281879195,"no",0.1241,1446190,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"non-acute","chronic","non-cancer","2","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,75,88.3686,15.5867,48.5,68.9,5134668,86.316692631,44648,20,1380254,15.1,7.8918800096186,"1","1","2","0","0","2","2","1","0","2","1","2","1","non-elderly",11.9554773337713,"general"
"148","NCT01444924",218,"Interventional","Phase 2",2011-09-30,2013-03-31,"Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial",75,"Other","United States",94,6,0,6,100,64,2011,2013,2,"North America",0,"United States","Non-Industry","Earlier 2013",4950445,"Bupivicaine, Placebo",1,"Non-opioids",64,60,4,0,4,"Early Phase","cancer","female",6.25,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"0",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","0",0.45,"R","small",30.1959597752958,"non-acute","non-chronic","cancer","1","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",86.2985410000457,80.3,90.4802,17.2444,48.3,68.5,2632919,89.6380005175961,52058,4,349932,13.1,5.85443389695935,"2","3","3","0","0","2","1","2","1","0","0","1","0","non-elderly",6.12651041262713,"female"
"149","NCT01446419",219,"Interventional",NA,2011-10-31,2016-03-31,"A Prospective Randomized, Double-blind, Controlled Investigation Evaluating the Intracept Intraosseous Nerve Ablation System for the Reduction of Pain in Patients With Chronic Axial Low Back Pain",225,"Industry","Germany",91,4,5,9,NA,NA,2011,2016,5,"North America",0,"United States","Industry","Earlier 2013",4950342,"Intracept Treatment, Sham Treatment",0,"Non-opioids",225,205,8,12,20,NA,"chronic",NA,3.55555555555556,"yes",0.120281818181818,1514532.36363636,"Mixed","non-kids","Non-Government","non-female","non-veterans",17.7233574279641,8763.07692307692,21.2270356471666,87.3616151475821,23.5042778671454,92.2542888395451,85.9147964483559,90.7,9.3,"0",44488.6153846154,"Arizona,California,California,California,Georgia,Indiana,Maine,Michigan,North Carolina,Oregon,Pennsylvania,Texas,Virginia","60,808,808,808,542,144,4,277,264,18,308,624,249",378,38.7307692307692,21.2181818181818,10.0909090909091,6614576.46153846,64.4442307692308,12.5076923076923,"After","0",0.536923076923077,"Mixed","small",32.2696077626521,"non-acute","chronic","non-cancer","3","2","1","1","2","1","2","2","2","2","1","2","2","1","2","1","2","1",87.4459000613651,76.4384615384615,85.5137615384615,17.8466,50.3923076923077,65.8711538461538,6254423.76923077,83.9778745176154,50462.8461538462,23.9090909090909,1507061.07692308,15.5,10.8867109132917,"2","2","1","1","0","1","2","1","1","2","1","3","3","non-elderly",10.7088130237683,"general"
"150","NCT01451606",220,"Interventional","Phase 4",2011-07-11,2015-11-04,"Evaluating Duloxetine's Analgesic Effectiveness in Chronic Pelvic Pain",34,"Other","United States",29,62,9,71,100,34,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4949947,"Duloxetine, Placebo",1,"Non-opioids",34,10,21,3,24,"Late Phase","chronic","female",61.7647058823529,"no",0.2989,1799090,"GOVERNMENT","non-kids","Government","female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"1",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","0","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,81.4,89.018,20.4528,60.2,69.7,2386743,86.191573981,68876,15,1696598,9.3,10.8327699960329,"3","3","3","2","3","3","1","1","3","1","2","0","2","non-elderly",29.1097095562694,"female"
"151","NCT01452529",221,"Interventional","Phase 3",2011-10-31,2013-10-31,"A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of Hydrocodone Bitartrate (HYD) Tablets 20 to 120 mg Once-daily in Subjects With Moderate to Severe Chronic Low Back Pain",905,"Industry",NA,70,20,10,30,59,NA,2011,2013,2,"North America",0,"United States","Industry","Earlier 2013",4949876,"Hydrocodone bitartrate q24h film-coated tablets, Placebo to match hydrocodone bitartrate q24h tablets",1,"Opioids",588,402,118,68,186,"Late Phase","chronic",NA,20.0680272108844,"yes",0.128409375,1181069.1875,"Mixed","non-kids","Non-Government","non-female","non-veterans",22.767635474862,7233.71568627451,22.621819237602,86.7170923137252,21.7557286713785,91.9427021008732,85.1450967055486,89.9450980392157,10.0549019607843,"1",42699.0098039216,"Alabama,Alabama,Arizona,Arizona,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Georgia,Illinois,Indiana,Indiana,Iowa,Kansas,Kentucky,Kentucky,Louisiana,Maryland,Massachusetts,Massachusetts,Michigan,Michigan,Missouri,Missouri,Missouri,Missouri,Missouri,Nebraska,Nevada,Nevada,New Jersey,New Jersey,New Mexico,New Mexico,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Oklahoma,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Dakota,Tennessee,Tennessee,Tennessee,Tennessee,Texas,Texas,Texas,Texas,Texas,Utah,Utah,Virginia,Washington,Washington","278,278,60,60,60,60,60,808,808,808,808,808,808,808,808,808,808,41,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,542,532,144,144,34,60,76,76,341,269,45,45,277,277,318,318,318,318,318,33,80,80,243,243,8,8,292,292,292,292,264,264,264,264,368,368,368,368,140,308,308,308,308,229,229,1,201,201,201,201,624,624,624,624,624,14,14,249,79,79",378.21568627451,39.093137254902,22.209375,10.8791666666667,6212729.14851485,65.0262254901961,12.8303921568627,"After",NA,0.566078431372549,"Mixed","large",31.4345719916566,"non-acute","chronic","non-cancer","3","2","2","2","2","1","2","1","2","1","1","1","2","1","2","1","2","2",86.6516158884779,76.3362745098039,85.6245284313726,17.2499421568627,52.4480392156863,66.6397058823529,5810213.23529412,83.3975161133431,48384.0098039216,22.989010989011,1667805,15.3764705882353,9.26725437149075,"2","2","1","0","1","2","2","0","0","2","2","3","2","non-elderly",12.8337359238525,"general"
"152","NCT01453452",222,"Interventional",NA,2012-03-31,2017-01-31,"S1008: Feasibility Study of a Physical Activity and Dietary Change Weight Loss Intervention In Breast and Colorectal Cancer Survivors, Phase II",50,"NIH",NA,85,8,7,15,100,NA,2012,2017,5,"North America",0,"United States","Non-Industry","Earlier 2013",4949805,"behavioral dietary intervention, exercise intervention, counseling intervention, quality-of-life assessment",0,"Non-opioids",48,41,4,3,7,NA,"cancer","female",8.33333333333333,"yes",0.10432,1409529.1,"Mixed","non-kids","Non-Government","female","non-veterans",20.7673021894756,10629.3275862069,22.6981151582246,88.2332806237157,22.9743546434674,92.8506545877059,86.2283324773993,91.3568965517241,8.64310344827586,"0",44564.5517241379,"Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Hawaii,Illinois,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Michigan,Michigan,New York,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,Texas,Washington,Washington,Washington","60,60,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,2,532,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,277,277,292,229,229,229,229,229,229,229,624,79,79,79",380.551724137931,38.5068965517241,18.9754385964912,8.69473684210526,6780240.44827586,63.4948275862069,11.9655172413793,"After","0",0.537758620689655,"Mixed","small",33.0654716147201,"non-acute","non-chronic","cancer","1","2","1","2","3","2","2","2","3","2","1","2","2","0","2","1","2","1",87.4529028021202,69.251724137931,85.9052775862069,18.9523396551724,51.3931034482759,61.3637931034483,6478014.20689655,84.9833140041724,52527.0689655172,18.1228070175439,1189638.79310345,15.1310344827586,9.35802614745949,"2","1","2","1","0","0","2","1","2","2","1","2","2","non-elderly",8.72228091069927,"female"
"153","NCT01455519",NA,"Interventional","Phase 4",2011-10-31,2014-12-31,"True Functional Restoration and Analgesia in Non-Radicular Low Back Pain: a Prospective Double Blind, Placebo-controlled Study of Hydromorphone ER",51,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4949646,NA,NA,"Opioids",35,9,21,5,26,"Late Phase","chronic",NA,60,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"1",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"non-acute","chronic","non-cancer","0","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,78.2,87.2843,19.2183,46.1,68.4,5302784,85.261702238,50637,36,1843317,14.2,6.03837995473793,"2","2","2","1","0","2","2","1","1","3","2","2","0","non-elderly",14.3234120938898,"general"
"154","NCT01462435",223,"Interventional","Phase 3",2011-10-31,2012-08-31,"A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Active- and Placebo-Controlled Study of Diclofenac [Test] Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy",428,"Industry","United States",77,19,4,23,87,NA,2011,2012,1,"North America",0,"United States","Industry","Earlier 2013",4949120,"Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib, Placebo",1,"Non-opioids",428,329,82,17,99,"Late Phase","acute",NA,19.1588785046729,"yes",0.119275,1395402.75,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.0344697475944,4469.25,23.6273824301206,89.5736920051706,25.6475263545754,93.8228749094436,87.4849477991076,88.65,11.35,"1",50823.25,"Arizona,Maryland,Texas,Utah","60,269,624,14",241.75,39.2,20.4,9.83333333333333,4490792.75,67.2125,10.775,"After","0",0.5875,"Mixed","large",33.9178723836309,"acute","non-chronic","non-cancer","3","2","1","1","1","2","3","3","3","3","0","3","1","0","1","2","1","2",89.3532619450678,77.9,86.636225,18.828925,61.35,67.85625,4078655.5,82.61683182975,55509.25,24,1229513.25,13.725,9.65786408306117,"3","2","2","1","3","2","1","0","2","2","1","1","2","non-elderly",11.3606109003346,"general"
"155","NCT01467843",224,"Interventional","Phase 3",2012-06-30,2015-11-30,"Comparison of CAM and Conventional Mind-Body Therapies for Chronic Back Pain",342,"Other",NA,82.5,3.3,14.2,17.5,65.7,NA,2012,2015,3,"North America",0,"United States","Non-Industry","Earlier 2013",4948708,"Cognitive Behavioral Therapy, Mindfulness Based Stress Reduction",0,"Non-opioids",341,278,11,52,63,"Late Phase","chronic",NA,3.2258064516129,"no",0.038,281683,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",36.3274444869134,9176,31.6889445945946,89.9549312007655,27.2652644054344,94.6878709316023,90.128095190568,93.4,6.6,"0",52742,"Washington","79",79,40.1,19.5,7.1,3195004,63.75,10.3,"After","0",0.45,"D","large",36.6505101649993,"non-acute","chronic","non-cancer","3","2","0","3","2","3","3","3","3","3","2","3","0","0","1","1","0","0",91.3957683421682,76.1,90.5973,20.5907,61.1,63.5,2929600,86.431036807,62187,3,239399,11.6,13.486176059384,"3","2","3","2","3","1","1","1","3","0","0","0","3","non-elderly",3.47105384186659,"general"
"156","NCT01471639",225,"Interventional",NA,2011-11-30,2012-06-30,"A Prospective, Open-label, Nonrandomized Efficacy and Safety Trial of Intranasal Ketorolac in Emergency Department Patients for the Treatment of Acute Pain",37,"Other","United States",35,65,0,65,62,37,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4948430,"intranasal ketorolac",1,"Non-opioids",37,13,24,0,24,NA,"acute",NA,64.8648648648649,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","1","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,75,88.3686,15.5867,48.5,68.9,5134668,86.316692631,44648,20,1380254,15.1,7.8918800096186,"1","1","2","0","0","2","2","1","0","2","1","2","1","non-elderly",11.9554773337713,"general"
"157","NCT01473615",226,"Interventional",NA,2011-11-30,2014-06-30,"Mindfulness Based Cognitive Therapy for Chronic Pain and Comorbid Unipolar Depression",60,"Other",NA,90,10,0,10,75,NA,2011,2014,3,"North America",0,"United States","Non-Industry","Earlier 2013",4948271,"Mindfulness Based Cognitive Therapy",0,"Non-opioids",40,36,4,0,4,NA,"chronic",NA,10,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","1",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","1","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.5,89.054,22.2431,55.3,65.3,2817715,96.63637334,63313,4,406157,10.6,9.2587366295912,"3","3","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.16553746347648,"general"
"158","NCT01480089",NA,"Interventional","Phase 4",2011-11-30,2013-02-28,"Surgical Pain Control With Ropivacaine by Atomized Delivery",56,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4947777,NA,NA,"Non-opioids",55,43,7,5,12,"Late Phase","acute",NA,12.7272727272727,"no",0.142,1813590,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","1","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,78.2,87.2843,19.2183,46.1,68.4,5302784,85.261702238,50637,36,1843317,14.2,6.03837995473793,"2","2","2","1","0","2","2","1","1","3","2","2","0","non-elderly",14.3234120938898,"general"
"159","NCT01484652",NA,"Interventional","Phase 3",2011-11-30,2012-09-30,"A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension",329,"Industry",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Industry",NA,4947427,NA,NA,"Non-opioids",329,201,98,30,128,"Late Phase","acute",NA,29.7872340425532,"yes",0.1225,1884564.75,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",22.2989231229835,12732.6,23.930825195139,90.0943617421697,26.3077127316484,94.1529574480825,88.2354548895191,90.1,9.9,"1",51916.2,"California,California,Maryland,Texas,Utah","808,808,269,624,14",504.6,39.2,24.825,10.975,8723972.4,62.535,10.74,"After",NA,0.56,"Mixed","large",34.9579903322437,"acute","non-chronic","non-cancer","3","2","1","2","3","2","3","3","3","3","1","3","3","2","3","1","1","2",89.8627606905368,77.76,84.60588,19.35624,57.4,63.205,8182298,81.6678416322,56030,36.5,1792998.6,14.3,12.2275564711158,"3","2","1","1","2","1","3","0","2","3","2","2","3","non-elderly",10.5964587001377,"general"
"160","NCT01495858",229,"Interventional","Phase 3",2011-12-31,2012-02-29,"A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium and Diphenhydramine Combination in Postsurgical Dental Pain With Phase Advanced Sleep",267,"Industry",NA,87,6,7,13,65,NA,2011,2012,1,"North America",0,"United States","Industry","Earlier 2013",4946570,"Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111), Naproxen Sodium 440 mg (BAYH6689), DPH 50 mg",1,"Non-opioids",267,234,17,16,33,"Late Phase","acute","kids",6.36704119850187,"yes",0.0666,1732529.5,NA,"kids",NA,"non-female","non-veterans",12.9552907511195,5974.5,24.3950849511503,89.2398523990309,23.7788973226473,94.3715405082215,87.4852544562023,85.95,14.05,"0",44162,"Texas,Utah","624,14",319,39.85,26.5,9.3,6208437,67.125,10.8,"After",NA,0.64,"R","small",32.6611018288079,"acute","non-chronic","non-cancer","3","2","0","1","1","3","3","2","3","3","0","2","2","3","2","2","1","3",89.8496184325011,77.1,85.9063,18.925,66.3,67.8625,5533950.5,80.802672687,52270,33,1485579.5,14.2,10.8907354149896,"3","2","2","1","3","2","2","0","1","3","1","2","3","non-elderly",6.23581702681531,"kids"
"161","NCT01505101",231,"Interventional","Phase 1",2011-10-31,2013-07-31,"Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy: Exploration of Cognitive, Affective, and Physiological Mechanisms",115,"Other",NA,74.5,21.8,3.7,25.5,61.8,NA,2011,2013,2,"North America",0,"United States","Non-Industry","Earlier 2013",4945864,"Mindfulness-Oriented Recovery Enhancement, Conventional Support Group (SG)",0,"Non-opioids",55,41,12,2,14,"Early Phase","chronic",NA,21.8181818181818,"no",0.1607,3359030,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"1",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"After","0",0.54,"R","small",30.4516559104648,"non-acute","chronic","non-cancer","1","2","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",87.4857684869649,78.8,85.9484,16.5154,51.3,68.975,9020844,80.196753723,45105,36,2922969,14.9,10.0831815208954,"2","2","2","0","0","2","3","0","0","3","3","2","2","non-elderly",15.3375970521277,"general"
"162","NCT01506453",232,"Interventional","Phase 2",2012-01-24,2018-01-02,"Therapeutic Interventions For Peripheral Neuropathy/Neuropathic Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL) On Total XVI Protocol",51,"Other","United States",86,6,8,14,41,51,2012,2018,6,"North America",0,"United States","Non-Industry","Earlier 2013",4945760,"gabapentin, placebo",1,"Non-opioids",51,44,3,4,7,"Early Phase","cancer","kids",5.88235294117647,"no",0.1676,1124470,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",4.52218646785983,2324,20.9540659574468,85.8662841877553,19.9805891026834,89.389189315855,82.3504396793573,89.9,10.1,"0",38791,"Tennessee","201",201,40,13.9,8.6,3028213,68.775,12.6,"After","0",0.73,"R","small",27.3673170485781,"non-acute","non-chronic","cancer","1","2","3","0","0","1","1","0","0","0","1","1","0","0","1","3","2","3",82.6746073431892,64.6,85.092,15.7881,55.4,67.95,2839707,86.122072599,42995,13,1084643,18.6,9.83923120462473,"1","0","1","0","2","2","1","1","0","1","1","3","2","non-elderly",16.7999097927386,"kids"
"163","NCT01517295",234,"Interventional","Phase 4",2012-02-29,2012-09-30,"Evaluating the Pharmacokinetic Profile of Hydromorphone in Chronic Pain Patients Taking Hydrocodone/APAP",30,"Industry","United States",93,7,0,7,70,30,2012,2012,0,"North America",0,"United States","Industry","Earlier 2013",4944938,"Hydrocodone",1,"Opioids",30,28,2,0,2,"Late Phase","chronic",NA,6.66666666666667,"yes",0.1096,1764660.5,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.81244150363773,4273.5,21.4694162660256,85.0735370355051,20.1950864355634,92.6424364576718,84.9877916094945,88.8,11.2,"0",39890.5,"Florida,Kansas","620,60",340,38.7,15.9,7.65,5481041.5,67.6125,12.2,"After","1",0.545,"R","small",31.9189890858908,"non-acute","chronic","non-cancer","0","2","1","0","1","1","0","0","2","1","0","1","2","0","2","2","2","1",86.7127559576191,71.6,88.25745,18.2716,54.25,65.1125,5145993,82.9504216085,48037,20,1560580.5,14.65,7.48675403195628,"2","1","2","1","1","1","2","0","0","2","1","2","1","non-elderly",10.4744526978538,"general"
"164","NCT01524913",236,"Interventional","Phase 4",2012-01-31,2016-04-30,"A Double Blind Randomised Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint Dysfunction",102,"Other","United States",75,19,6,25,87,102,2012,2016,4,"North America",0,"United States","Non-Industry","Earlier 2013",4944355,"Hyaluronic acid, Corticosteroid, Lactated Ringers",1,"Non-opioids",102,76,19,7,26,"Late Phase","chronic",NA,18.6274509803922,"yes",0.1258,1703731.8,"Mixed","non-kids","Non-Government","non-female","non-veterans",23.1969553481118,8334.8,22.8617657483772,88.048202619514,23.3018133868218,92.1012406237624,86.096250718888,91.86,8.14,"1",41999.6,"California,Georgia,Ohio,Oregon,Pennsylvania","808,542,368,18,308",408.8,38.7,21.375,9.775,6303737.8,63.805,12.42,"After","0",0.548,"Mixed","small",32.2569235748353,"non-acute","chronic","non-cancer","2","2","2","2","2","2","2","2","2","2","1","1","2","1","2","1","2","1",87.511517570956,70.86,86.90778,17.89566,50.98,64.755,6063577.8,84.6562740304,50639,21,1594650.8,15.36,11.1874167376946,"2","1","2","1","0","1","2","1","1","2","1","3","3","non-elderly",12.0814503754843,"general"
"165","NCT01533428",237,"Interventional","Phase 3",2012-02-29,2014-02-28,"A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study Evaluating the Efficacy and Safety of QUTENZA® in Subjects With Painful Diabetic Peripheral Neuropathy",369,"Industry",NA,72,20,8,28,42,NA,2012,2014,2,"North America",0,"United States","Industry","Earlier 2013",4943712,"Capsaicin 8%, Placebo",1,"Non-opioids",369,263,74,32,106,"Late Phase","chronic",NA,20.0542005420054,"yes",0.129666666666667,1673355.16666667,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",23.2724574705469,10038.8965517241,22.8140322745676,87.4311069665257,23.1342303861425,92.532226455489,85.7716394253769,88.8931034482759,11.1068965517241,"1",45482.9310344828,"Alabama,California,California,California,California,California,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Hawaii,Massachusetts,Michigan,Missouri,New York,North Carolina,Ohio,Texas,Texas,Texas,Texas,Texas,Texas","278,808,808,808,808,808,41,41,620,620,620,620,620,620,620,620,2,45,277,318,292,264,368,624,624,624,624,624,624",505.862068965517,39.051724137931,25.2571428571429,13.0607142857143,8674802.65517241,62.9215517241379,12.7655172413793,"After",NA,0.546896551724138,"Mixed","large",32.2969521011837,"non-acute","chronic","non-cancer","3","2","2","2","2","2","2","2","2","2","0","2","3","2","3","1","2","1",87.3612962821307,68.8827586206897,85.0866517241379,18.2099413793103,52.5206896551724,64.1862068965517,8129621.75862069,82.1945559874483,51396.1379310345,30.2857142857143,2181344.4137931,15.3275862068966,10.2278137212826,"2","0","1","1","1","1","3","0","1","3","3","3","2","non-elderly",11.9514613864123,"general"
"166","NCT01534416",NA,"Interventional","N/A",2011-09-30,2013-09-30,"Use of Paracervical Block in Laparoscopic Gynecologic Surgery: A Randomized Controlled Trial",132,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4943639,NA,NA,"Non-opioids",132,64,32,37,69,NA,"acute","female",24.2424242424242,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,79.7,85.0733,18.8331,50.8,53.6,8143255,87.824723438,50636,13,2808414,16,6.33298278377812,"2","2","1","1","0","0","3","2","1","1","3","3","0","non-elderly",14.4278735016142,"female"
"167","NCT01534520",238,"Interventional",NA,2012-06-30,2013-05-31,"Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women: a Randomized Controlled Trial",61,"Other",NA,81,8,11,19,100,NA,2012,2013,1,"North America",0,"United States","Non-Industry","Earlier 2013",4943631,"Lidocaine, Placebo",1,"Non-opioids",59,48,5,6,11,NA,"acute","female",8.47457627118644,"no",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","1","2","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,71.8,88.9364,17.1477,52.3,71,5599169,88.019549326,51904,21,1340316,13.9,12.1914636349471,"1","1","3","0","1","3","2","2","1","2","1","2","3","non-elderly",10.5011338550696,"female"
"168","NCT01535066",239,"Interventional",NA,2012-03-27,2018-07-31,"Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women With Early Stage Breast Cancer",226,"NIH",NA,85.4,4.4,10.2,14.6,100,NA,2012,2018,6,"North America",0,"United States","Non-Industry","Earlier 2013",4943592,"acupuncture therapy, sham acupuncture",0,"Non-opioids",226,193,10,23,33,NA,"cancer","female",4.42477876106195,"yes",0.0858111111111111,998835.111111111,"Mixed","non-kids","Non-Government","female","non-veterans",25.8595538720017,12702.7659574468,22.9577132406519,88.4653576357067,23.3538343253833,93.1161769357897,86.8711864598767,92.1765957446809,7.82340425531915,"0",44932.2553191489,"California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Idaho,Idaho,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,New York,Oregon,Oregon,Oregon,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,Utah,Washington,Washington,Washington","808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,1,1,45,277,277,277,277,277,277,277,277,292,18,18,18,229,229,229,229,229,229,229,229,14,79,79,79",443.659574468085,38.5936170212766,23.880487804878,10.6390243902439,7918152.06382979,63.1058510638298,12.0340425531915,"After","0",0.52936170212766,"Mixed","small",32.6325280507084,"non-acute","non-chronic","cancer","3","2","1","2","3","2","2","2","3","2","1","2","3","1","2","1","2","1",88.1956005943527,70.0574468085106,85.3611021276596,18.4664829787234,49.2808510638298,63.5420212765957,7580085.12765957,84.9578027024043,53258.1914893617,20.8222222222222,1459297.59574468,14.9957446808511,11.4735167026871,"2","1","1","1","0","1","3","1","2","2","1","2","3","non-elderly",10.2588159957032,"female"
"169","NCT01553201",NA,"Interventional","Phase 1/Phase 2",2014-07-30,2019-07-24,"The Effectiveness of Botulinum Toxin on Persistent Pelvic Pain in Women With Endometriosis",30,"NIH",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4942208,NA,NA,"Non-opioids",29,23,3,3,6,"Early Phase","chronic","female",10.3448275862069,"no",0.2989,1799090,"GOVERNMENT","non-kids","Government","female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","0","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,89.7927,27.8278,59.5,66.225,2416438,92.1,76165,19,1744971,9.8,10.8327699960329,"3","3","3","3","3","1","1","3","3","2","2","0","2","non-elderly",29.1976600656548,"female"
"170","NCT01559454",241,"Interventional","Phase 4",2012-02-29,2014-05-31,"A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients",19,"Other","United States",79,16,5,21,68,19,2012,2014,2,"North America",0,"United States","Non-Industry","Earlier 2013",4941732,"Methadone, Buprenorphine/naloxone",1,"Opioids",19,15,3,1,4,"Late Phase","chronic",NA,15.7894736842105,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,69.1,85.3723,19.1611,50.6,53.575,8170062,88.694462729,47680,25,2820905,17.2,6.33298278377812,"2","1","1","1","0","0","3","2","0","2","3","3","0","non-elderly",14.4142431212338,"general"
"171","NCT01569438",243,"Interventional","Phase 2",2012-04-13,2014-05-14,NA,74,"Industry","United States",86,8,6,14,100,74,2012,2014,2,"North America",0,"United States","Industry","Earlier 2013",4940971,"Gefapixant, Placebo",1,"Non-opioids",107,92,11,4,15,"Early Phase","chronic","female",10.2803738317757,"yes",0.145178947368421,1480748.15789474,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",22.0070692920581,7050.73170731707,22.391340608865,87.3656820470656,21.84535973973,91.6706268518475,85.0535775300582,90.6804878048781,9.31951219512195,"0",42419.1707317073,"Alabama,Alabama,Alabama,Arizona,California,California,California,California,Connecticut,Connecticut,Florida,Florida,Idaho,Idaho,Idaho,Louisiana,Maryland,Michigan,Michigan,Michigan,Michigan,New Jersey,New Mexico,New York,New York,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Ohio,Ohio,Pennsylvania,Pennsylvania,South Carolina,Texas,Texas,Texas,Texas,Utah,Virginia","278,278,278,60,808,808,808,808,41,41,620,620,1,1,1,341,269,277,277,277,277,243,8,292,292,264,264,264,368,368,368,368,308,308,229,624,624,624,624,14,249",338.341463414634,38.4878048780488,24.3,12.3888888888889,5740122.82926829,65.865243902439,12.6731707317073,"After",NA,0.573658536585366,"Mixed","small",31.4600232195461,"non-acute","chronic","non-cancer","2","2","2","2","2","1","2","1","1","1","1","1","2","2","2","2","2","2",86.400253396022,69.5146341463415,86.2936707317073,17.6469243902439,53.0585365853659,67.0591463414634,5443349.87804878,84.4490174739512,50424.8780487805,20.5675675675676,1565281.7804878,15.190243902439,9.67824229397895,"2","1","2","0","1","2","2","1","1","2","1","2","2","non-elderly",13.2467777445805,"female"
"172","NCT01583179",NA,"Interventional","N/A",2012-04-30,2015-12-31,"Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution",26,"Other",NA,NA,NA,NA,NA,NA,NA,2012,NA,NA,"North America",NA,"United States","Non-Industry",NA,4939926,NA,NA,"Non-opioids",26,22,1,3,4,NA,"acute",NA,3.84615384615385,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"0",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","0",0.45,"R","small",30.1959597752958,"acute","non-chronic","non-cancer","0","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",6.15884540334081,"general"
"173","NCT01583985",244,"Interventional",NA,2013-06-01,2017-05-31,"Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) Trial",265,"U.S. Fed","United States",86,8,6,14,30,240,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4939866,"Opioid-intensive prescribing strategy, Opioid-avoidant prescribing strategy",0,"Opioids",240,207,18,15,33,NA,"chronic","veterans",7.5,"no",0.0641,356515,"GOVERNMENT","non-kids","Government","non-female","veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"1",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"After","0",0.49,"R","small",37.1630582351401,"non-acute","chronic","non-cancer","3","2","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",89.2519769380513,80.1058558348779,79.9482,17.8137,60,73.4,2375704,91.8,64324,3,289817,11,7.83802073605776,"2","2","0","1","3","3","1","3","3","0","0","0","1","non-elderly",5.34680225371653,"veterans"
"174","NCT01588197",245,"Interventional",NA,2010-11-30,2016-12-31,"Real-Time fMRI Feedback Effects on Pain Perception",20,"Other","United States",94,6,0,6,50,18,2010,2016,6,"North America",0,"United States","Non-Industry","Earlier 2013",4939549,"Attention/Distraction Strategy, Stimulus Quality/Severity Strategy, Control Strategy",0,"Non-opioids",18,17,1,0,1,NA,"acute","healthy",5.55555555555556,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","non-female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"0",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"Before","0",0.7,"R","small",28.2226091262223,"acute","non-chronic","non-cancer","0","2","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",76.1,57.5,84.2453,15.6606,48.4,74.8,2140804,79.51539959,41698,13,1294689,16.9,6.67607176575867,"0","0","1","0","0","3","0","0","0","1","1","3","0","non-elderly",27.924975713455,"general"
"175","NCT01595282",247,"Interventional",NA,2011-06-30,2012-06-30,"Intramuscular Ketorolac Versus Oral Ibuprofen for Pain Relief in First Trimester Suction Curettage: a Randomized Clinical Trial.",94,"Other","United States",27,39,34,73,100,94,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4939010,"Ketorolac, Ibuprofen",1,"Non-opioids",94,25,37,32,69,NA,"acute","female",39.3617021276596,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After",NA,0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","2","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.5,89.054,22.2431,55.3,65.3,2817715,96.63637334,63313,4,406157,10.6,9.2587366295912,"3","3","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.16553746347648,"female"
"176","NCT01598298",248,"Interventional","Phase 3",2013-05-15,2018-02-28,"A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer",299,"NIH",NA,86,9,5,14,100,NA,2013,2018,5,"North America",0,"United States","Non-Industry","Earlier 2013",4938779,"duloxetine hydrochloride, placebo",1,"Non-opioids",289,248,27,14,41,"Late Phase","cancer","female",9.34256055363322,"yes",0.111417391304348,853635.869565217,"Mixed","non-kids","Non-Government","female","non-veterans",23.4573186449833,5983.06722689076,22.8787057344981,86.9442111437698,21.5182988749834,91.9619700803408,85.7198259524453,92.1948179271709,7.80518207282913,"0",41640.6288515406,"Alaska,Alaska,Alaska,Alaska,Alaska,Arkansas,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Connecticut,Connecticut,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Hawaii,Idaho,Idaho,Idaho,Idaho,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Indiana,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kentucky,Kentucky,Kentucky,Kentucky,Kentucky,Kentucky,Kentucky,Kentucky,Louisiana,Louisiana,Louisiana,Louisiana,Maine,Maine,Maine,Maine,Maryland,Maryland,Maryland,Maryland,Maryland,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Mississippi,Mississippi,Mississippi,Mississippi,Mississippi,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Montana,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nebraska,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,New Hampshire,New Hampshire,New Jersey,New Jersey,New Jersey,New Jersey,New Jersey,New Jersey,New Mexico,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Ohio,Oklahoma,Oklahoma,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Dakota,South Dakota,South Dakota,Tennessee,Tennessee,Tennessee,Texas,Texas,Texas,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Utah,Vermont,Vermont,Virginia,Virginia,Virginia,Virginia,Virginia,Virginia,Virginia,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin","7,7,7,7,7,106,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,41,41,41,41,620,620,620,620,620,620,620,542,542,542,542,2,2,2,2,2,2,2,2,2,2,2,2,1,1,1,1,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,144,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,34,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,76,76,76,76,76,76,76,76,341,341,341,341,4,4,4,4,269,269,269,269,269,45,45,45,45,45,45,45,45,45,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,208,208,208,208,208,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,1,1,1,1,1,1,1,1,1,1,1,33,33,33,33,33,33,33,33,33,33,33,33,33,33,33,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,1,1,243,243,243,243,243,243,8,292,292,292,292,292,292,292,292,292,292,292,292,292,292,292,292,292,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,1,1,1,1,1,1,1,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,368,140,140,18,18,18,18,18,18,18,18,18,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,308,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,229,1,1,1,201,201,201,624,624,624,14,14,14,14,14,14,14,14,14,1,1,249,249,249,249,249,249,249,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96",249.187853107345,38.7295518207283,22.5998284734134,10.314922813036,4283029.62481963,65.8214985994398,11.3971988795518,"After","0",0.530561009817672,"Mixed","small",32.4859466277671,"non-acute","non-chronic","cancer","3","2","1","2","1","2","2","1","2","2","2","1","1","1","1","2","1","1",87.252317939311,77.9727779741549,85.1641610644258,18.7096277962483,53.5457983193277,66.1960084033613,4042795.78151261,86.9383753501401,55134.8851540616,15.9892141756549,992683.987394958,13.7557422969188,8.70627571720064,"2","2","1","1","1","1","1","1","2","1","1","2","1","non-elderly",9.89737912412453,"female"
"177","NCT01598506",249,"Interventional","Phase 2",2013-09-30,2014-02-28,"Determination of the ED50 of Intrathecal Hydromorphone in Laboring Women Using the Up-and-down Sequential Allocation Method",22,"Other","United States",0,90,10,100,100,NA,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4938763,"Hydromorphone",1,"Opioids",20,0,18,2,20,"Early Phase","acute","female",90,"no",0.3161,3289020,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",13.6741976969953,2746,24.2397516666667,87.617356953251,24.5959842592997,91.5827047750272,83.9380333761502,86.6,13.4,"1",44670,"Georgia","542",542,39.2,24.3,11.9,4378391,64.425,14.7,"After","0",0.66,"R","small",32.0235221190875,"acute","non-chronic","non-cancer","0","2","3","1","0","3","2","2","1","0","0","2","3","2","1","1","3","3",86.8169345665672,75.4048719465551,84.6462,21.3397,56.6,64.225,4134096,81.2,46992,29,3050004,18.5,7.01779725996106,"2","1","1","2","2","1","1","0","0","3","3","3","0","non-elderly",30.5239494095725,"female"
"178","NCT01608321",251,"Interventional","Phase 3",2012-09-30,2015-09-30,"rTMS for the Treatment of Chronic Pain in GW1 Veterans",17,"U.S. Fed","United States",76,24,0,24,18,17,2012,2015,3,"North America",0,"United States","Non-Industry","Earlier 2013",4938011,"rTMS, Sham device",0,"Non-opioids",17,13,4,0,4,"Late Phase","chronic","veterans",23.5294117647059,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","0","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,68.5,81.4091,19.7226,47.1,54.525,13771156,82.131100522,57020,36,2150453,15.9,14.2617707647834,"3","0","0","2","0","0","3","0","2","3","2","3","3","non-elderly",5.65292366769598,"veterans"
"179","NCT01620606",252,"Interventional",NA,2011-09-30,2016-05-31,"Parent Training to Address Pediatric Functional Abdominal Pain",300,"Other",NA,81,4.6,14.4,19,79.7,NA,2011,2016,5,"North America",0,"United States","Non-Industry","Earlier 2013",4937073,"Cognitive Behavioral Therapy & Social Learning, Education and Support",0,"Non-opioids",316,265,14,37,51,NA,"chronic","kids",4.43037974683544,"yes",0.1262,1241221.5,"Mixed","kids","Non-Government","non-female","non-veterans",26.5044705364051,7428,27.6681411880631,88.8527711937285,25.3183354890395,93.4967645548507,87.9908847832739,91.8333333333333,8.16666666666667,"0",48197.3333333333,"North Carolina,Washington,Washington","264,79,79",140.666666666667,39.5666666666667,21.5,8.93333333333333,3712650.33333333,64.1833333333333,11.5666666666667,"After","0",0.516666666666667,"Mixed","large",35.0654822066642,"non-acute","chronic","non-cancer","3","2","2","2","2","3","3","3","3","3","1","2","0","1","1","1","1","1",89.2838368633538,81.4,88.2815,19.2972666666667,51.1333333333333,65.575,3393389,84.9211514126667,52968.6666666667,4,842387.333333333,13.4666666666667,11.7914420484496,"3","3","2","1","0","1","1","1","2","0","1","1","3","non-elderly",9.38498745645599,"kids"
"180","NCT01626118",NA,"Interventional","Phase 3",2012-05-31,2012-08-31,"A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Indomethacin Nanoformulation Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy",373,"Industry",NA,NA,NA,NA,NA,NA,NA,2012,NA,NA,"North America",NA,"United States","Industry",NA,4936653,NA,NA,"Non-opioids",373,282,80,11,91,"Late Phase","acute",NA,21.4477211796247,"yes",0.119275,1395402.75,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.0344697475944,4469.25,23.6273824301206,89.5736920051706,25.6475263545754,93.8228749094436,87.4849477991076,88.65,11.35,"1",50823.25,"Arizona,Maryland,Texas,Utah","60,269,624,14",241.75,39.2,20.4,9.83333333333333,4490792.75,67.2125,10.775,"After","0",0.5875,"Mixed","large",33.9178723836309,"acute","non-chronic","non-cancer","3","2","1","1","1","2","3","3","3","3","0","3","1","0","1","2","1","2",89.3532619450678,68.675,86.945275,18.91785,59.8,67.29375,4109028,82.63109605,57286.75,17.25,1250893.5,14.225,9.65786408306117,"3","0","2","1","3","2","1","0","2","2","1","2","2","non-elderly",11.3504504173543,"general"
"181","NCT01635101",253,"Interventional","Phase 3",2012-06-30,2015-11-30,"A Randomized, Placebo Controlled, Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients",197,"Industry","United States",69,15,16,31,36,197,2012,2015,3,"North America",0,"United States","Industry","Earlier 2013",4935967,"IV Acetaminophen, IV Control",1,"Non-opioids",197,135,30,32,62,"Late Phase","acute","kids",15.2284263959391,"yes",0.1347125,1634416.875,"Mixed","kids","Non-Government","non-female","non-veterans",25.2733436462826,8615.95454545455,21.0314311042666,86.867607585513,21.4507930156567,91.2775405008151,84.9780972615264,91.2954545454545,8.70454545454546,"1",41123.5,"Alabama,California,California,California,Florida,Illinois,Indiana,Kentucky,Michigan,Minnesota,New York,North Carolina,North Carolina,Ohio,Pennsylvania,Pennsylvania,Pennsylvania,Tennessee,Texas,Texas,Virginia,Wisconsin","278,808,808,808,620,532,144,76,277,71,292,264,264,368,308,308,308,201,624,624,249,96",378.545454545455,38.8818181818182,22.5636363636364,10.4636363636364,6576987.95454545,65.2329545454545,12.3772727272727,"After",NA,0.567272727272727,"Mixed","small",31.6253262113181,"acute","non-chronic","non-cancer","2","2","2","2","2","1","2","1","1","1","1","1","2","1","2","2","2","2",86.0303871989754,69.6772727272727,86.0559909090909,17.71605,52.3090909090909,66.2602272727273,6255329.45454545,84.9643673595454,50309.9090909091,21.4285714285714,1658855.22727273,15.0863636363636,9.30367330273224,"1","1","2","0","1","1","2","1","1","2","2","2","2","non-elderly",12.4674312848648,"kids"
"182","NCT01664559",255,"Interventional",NA,2012-07-31,2014-03-31,"Pain Control for Intrauterine Device Placement: A Randomized, Double Blind Control Trial of Ketorolac Prior to Intrauterine Device Placement.",67,"Other",NA,37,42,21,63,100,NA,2012,2014,2,"North America",0,"United States","Non-Industry","Earlier 2013",4933789,"Ketorolac, Normal Saline",1,"Non-opioids",67,25,26,16,42,NA,"acute","female",38.8059701492537,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","1",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","1","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,68.5,81.4091,19.7226,47.1,54.525,13771156,82.131100522,57020,36,2150453,15.9,14.2617707647834,"3","0","0","2","0","0","3","0","2","3","2","3","3","non-elderly",5.65292366769598,"female"
"183","NCT01665521",256,"Interventional",NA,2012-09-30,2018-01-15,"Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain",282,"Other",NA,65,33,2,35,57,NA,2012,2018,6,"North America",0,"United States","Non-Industry","Earlier 2013",4933716,"HEART Pathway",0,"Non-opioids",282,183,94,5,99,NA,"cardio",NA,33.3333333333333,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","non-chronic","non-cancer","3","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,67.2,85.0726,18.0042,55.3,67.175,4386498,82.821313163,41553,10,2075668,17.2,8.40197402658067,"1","0","1","1","1","2","1","0","0","1","2","3","1","non-elderly",21.2843771780626,"general"
"184","NCT01667029",257,"Interventional","Phase 2",2013-05-31,2017-08-10,"A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Neuropathy",8,"Other","United States",75,25,0,25,50,8,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4933600,"Sulfasalazine, placebo",1,"Non-opioids",8,6,2,0,2,"Early Phase","chronic",NA,25,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","0","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.3426629317023,83.0378,24.1936,54.2,65.275,2838058,96.3,62529,6,429760,12.1,9.2587366295912,"3","3","0","3","1","1","1","3","3","0","0","1","2","non-elderly",6.42120575709148,"general"
"185","NCT01670292",258,"Interventional",NA,2012-09-30,2014-06-30,"Patient Response to Spinal Manipulation",82,"Other",NA,85,10,5,15,48,NA,2012,2014,2,"North America",0,"United States","Non-Industry","Earlier 2013",4933350,"HVLA-SM",0,"Non-opioids",82,70,8,4,12,NA,"chronic",NA,9.75609756097561,"no",0.0371,116359,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"After","1",0.55,"R","small",28.6266618238787,"non-acute","chronic","non-cancer","1","2","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",85.4579609796303,71,92.0531,18.3738,58.5,70.175,1348745,89.856219171,53442,2,89449,10.3,6.7023965919847,"1","1","3","1","2","3","0","2","2","0","0","0","0","non-elderly",2.90968080656148,"general"
"186","NCT01675960",260,"Interventional","Phase 2",2012-04-30,2017-07-31,"A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children",2,"Other","United States",100,0,0,0,0,2,2012,2017,5,"North America",0,"United States","Non-Industry","Earlier 2013",4932917,"Gabapentin, placebo",1,"Non-opioids",2,2,0,0,0,"Early Phase","chronic","kids",0,"no",0.0641,356515,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"0",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"After","0",0.49,"R","small",37.1630582351401,"non-acute","chronic","non-cancer","0","2","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",89.2519769380513,78.6,92.3837,22.0898,56.6,72.025,2362646,91.730274774,61795,6,282628,10,7.83802073605776,"2","2","3","2","2","3","1","3","3","0","0","0","1","non-elderly",5.25414940941292,"kids"
"187","NCT01685684",261,"Interventional","Phase 3",2012-08-31,2014-07-31,"A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of Oxycodone DETERx™ Versus Placebo in Opioid-Experienced and Opioid-Naive Subjects With Moderate-to-Severe Chronic Low Back Pain",740,"Industry",NA,69,11,20,31,57,NA,2012,2014,2,"North America",0,"United States","Industry","Earlier 2013",4932171,"Oxycodone DETERx, Placebo",1,"Opioids",88,61,10,17,27,"Late Phase","chronic",NA,11.3636363636364,"yes",0.1315,1310243.69565217,NA,"non-kids",NA,"non-female","non-veterans",31.6264580603537,9004.66666666667,22.8084977506664,87.2802030734713,23.1038851699483,92.4397724029543,85.9061878453866,90.2222222222222,9.77777777777778,"0",44717.1333333333,"Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Indiana,Indiana,Kansas,Massachusetts,Massachusetts,Massachusetts,Mississippi,Missouri,Nevada,New Jersey,New York,New York,New York,North Carolina,Ohio,Oklahoma,Pennsylvania,South Carolina,South Dakota,Tennessee,Texas,Texas,Texas,Utah,Utah,Virginia,Washington","60,60,60,808,808,808,808,808,808,808,808,620,620,620,620,620,542,542,144,144,60,45,45,45,208,318,80,243,292,292,292,264,368,140,308,229,1,201,624,624,624,14,14,249,79",372.777777777778,39.1911111111111,22.3571428571429,10.9690476190476,6613734.22222222,63.3916666666667,12.48,"After","0",0.547555555555556,"Mixed","small",32.6826553669851,"non-acute","chronic","non-cancer","2","2","2","2","2","2","2","2","2","2","1","2","2","1","2","1","2","1",87.410192265962,68.9533333333333,85.8055577777778,18.3360177777778,53.3333333333333,63.9683333333333,6264837.33333333,83.9016475997778,51621.6666666667,20.5909090909091,1587364.95555556,15.4866666666667,9.31093173598403,"2","0","2","1","1","1","2","1","1","2","1","3","2","non-elderly",11.2500686539851,"general"
"188","NCT01692275",262,"Interventional",NA,2012-09-30,2016-11-28,"Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel",750,"Other",NA,68,20,13,32,23,NA,2012,2016,4,"North America",0,"United States","Non-Industry","Earlier 2013",4931665,"Medical Care + Chiropractic Care, Conventional Medical Care Only",0,"Non-opioids",750,507,149,94,243,NA,"chronic","veterans",19.8666666666667,"yes",0.1725,2477410,"GOVERNMENT","non-kids","Government","non-female","veterans",21.391048527001,11725.3333333333,23.2347074844546,88.2172820970562,25.6813321945941,93.6105911590021,87.5671884393607,91.0333333333333,8.96666666666667,"1",53707.3333333333,"California,Florida,Maryland","808,620,269",565.666666666667,39,23.7333333333333,11.4333333333333,8836778,63.2083333333333,11.0666666666667,"After","0",0.523333333333333,"Mixed","large",35.1847917116426,"non-acute","chronic","non-cancer","3","2","3","2","3","2","2","3","3","3","1","3","3","1","3","1","1","1",89.1101597661407,71.8,85.6735666666667,19.0566,54.0333333333333,63.3416666666667,8405312.66666667,82.7521589256667,58309,31.3333333333333,2268397,13.7,11.7259074272372,"2","1","2","1","1","1","3","0","2","3","3","1","3","non-elderly",16.5973955089218,"veterans"
"189","NCT01694199",263,"Interventional",NA,2012-09-30,2012-12-31,"A Multicenter, Randomized, Sham-Controlled, Double-Blinded Study to Evaluate the Analgesic Efficacy and Safety of Pulsed Radiofrequency Energy (PRFE) in Bunionectomy Surgery for the Treatment of Post-Operative Pain",139,"Industry","United States",47,47,6,53,81,139,2012,2012,0,"North America",0,"United States","Industry","Earlier 2013",4931518,"Pulsed Radiofrequency Energy (PRFE), No Pulsed Radiofrequency Energy (PRFE)",0,"Non-opioids",139,66,65,8,73,NA,"acute",NA,46.7625899280576,"yes",0.159366666666667,2500470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.1174868934974,12629,24.3257417866835,90.3173926825206,27.3680570577139,93.3675443335858,87.32609733008,89.3,10.7,"1",55330.6666666667,"California,Maryland,Texas","808,269,624",567,39.2333333333333,25.0333333333333,10.9333333333333,9373335,62.0083333333333,11.1,"After","1",0.556666666666667,"Mixed","small",35.1266774447711,"acute","non-chronic","non-cancer","2","2","3","2","3","3","3","3","3","2","0","3","3","2","3","0","1","2",88.8371505923272,68.3,84.0406,19.2566,55.9333333333333,62.4333333333333,8777972,81.7022464883333,60260.6666666667,34,2287333.33333333,14.2666666666667,11.5089533532233,"2","0","1","1","2","1","3","0","3","3","3","2","3","non-elderly",15.3493299547059,"general"
"190","NCT01710345",266,"Interventional","Phase 2",2012-10-31,2013-02-28,NA,101,"Industry","United States",71,23,6,29,49,100,2012,2013,1,"North America",0,"United States","Industry","Earlier 2013",4930282,"Sufentanil NanoTab 20 mcg, Sufentanil NanoTab 30 mcg, Placebo NanoTab",1,"Non-opioids",100,71,23,6,29,"Early Phase","acute",NA,23,"yes",0.0349,1155479.5,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",24.0710774672127,12888,23.3384503078223,89.7598153316434,24.7171962425501,95.3310771198275,89.5994912286776,91.3,8.7,"1",46794.5,"California,Utah","808,14",411,39.15,24.2,11.1,7749928.5,63.325,10.2,"After",NA,0.565,"Mixed","small",34.7049596634527,"acute","non-chronic","non-cancer","2","2","0","2","3","2","3","2","3","3","1","2","2","2","2","1","0","2",91.4011758378512,72.25,86.3609,20.05085,55.25,62.825,7385928.5,83.857800256,57680.5,18.5,1089154.5,13.45,13.3054611479545,"3","1","2","2","1","1","3","1","2","2","1","1","3","non-elderly",3.3142586822909,"general"
"191","NCT01712009",267,"Interventional","Phase 2",2012-11-01,2015-03-18,"Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim",600,"Industry",NA,83,14,3,17,100,NA,2012,2015,3,"North America",0,"United States","Industry","Earlier 2013",4930156,"Naproxen, Loratadine, Pegfilgrastim, Chemotherapy",1,"Non-opioids",587,487,83,17,100,"Early Phase","cancer","female",14.1396933560477,"yes",0.125083333333333,1087076.97222222,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",20.2928928438919,5956.4578313253,21.4834794795754,86.2264907369042,21.184346491843,91.5207341400034,85.0657916666045,91.3566265060241,8.6433734939759,"1",41986.6746987952,"Alabama,California,California,California,California,California,California,Colorado,Colorado,Colorado,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Iowa,Iowa,Kansas,Kentucky,Kentucky,Kentucky,Kentucky,Louisiana,Louisiana,Louisiana,Louisiana,Maryland,Maryland,Maryland,Maryland,Massachusetts,Michigan,Minnesota,Minnesota,Mississippi,Missouri,Missouri,Missouri,Missouri,Montana,Nebraska,New Hampshire,New Jersey,New York,New York,North Carolina,North Carolina,North Carolina,Ohio,Ohio,Oregon,Pennsylvania,Pennsylvania,South Carolina,South Dakota,Tennessee,Tennessee,Texas,Texas,Texas,Utah,Virginia,Washington,West Virginia,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin","278,808,808,808,808,808,808,52,52,52,41,41,620,620,620,620,620,620,620,620,542,542,532,532,532,532,532,144,144,34,34,60,76,76,76,76,341,341,341,341,269,269,269,269,45,277,71,71,208,318,318,318,318,1,33,1,243,292,292,264,264,264,368,368,18,308,308,229,1,201,201,624,624,624,14,249,79,18,96,96,96,96,96",307.710843373494,38.8939759036145,23.7356164383562,11.7027397260274,4889600.66666667,66.0674698795181,12.1036144578313,"After",NA,0.556746987951807,"Mixed","large",32.1528785624523,"non-acute","non-chronic","cancer","3","2","2","2","1","1","1","1","1","1","1","1","2","1","1","2","2","2",86.4843053308602,69.9602409638554,87.0783759036145,18.0645987951807,54.2566265060241,67.0069277108434,4567897.79518072,85.1561022238193,51390.0120481928,18.9066666666667,1335955.69879518,14.5012048192771,8.59090889040394,"2","1","2","1","1","2","2","1","1","2","1","2","1","non-elderly",12.961984958132,"female"
"192","NCT01726803",268,"Interventional",NA,2011-04-30,2014-11-30,"Comparative Effectiveness of Management Strategies for Acute Low Back Pain",220,"Other","United States",81,2,17,19,52,220,2011,2014,3,"North America",0,"United States","Non-Industry","Earlier 2013",4929027,"Early Physical Therapy with Usual Care, Usual Care",0,"Non-opioids",220,179,5,36,41,NA,"acute",NA,2.27272727272727,"yes",0.0119,36849,"Mixed","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah,Utah","14,14",14,39.6,NA,NA,1133521,71.825,7.9,"After","0",0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","3","2","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.01014403550732,"general"
"193","NCT01729728",269,"Interventional","Phase 2",2012-11-30,2014-02-28,"Open-label Evaluation of the Pharmacokinetic Profile, Safety, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children and Adolescents Aged From 2 Years to Less Than 18 Years.",86,"Industry","United States",95,2,3,5,52,132,2012,2014,2,"North America",0,"United States","Industry","Earlier 2013",4928804,"Tapentadol",1,"Opioids",66,63,1,2,3,"Early Phase","acute","kids",1.51515151515152,"no",0.0119,36849,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","1","2","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",93.0324958994779,76,91.3127,20.3791,63.4,71.125,1000701,85.58449999,58341,1,27856,11,12.3491515311256,"3","2","3","2","3","3","0","1","2","0","0","0","3","non-elderly",0.975593696885812,"kids"
"194","NCT01731470",270,"Interventional",NA,2012-07-31,2013-08-31,"Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)",14,"Other","United States",94,6,0,6,NA,NA,2012,2013,1,"North America",0,"United States","Non-Industry","Earlier 2013",4928670,"Liposomes",0,"Non-opioids",16,15,1,0,1,NA,"chronic",NA,6.25,"no",0.1379,1374310,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan","277",277,37.9,23.2,9.1,4629611,73.025,11,"After","0",0.53,"R","small",29.5564246895313,"non-acute","chronic","non-cancer","0","2","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",86.1674818732829,72,89.5718,16.1767,44.7,74.8,4539456,89.121533641,50015,9,1375814,13.7,8.29877292639095,"1","1","3","0","0","3","2","2","1","1","1","1","1","non-elderly",13.920508814816,"general"
"195","NCT01735708",271,"Interventional",NA,2012-11-30,2015-08-31,"Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings",23,"Other",NA,52.2,13,34.8,47.8,43.5,NA,2012,2015,3,"North America",0,"United States","Non-Industry","Earlier 2013",4928350,"HIVPASS, Health Education",0,"Non-opioids",23,12,3,8,11,NA,"chronic",NA,13.0434782608696,"no",0.0677,71561,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",15.5824957672408,334,20.73832,87.74185136897,23.5593220338983,89.3463952618945,85.5670280587147,95.9,4.1,"1",45727,"Rhode Island","7",7,38.3,20.9,12.2,470168,63.825,10.3,"After","0",0.49,"D","small",34.5314266746905,"non-acute","chronic","non-cancer","0","2","0","1","0","1","2","2","0","2","3","2","0","0","0","1","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",4.99860991038683,"general"
"196","NCT01744197",273,"Interventional","Phase 2",2013-01-31,2013-11-30,"Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures",61,"Industry","United States",90,8,2,10,56,61,2013,2013,0,"North America",0,"United States","Industry","Earlier 2013",4927699,"Synera (lidocaine 70mg/tetracaine 70mg)",1,"Non-opioids",61,55,5,1,6,"Early Phase","acute",NA,8.19672131147541,"no",0.1213,3428210,NA,"non-kids",NA,"non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","1","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,87.7181,22.2968,59,63.25,10298263,77.9,51406,49,3068699,16.9,9.43231929885351,"2","1","2","2","3","1","3","0","1","3","3","3","2","non-elderly",11.6026792454214,"general"
"197","NCT01748227",274,"Interventional",NA,2013-01-31,2013-12-31,"Improving Pain Using Peer RE-inforced Self-management Skills (IMPPRESS)",20,"U.S. Fed","United States",61.5,34.6,3.9,38.5,0,NA,2013,2013,0,"North America",0,"United States","Non-Industry","Earlier 2013",4927391,"Peer-Delivered Pain Self-Management",0,"Non-opioids",26,16,9,1,10,NA,"chronic","veterans",34.6153846153846,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"After",NA,0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","0","2","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",85.0256665939072,74.1462592296165,85.0181,15.1376,51,71.7,2826106,86,49455,18,594384,16.5,8.67182330071009,"1","1","1","0","0","3","1","1","1","2","0","3","1","non-elderly",9.04569874881713,"veterans"
"198","NCT01752010",275,"Interventional",NA,2010-05-31,2014-04-30,"A Randomized Study Comparing the Tennant BioModulator to Transcutaneous Electrical Nerve Stimulation (TENS) and Traditional Chinese Acupuncture for the Symptomatic Treatment of Chronic Pain Among Injured Service Members.",98,"Other",NA,43,24,33,57,22,NA,2010,2014,4,"North America",0,"United States","Non-Industry","Earlier 2013",4927101,"Traditional Chinese Acupuncture, Tennantâ„¢ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment",0,"Non-opioids",100,43,24,33,57,NA,"chronic","veterans",24,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"Before","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","2","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",79,59.9,81.0773,17.7566,57,65.35,9996584,75.391376734,47266,31,2904687,18.4,9.43231929885351,"0","0","0","1","2","1","3","0","0","3","3","3","2","non-elderly",11.5004707188636,"veterans"
"199","NCT01755546",NA,"Interventional","Phase 3",2012-12-31,2014-11-30,"A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time",304,"Industry",NA,NA,NA,NA,NA,NA,NA,2012,NA,NA,"North America",NA,"United States","Industry",NA,4926829,NA,NA,"Non-opioids",224,158,57,9,66,"Late Phase","chronic",NA,25.4464285714286,"yes",0.141777272727273,1343330.72727273,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.5739223910565,7240.14035087719,22.6987368862494,85.5338177257055,20.817503920595,91.6735295149412,84.5403057178956,89.4982456140351,10.5017543859649,"1",40941.0175438596,"Alabama,Alabama,Arizona,California,California,California,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Indiana,Iowa,Louisiana,Louisiana,Louisiana,Louisiana,Massachusetts,Michigan,Michigan,Mississippi,New York,New York,North Carolina,North Dakota,Ohio,Ohio,Ohio,Ohio,Pennsylvania,Pennsylvania,South Carolina,South Dakota,Texas,Texas,Texas,Texas,Texas,Utah,Wisconsin","278,278,60,808,808,808,808,808,41,620,620,620,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,144,34,341,341,341,341,45,277,277,208,292,292,264,1,368,368,368,368,308,308,229,1,624,624,624,624,624,14,96",437.035087719298,39.1087719298246,23.4679245283019,11.3622641509434,6889117.78571429,65.069298245614,13.4736842105263,"After","0",0.576140350877193,"Mixed","small",30.6011044458346,"non-acute","chronic","non-cancer","3","2","2","1","2","2","0","1","1","0","0","1","3","1","2","2","3","2",86.2729521932392,68.6736842105263,85.9130175438597,17.4288719298246,52.8421052631579,66.2276315789474,6402997.45614035,82.7729733428947,48455.9298245614,26.8148148148148,1999473.80701754,15.8421052631579,9.49702317914685,"2","0","2","0","1","1","2","0","0","3","2","3","2","non-elderly",15.3037359802072,"general"
"200","NCT01757301",276,"Interventional",NA,2014-01-02,2017-11-30,"Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) Trial",296,"U.S. Fed","United States",79,15,6,21,13,294,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4926696,"Assisted Symptom Management (ASM), Comprehensive Symptom Management (CSM)",0,"Non-opioids",294,233,45,16,61,NA,"chronic","veterans",15.3061224489796,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"After","0",0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","3","2","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",85.0256665939072,74.1462592296165,86.2946,16.5363,50.8,70.1,2840421,88.1,48060,5,605194,14.6,8.67182330071009,"1","1","2","0","0","3","1","2","0","0","0","2","1","non-elderly",9.17397759993209,"veterans"
"201","NCT01761617",277,"Interventional",NA,2011-09-30,2011-12-31,"Yoga Dosing Study for Chronic Low Back Pain in a Predominantly Low-Income Minority Population",96,"Other",NA,31,53,16,69,76,NA,2011,2011,0,"North America",0,"United States","Non-Industry","Earlier 2013",4926365,"Yoga class once per week, Yoga class twice per week",0,"Non-opioids",45,14,24,7,31,NA,"chronic","minority",53.3333333333333,"yes",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts,Massachusetts","45,45,45,45,45,45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","1","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.5,89.054,22.2431,55.3,65.3,2817715,96.63637334,63313,4,406157,10.6,9.2587366295912,"3","3","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.16553746347648,"minority"
"202","NCT01764464",278,"Interventional","Phase 4",2012-12-31,2016-04-30,"Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome",53,"Other","United States",94,6,0,6,38,32,2012,2016,4,"North America",0,"United States","Non-Industry","Earlier 2013",4926146,"GraliseÂ®, Placebo",1,"Non-opioids",32,30,2,0,2,"Late Phase","chronic",NA,6.25,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,69.1,85.3723,19.1611,50.6,53.575,8170062,88.694462729,47680,25,2820905,17.2,6.33298278377812,"2","1","1","1","0","0","3","2","0","2","3","3","0","non-elderly",14.4142431212338,"general"
"203","NCT01767935",280,"Interventional",NA,2014-07-31,2014-12-31,"A Pilot Study of The Tandem Treatment of Painful Osseous Metastases With Cryoablation Followed by Radiation Therapy",1,"Other","United States",100,0,0,0,100,1,2014,2014,0,"North America",0,"United States","Non-Industry","After 2013",4925880,"cryosurgery, radiation therapy, quality-of-life assessment",0,"Non-opioids",1,1,0,0,0,NA,"cancer",NA,0,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","non-chronic","cancer","0","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.0046,19.2992,53.9,66.425,4472159,86.9,46784,21,2124971,17.1,8.40197402658067,"1","1","0","1","1","1","1","1","0","2","2","3","1","non-elderly",21.3694558829859,"general"
"204","NCT01775995",281,"Interventional","Phase 1/Phase 2",2013-01-31,2013-12-31,"Randomized Controlled Trial of Mindfulness Meditation and Cognitive Behavioral Therapy Intervention for Opioid-treated Chronic Low Back Pain",35,"Other","United States",80,17,3,20,80,70,2013,2013,0,"North America",0,"United States","Non-Industry","Earlier 2013",4925264,"Meditation-CBT Intervention + Usual Care, Usual Care Alone",0,"Non-opioids",35,28,6,1,7,"Early Phase","chronic",NA,17.1428571428571,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"1",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","0",0.45,"R","small",30.1959597752958,"non-acute","chronic","non-cancer","0","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",86.2985410000457,77.8766338411077,78.7659,12.7665,53.3,68.5,2647111,90.9,51726,7,351135,13.5,5.85443389695935,"2","2","0","0","1","2","1","2","1","0","0","1","0","non-elderly",6.11444451429142,"general"
"205","NCT01789476",283,"Interventional","Phase 2",2013-05-31,2013-08-31,"A Single-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of CR845 Dosed in Patients With Pain Following Bunionectomy Surgery",51,"Industry","United States",92,4,4,8,88,51,2013,2013,0,"North America",0,"United States","Industry","Earlier 2013",4924235,"CR845, Placebo",1,"Non-opioids",51,47,2,2,4,"Early Phase","acute",NA,3.92156862745098,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After","0",0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","1","2","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.04668527256632,"general"
"206","NCT01789970",NA,"Interventional","Phase 3",2013-03-31,2014-02-28,"A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time",625,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4924198,NA,NA,"Opioids",371,262,80,29,109,"Late Phase","chronic",NA,21.5633423180593,"yes",0.138651851851852,1260187.55555556,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",25.049816119436,9088.93103448276,23.4571315986399,87.3923715833305,22.5015749851807,92.0845465831613,85.3264645577773,89.6172413793103,10.3827586206897,"1",43464.5057471264,"Alabama,Alabama,Alabama,Alabama,Alabama,Alabama,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Idaho,Idaho,Illinois,Indiana,Indiana,Indiana,Kansas,Louisiana,Louisiana,Massachusetts,Michigan,Mississippi,Missouri,Missouri,Nebraska,Nebraska,Nevada,Nevada,New Jersey,New York,New York,New York,New York,North Carolina,North Carolina,Oklahoma,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Virginia,Washington,Washington","278,278,278,278,278,278,60,60,60,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,808,41,620,620,620,620,620,620,620,620,620,620,620,620,542,542,542,542,1,1,532,144,144,144,60,341,341,45,277,208,318,318,33,33,80,80,243,292,292,292,292,264,264,140,308,308,308,308,229,229,624,624,624,624,624,624,624,624,624,14,249,79,79",429.091954022988,39.0735632183908,22.9452380952381,11.2261904761905,7087655.62068965,63.7824712643678,13.048275862069,"After",NA,0.567701149425287,"Mixed","large",31.3996878883729,"non-acute","chronic","non-cancer","3","2","2","2","2","2","2","1","2","1","0","2","3","1","2","1","3","2",86.8015819323616,76.9918564203454,84.9933275862069,19.5517551724138,52.7735632183908,64.3094827586207,6732243.33333333,83.7287356321839,52697.0114942529,28.8095238095238,1818959.71264368,15.5252873563218,9.5453023349267,"2","2","1","2","1","1","2","0","2","3","2","3","2","non-elderly",13.1606823347295,"general"
"207","NCT01794689",NA,"Interventional","N/A",2013-05-31,2019-03-12,"Mechanisms of Sleep Disruption Hyperalgesia",100,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4923840,NA,NA,"Opioids",100,45,37,18,55,NA,"chronic",NA,37,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"1",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","2","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,88.5777,25.4838,61.2,66.9,2404438,89.8,69353,23,1727400,10.5,10.8327699960329,"3","3","3","3","3","2","1","2","3","2","2","0","2","non-elderly",29.1356753644152,"general"
"208","NCT01800318",NA,"Interventional","N/A",2013-03-31,2015-02-28,"Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?",162,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4923412,NA,NA,"Non-opioids",162,100,50,12,62,NA,"acute","kids",30.8641975308642,"yes",0.10555,1366826,"Mixed","kids","Non-Government","non-female","non-veterans",17.1502677170435,12461.5,23.3872056721948,88.591713527215,21.8980683941213,91.4579779678347,83.3302283628884,91.6,8.4,"1",41953.5,"Arkansas,California","106,808",457,38.55,21.15,9.55,7877732.5,60.0625,14,"After","0",0.595,"Mixed","small",28.8271792972843,"acute","non-chronic","non-cancer","2","2","1","1","3","2","2","1","1","0","1","1","3","1","2","0","3","2",85.7485228340217,73.4721267965398,85.35635,18.22015,46.85,59.8375,7583217,83.4,50085,26.5,1314293,14.5,11.9183138647952,"1","1","1","1","0","0","3","0","1","3","1","2","3","non-elderly",10.6197283849349,"kids"
"209","NCT01812057",284,"Interventional","Phase 4",2012-12-31,2016-09-21,"Dexamethasone as an Analgesic Adjunct for Post-cesarean Delivery Pain Relief",53,"Other","United States",66,23,11,34,100,47,2012,2016,4,"North America",0,"United States","Non-Industry","Earlier 2013",4922515,"Dexamethasone, Placebo",1,"Non-opioids",47,31,11,5,16,"Late Phase","acute","female",23.4042553191489,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,67.2,85.0726,18.0042,55.3,67.175,4386498,82.821313163,41553,10,2075668,17.2,8.40197402658067,"1","0","1","1","1","2","1","0","0","1","2","3","1","non-elderly",21.2843771780626,"female"
"210","NCT01826851",285,"Interventional","Phase 2",2013-03-31,2017-06-30,"Parasternal Intercostal Nerve Block in Post-Cardiac Surgery Patients: A Randomized, Controlled Trial of Extended-release Liposomal Bupivacaine (Exparel) Versus Placebo",79,"Other","United States",99,1,0,1,15,79,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4921385,"Exparel, Placebo",1,"Non-opioids",79,78,1,0,1,"Early Phase","acute",NA,1.26582278481013,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","1","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,82.6101,22.0535,51.9,53.025,8193686,89.3,49966,25,2831270,17.3,6.33298278377812,"2","2","0","2","0","0","3","2","1","2","3","3","0","non-elderly",14.4076723945655,"general"
"211","NCT01830881",286,"Interventional","Phase 4",2013-04-30,2014-01-31,"An Evaluation of Oral Midazolam for Anxiety and Pain in First-trimester Surgical Abortion: a Randomized Controlled Trial",124,"Other",NA,69,7,24,31,100,NA,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4921078,"Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine",1,"Non-opioids",124,86,9,29,38,"Late Phase","acute","female",7.25806451612903,"no",0.0191,78679,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",29.9686163978885,2691,21.7010141509434,88.5981383084975,27.5718109544165,94.3852426028864,88.1124219799947,92.8,7.2,"1",41773,"Oregon","18",18,38.7,NA,NA,1808465,62.375,10.6,"After","0",0.48,"D","small",34.2300108729167,"acute","non-chronic","non-cancer","2","2","0","2","0","1","2","3","3","3","2","1","0",NA,"0","0","0","0",90.8657845331328,81.713413048125,86.9456,19.1856,46.3,64.225,1701000,85.3,48999,1,67906,14,14.574172019163,"3","3","2","1","0","1","0","1","1","0","0","2","3","non-elderly",1.7278594628842,"female"
"212","NCT01835756",287,"Interventional",NA,2012-09-30,2014-09-30,"A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Low Back Pain Clinical Study",62,"Industry","United States",92,6,2,8,47,62,2012,2014,2,"North America",0,"United States","Industry","Earlier 2013",4920707,"Erchonia MLS, Placebo Laser",0,"Non-opioids",62,57,4,1,5,NA,"chronic",NA,6.45161290322581,"yes",0.045,317462,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",13.1690644369743,2618,21.9949418181818,89.8384852939726,25.0101131688258,93.3056955655765,86.6387024886614,88.7,11.3,"1",47386,"Arizona,Arizona","60,60",60,38.2,10.3,7.8,3075981,65.825,14.4,"After","0",0.53,"R","small",29.6115954315844,"non-acute","chronic","non-cancer","1","2","0","1","0","1","3","2","3","2","0","2","0","0","1","2","3","1",87.6389558800363,62.3,85.7557,17.2451,55.1,65.275,2872651,81.964245267,47044,2,264171,19,6.01721550623265,"2","0","2","0","1","1","1","0","0","0","0","3","0","non-elderly",4.03114177610973,"general"
"213","NCT01840345",NA,"Interventional","Phase 2",2014-01-31,2017-04-01,"The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain",11,"Other",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4920358,NA,NA,"Non-opioids",11,3,8,NA,8,"Early Phase","chronic",NA,72.7272727272727,"no",0.1918,1621590,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.90867222743972,3685,15.3311136986301,86.1120794921748,24.5399464956516,91.8161068524883,85.8209274833271,92.1,7.9,"1",51654,"Virginia","249",249,39.7,22.4,9.8,3562143,67.55,10.7,"After","0",0.61,"D","small",39.4719593291509,"non-acute","chronic","non-cancer","0","2","3","0","1","0","1","2","1","2","1","3","1","1","1","2","0","3",88.230513471671,79.2878408955579,84.4107,21.1782,59.9,68.725,3446117,89.1,66155,6,1572488,10.2,7.19580739137292,"2","2","1","2","3","2","1","2","3","0","1","0","1","non-elderly",18.8858205618373,"general"
"214","NCT01841216",NA,"Interventional","N/A",2013-04-30,2013-12-31,"EMG Activation of Gluteal Musculature and Perceived Exertion During Therapeutic Exercises With and Without Thera-Band® Resistance",30,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4920291,NA,NA,"Non-opioids",30,22,3,5,8,NA,"chronic",NA,10,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","0","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,88.5777,25.4838,61.2,66.9,2404438,89.8,69353,23,1727400,10.5,10.8327699960329,"3","3","3","3","3","2","1","2","3","2","2","0","2","non-elderly",29.1356753644152,"general"
"215","NCT01842633",NA,"Interventional","Phase 3",2013-04-01,2015-03-31,"A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache",365,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4920183,NA,NA,"Non-opioids",157,139,14,4,18,"Late Phase","acute",NA,8.9171974522293,"no",0.0763,522357,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After",NA,0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","2","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.3426629317023,83.0378,24.1936,54.2,65.275,2838058,96.3,62529,6,429760,12.1,9.2587366295912,"3","3","0","3","1","1","1","3","3","0","0","1","2","non-elderly",6.42120575709148,"general"
"216","NCT01846221",289,"Interventional","Phase 4",2014-07-15,2017-01-20,"Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia",101,"Other","United States",59,27,14,41,100,98,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4919908,"Clonidine, Fentanyl",1,"Opioids",98,58,26,14,40,"Late Phase","acute","female",26.530612244898,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,83.3533,23.3889,53.8,52.925,8219287,91.3,54310,15,2850956,14,6.33298278377812,"2","2","0","3","1","0","3","3","2","1","3","2","0","non-elderly",14.4379784553272,"female"
"217","NCT01847885",NA,"Interventional","N/A",2013-04-30,2016-11-14,"A Randomized, Double-Blinded, Placebo-Control Multicenter Pivotal Study of the Smartpatch Peripheral Nerve Stimulation (PNS) System for the Treatment of Chronic Post-Stroke Shoulder Pain",88,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4919782,NA,NA,"Non-opioids",43,26,11,6,17,NA,"acute",NA,25.5813953488372,"yes",0.15434,1944178,"Mixed","non-kids","Non-Government","non-female","non-veterans",61.8522287061172,9291.4,22.0851776037376,86.2669466222401,22.2909313535686,91.4839925015884,85.5634019618822,92.32,7.68,"1",42528.6,"Illinois,New Jersey,New York,North Carolina,Ohio","532,243,292,264,368",339.8,38.62,30.2,12.88,5483014.2,63.085,11.74,"After",NA,0.55,"Mixed","small",34.7492569210282,"acute","non-chronic","non-cancer","1","2","2","3","2","1","1","1","1","2","2","1","2","3","2","1","1","2",86.3222480384913,77.7889089180508,84.04108,19.49486,52.14,64.08,5332398,87.36,52948.4,19.8,1850267.4,14.08,7.02572434891652,"2","2","1","2","1","1","2","1","2","2","2","2","1","non-elderly",14.8815727315152,"general"
"218","NCT01861587",291,"Interventional",NA,2014-10-31,2014-10-31,"Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain",27,"Other","United States",85,15,0,15,63,27,2014,2014,0,"North America",0,"United States","Non-Industry","After 2013",4918739,"tDCS",0,"Non-opioids",27,23,4,0,4,NA,"acute",NA,14.8148148148148,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","non-female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"0",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"After","0",0.7,"R","small",28.2226091262223,"acute","non-chronic","non-cancer","0","2","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",83.3964736178037,70.2770205967591,79.8226,14.7453,52,72.975,2201469,86.4,44929,7,1311369,16.5,6.67607176575867,"1","1","0","0","0","3","0","1","0","0","1","3","0","non-elderly",27.1365521899513,"general"
"219","NCT01868633",NA,"Interventional","Phase 4",2013-03-31,2015-05-31,"The Effect of a Single Intraoperative Dose of Dexamethasone in Combination With Intrathecal Morphine for Post Cesarean Delivery Analgesia",52,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4918202,NA,NA,"Non-opioids",52,48,4,NA,4,"Late Phase","acute",NA,7.69230769230769,"no",0.0371,116359,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"After","1",0.55,"R","small",28.6266618238787,"acute","non-chronic","non-cancer","1","2","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",85.4579609796303,75.7108862245299,85.2463,17.9807,57,69.825,1356423,91.9,60156,2,100538,13.2,6.7023965919847,"1","2","1","1","2","3","0","3","3","0","0","1","0","non-elderly",3.25321898411088,"general"
"220","NCT01872910",292,"Interventional","Phase 2",2013-06-30,2013-10-31,"Evaluation of the Acute Analgesic Efficacy of a Single Dose of LY3023703 in Patients With Postsurgical Dental Pain: A Parallel, Double-Blind, Randomized, Placebo and Positive Control Study",124,"Industry","United States",81,2,17,19,60,124,2013,2013,0,"North America",0,"United States","Industry","Earlier 2013",4917874,"Placebo, LY3023703, Celecoxib",1,"Non-opioids",124,101,3,20,23,"Early Phase","acute",NA,2.41935483870968,"no",0.1213,3428210,NA,"non-kids",NA,"non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After",NA,0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","2","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,87.7181,22.2968,59,63.25,10298263,77.9,51406,49,3068699,16.9,9.43231929885351,"2","1","2","2","3","1","3","0","1","3","3","3","2","non-elderly",11.6026792454214,"general"
"221","NCT01878006",NA,"Interventional","Phase 2",2013-06-13,2017-04-27,"OPRM1 A118G SNP Effect on Striatal Dopamine Response to an IV Opiate",15,"NIH",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4917488,NA,NA,"Opioids",10,7,2,1,3,"Early Phase","acute",NA,20,"no",0.2989,1799090,"GOVERNMENT","non-kids","Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","1",0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","0","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,88.5777,25.4838,61.2,66.9,2404438,89.8,69353,23,1727400,10.5,10.8327699960329,"3","3","3","3","3","2","1","2","3","2","2","0","2","non-elderly",29.1356753644152,"general"
"222","NCT01883895",NA,"Interventional","N/A",2013-06-30,2014-05-31,"Exercise-induced Hypoalgesia After Comparative Forms of Anaerobic Training in Healthy Adults",34,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4917038,NA,NA,"Non-opioids",32,24,1,7,8,NA,"acute",NA,3.125,"no",0.0641,371200,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"0",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","1",0.45,"R","small",30.1959597752958,"acute","non-chronic","non-cancer","0","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",86.2985410000457,77.8766338411077,78.7659,12.7665,53.3,68.5,2647111,90.9,51726,7,351135,13.5,5.85443389695935,"2","2","0","0","1","2","1","2","1","0","0","1","0","non-elderly",6.11444451429142,"general"
"223","NCT01890642",295,"Interventional",NA,2013-07-31,2013-08-31,"Use Of The Needle Free Jet-Injection System With Buffered Lidocaine (J-Tip) For The Treatment Of Pain During Venipuncture For Blood Draws In Young Children",205,"Other","United States",54,19,27,46,40,205,2013,2013,0,"North America",0,"United States","Non-Industry","Earlier 2013",4916520,"J tip, Pain Ease Spray, 1% buffered lidocaine, placebo cooling spray (normal saline spray), Sucrose",1,"Non-opioids",205,110,38,57,95,NA,"acute","kids",18.5365853658537,"no",0.0641,371200,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",9.88562303133289,2838,15.7519324561403,85.1892391178848,15.7958665281145,90.5308388031348,85.0334933555034,94.3,5.7,"1",31351,"Wisconsin","96",96,38.4,19,8.2,2725296,66.1,9.5,"After","0",0.45,"R","small",30.1959597752958,"acute","non-chronic","non-cancer","2","2","0","0","0","0","0","0","0","1","3","0","0","0","0","2","0","0",86.2985410000457,77.8766338411077,78.7659,12.7665,53.3,68.5,2647111,90.9,51726,7,351135,13.5,5.85443389695935,"2","2","0","0","1","2","1","2","1","0","0","1","0","non-elderly",6.11444451429142,"kids"
"224","NCT01892709",296,"Interventional","Phase 4",2013-06-30,2014-04-30,"Efficacy of an Acute Pain Titration Protocol Driven by Patient Response to a Simple Query: Do You Want More Pain Medication?",215,"Other","United States",10,21,69,90,59,207,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4916362,"Hydromorphone",1,"Opioids",207,20,44,143,187,"Late Phase","acute",NA,21.256038647343,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,82.6101,22.0535,51.9,53.025,8193686,89.3,49966,25,2831270,17.3,6.33298278377812,"2","2","0","2","0","0","3","2","1","2","3","3","0","non-elderly",14.4076723945655,"general"
"225","NCT01898013",297,"Interventional","Phase 2",2013-09-13,2017-04-03,"Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans",94,"U.S. Fed","United States",60,34,6,40,11,94,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4915959,"Pregnenolone, Placebo",1,"Non-opioids",94,56,32,6,38,"Early Phase","chronic","veterans",34.0425531914894,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","2","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,83.1396,18.2358,55.1,67.375,4427718,84.4,46337,20,2090265,14.7,8.40197402658067,"1","1","0","1","1","2","1","1","0","2","2","2","1","non-elderly",21.225144850864,"veterans"
"226","NCT01901393",298,"Interventional","Phase 4",2013-07-31,2014-08-31,"A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery",100,"Industry","United States",92,7,1,8,39,100,2013,2014,1,"North America",0,"United States","Industry","Earlier 2013",4915702,"IV ibuprofen, Ketorolac",1,"Non-opioids",100,92,7,1,8,"Late Phase","acute",NA,7,"yes",0.201,1936107.5,"Mixed","non-kids","Non-Government","non-female","non-veterans",16.5029206091618,5830.5,21.9051266861203,84.2978255967442,19.0984777879786,90.4892406871098,83.0951692575077,89.95,10.05,"0",36036.75,"Florida,Illinois,Mississippi,Ohio","620,532,208,368",432,38.8,27.85,12,5408409.5,68.0125,14.275,"After","0",0.6,"Mixed","small",29.4796207013272,"acute","non-chronic","non-cancer","2","2","3","1","1","1","0","0","0","0","1","0","3","3","2","2","3","3",84.5584877006829,73.5217702064405,81.5057,16.751825,49.375,68.85625,5214267.25,84.8,46388.75,23.75,1834836.75,15.6,8.03968328845171,"1","1","0","0","0","2","2","1","0","2","2","3","1","non-elderly",19.7652454334066,"general"
"227","NCT01909076",299,"Interventional",NA,2014-01-31,2016-03-31,"Implementing Opioid Risk Reduction Strategies Into Primary Care Practice",53,"NIH",NA,52,36,12,48,47,NA,2014,2016,2,"North America",0,"United States","Non-Industry","After 2013",4915118,"Electronic decision support tools, Enhanced patient education materials, Nurse care management, Electronic Patient Registry, Academic detailing",0,"Non-opioids",985,512,361,112,473,NA,"chronic",NA,36.6497461928934,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","large",44.4377437165865,"non-acute","chronic","non-cancer","3","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.3426629317023,83.8417,23.4728,54.8,63,2851556,96.7,63151,3,439433,13.6,9.2587366295912,"3","3","0","3","1","1","1","3","3","0","0","1","2","non-elderly",6.51455034298889,"general"
"228","NCT01918189",301,"Interventional",NA,2014-07-01,2018-12-31,"Development of an Internet-based Behavioral Pain Management Intervention",59,"U.S. Fed","United States",60,33,7,40,7,58,2014,2018,4,"North America",0,"United States","Non-Industry","After 2013",4914425,"behavioral pain self-management intervention Pain EASE",0,"Non-opioids",58,35,19,4,23,NA,"chronic","veterans",32.7586206896552,"no",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After","0",0.43,"D","small",39.6963200211786,"non-acute","chronic","non-cancer","1","2","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",88.3766067526777,82.1959300560243,86.774,22.9186,55.2,67.375,1502807,93.1,70161,2,349742,8.6,10.6706250487306,"2","3","2","2","1","2","0","3","3","0","0","0","2","non-elderly",9.72403137674025,"veterans"
"229","NCT01922739",NA,"Interventional","Phase 3",2013-07-31,2014-08-31,"A 6-Month, Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time",182,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4914076,NA,NA,"Opioids",182,127,39,16,55,"Late Phase","chronic",NA,21.4285714285714,"yes",0.135582608695652,1326331.60869565,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",24.1432945749265,9418.5737704918,23.4750561995428,87.7576335764625,22.9605743198539,92.2488767121349,85.521651829429,89.4327868852459,10.5672131147541,"1",43964.4098360656,"Alabama,Alabama,Alabama,Arizona,Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Georgia,Georgia,Georgia,Idaho,Idaho,Illinois,Indiana,Louisiana,Louisiana,Massachusetts,Michigan,Mississippi,Missouri,Missouri,Nebraska,Nevada,New Jersey,New York,New York,North Carolina,Oklahoma,Pennsylvania,Pennsylvania,Pennsylvania,Texas,Texas,Texas,Texas,Texas,Texas,Texas,Utah,Washington,Washington","278,278,278,60,60,60,808,808,808,808,808,808,808,808,808,808,808,808,620,620,620,620,620,620,620,620,542,542,542,542,1,1,532,144,341,341,45,277,208,318,318,33,80,243,292,292,264,140,308,308,308,624,624,624,624,624,624,624,14,79,79",445.44262295082,39.0606557377049,23.1068965517241,10.8741379310345,7290136.13114754,63.5872950819672,13.1213114754098,"After",NA,0.565245901639344,"Mixed","small",31.4302811560098,"non-acute","chronic","non-cancer","2","2","2","2","2","2","2","2","2","1","0","2","3","1","2","1","3","2",87.0244062503312,77.2184342161058,85.2948803278689,19.9632770491803,52.772131147541,64.1147540983606,6920802.1147541,83.4508196721311,52829.7704918033,29.4655172413793,1839647.55737705,15.616393442623,9.785561778702,"2","2","1","2","1","1","2","0","2","3","2","3","2","non-elderly",12.7443542793466,"general"
"230","NCT01925469",302,"Interventional","Phase 4",2011-12-31,2012-04-30,"A Randomized Controlled Trial of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram",30,"Other","United States",47,37,16,53,100,30,2011,2012,1,"North America",0,"United States","Non-Industry","Earlier 2013",4913868,"Benzocaine, Saline spray",1,"Non-opioids",30,14,11,5,16,"Late Phase","acute","female",36.6666666666667,"no",0.1118,1430660,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"1",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","1",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","0","2","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,75.4,88.7087,16.44,51.2,71.15,5587336,89.18957699,49910,17,1326494,12.6,12.1914636349471,"1","1","3","0","0","3","2","2","1","2","1","1","3","non-elderly",10.4096827045302,"female"
"231","NCT01928381",NA,"Interventional","Phase 2",2013-11-30,2015-05-31,"A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability",150,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4913646,NA,NA,"Non-opioids",83,43,35,5,40,"Early Phase","chronic",NA,42.1686746987952,"yes",0.17586,2160365.4,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",31.3363156146068,5769.33333333333,20.867777577862,86.3144494884892,24.0297977536755,91.7763524961911,85.847095310721,92.0333333333333,7.96666666666667,"1",44425.3333333333,"Florida,Florida,Georgia,Massachusetts,Massachusetts,Massachusetts,North Carolina,Pennsylvania,Pennsylvania","620,620,542,45,45,45,264,308,308",310.777777777778,39,22.3555555555556,11.5777777777778,5413905.55555556,64.8833333333333,12.0444444444444,"After",NA,0.493333333333333,"Mixed","small",35.7527474471715,"non-acute","chronic","non-cancer","1","2","3","2","1","1","1","2","1","2","1","2","2","1","2","1","2","0",87.1048013558151,78.8038665695645,83.1215777777778,19.9420555555556,54.2777777777778,66.9694444444444,5167465.55555556,88.3444444444444,54254.6666666667,19.6666666666667,1686453.44444444,13.5,9.7494746096667,"2","2","0","2","1","2","2","2","2","2","2","1","2","non-elderly",13.6785535412239,"general"
"232","NCT01928849",303,"Interventional","Phase 2",2013-12-31,2017-09-26,"Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain",128,"Other","United States",77,21,2,23,17,256,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4913610,"Valproic Acid, Cherry Syrup",1,"Non-opioids",128,98,27,3,30,"Early Phase","chronic","veterans",21.09375,"yes",0.25665,1999925,"GOVERNMENT","non-kids","Government","non-female","veterans",13.9583778432764,3621,21.6754761875,88.3125145541513,25.7233376302153,92.1786374285512,86.023521882025,91.35,8.65,"0",53345.5,"Maryland,North Carolina","269,264",266.5,38.7,24.95,12.5,3609129.5,66.9125,10.6,"After","0",0.595,"Mixed","small",36.3165583676587,"non-acute","chronic","non-cancer","2","2","3","1","1","1","2","3","2","2","1","3","1","2","1","2","0","2",87.5674144704789,78.3505355397216,85.85865,21.8598,58.15,67.1375,3416078,87.1,57845,21.5,1908832.5,12.6,9.61737201130678,"2","2","2","2","2","2","1","1","2","2","2","1","2","non-elderly",25.1804101076396,"veterans"
"233","NCT01933399",305,"Interventional",NA,2007-09-30,2013-12-31,"Comparison of Inextensible and Extensible Lumbosacral Orthoses for the Management of Episodes of Lower Back Pain",98,"Other","United States",27,73,0,73,61,98,2007,2013,6,"North America",0,"United States","Non-Industry","Earlier 2013",4913262,"Inextensible LSO (stiff back support), Extensible LSO, a back support that is flexible, Standard of Care",0,"Non-opioids",98,26,72,0,72,NA,"chronic",NA,73.469387755102,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","non-female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"1",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"Before","0",0.7,"R","small",28.2226091262223,"non-acute","chronic","non-cancer","2","1","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",76.1,59.5,84.2453,15.6606,57.8,74.075,459420,84.0662404083938,44213,7,1294689,14.1,6.67607176575867,"0","0","1","0","2","3","0","1","0","0","1","2","0","non-elderly",27.924975713455,"general"
"234","NCT01940744",307,"Interventional",NA,2013-10-31,2014-12-31,"The Investigation of a Prescriptively Prescribed Non-Thrust Manipulation Versus a Pragmatically Prescribed Non-Thrust Manipulation for Treatment of Individuals With Low Back Pain: A Randomized Controlled Trial",46,"Other",NA,96,2,2,4,66,NA,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4912705,"Prescriptive Mobilization, Pragmatic Mobilization",0,"Non-opioids",63,61,1,1,2,NA,"chronic",NA,1.58730158730159,"yes",0.0806,781274.5,"Mixed","non-kids","Non-Government","non-female","non-veterans",7.8347257580276,3590,22.2262757861635,84.0845789535229,15.7347116379342,90.4279198356586,84.5696320139267,93.9333333333333,6.06666666666667,"0",32818.3333333333,"Iowa,Ohio,Ohio","34,368,368",256.666666666667,38.4333333333333,19.3,7.3,5232869,68.625,11.6,"After","0",0.57,"R","small",28.7731794617234,"non-acute","chronic","non-cancer","1","2","0","0","1","1","0","0","0","0","2","0","1","0","1","3","1","2",85.5177915014579,76.3375188854677,83.7408333333333,16.0947,51.4666666666667,68.525,3885459,89.9666666666667,53884,12.6666666666667,958782.666666667,14.3333333333333,7.49538553707397,"1","2","0","0","0","2","1","2","2","1","1","2","1","non-elderly",9.08099567598916,"general"
"235","NCT01944098",308,"Interventional","Phase 3",2013-08-31,2014-09-30,"Systemic Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients: A Randomized, Placebo-Controlled Pilot Study",20,"Other","United States",0,0,100,100,70,20,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4912447,"Lidocaine, Placebo",1,"Non-opioids",100,0,0,0,100,"Late Phase","acute",NA,0,"no",0.1607,3359030,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"After","0",0.54,"R","small",30.4516559104648,"acute","non-chronic","non-cancer","2","2","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",87.4857684869649,77.9851138742128,81.0207,17.1729,55.3,66.15,9100944,80,48532,41,3020029,14.8,10.0831815208954,"2","2","0","0","1","1","3","0","1","3","3","2","2","non-elderly",15.4454591297641,"general"
"236","NCT01951105",NA,"Interventional","Phase 4",2015-02-24,2017-09-25,"Corticostriatal Plasticity in the Transition to Chronic Pain: Effect of L-dopa",72,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4911911,NA,NA,"Non-opioids",59,36,20,3,23,"Late Phase","acute",NA,33.8983050847458,"no",0.142,1813590,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"1",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","1","3","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,86.1599,20.0284,52.8,65.4,5333389,92.9,60413,17,1813447,10.9,6.03837995473793,"2","2","2","2","1","1","2","3","3","2","2","0","0","non-elderly",14.101459603989,"general"
"237","NCT01956279",310,"Interventional","Phase 2",2013-10-01,2018-10-10,"Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)",170,"U.S. Fed","United States",42,56,2,58,12,170,2013,2018,5,"North America",0,"United States","Non-Industry","Earlier 2013",4911516,"Pregnenolone, Placebo",1,"Non-opioids",170,72,96,2,98,"Early Phase","chronic","veterans",56.4705882352941,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","2","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,83.1396,18.2358,55.1,67.375,4427718,84.4,46337,20,2090265,14.7,8.40197402658067,"1","1","0","1","1","2","1","1","0","2","2","2","1","non-elderly",21.225144850864,"veterans"
"238","NCT01967342",312,"Interventional",NA,2013-09-12,2016-12-31,"Reducing Disparities With Literacy-Adapted Psychosocial Treatments for Chronic Pain: A Comparative Trial",290,"Other",NA,33,67,0,67,70,NA,2013,2016,3,"North America",0,"United States","Non-Industry","Earlier 2013",4910673,"Pain Ed, CBT for Pain, Usual Care",0,"Non-opioids",290,194,96,0,96,NA,"chronic","minority",33.1034482758621,"yes",0.2404,1749905,"Mixed","non-kids","Non-Government","non-female","non-veterans",3.36955467834323,1910.66666666667,21.634990369898,84.4570749741659,18.6049242677819,88.7950212535985,81.3512700656808,89.7666666666667,10.2333333333333,"1",35654.6666666667,"Alabama,Alabama,North Carolina","278,278,264",273.333333333333,38.9,22.3,12.4666666666667,3105879,68.8333333333333,15.3666666666667,"After","0",0.73,"R","small",27.4993964811588,"non-acute","chronic","non-cancer","3","2","3","0","0","1","0","0","0","0","0","0","1","1","1","3","3","3",82.1789477965205,70.613297729199,81.8202,16.7218,48.8333333333333,70.9416666666667,2944911.33333333,85.7333333333333,46992.3333333333,23.3333333333333,1550261.66666667,17.2333333333333,7.34142439936486,"1","1","0","0","0","3","1","1","0","2","1","3","1","non-elderly",24.7323870107278,"minority"
"239","NCT01969240",313,"Interventional",NA,2013-10-31,2015-12-31,"Shared Decision Making in the Emergency Department: The Chest Pain Choice Trial",898,"Other","United States",59,34,7,41,59,898,2013,2015,2,"North America",0,"United States","Non-Industry","Earlier 2013",4910527,"Chest Pain Choice Decision Aid",0,"Non-opioids",898,531,309,58,367,NA,"cardio",NA,34.4097995545657,"yes",0.0977,1609380.4,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.7290054428005,8880.8,20.3979316641402,86.010413202223,21.6828385372731,92.07072282059,85.9061324471214,91.94,8.06,"1",40961,"California,Florida,Indiana,Minnesota,Pennsylvania","808,620,144,71,308",390.2,39.08,17.76,9.28,7034286.2,66.21,11.62,"After","0",0.518,"Mixed","large",32.1364654286847,"non-acute","non-chronic","non-cancer","3","2","1","1","2","1","1","1","2","2","1","1","2","0","2","2","1","1",87.2181148023264,78.1414832917963,83.8179,17.87324,53.02,67.41,6749041,86.18,55652.2,24.4,1485164.8,13.72,10.6092519914788,"2","2","0","1","1","2","2","1","2","2","1","1","2","non-elderly",9.21874615448683,"general"
"240","NCT01981174",314,"Interventional",NA,2013-11-30,2014-01-31,"The Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin A Injections",20,"Other",NA,85,5,10,15,20,NA,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4909614,"30-gauge needle, 32-gauge needle",0,"Non-opioids",20,17,1,2,3,NA,"acute","healthy",5,"no",0.142,1813590,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","1",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","0","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,85.2169,20.2469,49,67.175,5313209,87.3,53937,25,1806889,13.6,6.03837995473793,"2","2","1","2","0","2","2","1","2","2","2","1","0","non-elderly",14.0263162899628,"general"
"241","NCT01986751",315,"Interventional","Phase 1/Phase 2",2014-01-31,2015-12-31,"Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery",14,"Other","United States",0,0,100,100,64,14,2014,2015,1,"North America",0,"United States","Non-Industry","After 2013",4909188,"Clonidine, ropivacaine",1,"Non-opioids",14,0,0,0,14,"Early Phase","acute",NA,0,"no",0.2664,1299050,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.62507069982056,900,22.6392183673469,83.3613868714217,17.195147573548,87.6352559797239,80.1686731141783,90.3,9.7,"0",33928,"Alabama","278",278,39.1,20.7,12.4,2284847,70.725,16,"After","1",0.77,"R","small",25.3013815767412,"acute","non-chronic","non-cancer","0","2","3","0","0","1","0","0","0","0","1","0","1","0","0","3","3","3",80.7384347419183,68.6905055914454,79.7757,15.0722,49.1,72.125,2213610,87.9,42278,12,1285731,17.8,6.81114958575696,"0","0","0","0","0","3","0","2","0","1","1","3","0","non-elderly",26.5133232578123,"general"
"242","NCT01996254",NA,"Interventional","N/A",2013-10-31,2019-01-28,"A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Pilot Study of the SPRINT Peripheral Nerve Stimulation (PNS) System for the Treatment of Post-Amputation Pain",28,"Industry",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Industry",NA,4908466,NA,NA,"Non-opioids",26,25,1,NA,1,NA,"chronic",NA,3.84615384615385,"yes",0.17148,1657885,"Mixed","non-kids","Non-Government","non-female","non-veterans",92.4168220845,8711.3,22.7858993208689,87.8453452698235,25.233025449637,92.8322609215592,86.913240387902,91.85,8.15,"0",48474.2,"Arizona,California,Colorado,Florida,Illinois,Maryland,New Jersey,New York,North Carolina","60,808,52,620,532,269,243,292,264",348.888888888889,38.7,28.8666666666667,13.9666666666667,5455547.4,60.765,11.73,"After","0",0.526666666666667,"Mixed","small",38.2301422682959,"non-acute","chronic","non-cancer","0","2","3","3","2","2","2","3","3","2","1","2","2","3","2","0","1","1",88.163346548774,79.357129238437,85.50634,21.64691,53.36,61.405,5230010.2,86.25,57325.3,22,1554874.9,14.76,8.57287888787122,"2","2","1","2","1","0","2","1","2","2","1","2","1","non-elderly",16.8337591144389,"general"
"243","NCT02024724",NA,"Interventional","Phase 4",2013-11-30,2017-03-31,"Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial.",60,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4906292,NA,NA,"Non-opioids",60,47,8,5,12,"Late Phase","chronic",NA,13.3333333333333,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"non-acute","chronic","non-cancer","1","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,85.2169,20.2469,49,67.175,5313209,87.3,53937,25,1806889,13.6,6.03837995473793,"2","2","1","2","0","2","2","1","2","2","2","1","0","non-elderly",14.0263162899628,"general"
"244","NCT02027623",NA,"Interventional","N/A",2013-12-31,2017-11-30,"Spinal Control During Functional Activities to Improve Low Back Pain Outcomes",154,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4906070,NA,NA,"Non-opioids",149,110,23,16,39,NA,"chronic",NA,15.4362416107383,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"non-acute","chronic","non-cancer","2","2","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,85.7808,15.8469,53.4,71.325,2735758,87,46303,13,686360,17.5,6.97619334002276,"1","1","2","0","1","3","1","1","0","1","0","3","0","non-elderly",11.3557343099658,"general"
"245","NCT02043704",317,"Interventional","Phase 4",2014-01-31,2016-08-31,"The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial",100,"Other","United States",100,0,0,0,100,90,2014,2016,2,"North America",0,"United States","Non-Industry","After 2013",4904840,"IV Acetaminophen",1,"Non-opioids",90,90,0,0,0,"Late Phase","acute","female",0,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","2","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,83.7712,16.2176,51.5,67.375,5162087,91.6,49644,21,1402190,15.6,7.8918800096186,"1","2","0","0","0","2","2","3","1","2","1","3","1","non-elderly",12.0939303682379,"female"
"246","NCT02044991",NA,"Interventional","Phase 2",2013-10-24,2017-02-22,"The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial",2,"Other",NA,NA,NA,NA,NA,NA,NA,2013,NA,NA,"North America",NA,"United States","Non-Industry",NA,4904741,NA,NA,"Non-opioids",2,2,0,0,0,"Early Phase","acute","female",0,"no",0.142,1813590,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","0","2","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,85.2169,20.2469,49,67.175,5313209,87.3,53937,25,1806889,13.6,6.03837995473793,"2","2","1","2","0","2","2","1","2","2","2","1","0","non-elderly",14.0263162899628,"female"
"247","NCT02046382",318,"Interventional","Phase 4",2014-01-31,2017-05-31,"Randomized Control Trial of IV Acetaminophen for Post Cesarean Delivery Pain Relief",132,"Other","United States",58,38,4,42,100,104,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4904635,"IV Acetaminophen, Placebo",1,"Non-opioids",104,60,40,4,44,"Late Phase","acute","female",38.4615384615385,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","2","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,83.7712,16.2176,51.5,67.375,5162087,91.6,49644,21,1402190,15.6,7.8918800096186,"1","2","0","0","0","2","2","3","1","2","1","3","1","non-elderly",12.0939303682379,"female"
"248","NCT02049086",319,"Interventional",NA,2014-03-31,2018-01-31,"Pain Management for Veterans Filing Compensation Claims",120,"Other",NA,60,15,25,40,16,NA,2014,2018,4,"North America",0,"United States","Non-Industry","After 2013",4904428,"SBIRT-PM, Pain Module",0,"Non-opioids",358,215,54,89,143,NA,"chronic","veterans",15.0837988826816,"no",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After",NA,0.43,"D","large",39.6963200211786,"non-acute","chronic","non-cancer","3","2","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",88.3766067526777,82.1959300560243,86.774,22.9186,55.2,67.375,1502807,93.1,70161,2,349742,8.6,10.6706250487306,"2","3","2","2","1","2","0","3","3","0","0","0","2","non-elderly",9.72403137674025,"veterans"
"249","NCT02062879",320,"Interventional","Phase 3",2014-04-30,2016-06-30,"Ketamine Patient-Controlled Analgesia for Acute Pain in Native Airway Multiple and Orthopedic Trauma Patients: A Randomized, Active Comparator, Blinded Trial",20,"Other",NA,75,20,5,25,20,NA,2014,2016,2,"North America",0,"United States","Non-Industry","After 2013",4903373,"Ketamine, Hydromorphone",1,"Opioids",20,15,4,1,5,"Late Phase","acute",NA,20,"no",0.1241,1446190,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","0","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,83.7712,16.2176,51.5,67.375,5162087,91.6,49644,21,1402190,15.6,7.8918800096186,"1","2","0","0","0","2","2","3","1","2","1","3","1","non-elderly",12.0939303682379,"general"
"250","NCT02068027",321,"Interventional","Phase 2",2014-03-31,2015-03-31,"A Multicenter Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group Study to Determine the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy",260,"Industry","United States",74,23,3,26,42,260,2014,2015,1,"North America",0,"United States","Industry","After 2013",4902981,"Clonidine Gel 0.1%, Placebo",1,"Non-opioids",260,192,61,7,68,"Early Phase","chronic",NA,23.4615384615385,"yes",0.132514285714286,1433513.85714286,NA,"non-kids",NA,"non-female","non-veterans",12.8248957582257,6811.5652173913,22.4308099970444,86.9736762209888,22.4101310544272,92.4114780746052,85.5482899963388,88.9173913043478,11.0826086956522,"1",44266.6956521739,"Arizona,California,California,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Indiana,Kansas,Missouri,North Carolina,Rhode Island,South Carolina,Texas,Texas,Texas,Virginia,Washington","60,808,808,41,41,620,620,620,620,620,620,542,144,60,318,264,7,229,624,624,624,249,79",401.826086956522,39.1608695652174,22.9304347826087,12.8521739130435,6629762.56521739,64.8858695652174,12.6347826086957,"After","1",0.555652173913043,"Mixed","small",32.3447338293532,"non-acute","chronic","non-cancer","3","2","2","1","2","1","2","1","2","2","0","2","2","1","2","1","2","2",87.2656158500198,77.6992744285694,85.1862956521739,19.8842086956522,56.0086956521739,64.5380434782609,6290280.43478261,86.395652173913,53577.0869565217,25.6521739130435,1875287.91304348,14.8,9.4075765222896,"2","2","1","2","2","1","2","1","2","3","2","2","2","non-elderly",12.8803773677242,"general"
"251","NCT02077140",NA,"Interventional","Phase 2",2014-02-28,2016-02-29,"A Phase II, Dose-escalating, Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetic Profile of MDT-10013 Versus Standard of Care in the Treatment of Acute Postoperative Pain Following Bunionectomy",192,"Industry",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Industry",NA,4902284,NA,NA,"Non-opioids",192,159,24,9,33,"Early Phase","acute",NA,12.5,"yes",0.08315,1872836,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.6001957677726,6496.5,23.8389900707676,89.9031612104085,25.0564005167016,92.8880569632359,85.674160906812,85.15,14.85,"1",46979,"Arizona,Texas","60,624",342,39.15,18.4,8.55,7179667,64.125,14.05,"After",NA,0.585,"R","small",29.9444542707173,"acute","non-chronic","non-cancer","2","2","1","1","2","2","3","2","3","2","0","2","2","0","2","1","3","2",87.1528484227803,76.5950178931972,89.0534,23.5561,58.8,62.8625,6677985.5,83.65,51564.5,27.5,1708115.5,18.8,7.72476740254308,"2","2","3","3","2","1","2","0","1","3","2","3","1","non-elderly",7.81703251358408,"general"
"252","NCT02087748",NA,"Interventional","Phase 4",2014-03-31,2014-05-31,"A Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness",24,"Other",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4901474,NA,NA,"Non-opioids",24,13,9,2,11,"Late Phase","acute",NA,37.5,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","1",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","0","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.7711,22.752,50.5,54.225,13906691,87.6,60487,40,2155733,15.8,14.2617707647834,"3","3","3","2","0","0","3","2","3","3","3","3","3","non-elderly",5.55565491914181,"general"
"253","NCT02093793",NA,"Interventional","N/A",2014-03-27,2019-08-29,"A Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Precision Spinal Cord Stimulator Systems Adapted for High-Rate Spinal Cord Stimulation",383,"Industry",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Industry",NA,4901014,NA,NA,"Non-opioids",256,216,17,23,40,NA,"chronic",NA,6.640625,"yes",0.117821428571429,1373314.85714286,"Mixed","non-kids","Non-Government","non-female","non-veterans",23.5662734017788,7513.45,23.7585895119448,87.429261533265,23.6478542207804,92.8763189240904,86.5536458946326,91.265,8.735,"0",42973.3,"Arizona,California,California,California,Florida,Illinois,Louisiana,Minnesota,Minnesota,Missouri,Nevada,New Jersey,North Carolina,Ohio,Oregon,Oregon,Oregon,Oregon,Texas,Washington","60,808,808,808,620,532,341,71,71,318,80,243,264,368,18,18,18,18,624,79",308.35,38.95,22.29375,9.9875,5386096.4,63.555,12.005,"After","0",0.531,"Mixed","small",32.8284066340622,"non-acute","chronic","non-cancer","3","2","1","2","2","2","2","2","3","2","1","1","2","1","2","1","2","1",88.2802141937464,79.0712012322754,86.09273,20.728445,54.825,63.4125,5169320.75,88.495,56264.2,22.375,1150720.55,14.805,10.2037847922101,"2","2","2","2","1","1","2","2","2","2","1","2","2","non-elderly",9.08386517309547,"general"
"254","NCT02101554",NA,"Interventional","Phase 4",2015-04-24,2019-06-26,"AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PF-06412528 IN CHILDREN 7-17 YEARS FOR THE TREATMENT OF MODERATE-TO-SEVERE PAIN",19,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4900420,NA,NA,"Opioids",19,11,6,2,7,"Late Phase","chronic","kids",31.5789473684211,"yes",0.11738,1936867.8,"Mixed","kids","Non-Government","non-female","non-veterans",23.2229057845499,12294.1052631579,22.451120218947,87.2886895458433,22.9579043560718,93.4329914750565,86.8631848141292,90.0210526315789,9.97894736842105,"1",44140.6842105263,"California,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Florida,Illinois,Illinois,Illinois,North Carolina,North Carolina,Utah,Utah","808,808,808,808,808,808,620,620,620,620,620,620,532,532,532,264,264,14,14",564.210526315789,38.9473684210526,27.1058823529412,12.2294117647059,9061433.36842105,62.8618421052632,12.2789473684211,"After",NA,0.541578947368421,"Mixed","small",33.0690643035909,"non-acute","chronic","non-cancer","0","3","1","2","3","1","2","2","3","2","1","2","3","3","3","1","2","1",88.3619307988568,79.348849213219,86.3073631578947,20.4444210526316,55.9789473684211,62.1421052631579,8762691.10526316,89.678947368421,57374.4736842105,30.0526315789474,2201038.26315789,13.8157894736842,10.8256370891421,"2","2","2","2","2","0","3","2","2","3","3","2","2","non-elderly",11.2549743642694,"kids"
"255","NCT02111746",324,"Interventional","Phase 4",2013-11-20,2017-06-30,"A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control",350,"Other","United States",59,17,24,41,36,343,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4899645,"Exparel, Bupivacaine hydrochloride, Patient Controlled Analgesia (PCA)",1,"Non-opioids",290,201,60,29,89,"Late Phase","acute",NA,20.6896551724138,"no",0.1213,3428210,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","1",0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","3","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,87.7181,22.2968,59,63.25,10298263,77.9,51406,49,3068699,16.9,9.43231929885351,"2","1","2","2","3","1","3","0","1","3","3","3","2","non-elderly",11.6026792454214,"general"
"256","NCT02113592",325,"Interventional",NA,2014-04-10,2018-02-28,"Collaborative Care for Chronic Pain in Primary Care",851,"NIH",NA,84,13,3,16,67,NA,2014,2018,4,"North America",0,"United States","Non-Industry","After 2013",4899503,"Interdisciplinary pain program",0,"Non-opioids",851,714,110,27,137,NA,"chronic",NA,12.9259694477086,"yes",0.117833333333333,1131241.33333333,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",30.3870611790143,2248.66666666667,21.5327580503145,90.6601583003579,27.6684971829316,92.5864973527876,85.9763728372195,91.7333333333333,8.26666666666667,"1",52040.3333333333,"Georgia,Hawaii,Oregon","542,2,18",187.333333333333,38.0666666666667,24.3,11.9,2245709.66666667,62.2666666666667,11.6,"After","0",0.536666666666667,"Mixed","large",33.1565078370529,"non-acute","chronic","non-cancer","3","2","1","2","0","1","3","3","2","2","1","3","0","2","0","0","1","1",88.9575249916367,79.9689850138419,89.8,24.4338666666667,55.8666666666667,61.4166666666667,2137061.66666667,89.7333333333333,59884.3333333333,24,1071098,14,11.4391353376391,"2","2","3","3","2","0","0","2","3","2","1","2","3","non-elderly",11.5308782243378,"general"
"257","NCT02116621",326,"Interventional",NA,2014-07-31,2017-05-01,"N-of-1 Trials Using mHealth in Chronic Pain Aka PREEMPT (Personalized Research for Monitoring Pain Treatment)",215,"Other","United States",72,13,15,28,47,430,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4899270,"Trialist Intervention, smartphone",0,"Non-opioids",215,155,27,33,60,NA,"chronic",NA,12.5581395348837,"yes",0.0579,2274110,"Mixed","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California,California","808,808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","2","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.7711,22.752,50.5,54.225,13906691,87.6,60487,40,2155733,15.8,14.2617707647834,"3","3","3","2","0","0","3","2","3","3","3","3","3","non-elderly",5.55565491914181,"general"
"258","NCT02120261",328,"Interventional","Phase 4",2014-05-31,2016-11-30,"Using Saline for Myofascial Pain Syndromes (USAMPS)",51,"Other","United States",12,33,55,88,73,48,2014,2016,2,"North America",0,"United States","Non-Industry","After 2013",4898991,"Normal Saline, Lidocaine Hydrochloride, Triamcinolone acetonide",1,"Non-opioids",48,6,16,26,42,"Late Phase","chronic",NA,33.3333333333333,"yes",0.1213,3428210,"Mixed","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas,Texas","624,624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","1","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,88.2289,21.8976,60.2,62.225,10441871,80.9,53875,50,3150560,16.4,9.43231929885351,"2","1","2","2","3","0","3","0","2","3","3","3","2","non-elderly",11.6873721433999,"general"
"259","NCT02130258",330,"Interventional",NA,2012-05-31,2017-12-31,"Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome",23,"Other","United States",80,5,15,20,65,20,2012,2017,5,"North America",0,"United States","Non-Industry","Earlier 2013",4898226,"Quantitative Sensory Testing (QST), Epidural Steroid Injection (ESI)",0,"Non-opioids",20,16,1,3,4,NA,"chronic",NA,5,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","1",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","0","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,76,89.7075,22.3615,52.4,65.825,2826209,95.861080399,63656,3,425654,11.3,9.2587366295912,"3","2","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.40452569188991,"general"
"260","NCT02143947",331,"Interventional",NA,2008-09-30,2010-04-30,"The Effect of Two Different Custom Molded Foot Orthoses on Inter-segmental Foot Kinematics and the EMG Activity of Selected Lower Leg Muscles During Walking and Running.",80,"Other","United States",0,0,100,100,71,80,2008,2010,2,"North America",0,"United States","Non-Industry","Earlier 2013",4897184,"Maximal Arch Subtalar Stabilization, Full Contact Orthosis",0,"Non-opioids",80,0,0,0,80,NA,"acute",NA,0,"no",0.1072,383416,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"0",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"Before","0",0.43,"D","small",39.6963200211786,"acute","non-chronic","non-cancer","1","1","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",86.8,82,89.0157,20.5814,61.5,70.7,2186987,90.630228110436,64682,2,335151,8.1,10.6706250487306,"2","3","3","2","3","3","0","2","3","0","0","0","2","non-elderly",9.36942019354931,"general"
"261","NCT02148588",332,"Interventional",NA,2014-08-31,2017-01-25,"How ""Central"" is Central Post-stroke Pain? Investigating the Role of Peripheral Sensory Input in Maintaining Central Pain",8,"Other","Denmark",38,62,0,62,50,8,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4896827,"Ultrasound-guided peripheral nerve block with 2% lidocaine",1,"Non-opioids",8,5,3,0,3,NA,"chronic",NA,37.5,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"non-acute","chronic","non-cancer","0","2","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,85.34,17.2099,55.4,70.525,2746573,88.3,56630,20,703873,10.4,6.97619334002276,"1","1","1","0","2","3","1","2","2","2","0","0","0","non-elderly",11.6081911224524,"general"
"262","NCT02161484",335,"Interventional",NA,2014-01-31,2014-06-17,"A Prospective, Randomized, Blinded, Controlled Study Evaluating the Efficacy of Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement",10,"Other","United States",100,0,0,0,60,10,2014,2014,0,"North America",0,"United States","Non-Industry","After 2013",4895839,"Continuous Lumbar Plexus Block, Parasacral Nerve Block, Ropivacine 0.2%, Bupivacaine 0.0625%",1,"Non-opioids",10,10,0,0,0,NA,"acute",NA,0,"no",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","0","2","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,76.6864143156432,85.2831,16.496,51.1,69.675,5632733,91.5,55173,11,1359575,12.5,12.1914636349471,"1","2","1","0","0","3","2","3","2","1","1","1","3","non-elderly",10.6323045161771,"general"
"263","NCT02161705",336,"Interventional","Phase 3",2014-07-31,2019-02-28,"Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy With Immediate Tissue Expander Reconstruction",18,"Other","United States",83,11,6,17,100,18,2014,2019,5,"North America",0,"United States","Non-Industry","After 2013",4895822,"Ropivacaine, Saline",1,"Non-opioids",18,15,2,1,3,"Late Phase","acute","female",11.1111111111111,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","0","2","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,89.7927,27.8278,59.5,66.225,2416438,92.1,76165,19,1744971,9.8,10.8327699960329,"3","3","3","3","3","1","1","3","3","2","2","0","2","non-elderly",29.1976600656548,"female"
"264","NCT02169336",NA,"Interventional","Phase 2",2014-06-30,2014-10-31,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy",95,"Industry",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Industry",NA,4895242,NA,NA,"Non-opioids",95,69,24,2,26,"Early Phase","acute",NA,25.2631578947368,"yes",0.0896,2851160,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",24.8523760533617,19593,24.2741921322493,90.6611210369943,26.3537530911145,93.7498005097033,87.528601688263,88.7333333333333,11.2666666666667,"1",50082,"California,California,Texas","808,808,624",746.666666666667,39.1666666666667,24.9666666666667,10.5,13338675,57.3583333333333,12.9,"After","1",0.54,"Mixed","small",33.0024568893766,"acute","non-chronic","non-cancer","2","2","1","2","3","3","3","3","3","3","0","3","3","2","3","0","3","1",88.7354841726577,79.4378625356392,89.2570333333333,22.4672,53.7333333333333,56.8916666666667,12751751,85.3666666666667,58283,43.3333333333333,2487342,16,12.6519536094734,"2","2","3","2","1","0","3","1","2","3","3","3","3","non-elderly",7.59956066056117,"general"
"265","NCT02178553",NA,"Interventional","Phase 4",2014-10-15,2019-01-25,"Randomized Non-inferiority Trial of Continuous Thoracic Epidural Analgesia Versus Single Intercostal Nerve Block After Thoracotomy",102,"Other",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4894536,NA,NA,"Non-opioids",84,82,0,2,2,"Late Phase","acute",NA,0,"no",0.0641,356515,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"0",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"After","0",0.49,"R","small",37.1630582351401,"acute","non-chronic","non-cancer","1","2","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",89.2519769380513,80.1058558348779,82.9852,18.9775,63,71.425,2389731,94.1,67244,2,307850,8.3,7.83802073605776,"2","2","0","1","3","3","1","3","3","0","0","0","1","non-elderly",5.64119920698867,"general"
"266","NCT02181387",338,"Interventional","Phase 4",2013-09-05,2014-06-30,"Does Acetaminophen Reduce Neuraxial Analgesic Requirement During Labor",33,"Other","United States",67,26,7,33,100,27,2013,2014,1,"North America",0,"United States","Non-Industry","Earlier 2013",4894320,"Acetaminophen, Placebo",1,"Non-opioids",27,18,7,2,9,"Late Phase","acute","female",25.9259259259259,"no",0.2144,2200760,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","0","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,83.1396,18.2358,55.1,67.375,4427718,84.4,46337,20,2090265,14.7,8.40197402658067,"1","1","0","1","1","2","1","1","0","2","2","2","1","non-elderly",21.225144850864,"female"
"267","NCT02205385",341,"Interventional",NA,2014-10-31,2018-01-01,"Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation",27,"U.S. Fed",NA,71.4,10.7,17.9,28.6,28.6,NA,2014,2018,4,"North America",0,"United States","Non-Industry","After 2013",4892484,"Targeted Muscle Reinnervation, Traction Neurectomy",0,"Non-opioids",28,20,3,5,8,NA,"chronic",NA,10.7142857142857,"yes",0.15445,1649651,"Mixed","non-kids","Non-Government","non-female","non-veterans",15.3169400879123,5399,23.5756161536107,88.0827150764386,22.3625513316355,91.2816495707603,84.6359660584665,89.5333333333333,10.4666666666667,"0",43328.8333333333,"Illinois,Maryland,Ohio,Oklahoma,Tennessee,Texas","532,269,368,140,201,624",355.666666666667,39.4833333333333,25.6666666666667,12.7,4858713.5,67.025,11.85,"After",NA,0.61,"Mixed","small",31.3741290252712,"non-acute","chronic","non-cancer","0","2","2","1","1","2","2","1","1","0","0","2","2","2","1","2","2","3",85.8333353814998,75.6060644039707,86.71275,20.6774666666667,55.4,66.3833333333333,4653165.33333333,87.9166666666667,54252.5,22.5,1581678.66666667,15.0166666666667,8.13730460142608,"1","2","2","2","2","1","2","2","2","2","1","2","1","non-elderly",15.1791269213844,"general"
"268","NCT02211534",NA,"Interventional","N/A",2014-09-30,2016-03-31,"A Randomized, Sham-Controlled Pilot Study of Pulsed Electromagnetic Field Therapy in the Treatment of Persistent Post-Operative Pain Following Total Knee Arthroplasty",35,"Industry",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Industry",NA,4892013,NA,NA,"Non-opioids",35,32,3,NA,3,NA,"acute",NA,8.57142857142857,"yes",0.1286,1358733,NA,"non-kids",NA,"non-female","non-veterans",28.7806980590531,6410.5,24.4922239748846,87.1843416958997,22.6023326916676,92.7490990575739,86.1717596354692,90.1928571428571,9.80714285714286,"0",44682.6428571429,"Alabama,Arizona,Arizona,California,Colorado,Florida,Florida,Nevada,New York,North Carolina,South Carolina,Utah,Virginia,Washington","278,60,60,808,52,620,620,80,292,264,229,14,249,79",264.642857142857,38.9857142857143,21.4083333333333,10.7166666666667,4949616.78571429,64.6375,12.4642857142857,"After",NA,0.562142857142857,"Mixed","small",32.5157197725706,"acute","non-chronic","non-cancer","0","2","2","2","1","3","2","1","2","2","1","2","1","1","1","1","2","2",87.7933107202351,78.2776428657791,85.43945,20.6442285714286,55.6142857142857,64.2517857142857,4724701.28571429,87.2571428571429,52785.5,14.8571428571429,1336595.71428571,15.6214285714286,8.63932485455923,"2","2","1","2","2","1","2","1","2","1","1","3","1","non-elderly",12.0940354474456,"general"
"269","NCT02219308",343,"Interventional",NA,2014-10-31,2017-10-31,"Pain Control for Intrauterine Device Placement: A Randomized Controlled Trial of Paracervical Block",67,"Other","United States",64,3,33,36,100,64,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4891420,"Paracervical Block (PCB), No Paracervical Block (Sham PCB)",0,"Non-opioids",64,41,2,21,23,NA,"acute","female",3.125,"yes",0.0579,2274110,"Mixed","non-kids","Non-Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California,California","808,808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After",NA,0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","1","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.7711,22.752,50.5,54.225,13906691,87.6,60487,40,2155733,15.8,14.2617707647834,"3","3","3","2","0","0","3","2","3","3","3","3","3","non-elderly",5.55565491914181,"female"
"270","NCT02222129",344,"Interventional","Phase 4",2012-12-31,2013-12-31,"A Randomized Controlled Trial for Pain Control in Laparoscopic Urologic Surgery: 0.25% Bupivacaine Versus Long-Acting Liposomal Bupivacaine",206,"Other","United States",38,6,56,62,37,191,2012,2013,1,"North America",0,"United States","Non-Industry","Earlier 2013",4891203,"Bupivacaine, liposomal bupivacaine",1,"Non-opioids",191,73,11,107,118,"Late Phase","acute",NA,5.75916230366492,"yes",0.1213,3428210,"Mixed","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas,Texas","624,624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","2","2","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,61.2,81.5241,17.8842,58.6,64.3,10167972,75.392710262,51926,45,3015396,17,9.43231929885351,"2","0","0","1","2","1","3","0","1","3","3","3","2","non-elderly",11.5713285628881,"general"
"271","NCT02229539",345,"Interventional","Phase 3",2014-11-30,2019-03-15,"A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy",275,"Other","United States",92,6,2,8,23,228,2014,2019,5,"North America",0,"United States","Non-Industry","After 2013",4890634,"doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo",1,"Non-opioids",228,210,14,4,18,"Late Phase","cancer",NA,6.14035087719298,"yes",0.100671428571429,813615.428571429,"Mixed","non-kids","Non-Government","non-female","non-veterans",21.1509918246409,4675.66857142857,23.1334467628598,86.9730260714271,21.2889623315575,92.2381583885303,85.8407997561428,91.8088571428571,8.19114285714286,"0",40996.4314285714,"Alaska,Alaska,Alaska,Alaska,Alaska,Alaska,Alaska,Alaska,California,California,California,California,California,California,California,California,California,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Colorado,Connecticut,Connecticut,Florida,Florida,Florida,Florida,Florida,Idaho,Idaho,Idaho,Idaho,Idaho,Idaho,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Illinois,Indiana,Indiana,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Iowa,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Kansas,Maine,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Michigan,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Minnesota,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Missouri,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,Nevada,New York,New York,New York,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Carolina,North Dakota,North Dakota,North Dakota,North Dakota,North Dakota,Oklahoma,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Oregon,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Carolina,South Dakota,South Dakota,South Dakota,South Dakota,Virginia,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Washington,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin,Wisconsin","7,7,7,7,7,7,7,7,808,808,808,808,808,808,808,808,808,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,52,41,41,620,620,620,620,620,1,1,1,1,1,1,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,532,144,144,34,34,34,34,34,34,34,34,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,60,4,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,277,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,71,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,318,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,80,292,292,292,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,264,1,1,1,1,1,140,18,18,18,18,18,18,18,18,308,308,308,308,308,308,308,308,229,229,229,229,229,229,229,229,229,229,229,229,229,229,1,1,1,1,249,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,79,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96,96",198.272988505747,38.72,22.8643636363636,10.3938181818182,3444366.07602339,66.1567857142857,11.1077142857143,"After","0",0.523667621776504,"Mixed","small",32.7584822613699,"non-acute","non-chronic","cancer","3","2","1","2","1","2","2","1","2","2","1","1","0","1","1","2","1","1",87.5791833761471,78.1227844751979,85.1269291428571,19.0139737820034,54.9865714285714,66.4076428571429,3272632.39428571,89.5328571428571,55698.8371428571,12.4259259259259,841951.208571429,13.2122857142857,8.17025378429277,"2","2","1","1","1","1","1","2","2","1","0","1","1","non-elderly",9.71104102112447,"general"
"272","NCT02242630",347,"Interventional",NA,2014-09-30,2016-03-31,"Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone",61,"U.S. Fed","United States",85,5,10,15,50,NA,2014,2016,2,"North America",0,"United States","Non-Industry","After 2013",4889634,"Methylprednisolone, 20 mg, Methylprednisolone, 40 mg, Triamcinolone, 20 mg, Triamcinolone, 40 mg",1,"Non-opioids",61,52,3,6,9,NA,"chronic",NA,4.91803278688525,"no",0.3772,1125620,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.48553219721085,691,17.684724137931,81.4430344745015,16.6604189620448,86.5523577234306,76.7265632540255,87,13,"0",30714,"Mississippi","208",208,38.8,26.5,12.8,1339021,72.675,19.8,"After","0",0.77,"R","small",23.4432286291715,"non-acute","chronic","non-cancer","1","2","3","0","0","0","0","0","0","0","0","0","0","3","0","3","3","3",78.8144755571492,61.8841296229894,76.757,14.9389,44.5,73.225,1299780,85.5,35521,18,1128351,22.1,8.14529166855491,"0","0","0","0","0","3","0","1","0","2","1","3","1","non-elderly",37.6860797594185,"general"
"273","NCT02244619",NA,"Interventional","Phase 4",2014-09-30,2016-04-30,"Randomized, Double-Blind, Study Comparing Oral Acetaminophen Plus Intravenous (IV) Placebo to Oral Placebo Plus IV Acetaminophen Given Perioperatively for Controlling Pain in the 24hr Post-op Period After Total Hip or Knee Joint Replacement",515,"Other",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4889481,NA,NA,"Opioids",486,464,14,8,22,"Late Phase","acute",NA,2.88065843621399,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After",NA,0.58,"R","large",28.8464382806458,"acute","non-chronic","non-cancer","3","2","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,83.7712,16.2176,51.5,67.375,5162087,91.6,49644,21,1402190,15.6,7.8918800096186,"1","2","0","0","0","2","2","3","1","2","1","3","1","non-elderly",12.0939303682379,"general"
"274","NCT02262039",NA,"Interventional","N/A",2014-08-31,2016-02-29,"Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System: A Randomized Control Trial",41,"Other",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Non-Industry",NA,4888151,NA,NA,"Non-opioids",41,33,4,4,8,NA,"acute",NA,9.75609756097561,"no",0.1072,383416,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"0",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After","1",0.43,"D","small",39.6963200211786,"acute","non-chronic","non-cancer","1","2","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",88.3766067526777,82.1959300560243,86.774,22.9186,55.2,67.375,1502807,93.1,70161,2,349742,8.6,10.6706250487306,"2","3","2","2","1","2","0","3","3","0","0","0","2","non-elderly",9.72403137674025,"general"
"275","NCT02262377",349,"Interventional",NA,2015-04-30,2016-11-30,"Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression in a Disparate Urban Population",159,"Other",NA,19,56,25,81,86,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4888125,"Integrative Medicine Group Visits",0,"Non-opioids",155,29,87,39,126,NA,"chronic","minority",56.1290322580645,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","2","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.3426629317023,85.3926,24.045,60,60.5,2865240,97.2,67861,3,459884,11.5,9.2587366295912,"3","3","1","3","3","0","1","3","3","0","0","0","2","non-elderly",6.76855220355757,"minority"
"276","NCT02265848",350,"Interventional","Phase 4",2014-10-31,2015-01-31,"Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief",22,"Other","United States",91,9,0,9,36,66,2014,2015,1,"North America",0,"United States","Non-Industry","After 2013",4887860,"High frequency stimulation, Low frequency stimulation",0,"Non-opioids",22,20,2,0,2,"Late Phase","chronic",NA,9.09090909090909,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","0","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.0046,19.2992,53.9,66.425,4472159,86.9,46784,21,2124971,17.1,8.40197402658067,"1","1","0","1","1","1","1","1","0","2","2","3","1","non-elderly",21.3694558829859,"general"
"277","NCT02284243",351,"Interventional","Phase 2",2014-10-31,2015-06-30,"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy",168,"Industry","United States",68,24,8,32,92,168,2014,2015,1,"North America",0,"United States","Industry","After 2013",4886452,"Intranasal Dexmedetomidine, Intranasal Placebo",1,"Non-opioids",168,115,41,12,53,"Early Phase","acute",NA,24.4047619047619,"yes",0.0896,2851160,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",24.8523760533617,19593,24.2741921322493,90.6611210369943,26.3537530911145,93.7498005097033,87.528601688263,88.7333333333333,11.2666666666667,"1",50082,"California,California,Texas","808,808,624",746.666666666667,39.1666666666667,24.9666666666667,10.5,13338675,57.3583333333333,12.9,"After","1",0.54,"Mixed","small",33.0024568893766,"acute","non-chronic","non-cancer","2","2","1","2","3","3","3","3","3","3","0","3","3","2","3","0","3","1",88.7354841726577,79.4378625356392,89.2570333333333,22.4672,53.7333333333333,56.8916666666667,12751751,85.3666666666667,58283,43.3333333333333,2487342,16,12.6519536094734,"2","2","3","2","1","0","3","1","2","3","3","3","3","non-elderly",7.59956066056117,"general"
"278","NCT02284386",352,"Interventional","Phase 4",2014-12-31,2015-03-31,"Evaluation of the Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Subjects Undergoing for Unilateral Total Knee Arthroplasty",15,"Industry","United States",100,0,0,0,53,15,2014,2015,1,"North America",0,"United States","Industry","After 2013",4886442,"Bupivacaine SNB, EXPAREL Infiltration",1,"Non-opioids",15,15,0,0,0,"Late Phase","acute",NA,0,"yes",0.16525,827782.5,"Mixed","non-kids","Non-Government","non-female","non-veterans",10.0939763084642,2046,20.8247390687309,82.5525719723894,20.1092022634362,90.1471749409561,83.8178033183584,92.7,7.3,"0",35869.5,"Alabama,Minnesota","278,71",174.5,38.8,17.05,9.85,2381300,71.075,12.35,"After","0",0.63,"R","small",31.2322199059406,"acute","non-chronic","non-cancer","0","2","3","1","0","1","0","0","0","0","2","0","0","0","0","3","2","3",84.9952058399848,74.3981807131617,81.38045,17.02485,56.05,71.775,2301670.5,91,54761,7,796790.5,13.05,7.32458516090736,"1","1","0","0","2","3","0","2","2","0","0","1","1","non-elderly",16.0772612324005,"general"
"279","NCT02288364",354,"Interventional","Phase 4",2014-12-31,2015-08-31,"Does Sodium Bicarbonate Reduce the Pain of Lidocaine for Local Anesthesia in Percutaneous Breast Biopsies?",88,"Other","United States",69,28,3,31,100,86,2014,2015,1,"North America",0,"United States","Non-Industry","After 2013",4886136,"1% Lidocaine, 1% Lidocaine plus sodium bicarbonate",1,"Non-opioids",86,59,24,3,27,"Late Phase","acute","female",27.906976744186,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","2","2","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.0046,19.2992,53.9,66.425,4472159,86.9,46784,21,2124971,17.1,8.40197402658067,"1","1","0","1","1","1","1","1","0","2","2","3","1","non-elderly",21.3694558829859,"female"
"280","NCT02290223",NA,"Interventional","N/A",2015-06-30,2017-09-06,"Patient Activation to Address Chronic Pain and Opioid Management in Primary Care",376,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4885995,NA,NA,"Non-opioids",376,280,18,78,96,NA,"chronic",NA,4.78723404255319,"yes",0.0579,2274110,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California,California","808,808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","large",34.3650287791398,"non-acute","chronic","non-cancer","3","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.0021,24.4005,53.8,54.275,13985614,91.4,63636,44,2192844,13.9,14.2617707647834,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.60187557903577,"general"
"281","NCT02300077",355,"Interventional",NA,2014-12-31,2018-02-12,"Methadone in Ambulatory Surgery",60,"Other","United States",67,32,1,33,92,60,2014,2018,4,"North America",0,"United States","Non-Industry","After 2013",4885239,"methadone, Control (Intra-operative administration of opioids, other than methadone)",1,"Opioids",60,40,19,1,20,NA,"acute",NA,31.6666666666667,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"acute","non-chronic","non-cancer","1","2","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,85.34,17.2099,55.4,70.525,2746573,88.3,56630,20,703873,10.4,6.97619334002276,"1","1","1","0","2","3","1","2","2","2","0","0","0","non-elderly",11.6081911224524,"general"
"282","NCT02301741",356,"Interventional",NA,2015-01-31,2016-04-30,"Using an Interactive Game to Reduce Fear & Increase Spine Motion in Low Back Pain",53,"Other",NA,85,11,4,15,48,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4885112,"Game",0,"Non-opioids",52,42,6,4,10,NA,"chronic",NA,11.5384615384615,"no",0.1241,1446190,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After",NA,0.58,"R","small",28.8464382806458,"non-acute","chronic","non-cancer","1","3","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,85.2096,16.7513,53.5,66.475,5173946,93.5,53301,22,1409506,13.6,7.8918800096186,"1","2","1","0","1","2","2","3","2","2","1","1","1","non-elderly",12.1368695517248,"general"
"283","NCT02308475",357,"Interventional",NA,2014-12-31,2015-07-06,"Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System",2,"Other","United States",0,100,0,100,100,2,2014,2015,1,"North America",0,"United States","Non-Industry","After 2013",4884595,"Somatom Force CT Scanner",0,"Non-opioids",2,0,2,0,2,NA,"cardio",NA,100,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","non-female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"1",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"After",NA,0.7,"R","small",28.2226091262223,"non-acute","non-chronic","non-cancer","0","2","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",83.3964736178037,70.2770205967591,79.8226,14.7453,52,72.975,2201469,86.4,44929,7,1311369,16.5,6.67607176575867,"1","1","0","0","0","3","0","1","0","0","1","3","0","non-elderly",27.1365521899513,"general"
"284","NCT02327325",358,"Interventional",NA,2015-05-21,2017-03-01,"Physical Activity for Older Adults With Chronic Low Back Pain: PACe-LBP",60,"Other",NA,47,50,3,53,7,NA,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4883156,"Physical Activity, Cognitive Behavioral Therapy",0,"Non-opioids",60,28,31,1,32,NA,"chronic","elderly",51.6666666666667,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","1","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.8782,20.0125,56.1,65.2,4515185,88.8,50797,13,2141818,15.3,8.40197402658067,"1","1","1","2","2","1","2","2","1","1","2","2","1","elderly",21.3268966170995,"elderly"
"285","NCT02327559",359,"Interventional",NA,2011-10-31,2015-02-28,"Randomized Controlled Trial of a Mindfulness Intervention for Labor-Related Pain and Fear",33,"Other",NA,59,7,34,41,100,NA,2011,2015,4,"North America",0,"United States","Non-Industry","Earlier 2013",4883139,"Mind in Labor (MIL): Working with Pain in Childbirth, Treatment as usual (TAU)",0,"Non-opioids",29,17,2,10,12,NA,"acute","female",6.89655172413793,"no",0.0579,2274110,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","0","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,76.6,81.0994,19.2392,47.1,55.3,13728423,80.271144403,53367,49,2148618,16.9,14.2617707647834,"3","2","0","1","0","0","3","0","2","3","2","3","3","non-elderly",5.70047494539412,"female"
"286","NCT02329743",NA,"Interventional","Phase 2",2014-12-31,2015-09-30,"A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery",256,"Industry",NA,NA,NA,NA,NA,NA,NA,2014,NA,NA,"North America",NA,"United States","Industry",NA,4882972,NA,NA,"Non-opioids",236,197,20,19,39,"Early Phase","acute",NA,8.47457627118644,"no",0.1346,1194880,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",45.8441178126936,7207,19.0587173913044,87.9523561065641,25.3564725763369,93.0681905605973,88.3455657210031,92.1,7.9,"0",53247,"New Jersey","243",243,39.2,26.2,9.6,3641812,65.025,9.1,"After","0",0.55,"D","small",40.5519319574834,"acute","non-chronic","non-cancer","3","2","2","3","2","0","2","3","3","3","1","3","1","2","1","1","0","2",88.1893861377939,82.1778985515202,87.9605,23.6343,57,65.15,3583860,89.1,65243,10,1145128,11.3,6.46340496986729,"2","3","2","3","2","1","1","2","3","1","1","0","0","non-elderly",12.8116533856184,"general"
"287","NCT02340806",NA,"Interventional","N/A",2015-01-31,2017-03-31,"Effect of Epidural Infusion Bolus Delivery Rate on the Duration of Labor Analgesia",220,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4882125,NA,NA,"Non-opioids",210,165,12,33,45,NA,"acute","female",5.71428571428571,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","2","3","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,86.1599,20.0284,52.8,65.4,5333389,92.9,60413,17,1813447,10.9,6.03837995473793,"2","2","2","2","1","1","2","3","3","2","2","0","0","non-elderly",14.101459603989,"female"
"288","NCT02343263",363,"Interventional","Phase 2",2015-03-31,2017-05-31,"Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage: a Clinical Trial.",18,"Other","United States",78,11,11,22,89,9,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4881938,"Bupivacaine, Fibrin Sealant",1,"Non-opioids",9,7,1,1,2,"Early Phase","acute","kids",11.1111111111111,"no",0.094,626587,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"After","0",0.54,"R","small",26.882966396292,"acute","non-chronic","non-cancer","0","3","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",85.0256665939072,74.1462592296165,85.3015,16.7549,57.8,69.425,2854584,90.4,51983,10,596275,13.5,8.67182330071009,"1","1","1","0","2","2","1","2","1","1","0","1","1","non-elderly",9.00761063978923,"kids"
"289","NCT02351700",365,"Interventional","Phase 4",2015-02-01,2016-04-01,"Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors",62,"Other",NA,80,2,18,20,46,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4881295,"IV Caldolor (IV Ibuprofen), IV Ibuprofen placebo",1,"Non-opioids",62,50,1,11,12,"Late Phase","acute",NA,1.61290322580645,"no",0.045,317462,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",13.1690644369743,2618,21.9949418181818,89.8384852939726,25.0101131688258,93.3056955655765,86.6387024886614,88.7,11.3,"0",47386,"Arizona","60",60,38.2,10.3,7.8,3075981,65.825,14.4,"After","0",0.53,"R","small",29.6115954315844,"acute","non-chronic","non-cancer","1","3","0","1","0","1","3","2","3","2","0","2","0","0","1","2","3","1",87.6389558800363,78.4439945887393,88.4795,24.2778,62.9,61.725,2936981,89.2,52248,1,282718,17.2,6.01721550623265,"2","2","2","3","3","0","1","2","1","0","0","3","0","non-elderly",4.1405288321069,"general"
"290","NCT02352714",366,"Interventional","Phase 4",2015-01-31,2016-07-31,"Study of Pain Control With Hormonal IUS Insertion (SOPHI Study)",98,"Industry",NA,48,36,15,51,100,NA,2015,2016,1,"North America",0,"United States","Industry","After 2013",4881218,"Paracervical Nerve Block, Sham Paracervical Block",1,"Non-opioids",95,45,24,16,40,"Late Phase","acute","female",25.2631578947368,"yes",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"1",38560,"Pennsylvania,Pennsylvania,Pennsylvania","308,308,308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","1",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","2","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,76.6864143156432,84.9899,17.3603,53.8,69.575,5654171,93.6,60389,15,1349101,12.3,12.1914636349471,"1","2","1","0","1","2","2","3","3","1","1","1","3","non-elderly",10.5377909304142,"female"
"291","NCT02355158",367,"Interventional","Phase 2",2014-06-30,2015-09-30,"A Multicenter, Open-label, Single-arm Study to Evaluate the Long-term Use of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy",197,"Industry","United States",74,24,2,26,45,197,2014,2015,1,"North America",0,"United States","Industry","After 2013",4881031,"clonidine hydrochloride topical gel, 0.1%",1,"Non-opioids",197,146,47,4,51,"Early Phase","chronic",NA,23.8578680203046,"yes",0.118336363636364,1497897.90909091,NA,"non-kids",NA,"non-female","non-veterans",13.941098819764,7964.6,23.0999007361593,87.3387760280639,22.9463328592582,92.6397819140584,85.7184877447397,88,12,"1",44703.25,"Arizona,California,California,Connecticut,Florida,Florida,Florida,Florida,Florida,Florida,Georgia,Kansas,Missouri,North Carolina,Rhode Island,Texas,Texas,Texas,Texas,Washington","60,808,808,41,620,620,620,620,620,620,542,60,318,264,7,624,624,624,624,79",460.15,39.21,22.935,11.62,7670421.95,64.04375,12.89,"After","1",0.557,"Mixed","small",31.9966168156064,"non-acute","chronic","non-cancer","2","2","1","1","2","2","2","2","2","2","0","2","3","1","2","1","3","2",87.437332253996,77.7961151138397,85.51059,20.1928,56.525,63.37125,7256375.35,85.565,52842.15,31,2122169.45,15.345,9.62961259024711,"2","2","1","2","2","1","3","1","2","3","2","3","2","non-elderly",12.1507834936298,"general"
"292","NCT02359006",368,"Interventional",NA,2015-03-12,2017-04-19,"The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients",27,"Other","United States",65,15,20,35,25,20,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4880737,"Minocycline, Placebo",1,"Non-opioids",20,13,3,4,7,NA,"chronic","veterans",15,"no",0.1072,383416,"GOVERNMENT","non-kids","Government","non-female","veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"1",49000,"Connecticut","41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After","0",0.43,"D","small",39.6963200211786,"non-acute","chronic","non-cancer","0","3","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",88.3766067526777,82.1959300560243,87.4293,22.2105,55.4,66.5,1507299,94,72889,1,355469,9.1,10.6706250487306,"2","3","2","2","2","2","0","3","3","0","0","0","2","non-elderly",9.89920036447829,"veterans"
"293","NCT02363803",369,"Interventional",NA,2015-02-28,2018-10-17,"Predicting Individual Response to Analgesic Treatment in Painful Diabetic Neuropathy",34,"Other","United States",71,29,0,29,47,34,2015,2018,3,"North America",0,"United States","Non-Industry","After 2013",4880369,"lidocaine, Placebo",1,"Non-opioids",34,24,10,0,10,NA,"chronic",NA,29.4117647058824,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"non-acute","chronic","non-cancer","0","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,84.3617,16.6437,59.1,68.55,2760142,90.2,59196,14,704787,9.8,6.97619334002276,"1","1","1","0","3","2","1","2","2","1","0","0","0","non-elderly",11.5848947806522,"general"
"294","NCT02378025",370,"Interventional",NA,2015-06-01,2018-03-31,"A Multimodal Evaluation of the Comparative Efficacy of Yoga Versus a Patient Centered Support Group for Treating Chronic Pain in Gulf War Illness",75,"Other","United States",48,15,37,52,24,75,2015,2018,3,"North America",0,"United States","Non-Industry","After 2013",4879287,"Yoga Group, Pain Management Wellness Group",0,"Non-opioids",75,36,11,28,39,NA,"chronic","veterans",14.6666666666667,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","1","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.0021,24.4005,53.8,54.275,13985614,91.4,63636,44,2192844,13.9,14.2617707647834,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.60187557903577,"veterans"
"295","NCT02380742",371,"Interventional","Phase 2",2015-07-31,2016-02-29,"Topical Anesthetic Use In Pessary Management: A Randomized Double Blinded Placebo Controlled Trial",54,"Other",NA,89,2,9,11,100,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4879081,"lidocaine-prilocaine cream, Placebo cream",1,"Non-opioids",53,47,1,5,6,"Early Phase","acute","female",1.88679245283019,"no",0.142,1813590,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","1","3","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,86.1599,20.0284,52.8,65.4,5333389,92.9,60413,17,1813447,10.9,6.03837995473793,"2","2","2","2","1","1","2","3","3","2","2","0","0","non-elderly",14.101459603989,"female"
"296","NCT02383862",372,"Interventional",NA,2015-03-31,2016-10-31,"Incorporating PROMIS Symptom Measures Into Primary Care Practice",300,"Other",NA,45,49,6,55,72,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4878842,"Feedback Group",0,"Non-opioids",300,135,148,17,165,NA,"chronic",NA,49.3333333333333,"no",0.094,626587,"GOVERNMENT","non-kids","Government","non-female","non-veterans",4.87224867605803,1818,17.9853388888889,85.9917637754567,18.5947229808069,90.5223829489921,83.0146285385389,91.3,8.7,"1",34895,"Indiana","144",144,40.5,10.9,8.4,2921032,69.55,11.8,"After","0",0.54,"R","small",26.882966396292,"non-acute","chronic","non-cancer","3","3","1","0","0","0","1","0","0","0","1","0","0","0","0","3","1","1",85.0256665939072,74.1462592296165,85.3015,16.7549,57.8,69.425,2854584,90.4,51983,10,596275,13.5,8.67182330071009,"1","1","1","0","2","2","1","2","1","1","0","1","1","non-elderly",9.00761063978923,"general"
"297","NCT02394951",374,"Interventional",NA,2015-04-30,2018-04-02,"Investigation of Somatosensory Predictors of Response to Pregabalin in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)",26,"Other","United States",92,8,0,8,31,26,2015,2018,3,"North America",0,"United States","Non-Industry","After 2013",4877991,"Pregabalin, Placebo",1,"Non-opioids",26,24,2,0,2,NA,"cancer",NA,7.69230769230769,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"0",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"non-acute","non-chronic","cancer","0","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,84.3617,16.6437,59.1,68.55,2760142,90.2,59196,14,704787,9.8,6.97619334002276,"1","1","1","0","3","2","1","2","2","1","0","0","0","non-elderly",11.5848947806522,"general"
"298","NCT02397785",376,"Interventional",NA,2015-04-30,2017-06-30,"Treatment of Pain Using a Non-implanted Intra-vaginal Electrical Stimulation Device Compared to Sham Device in Chronic Pelvic Pain",58,"Other","United States",86,12,2,14,100,58,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4877774,"ApexM, Sham Device",0,"Non-opioids",58,50,7,1,8,NA,"chronic","female",12.0689655172414,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","1",0.58,"R","small",28.8464382806458,"non-acute","chronic","non-cancer","1","3","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",85.5477067623717,76.6508352159366,85.2096,16.7513,53.5,66.475,5173946,93.5,53301,22,1409506,13.6,7.8918800096186,"1","2","1","0","1","2","2","3","2","2","1","1","1","non-elderly",12.1368695517248,"female"
"299","NCT02424578",NA,"Interventional","Phase 2",2015-05-31,2016-04-19,"A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery",30,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4875725,NA,NA,"Non-opioids",30,20,7,3,10,"Early Phase","acute","kids",23.3333333333333,"yes",0.16372,1135273.6,NA,"kids",NA,"non-female","non-veterans",9.0463935998121,2899.8,21.6102155418706,86.8863215173154,18.9179489180019,89.4483758934688,81.6979104036908,89.96,10.04,"1",35792.4,"Alabama,Arkansas,North Carolina,Oklahoma,Pennsylvania","278,106,264,140,308",219.2,39.04,21.78,12.66,3180802.2,67.825,14.22,"After",NA,0.662,"R","small",27.6289221573508,"acute","non-chronic","non-cancer","0","3","3","0","0","1","2","0","0","0","1","0","1","1","1","2","3","3",83.1466013884763,71.2939654128901,84.063,16.79884,53.96,67.845,3092027.2,89.78,49114,12.4,1106982.4,14.84,8.35373827135609,"1","1","1","0","1","2","1","2","1","1","1","2","1","non-elderly",16.2788198520187,"kids"
"300","NCT02430818",378,"Interventional",NA,2015-04-30,2017-09-30,"Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures",13,"Other","United States",54,38,8,46,69,13,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4875250,"ketamine, morphine",1,"Opioids",13,7,5,1,6,NA,"acute",NA,38.4615384615385,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"acute","non-chronic","non-cancer","0","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",85.5301614499028,74.2014166617176,84.3617,16.6437,59.1,68.55,2760142,90.2,59196,14,704787,9.8,6.97619334002276,"1","1","1","0","3","2","1","2","2","1","0","0","0","non-elderly",11.5848947806522,"general"
"301","NCT02437188",380,"Interventional",NA,2015-02-28,2016-11-30,"Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT",88,"Other","United States",81,7,12,19,7,74,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4874761,"ACT (Acceptance and Commitment Therapy)",0,"Non-opioids",74,61,5,8,13,NA,"chronic","veterans",6.75675675675676,"no",0.0371,116359,"GOVERNMENT","non-kids","Government","non-female","veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"After","0",0.55,"R","small",28.6266618238787,"non-acute","chronic","non-cancer","1","3","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",3.34031285902649,"veterans"
"302","NCT02437669",NA,"Interventional","Phase 2",2015-05-31,2018-04-30,"Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.",35,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4874724,NA,NA,"Opioids",35,5,3,27,30,"Early Phase","acute","kids",8.57142857142857,"no",0.1566,3065470,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","0","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,83.4447,23.191,55,51.5,8243556,92.9,58005,12,2845960,14.2,6.33298278377812,"2","2","0","3","1","0","3","3","2","1","3","2","0","non-elderly",14.3765914683581,"kids"
"303","NCT02438384",381,"Interventional",NA,2015-09-30,2017-06-17,"Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial",75,"Other","United States",75,0,25,25,67,75,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4874669,"Video, Phone follow-up",0,"Non-opioids",75,56,19,0,19,NA,"acute","elderly",25.3333333333333,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.8782,20.0125,56.1,65.2,4515185,88.8,50797,13,2141818,15.3,8.40197402658067,"1","1","1","2","2","1","2","2","1","1","2","2","1","elderly",21.3268966170995,"elderly"
"304","NCT02449902",382,"Interventional","Phase 2",2013-07-31,2013-09-30,"A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)",50,"Industry","United States",90,8,2,10,NA,NA,2013,2013,0,"North America",0,"United States","Industry","Earlier 2013",4873787,"Estradiol, placebo",1,"Non-opioids",50,45,4,1,5,"Early Phase","chronic","female",8,"no",0.1607,3359030,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",10.8520119990814,7664,22.4099354166667,83.6675053704509,20.0425132752181,93.1995588371443,85.4328926528048,86.8,13.2,"0",41702,"Florida","620",620,39.4,22.6,10.8,9673682,66.025,13.6,"After",NA,0.54,"R","small",30.4516559104648,"non-acute","chronic","non-cancer","1","2","3","1","2","1","0","0","3","1","0","1","3","1","3","2","3","1",87.4857684869649,77.9851138742128,81.0207,17.1729,55.3,66.15,9100944,80,48532,41,3020029,14.8,10.0831815208954,"2","2","0","0","1","1","3","0","1","3","3","2","2","non-elderly",15.4454591297641,"female"
"305","NCT02452060",383,"Interventional","Phase 2/Phase 3",2014-10-31,2017-04-13,"Randomized, Double-blind, Placebo Controlled Study on the Effect of a Single Postoperative Administration of Low Dose Ketamine After Gastric Bypass and Gastrectomy Surgeries",90,"Other","United States",80,19,1,20,69,90,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4873621,"Ketamine, Placebo Comparator",1,"Non-opioids",90,72,17,1,18,"Early Phase","acute",NA,18.8888888888889,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,83.3533,23.3889,53.8,52.925,8219287,91.3,54310,15,2850956,14,6.33298278377812,"2","2","0","3","1","0","3","3","2","1","3","2","0","non-elderly",14.4379784553272,"general"
"306","NCT02454296",384,"Interventional",NA,2015-05-31,2015-12-31,"Paracervical Block for Pain Associated With Laminaria Insertion",41,"Other","United States",29,2,69,71,NA,NA,2015,2015,0,"North America",0,"United States","Non-Industry","After 2013",4873450,"Paracervical Block with lidocaine, Sham paracervical block",1,"Non-opioids",41,12,1,28,29,NA,"acute","female",2.4390243902439,"no",0.0183,26025,"GOVERNMENT","non-kids","Government","female","non-veterans",47.5183694421591,1309,18.6575083333333,95.7649796393252,30.8376963350785,91.7915446804492,85.8786631555135,95.8,4.2,"1",69678,"Hawaii","2",2,36.3,NA,NA,550273,60,9.5,"After",NA,0.47,"D","small",33.2159905191544,"acute","non-chronic","non-cancer","1","3","0","3","0","0","3","3","1","2","3","3","0",NA,"0","0","0","0",89.18985587521,82.7886700468456,95.2484,32.1464,59.7,59.325,534723,96,64514,1,27530,10.9,12.7254367337933,"2","3","3","3","3","0","0","3","3","0","0","0","3","non-elderly",1.92301916103836,"female"
"307","NCT02455518",385,"Interventional","Phase 4",2015-07-31,2017-10-04,"Comparative Efficacy of 4 Oral Analgesics for the Initial Management of Acute Musculoskeletal Extremity Pain",416,"Other","United States",6,30,64,94,48,411,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4873359,"Oxycodone/acetaminophen, Hydrocodone/acetaminophen, Codeine/acetaminophen, Ibuprofen/acetaminophen",1,"Opioids",411,23,122,266,388,"Late Phase","acute",NA,29.683698296837,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After",NA,0.46,"D","large",37.275328091991,"acute","non-chronic","non-cancer","3","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,83.4447,23.191,55,51.5,8243556,92.9,58005,12,2845960,14.2,6.33298278377812,"2","2","0","3","1","0","3","3","2","1","3","2","0","non-elderly",14.3765914683581,"general"
"308","NCT02468934",386,"Interventional",NA,2015-10-22,2017-07-17,"A Prospective Case Series Study of SPR Peripheral Nerve Stimulation (PNS) Therapy for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Utilizing Preoperative Lead Placement",24,"Industry","United States",92,4,4,8,62,48,2015,2017,2,"North America",0,"United States","Industry","After 2013",4872330,"SPRINT Peripheral Nerve Stimulation (PNS) System",0,"Non-opioids",24,22,1,1,2,NA,"acute",NA,4.16666666666667,"yes",0.132133333333333,1973686.66666667,"Mixed","non-kids","Non-Government","non-female","non-veterans",15.701833730022,10880.3333333333,22.9934140303142,87.6775640718984,21.9971118680032,92.0232402372427,85.8230491850564,91.4666666666667,8.53333333333333,"0",41367.6666666667,"California,North Carolina,Ohio","808,264,368",480,38.6,23,10.3333333333333,8115716,62.6833333333333,13.1333333333333,"After",NA,0.573333333333333,"Mixed","small",31.7022977832599,"acute","non-chronic","non-cancer","0","3","2","1","3","2","2","1","2","2","1","1","3","1","2","1","3","2",86.792512148107,77.6311634750914,86.3633,20.3881,54.4666666666667,61.9833333333333,7891581.66666667,91.2333333333333,55911.3333333333,26.3333333333333,1914722.66666667,14.2666666666667,10.1852082669942,"2","2","2","2","1","0","3","3","2","3","2","2","2","non-elderly",13.02188058262,"general"
"309","NCT02487303",388,"Interventional",NA,2015-03-17,2017-07-27,"Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery",148,"Other","United States",58,40,2,42,100,141,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4870926,"Acetaminophen Intravenous, Acetaminophen Oral",1,"Non-opioids",141,82,57,2,59,NA,"acute","female",40.4255319148936,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"1",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"After","0",0.7,"R","small",28.2226091262223,"acute","non-chronic","non-cancer","2","3","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",83.3964736178037,70.2770205967591,81.3422,15.1804,54.1,67.1,2225969,89.1,46360,14,1331987,14.3,6.67607176575867,"1","1","0","0","1","2","0","2","0","1","1","2","0","non-elderly",27.2048055756507,"female"
"310","NCT02498483",NA,"Interventional","Phase 4",2015-09-30,2018-06-30,"Acetaminophen and Post Circumcision Pain Control",11,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4870072,NA,NA,"Non-opioids",11,2,2,7,9,"Late Phase","acute","kids",18.1818181818182,"no",0.1566,3065470,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","0","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,83.4447,23.191,55,51.5,8243556,92.9,58005,12,2845960,14.2,6.33298278377812,"2","2","0","3","1","0","3","3","2","1","3","2","0","non-elderly",14.3765914683581,"kids"
"311","NCT02499159",389,"Interventional","Phase 4",2014-12-31,2017-07-31,"A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy",100,"Other","United States",79,8,13,21,56,98,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4870020,"Liposomal Bupivicaine, 0.25% standard bupivicaine",1,"Non-opioids",98,77,8,13,21,"Late Phase","acute",NA,8.16326530612245,"yes",0.1918,1621590,"Mixed","non-kids","Non-Government","non-female","non-veterans",7.90867222743972,3685,15.3311136986301,86.1120794921748,24.5399464956516,91.8161068524883,85.8209274833271,92.1,7.9,"0",51654,"Virginia,Virginia","249,249",249,39.7,22.4,9.8,3562143,67.55,10.7,"After","1",0.61,"D","small",39.4719593291509,"acute","non-chronic","non-cancer","2","2","3","0","1","0","1","2","1","2","1","3","1","1","1","2","0","3",88.230513471671,79.2878408955579,84.4107,21.1782,59.9,68.725,3446117,89.1,66155,6,1572488,10.2,7.19580739137292,"2","2","1","2","3","2","1","2","3","0","1","0","1","non-elderly",18.8858205618373,"general"
"312","NCT02503410",390,"Interventional",NA,2015-09-30,2017-06-30,"Augmenting Back Pain Exercise Therapy Using an Interactive Gaming-based Intervention in the Home Setting",7,"Other","United States",71,0,29,29,43,7,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4869694,"Usual care, Interactive gaming",0,"Non-opioids",7,5,0,2,2,NA,"chronic",NA,0,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","0","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.3426629317023,85.3926,24.045,60,60.5,2865240,97.2,67861,3,459884,11.5,9.2587366295912,"3","3","1","3","3","0","1","3","3","0","0","0","2","non-elderly",6.76855220355757,"general"
"313","NCT02508935",NA,"Interventional","Phase 4",2015-11-20,2017-04-26,"A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of XARTEMIS® XR (7.5 Oxycodone Hydrochloride/325 mg Acetaminophen) in Postsurgical Adolescent Subjects (Ages 12 to 17) With Moderate to Severe Acute Pain",23,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4869272,NA,NA,"Opioids",23,19,3,1,4,"Late Phase","acute",NA,13.0434782608696,"yes",0.1631,1815710,"Mixed","non-kids","Non-Government","non-female","non-veterans",19.4767533631932,5730,19.3204447916667,87.1448639897176,20.5994457144412,90.3488193159328,84.1972893102488,91.45,8.55,"0",38834,"North Carolina,Pennsylvania","264,308",286,38.4,21.6,10.7,5240285.5,67.1375,12.8,"After",NA,0.59,"R","small",31.8575220561903,"acute","non-chronic","non-cancer","0","3","3","1","1","0","2","0","0","0","1","1","1","1","2","2","2","2",84.8086400611045,75.5726481601748,84.93405,18.6864,54.95,67.3875,5084678,91.2,55593,14,1745459.5,13.8,10.2967188307639,"1","2","1","1","1","2","2","3","2","1","2","2","2","non-elderly",15.9323437737569,"general"
"314","NCT02512861",391,"Interventional","Phase 4",2014-04-30,2015-11-30,"Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery: A Prospective: Double-Blind, Randomized Controlled Trial",93,"Other","United States",72,6,22,28,42,78,2014,2015,1,"North America",0,"United States","Non-Industry","After 2013",4868970,"Bupivacaine, Placebo",1,"Non-opioids",78,56,5,17,22,"Late Phase","acute","kids",6.41025641025641,"no",0.0641,356515,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",18.5628819171079,3192,19.0102597701149,81.7437570733571,23.0232569533244,92.6590939021884,87.4669335225385,95.1,4.9,"1",37811,"Minnesota","71",71,38.5,13.4,7.3,2477753,71.425,8.7,"After","0",0.49,"R","small",37.1630582351401,"acute","non-chronic","non-cancer","1","2","0","1","0","0","0","2","2","3","3","0","0","0","0","3","0","0",89.2519769380513,80.1058558348779,82.9852,18.9775,63,71.425,2389731,94.1,67244,2,307850,8.3,7.83802073605776,"2","2","0","1","3","3","1","3","3","0","0","0","1","non-elderly",5.64119920698867,"kids"
"315","NCT02517996",392,"Interventional",NA,2015-02-28,2018-06-30,"Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial",18,"Other","United States",29,71,0,71,100,17,2015,2018,3,"North America",0,"United States","Non-Industry","After 2013",4868581,"Lidocaine, Placebo",1,"Non-opioids",17,5,12,0,12,NA,"acute","female",70.5882352941177,"yes",0.2989,1799090,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"1",67583,"Maryland,Maryland","269,269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","1",0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","0","3","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,89.9861,27.7006,59.8,67.1,2426669,93.4,73594,18,1743829,9.6,10.8327699960329,"3","3","3","3","3","2","1","3","3","2","2","0","2","non-elderly",29.0328434615005,"female"
"316","NCT02524158",393,"Interventional",NA,2013-04-30,2016-12-31,"Yoga Therapy to Improve Function Among Veterans With Chronic Low Back Pain",152,"U.S. Fed","United States",69,17,14,31,26,150,2013,2016,3,"North America",0,"United States","Non-Industry","Earlier 2013",4868110,"Yoga Therapy for CLBP",0,"Non-opioids",150,104,26,20,46,NA,"chronic","veterans",17.3333333333333,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","2","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,88.5257,22.7538,47,54.3,13827794,82.8,60794,46,2167357,15.1,14.2617707647834,"3","3","3","2","0","0","3","0","3","3","3","2","3","non-elderly",5.65409460024818,"veterans"
"317","NCT02538523",394,"Interventional",NA,2016-04-08,2017-12-10,"A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia FX-635 on Low Back Pain",58,"Industry","United States",69,9,22,31,47,58,2016,2017,1,"North America",0,"United States","Industry","After 2013",4867010,"Erchonia FX-635, Placebo Laser",0,"Non-opioids",58,40,5,13,18,NA,"chronic",NA,8.62068965517241,"yes",0.0802666666666667,1321960.66666667,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",18.2024820631653,10744.3333333333,21.1100992593187,89.0251031341594,23.2608097115818,92.9761675225117,86.776881490266,91.7333333333333,8.26666666666667,"1",44848.3333333333,"Arizona,California,Michigan","60,808,277",381.666666666667,38.2666666666667,19.2333333333333,9.33333333333333,7357309.33333333,64.5583333333333,12.6333333333333,"After","0",0.516666666666667,"Mixed","small",31.1776829667518,"non-acute","chronic","non-cancer","1","3","0","1","3","1","3","2","3","2","1","2","2","0","2","1","2","1",90.4932569368504,83.4794006501503,88.0771795841264,21.3917358007205,56.1666666666667,62.8583333333333,7206557,92.4333333333333,60276,19.3333333333333,1264171.66666667,13.7,8.8453169612403,"3","3","2","2","2","1","2","3","3","2","1","1","1","non-elderly",7.72602783591144,"general"
"318","NCT02540265",395,"Interventional","Phase 2",2015-08-31,2015-11-30,"A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy, and Pharmacokinetics of N1539 Following Bunionectomy",59,"Industry","United States",47,51,2,53,81,59,2015,2015,0,"North America",0,"United States","Industry","After 2013",4866879,"N1539, Intravenous Placebo",1,"Non-opioids",59,28,30,1,31,"Early Phase","acute",NA,50.8474576271186,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"1",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After",NA,0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","1","3","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",90.0748550352328,82.242189074737,89.9861,27.7006,59.8,67.1,2426669,93.4,73594,18,1743829,9.6,10.8327699960329,"3","3","3","3","3","2","1","3","3","2","2","0","2","non-elderly",29.0328434615005,"general"
"319","NCT02556632",NA,"Interventional","Phase 2",2015-10-13,2016-09-30,"Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis",191,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4865631,NA,NA,"Non-opioids",191,167,21,3,24,"Early Phase","cancer","female",10.9947643979058,"yes",0.14172,1378813.4,"Mixed","non-kids","Non-Government","female","non-veterans",48.5961485892109,7272.5,25.1689724502906,85.428289839817,21.2387216677613,91.5450878738976,86.0853503623792,93.7833333333333,6.21666666666667,"0",40269.6666666667,"Delaware,Illinois,Minnesota,New York,Ohio,Ohio","31,532,71,292,368,368",277,38.55,26.1833333333333,11.2166666666667,4529953.16666667,66.3416666666667,11.1,"After","0",0.523333333333333,"Mixed","small",33.0860727637764,"non-acute","non-chronic","cancer","2","3","2","3","2","3","0","1","1","2","2","1","1","2","1","2","1","1",86.7747352400394,77.9217537630543,85.0231166666667,19.0869166666667,55.1833333333333,65.55,4458562.66666667,93.7333333333333,58584.3333333333,13.3333333333333,1332001.5,11.8666666666667,10.2389594098395,"2","2","1","1","1","1","1","3","2","1","1","1","2","non-elderly",13.2742076412421,"female"
"320","NCT02571634",NA,"Interventional","Phase 4",2015-05-31,2016-01-31,"Open Label Feasibility Pilot Study to Assess the Efficacy and Safety of the Use of Lazanda for Anxiolysis During Radiofrequency Nerve Ablation of Lumbar Facet Joints",23,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4864483,NA,NA,"Opioids",23,19,2,2,4,"Late Phase","acute","veterans",8.69565217391304,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",85.059973905725,74.4588820047063,84.8782,20.0125,56.1,65.2,4515185,88.8,50797,13,2141818,15.3,8.40197402658067,"1","1","1","2","2","1","2","2","1","1","2","2","1","non-elderly",21.3268966170995,"veterans"
"321","NCT02574832",396,"Interventional",NA,2015-10-31,2016-08-31,"Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery",2,"Other","United States",100,0,0,0,100,2,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4864237,"Lidocaine Administration",1,"Non-opioids",2,2,0,0,0,NA,"acute","female",0,"no",0.142,1813590,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",45.6900602164346,10460,21.7419085106383,86.7042844980527,22.1034066712746,91.6393688615911,85.4066304066304,92.6,7.4,"0",38573,"Illinois","532",532,38.4,43,17.1,5388066,65.175,10.9,"After","0",0.51,"D","small",35.1771599850269,"acute","non-chronic","non-cancer","0","3","2","3","3","1","1","1","1","1","2","0","3","3","2","2","1","1",86.3859999962457,77.5670021126233,86.1599,20.0284,52.8,65.4,5333389,92.9,60413,17,1813447,10.9,6.03837995473793,"2","2","2","2","1","1","2","3","3","2","2","0","0","non-elderly",14.101459603989,"female"
"322","NCT02600715",NA,"Interventional","Phase 4",2015-11-30,2017-06-26,"Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial)",26,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4862254,NA,NA,"Non-opioids",26,26,0,0,0,"Late Phase","acute",NA,0,"yes",0.0585,170291,"Mixed","non-kids","Non-Government","non-female","non-veterans",2.77287100819405,883,20.5288971153846,86.4795687005593,20.3476595959087,92.0853140781993,84.5426905661842,90.8,9.2,"0",38079,"Kansas,Kansas","60,60",60,38,9.2,4.5,1288401,69.2,10.8,"After","0",0.55,"R","small",33.3863222613169,"acute","non-chronic","non-cancer","0","3","0","0","0","1","1","0","2","0","1","0","0","0","0","3","1","2",85.9397434282733,77.3827344860469,87.351,17.9502,62.5,64.85,1258999,90.9,54865,2,168293,14.2,4.89032654301717,"1","2","2","1","3","1","0","2","2","0","0","2","0","non-elderly",5.780005158603,"general"
"323","NCT02621619",400,"Interventional","Phase 4",2016-03-31,2017-10-31,"Randomized Clinical Trial of IV Acetaminophen as an Analgesic Adjunct to IV Hydromorphone in the Treatment of Acute Severe Pain in Elderly ED Patients",159,"Other","United States",13,20,67,87,38,159,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4860663,"IV acetaminophen + 0.5 mg IV hydromorphone, Normal saline + 0.5 mg IV hydromorphone",1,"Non-opioids",159,20,32,107,139,"Late Phase","acute","elderly",20.125786163522,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",88.603361859064,81.9366970419252,83.8814835822777,23.1116468141426,55,51.55,8281968,93.9,61437,15,2829419,11.9,5.82084523809524,"2","3","0","3","1","0","3","3","3","1","3","1","0","elderly",14.3295902126325,"elderly"
"324","NCT02624687",401,"Interventional",NA,2015-10-31,2016-12-31,"Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study",27,"Other","United States",81,11,8,19,78,27,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4860428,"Intervention, No intervention",0,"Non-opioids",27,22,3,2,5,NA,"chronic",NA,11.1111111111111,"no",0.1118,1430660,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After",NA,0.53,"R","small",31.8196178223866,"non-acute","chronic","non-cancer","0","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,76.6864143156432,84.9899,17.3603,53.8,69.575,5654171,93.6,60389,15,1349101,12.3,12.1914636349471,"1","2","1","0","1","2","2","3","3","1","1","1","3","non-elderly",10.5377909304142,"general"
"325","NCT02643251",402,"Interventional","Phase 2",2015-12-31,2016-11-30,"A Multicenter, Randomized, Double Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1%, to Clonidine Hydrochloride Gel Comparator in the Management of Painful Diabetic Neuropathy",138,"Industry","United States",67,30,3,33,57,138,2015,2016,1,"North America",0,"United States","Industry","After 2013",4859012,"Clonidine Hydrochloride Topical Gel, 0.1%, Clonidine Hydrochloride Gel Comparator",1,"Non-opioids",138,92,42,4,46,"Early Phase","chronic",NA,30.4347826086957,"yes",0.12081,1582045.4,NA,"non-kids",NA,"non-female","non-veterans",18.0058644425929,9622.76,22.8924533705673,87.9587474180994,22.9257214739907,92.7559359737516,85.8936319085836,89.004,10.996,"1",43823.04,"Arizona,Arizona,Arizona,California,California,California,California,California,Florida,Florida,Florida,Florida,Florida,Idaho,Idaho,Illinois,Illinois,Illinois,Missouri,Ohio,South Carolina,Tennessee,Texas,Texas,Texas","60,60,60,808,808,808,808,808,620,620,620,620,620,1,1,532,532,532,318,368,229,201,624,624,624",476.24,38.78,23.9695652173913,10.7826086956522,7775050.04,64.17,12.86,"After","1",0.5528,"Mixed","small",31.1240963270417,"non-acute","chronic","non-cancer","2","3","1","1","2","2","2","2","2","2","0","2","3","2","2","1","3","2",87.3285833389044,77.5082726569811,86.250524,21.2783083874069,57.06,62.837,7489072.6,89.04,55165.68,27.5217391304348,1886958.24,14.236,9.58684316164739,"2","2","2","2","2","1","3","2","2","3","2","2","2","non-elderly",10.5618977530322,"general"
"326","NCT02647658",NA,"Interventional","N/A",2016-03-31,2019-06-30,"Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients: A Multi-Site Pragmatic Cluster Randomized Controlled Trial",2300,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4858674,NA,NA,"Non-opioids",2300,1718,405,177,582,NA,"chronic",NA,17.6086956521739,"yes",0.15332,1026619.2,"Mixed","non-kids","Non-Government","non-female","non-veterans",25.9275272335835,3627.4,22.0019425052417,87.2461597336878,23.6030804154824,92.4335990418371,86.6618584918387,92.94,7.06,"1",46965.8,"Maryland,Massachusetts,Pennsylvania,South Carolina,Utah","269,45,308,229,14",173,39.02,22.375,11.45,2923296.6,68.745,10.08,"After","0",0.548,"Mixed","large",36.0525103316568,"non-acute","chronic","non-cancer","3","3","2","2","1","1","2","2","2","2","2","2","0","1","0","3","0","1",90.0271748447953,83.1351117328253,86.3916961330993,23.0256571724409,59.62,66.99,2861828,93.4,65764.4,11.25,986607.8,10.1,10.2865865443635,"3","3","2","2","3","2","1","3","3","1","1","0","2","non-elderly",14.8815450868362,"general"
"327","NCT02647788",NA,"Interventional","Phase 4",2015-12-31,2018-01-19,"Pilot Study, Blinded Randomized Control Trial, Single Center Study to Compare Acetaminophen & Codeine Versus Ibuprofen/Acetaminophen for Pain Control and Patient Satisfaction After Ambulatory Hand Surgery",144,"Other",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Non-Industry",NA,4858664,NA,NA,"Opioids",111,68,36,7,43,"Late Phase","acute",NA,32.4324324324324,"no",0.1118,1430660,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"1",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","2","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",84.557306216484,76.6864143156432,84.9899,17.3603,53.8,69.575,5654171,93.6,60389,15,1349101,12.3,12.1914636349471,"1","2","1","0","1","2","2","3","3","1","1","1","3","non-elderly",10.5377909304142,"general"
"328","NCT02660918",NA,"Interventional","N/A",2016-04-30,2017-03-31,"Decreasing Postoperative Pain Following Endometrial Ablation: A Randomized Controlled Trial",84,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4857660,NA,NA,"Non-opioids",82,59,20,3,23,NA,"acute",NA,24.390243902439,"no",0.2218,212302,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",8.47142851173364,618,34.479,88.7155780965911,22.1477942746097,92.8085358689267,88.4755978154442,93.4,6.6,"1",50361,"Delaware","31",31,38.8,25.1,10.5,443781,73.1,9.6,"After","0",0.52,"D","small",31.2080137092089,"acute","non-chronic","non-cancer","1","3","3","0","0","3","3","1","2","3","2","3","0","2","0","3","0","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",21.3512732849123,"general"
"329","NCT02662764",NA,"Interventional","Phase 3",2016-09-28,2017-05-05,"A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg",320,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4857520,NA,NA,"Non-opioids",320,280,35,5,40,"Late Phase","acute",NA,10.9375,"yes",0.153566666666667,1954936.83333333,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.94939637552237,5467.63636363636,23.2387345556239,86.117834490616,21.5297207441787,92.1973315478152,84.7568891765232,86.9636363636364,13.0363636363636,"0",41965.0909090909,"Alabama,Alabama,Arizona,Florida,Florida,Florida,Florida,Georgia,Texas,Texas,Utah","278,278,60,620,620,620,620,542,624,624,14",445.454545454545,39.3636363636364,21.94,10.63,6765365.54545455,66.5886363636364,13.7090909090909,"After","0",0.619090909090909,"R","large",29.9676382830436,"acute","non-chronic","non-cancer","3","3","2","1","1","2","1","1","2","1","0","1","3","1","2","2","3","3",89.371345416052,80.8643077432581,84.7789110109038,20.571706987823,58.5090909090909,65.0090909090909,6511946.81818182,87.9,53958.7272727273,25.8,2300137.09090909,13.8272727272727,8.81052679140478,"3","3","1","2","2","1","2","2","2","3","3","2","1","non-elderly",15.8449532707604,"general"
"330","NCT02673372",404,"Interventional","Phase 4",2016-04-30,2018-04-30,"Low-Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department Geriatric Population: A Prospective, Randomized, Double-Blind Study.",60,"Other","United States",53,7,40,47,77,60,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4856712,"Morphine, Ketamine",1,"Opioids",60,32,4,24,28,"Late Phase","acute","elderly",6.66666666666667,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","1","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",88.603361859064,81.9366970419252,83.8814835822777,23.1116468141426,55,51.55,8281968,93.9,61437,15,2829419,11.9,5.82084523809524,"2","3","0","3","1","0","3","3","3","1","3","1","0","elderly",14.3295902126325,"elderly"
"331","NCT02673684",NA,"Interventional","N/A",2016-02-29,2016-05-01,"Double Blind, Randomized, Sham-Controlled Study on the Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use in Pain Patients",17,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4856688,NA,NA,"Non-opioids",17,15,1,1,2,NA,"chronic",NA,5.88235294117647,"no",0.2989,1799090,"GOVERNMENT","non-kids","Government","non-female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"0",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","0",0.54,"D","small",40.7376904453232,"non-acute","chronic","non-cancer","0","3","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",91.6650566923594,85.8145163789065,90.2819774886078,29.7501767976976,61.5,66.55,2437416,93.9,73760,16,1765641,7.1,11.192558,"3","3","3","3","3","2","1","3","3","1","2","0","3","non-elderly",29.346905241582,"general"
"332","NCT02675907",405,"Interventional","Phase 3",2016-01-31,2016-07-31,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Bunionectomy",201,"Industry","United States",64,29,7,36,85,201,2016,2016,0,"North America",0,"United States","Industry","After 2013",4856517,"N1539, Intravenous Placebo",1,"Non-opioids",201,129,58,14,72,"Late Phase","acute",NA,28.8557213930348,"yes",0.159366666666667,2500470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",23.9038403028124,15522.25,24.1367485991869,90.4899852599078,27.2708642193812,93.6230311462161,87.7290962150383,90.05,9.95,"1",54457.25,"California,California,Maryland,Texas","808,808,269,624",627.25,39.1,24.825,10.975,10621585.25,60.2125,11.45,"After",NA,0.54,"Mixed","small",34.9362652783633,"acute","non-chronic","non-cancer","2","3","3","2","3","3","3","3","3","3","1","3","3","2","3","0","1","1",91.47276021274,84.4952979425658,89.5296923466726,25.4038316792033,57.725,58.9125,10339447,90.675,66295,31.75,2339583.25,12.175,11.2830937889942,"3","3","3","3","2","0","3","2","3","3","3","1","3","non-elderly",13.0242751657046,"general"
"333","NCT02678286",406,"Interventional","Phase 3",2016-01-31,2016-11-30,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery",219,"Industry","United States",63,33,4,37,98,219,2016,2016,0,"North America",0,"United States","Industry","After 2013",4856334,"N1539, Intravenous Placebo",1,"Non-opioids",219,138,73,8,81,"Late Phase","acute",NA,33.3333333333333,"yes",0.0896,2851160,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.5892204566174,13831.75,25.1547210016893,90.2278185931505,25.5718373245288,92.9501866666983,85.7667377112002,84.275,15.725,"1",47888.25,"California,Texas,Texas,Texas","808,624,624,624",670,39.75,25.925,9.75,12054098.75,60.525,13.4,"After",NA,0.6025,"Mixed","small",31.2992420271726,"acute","non-chronic","non-cancer","3","3","1","1","3","3","3","3","3","2","0","2","3","2","3","0","3","3",90.5193766634717,82.1172307721324,89.3276200399528,23.5094738342233,59.05,59.54375,11596199,85.725,60268.75,37,2993321.5,13.825,9.3444942623315,"3","3","3","3","3","0","3","1","3","3","3","2","2","non-elderly",10.1806176995449,"general"
"334","NCT02678416",NA,"Interventional","Phase 4",2015-12-07,2016-06-13,"A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study in Healthy Adult Male Subjects to Compare the Reduction in Pain Intensity After Single-Dose Administration of Intravenous or Oral Acetaminophen and Intravenous Morphine by Using UVB Burn and Intradermal Capsaicin Experimental Pain Models",79,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4856324,NA,NA,"Opioids",78,78,0,0,0,"Late Phase","acute",NA,0,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"0",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","1","3","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",93.0324958994779,83.6980211154065,95.4014,16.336,65.6,69.9,1045397,89.5,66258,1,32498,9.3,12.3491515311256,"3","3","3","0","3","3","0","2","3","0","0","0","3","non-elderly",1.08474227774516,"general"
"335","NCT02680847",NA,"Interventional","Phase 4",2016-01-21,2018-01-24,"An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia",32,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4856138,NA,NA,"Opioids",32,26,6,0,6,"Late Phase","chronic","kids",18.75,"yes",0.16066,2212162,"Mixed","kids","Non-Government","non-female","non-veterans",22.667694416645,12369.6875,22.9234689522318,87.7020570069074,22.3983642542261,92.3708230823191,85.5720855172987,90.4625,9.5375,"1",43243.5625,"California,California,California,California,California,California,Illinois,Illinois,Illinois,North Carolina,North Carolina,South Carolina,South Carolina,South Carolina,South Carolina,Texas","808,808,808,808,808,808,532,532,532,264,264,229,229,229,229,624",532,38.78125,27.93125,12.3,8284162.3125,62.95625,12.875,"After",NA,0.575625,"Mixed","small",32.4175159265404,"non-acute","chronic","non-cancer","0","3","3","2","3","2","2","1","2","2","1","2","3","3","2","1","3","2",89.5931225904202,81.8534764197445,86.2053504815959,21.2810325431136,54.4,61.7046875,8087969.5625,91.20625,60437.375,26,1950635.875,13.56875,9.00514996436176,"3","3","2","2","1","0","3","3","3","3","2","1","1","non-elderly",14.7555640593185,"kids"
"336","NCT02687165",NA,"Interventional","N/A",2016-01-16,2017-01-16,"Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome",4,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4855657,NA,NA,"Non-opioids",4,0,0,0,0,NA,"chronic",NA,0,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After",NA,0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",88.603361859064,81.9366970419252,83.8814835822777,23.1116468141426,55,51.55,8281968,93.9,61437,15,2829419,11.9,5.82084523809524,"2","3","0","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3295902126325,"general"
"337","NCT02689063",407,"Interventional","Phase 3",2016-10-26,2017-09-15,"Maxigesic IV Bunionectomy Study- A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group and Placebo-Controlled Study",276,"Industry",NA,62,33,5,38,81,NA,2016,2017,1,"North America",0,"United States","Industry","After 2013",4855511,"Maxigesic IV, IV Acetaminophen, IV Ibuprofen, Placebo IV",1,"Non-opioids",276,171,92,13,105,"Late Phase","acute",NA,33.3333333333333,"yes",0.2101,2613650,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.5447800748675,6842.5,24.7037281616767,89.9722075277463,27.5624427343792,92.856570708325,86.5200995601634,87.8,12.2,"1",57077.5,"Maryland,Texas","269,624",446.5,39.5,25.45,10.85,6876834.5,65.6,10.4,"After",NA,0.59,"Mixed","small",35.5075017775867,"acute","non-chronic","non-cancer","3","3","3","1","2","3","3","3","3","2","0","3","3","2","2","2","0","2",90.825431261097,83.3843752680235,89.8194055864579,26.4961524743159,61.05,64,6603630,88.65,65953,26.5,2518208.5,10.45,9.67789269426752,"3","3","3","3","3","1","2","2","3","3","3","0","2","non-elderly",20.5429272383033,"general"
"338","NCT02697435",NA,"Interventional","N/A",2016-04-01,2018-08-31,"Patient-Centered Versus Imaging-Directed Care for Older Veterans With Chronic LBP",55,"U.S. Fed",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4854872,NA,NA,"Non-opioids",55,37,17,1,18,NA,"chronic","elderly",30.9090909090909,"yes",0.1518,1526125,"GOVERNMENT","non-kids","Government","non-female","non-veterans",20.0018281592188,5606.5,17.1727344534817,86.8766781459778,22.1571801341422,90.6995968415032,85.2495210675694,93.15,6.85,"1",45107,"Pennsylvania,Virginia","308,249",278.5,39,20.05,9.3,4647385.5,68.3875,11.1,"After","0",0.57,"Mixed","small",35.6457885757687,"non-acute","chronic","non-cancer","1","3","2","2","1","0","2","1","0","1","2","2","1","0","1","3","1","2",88.7453149277166,82.5141196651743,85.3736250844298,21.0883581100084,56.05,67.4,4581080.5,92.85,63715,13,1463591.5,11.25,9.24359251601629,"2","3","1","2","2","2","2","3","3","1","1","0","2","elderly",14.6512933386864,"elderly"
"339","NCT02703259",408,"Interventional","Phase 4",2016-06-30,2017-07-31,"Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management",137,"Other","United States",69,31,0,31,100,129,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4854430,"Gabapentin, Acetaminophen, Celecoxib",1,"Non-opioids",129,89,40,0,40,"Late Phase","acute","female",31.0077519379845,"no",0.2218,212302,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",8.47142851173364,618,34.479,88.7155780965911,22.1477942746097,92.8085358689267,88.4755978154442,93.4,6.6,"1",50361,"Delaware","31",31,38.8,25.1,10.5,443781,73.1,9.6,"After","1",0.52,"D","small",31.2080137092089,"acute","non-chronic","non-cancer","2","3","3","0","0","3","3","1","2","3","2","3","0","2","0","3","0","1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",21.3512732849123,"female"
"340","NCT02710526",NA,"Interventional","Phase 2",2015-02-28,2017-07-03,"A Phase II, Open-label, Partially Randomized, 3 Treatment Groups, Multi-Site Study Assessing Pharmacokinetics After Administration of the Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) at Different Injection Sites in Opioid-Dependent Subjects With Chronic Pain",66,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4853872,NA,NA,"Opioids",65,60,4,1,5,"Early Phase","chronic",NA,6.15384615384615,"yes",0.157933333333333,926762,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",16.6949813940126,3175,21.7547544032106,87.3061905504484,20.6434915512015,90.3619890148379,83.5727250876986,89.3666666666667,10.6333333333333,"0",40823.6666666667,"Alabama,New Jersey,Oklahoma","278,243,140",220.333333333333,39.7333333333333,24.6,14.5,2558707.66666667,68.1916666666667,13.0333333333333,"After",NA,0.66,"Mixed","small",30.5640562721425,"non-acute","chronic","non-cancer","1","3","3","1","0","1","2","0","0","0","0","1","1","2","0","3","3","3",84.1926410220491,74.1139829690576,85.7688333333333,17.9859333333333,55.6333333333333,67.1166666666667,2510529,89.1,53314.3333333333,14.3333333333333,903911,13.9,6.02126723343769,"1","1","2","1","2","2","1","2","2","1","1","2","0","non-elderly",15.5092197475757,"general"
"341","NCT02711800",NA,"Interventional","Phase 2",2016-11-08,2017-09-18,"Probiotic Treatment: The Role of the Gut Microbiome in Childhood Abdominal Pain and Anxiety",9,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4853775,NA,NA,"Non-opioids",9,6,3,0,3,"Early Phase","chronic","kids",33.3333333333333,"no",0.2144,2200760,"PROPRIETARY","kids","Non-Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",88.0370717328552,79.5037835947125,84.6947733059304,20.3862351851095,56.1,65.75,4567285,89.6,53764,17,2144650,13.6,8.17658750000001,"2","2","1","2","2","1","2","2","2","2","2","1","1","non-elderly",21.1362452827437,"kids"
"342","NCT02713490",410,"Interventional","Phase 4",2016-03-31,2017-03-31,"A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty",300,"Industry",NA,89,8,3,11,59,NA,2016,2017,1,"North America",0,"United States","Industry","After 2013",4853646,"EXPAREL, Bupivacaine",1,"Non-opioids",139,122,12,5,17,"Late Phase","acute",NA,8.63309352517986,"yes",0.16039,2271231.9,"Mixed","non-kids","Non-Government","non-female","non-veterans",38.7709640399507,9615.41176470588,23.4772727966575,87.3781800571597,23.613965979322,92.4425838905574,86.0327970599922,90.1588235294118,9.84117647058824,"0",46001.7058823529,"California,California,Florida,Florida,Georgia,Illinois,Maryland,Maryland,New York,New York,North Carolina,North Carolina,Ohio,Ohio,Texas,Texas,Utah","808,808,620,620,542,532,269,269,292,292,264,264,368,368,624,624,14",445.764705882353,38.9647058823529,26.64375,11.975,7250455.17647059,63.2926470588235,12.0411764705882,"After","0",0.565294117647059,"Mixed","small",33.526078498041,"acute","non-chronic","non-cancer","2","3","3","3","2","2","2","2","2","2","1","2","3","3","2","1","2","2",89.9771976387449,82.5238848613243,86.6235827250364,22.3572744094292,57.0882352941176,62.2411764705882,7056068.94117647,90.7411764705882,60012,25.25,2266924.94117647,12.3588235294118,9.04012598229509,"3","3","2","2","2","1","2","2","3","3","3","1","1","non-elderly",15.6098591159184,"general"
"343","NCT02723175",411,"Interventional",NA,2014-12-31,2017-09-30,"The Effects of Cognitive Behavioral Therapy (CBT) and Transcranial Direct Current Stimulation (tDCS) on Fibromyalgia Patients",15,"Other","United States",93,7,0,7,87,15,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4852904,"Transcranial Direct Current Stimulation",0,"Non-opioids",15,14,1,0,1,NA,"chronic",NA,6.66666666666667,"no",0.2677,1344140,"GOVERNMENT","non-kids","Government","non-female","non-veterans",2.07178861578112,771,23.7987641025641,83.452185294448,15.5590626626048,90.4946478160247,81.7905931437688,89.2,10.8,"0",35092,"South Carolina","229",229,39,23.8,11.1,2351286,72.575,14.1,"After","0",0.7,"R","small",28.2226091262223,"non-acute","chronic","non-cancer","0","2","3","0","0","2","0","0","0","0","0","0","1","1","0","3","3","3",83.3964736178037,70.2770205967591,79.8226,14.7453,52,72.975,2201469,86.4,44929,7,1311369,16.5,6.67607176575867,"1","1","0","0","0","3","0","1","0","0","1","3","0","non-elderly",27.1365521899513,"general"
"344","NCT02736175",NA,"Interventional","Phase 3",2015-10-31,2016-07-31,"A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase 3C Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery",438,"Industry",NA,NA,NA,NA,NA,NA,NA,2015,NA,NA,"North America",NA,"United States","Industry",NA,4851907,NA,NA,"Non-opioids",438,363,53,22,75,"Late Phase","acute",NA,12.1004566210046,NA,NA,NA,NA,"non-kids",NA,"non-female","non-veterans",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"After",NA,NA,NA,"large",NA,"acute","non-chronic","non-cancer","3","3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",NA,"general"
"345","NCT02736890",NA,"Interventional","Phase 2",2016-03-31,2018-07-17,"Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury",8,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4851852,NA,NA,"Non-opioids",8,2,2,4,6,"Early Phase","chronic",NA,25,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",88.603361859064,81.9366970419252,83.8814835822777,23.1116468141426,55,51.55,8281968,93.9,61437,15,2829419,11.9,5.82084523809524,"2","3","0","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3295902126325,"general"
"346","NCT02748525",413,"Interventional","Phase 4",2016-05-03,2018-06-14,"Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively",50,"Other","United States",38,26,36,62,62,50,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4850961,"Milk, CCK",0,"Non-opioids",50,19,13,18,31,"Late Phase","acute",NA,26,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","1",0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","1","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",89.9858058298346,80.9542341571405,89.356833684308,23.2421281509342,60.6,61.45,10769844,83.4,58146,37,3270776,13.8,8.16322738853503,"3","3","3","3","3","0","3","0","2","3","3","2","1","non-elderly",11.7389492350246,"general"
"347","NCT02760654",414,"Interventional",NA,2016-04-30,2016-12-31,"Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy",60,"Other","United States",92,5,3,8,75,60,2016,2016,0,"North America",0,"United States","Non-Industry","After 2013",4850032,"Proactive Self Management Program for Effects of Cancer Treatment",0,"Non-opioids",60,55,3,2,5,NA,"cancer",NA,5,"yes",0.1379,1374310,"GOVERNMENT","non-kids","Government","non-female","non-veterans",9.17548122176441,5413,17.7655869230769,86.2290611164362,17.7930302615364,91.2333154178514,84.7538491122234,94.2,5.8,"0",35322,"Michigan,Michigan,Michigan,Michigan,Michigan","277,277,277,277,277",277,37.9,23.2,9.1,4629611,73.025,11,"After","0",0.53,"R","small",29.5564246895313,"non-acute","non-chronic","cancer","1","3","2","0","1","0","1","0","1","1","3","0","1","1","1","3","1","1",88.314796506838,81.0275580820563,85.2270546794231,16.9686580928314,50.8,72.825,4577865,94.6,57091,16,1347079,11.1,7.9182,"2","3","1","0","0","3","2","3","2","1","1","0","1","non-elderly",13.5680730840124,"general"
"348","NCT02762071",415,"Interventional",NA,2016-04-30,2019-04-15,"Liposomal Bupivacaine vs. Interscalene Nerve Block for Pain Control After Total Shoulder Arthroplasty: A Randomized Clinical Trial",108,"Other","United States",80,19,1,20,44,108,2016,2019,3,"North America",0,"United States","Non-Industry","After 2013",4849925,"Liposomal bupivacaine, Interscalene Nerve Block",1,"Non-opioids",108,86,21,1,22,NA,"acute",NA,19.4444444444444,"yes",0.2101,2613650,"Mixed","non-kids","Non-Government","non-female","non-veterans",15.5447800748675,6842.5,24.7037281616767,89.9722075277463,27.5624427343792,92.856570708325,86.5200995601634,87.8,12.2,"0",57077.5,"Maryland,Texas","269,624",446.5,39.5,25.45,10.85,6876834.5,65.6,10.4,"After","1",0.59,"Mixed","small",35.5075017775867,"acute","non-chronic","non-cancer","2","3","3","1","2","3","3","3","3","2","0","3","3","2","2","2","0","2",90.825431261097,83.3843752680235,89.8194055864579,26.4961524743159,61.05,64,6603630,88.65,65953,26.5,2518208.5,10.45,9.67789269426752,"3","3","3","3","3","1","2","2","3","3","3","0","2","non-elderly",20.5429272383033,"general"
"349","NCT02778880",417,"Interventional","Phase 3",2016-03-31,2017-03-21,"A Randomized Controlled Trial of Intranasal Sub-dissociative Dosing of Ketamine Compared to Intranasal Fentanyl for Treatment of Pain Associated With Acute Extremity Injuries in Children",90,"Other",NA,68,24,8,32,34,NA,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",5081545,"Ketamine, Fentanyl",1,"Opioids",86,59,21,6,27,"Late Phase","acute","kids",24.4186046511628,"no",0.1241,1446190,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"1",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","2","3","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",87.8973791893746,81.3767926661241,86.2387344027722,15.6154720917634,52.7,66.1,5186007,94.4,53985,20,1421393,13.7,8.09220707070707,"2","3","2","0","1","1","2","3","2","2","1","1","1","non-elderly",12.2382241383155,"kids"
"350","NCT02782169",418,"Interventional","Phase 4",2015-06-30,2016-12-31,"Prophylactic Pregabalin to Decrease Pain During Medical Abortion: a Randomized Controlled Trial",110,"Other",NA,38,6,55,62,100,NA,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4848388,"Pregabalin, Placebo",1,"Non-opioids",107,41,7,59,66,"Late Phase","acute","female",6.54205607476635,"no",0.0183,26025,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",47.5183694421591,1309,18.6575083333333,95.7649796393252,30.8376963350785,91.7915446804492,85.8786631555135,95.8,4.2,"1",69678,"Hawaii","2",2,36.3,NA,NA,550273,60,9.5,"After",NA,0.47,"D","small",33.2159905191544,"acute","non-chronic","non-cancer","2","3","0","3","0","0","3","3","1","2","3","3","0",NA,"0","0","0","0",89.18985587521,82.7886700468456,95.2484,32.1464,59.7,59.325,534723,96,64514,1,27530,10.9,12.7254367337933,"2","3","3","3","3","0","0","3","3","0","0","0","3","non-elderly",1.92301916103836,"female"
"351","NCT02786901",NA,"Interventional","Phase 3",2016-06-30,2017-07-01,"A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel",600,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4848027,NA,NA,"Non-opioids",600,490,60,50,110,"Late Phase","acute",NA,10,"yes",0.09096,1434858.6,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",22.2512105922152,7319.66666666667,20.1802431327997,87.3844834596909,23.4341291526134,92.4147561579338,85.9439129183637,90.8,9.2,"1",44520.8333333333,"Arizona,California,Florida,Massachusetts,Missouri,Missouri","60,808,620,45,318,318",361.5,39.3666666666667,20.4166666666667,10.1666666666667,5947249.5,64.35,12.35,"After",NA,0.515,"Mixed","large",33.006993269232,"acute","non-chronic","non-cancer","3","3","1","2","2","0","2","2","2","2","1","2","2","0","2","1","2","1",90.0719674533198,82.7256116411262,86.680359691018,21.1661236755299,60.9666666666667,62.2125,5801664.5,91.65,59535.1666666667,18.1666666666667,1243675.66666667,13.1,8.55589428308929,"3","3","2","2","3","0","2","3","3","2","1","1","1","non-elderly",9.09874204046337,"general"
"352","NCT02793817",419,"Interventional","Phase 3",2016-06-30,2017-03-31,"A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain",520,"Industry","United States",79,10,11,21,55,520,2016,2017,1,"North America",0,"United States","Industry","After 2013",4847497,"KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID",1,"Non-opioids",520,413,51,56,107,"Late Phase","acute",NA,9.80769230769231,"yes",0.11215,1311785.625,"Mixed","non-kids","Non-Government","non-female","non-veterans",20.8155353548357,11507.6,23.3377186163273,88.1515887472028,23.1984690848858,92.8206724659234,86.3208604543202,90.0714285714286,9.92857142857143,"0",44498.6,"Arizona,Arizona,California,California,California,California,California,California,California,California,California,California,California,Colorado,Florida,Florida,Florida,Florida,Illinois,Illinois,Kentucky,Michigan,Minnesota,Missouri,Nevada,North Carolina,Ohio,Oregon,Pennsylvania,South Carolina,South Carolina,Texas,Texas,Texas,Texas","60,60,808,808,808,808,808,808,808,808,808,808,808,52,620,620,620,620,532,532,76,277,71,318,80,264,368,18,308,229,229,624,624,624,624",495.371428571429,38.9,23.5181818181818,10.5424242424242,8476953.14285714,62.7078571428571,12.6428571428571,"After",NA,0.544,"Mixed","large",32.0596404219613,"acute","non-chronic","non-cancer","3","3","1","2","3","2","2","2","3","2","1","2","3","1","3","1","2","1",90.2468975874871,82.7677261874654,87.0678468268763,21.2887140009273,56.4857142857143,61.3507142857143,8253912.54285714,90.86,59928.3714285714,24.8,1843000.25714286,13.1857142857143,9.60434378912582,"3","3","2","2","2","0","3","2","3","2","2","1","2","non-elderly",10.1693708600881,"general"
"353","NCT02806713",420,"Interventional","Phase 3",2016-02-29,2017-08-31,"The Effect of Oral phenazopyrIdine on Perioperative Voiding After Mid-urethral Sling",92,"Other","United States",70,8,22,30,100,88,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4846514,"Phenazopyridine, no Phenazopyridine",1,"Non-opioids",88,62,7,19,26,"Late Phase","acute","female",7.95454545454545,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","2","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",90.5497018166255,85.5727163859935,85.7289189931723,25.3752200442972,63.2,59.775,2881140,97.5,72266,7,456681,9.6,9.66208148148148,"3","3","2","3","3","0","1","3","3","0","0","0","2","non-elderly",6.7042838588862,"female"
"354","NCT02809846",421,"Interventional",NA,2016-07-31,2017-10-31,"Quell Opioid Reduction and Pain Relief in Patients With Cancer",33,"Other","United States",76,12,12,24,52,33,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4846274,"Quell, Sham Quell",0,"Non-opioids",33,25,4,4,8,NA,"cancer",NA,12.1212121212121,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","1",0.49,"D","small",34.3650287791398,"non-acute","non-chronic","cancer","0","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",92.1200891643829,85.6062206171081,89.2399791068873,24.3115108840907,54.4,53.825,14075264,92.7,66637,37,2160958,13.9,12.8882948837209,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.50562309310592,"general"
"355","NCT02809911",422,"Interventional",NA,2016-06-30,2016-08-31,"A Randomized, Sham-Controlled, Double-Blind, Crossover Study to Evaluate PEMF Therapy on Pain Sensitivity to Different Qualities of Experimentally Induced Pain in Subjects With Painful Peripheral Diabetic Neuropathy",41,"Industry","United States",85,12,3,15,56,41,2016,2016,0,"North America",0,"United States","Industry","After 2013",4846269,"Provant",0,"Non-opioids",41,35,5,1,6,NA,"chronic",NA,12.1951219512195,"yes",0.1213,3428210,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas,Texas","624,624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After",NA,0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","1","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",89.9858058298346,80.9542341571405,89.356833684308,23.2421281509342,60.6,61.45,10769844,83.4,58146,37,3270776,13.8,8.16322738853503,"3","3","3","3","3","0","3","0","2","3","3","2","1","non-elderly",11.7389492350246,"general"
"356","NCT02820324",424,"Interventional","Phase 3",2016-05-31,2017-01-31,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty",401,"Industry",NA,64,31,5,36,99,NA,2016,2017,1,"North America",0,"United States","Industry","After 2013",4845476,"Oliceridine, Placebo, Morphine",1,"Non-opioids",401,257,125,19,144,"Late Phase","acute",NA,31.1720698254364,"yes",0.130775,1954718,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",17.3105704432075,10176,24.1310411003171,90.1517000936758,26.443394441309,93.1757493854458,86.6653227607728,87.64,12.36,"1",51990,"Arizona,California,Maryland,Texas,Texas","60,808,269,624,624",477,39.2,22.38,9.98,8495867.8,62.855,12.28,"After",NA,0.568,"Mixed","large",33.0537881751496,"acute","non-chronic","non-cancer","3","3","2","1","2","3","3","3","3","2","0","3","3","1","3","1","2","2",90.9603285311483,83.4267257123164,89.600025786036,24.6881964817792,60.08,61.04,8203782,88.68,62757.8,26.4,2150525.8,12.94,9.22735273215819,"3","3","3","3","3","0","3","2","3","3","2","1","2","non-elderly",12.4869628270706,"general"
"357","NCT02824562",425,"Interventional",NA,2016-07-31,2017-08-22,"Development of a Behavioral Intervention for Chronic Pain in Individuals With HIV",44,"Other",NA,11,86,3,89,61,NA,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4845153,"Intervention, Control",0,"Non-opioids",44,5,38,1,39,NA,"chronic",NA,86.3636363636364,"no",0.2664,1299050,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.62507069982056,900,22.6392183673469,83.3613868714217,17.195147573548,87.6352559797239,80.1686731141783,90.3,9.7,"1",33928,"Alabama","278",278,39.1,20.7,12.4,2284847,70.725,16,"After",NA,0.77,"R","small",25.3013815767412,"non-acute","chronic","non-cancer","1","3","3","0","0","1","0","0","0","0","1","0","1","0","0","3","3","3",83.9099923887051,75.2848297714992,81.2689247065191,17.8609180462361,52.9,69.625,2238800,90.9,47221,10,1294572,16.2,7.06413513513514,"1","1","0","1","1","3","0","2","0","1","1","3","1","non-elderly",26.6192091789526,"general"
"358","NCT02829944",426,"Interventional","Phase 4",2016-11-30,2019-09-30,"Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery",84,"Other","United States",56,34,10,44,100,71,2016,2019,3,"North America",0,"United States","Non-Industry","After 2013",4844739,"Ropivacaine, Ketorolac, Placebo",1,"Non-opioids",71,40,24,7,31,"Late Phase","acute","female",33.8028169014084,"no",0.2144,2200760,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",88.0370717328552,79.5037835947125,84.6947733059304,20.3862351851095,56.1,65.75,4567285,89.6,53764,17,2144650,13.6,8.17658750000001,"2","2","1","2","2","1","2","2","2","2","2","1","1","non-elderly",21.1362452827437,"female"
"359","NCT02837952",NA,"Interventional","Phase 3",2016-08-31,2017-02-01,"A Phase 3, Double-blind, Randomized Safety And Efficacy Study Comparing Multiple Administrations Of Ibu 250 Mg/Apap 500 Mg (Administered As Two Tablets Of Ibu/Apap 125 Mg/250 Mg) To Placebo In The Treatment Of Post Surgical Dental Pain In Adult Subjects",123,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4844127,NA,NA,"Non-opioids",123,112,3,8,11,"Late Phase","acute",NA,2.4390243902439,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","small",35.0448905477656,"acute","non-chronic","non-cancer","2","3","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.01320227306022,"general"
"360","NCT02839889",427,"Interventional","Phase 4",2016-09-30,2018-01-11,"A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation",12,"Other","United States",60,40,0,40,40,5,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4843978,"Naloxegol, Placebo",1,"Non-opioids",5,3,2,0,2,"Late Phase","cancer",NA,40,"yes",0.165033333333333,2237473.33333333,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",72.5756551671526,9596.66666666667,23.2084207055818,85.5593641688612,21.3315925067439,90.9041343619179,84.6882712272592,92.3,7.7,"1",40274.3333333333,"New York,North Carolina,Ohio","292,264,368",308,38.5,27.2666666666667,12.5666666666667,6128397.66666667,61.7416666666667,12.9,"After","0",0.563333333333333,"Mixed","small",32.6723975542103,"non-acute","non-chronic","cancer","0","3","3","3","2","2","0","1","0","0","2","1","2","3","2","0","3","2",88.1792709270979,80.9390911009206,84.9383304303268,19.7044513636718,54.6,61.1333333333333,6011753.33333333,92.6333333333333,56395.3333333333,17.3333333333333,2131820.66666667,13.0666666666667,7.36321326960077,"2","3","1","2","1","0","2","3","2","2","2","1","1","non-elderly",15.9013532112306,"general"
"361","NCT02844946",428,"Interventional",NA,2016-10-03,2018-12-31,"One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology",39,"U.S. Fed","United States",42,19,39,58,0,31,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4843593,"Acceptance and Commitment Therapy",0,"Non-opioids",31,13,6,12,18,NA,"chronic","veterans",19.3548387096774,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","0","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",89.9858058298346,80.9542341571405,89.356833684308,23.2421281509342,60.6,61.45,10769844,83.4,58146,37,3270776,13.8,8.16322738853503,"3","3","3","3","3","0","3","0","2","3","3","2","1","non-elderly",11.7389492350246,"veterans"
"362","NCT02848729",429,"Interventional","Phase 4",2016-02-29,2016-03-31,"A Randomized, 2-Way, Parallel, Single-Blind Pharmacokinetic Study to Evaluate the Interaction Between Intravenous Morphine and Orally or Intravenously Administered Acetaminophen in Healthy Subjects",50,"Industry",NA,68,32,NA,32,18,NA,2016,2016,0,"North America",0,"United States","Industry","After 2013",4843302,"Oral Acetaminophen, IV Acetaminophen, IV Morphine, Placebo Tablets, Saline",1,"Non-opioids",50,34,16,0,16,"Late Phase","acute","healthy",32,"yes",0.0911333333333333,1249351,"Mixed","non-kids","Non-Government","non-female","non-veterans",13.2011907344322,3538.66666666667,21.7143990782828,87.0826140111312,22.8706494926474,91.9505498882051,85.879541066727,90.4666666666667,9.53333333333333,"1",44938.3333333333,"Arizona,Florida,Rhode Island","60,620,7",229,38.6333333333333,17.9333333333333,10.2666666666667,4406610.33333333,65.225,12.7666666666667,"After",NA,0.52,"Mixed","small",31.5315593389132,"acute","non-chronic","non-cancer","1","3","1","1","1","1","2","2","2","2","1","2","1","0","1","2","2","1",89.7473786275402,82.7460336291435,85.5343944803053,20.1924038556349,60.6666666666667,60.8583333333333,4257059.66666667,91.0666666666667,56601.3333333333,13.3333333333333,1168490,13.5,8.19433533333333,"3","3","1","2","3","0","1","2","2","1","1","1","1","non-elderly",8.32887674151571,"general"
"363","NCT02852434",430,"Interventional","Phase 3",2016-07-31,2017-04-30,"Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation: A Randomized Controlled Trial",72,"Other","United States",48,33,19,52,100,69,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4843019,"Lidocaine Gel (2%), Lidocaine Paracervical Block (1%)",1,"Non-opioids",69,33,23,13,36,"Late Phase","acute","female",33.3333333333333,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After",NA,0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","1","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",92.1200891643829,85.6062206171081,89.2399791068873,24.3115108840907,54.4,53.825,14075264,92.7,66637,37,2160958,13.9,12.8882948837209,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.50562309310592,"female"
"364","NCT02855567",NA,"Interventional","N/A",2016-08-06,2017-12-05,"The Role of Acupuncture in Post-Operative Pain Management in Gynecological Patients",110,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4842778,NA,NA,"Non-opioids",110,47,23,40,63,NA,"acute","female",20.9090909090909,"no",0.1566,3065470,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",88.603361859064,81.9366970419252,83.8814835822777,23.1116468141426,55,51.55,8281968,93.9,61437,15,2829419,11.9,5.82084523809524,"2","3","0","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3295902126325,"female"
"365","NCT02863575",NA,"Interventional","Phase 3",2017-10-24,2018-04-06,"A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE ANALGESIC EFFICACY AND SAFETY OF A SINGLE ORAL DOSE OF A NOVEL FIXED-DOSE COMBINATION OF IBUPROFEN 400 MG WITH CAFFEINE 100 MG TO IBUPROFEN 400 MG AND TO PLACEBO IN THE TREATMENT OF POST-SURGICAL DENTAL PAIN IN OTHERWISE HEALTHY SUBJECTS",374,"Industry",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Industry",NA,4842167,NA,NA,"Non-opioids",374,346,4,24,28,"Late Phase","acute",NA,1.06951871657754,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"0",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","large",35.0448905477656,"acute","non-chronic","non-cancer","3","3","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",95.575054308435,88.0906907294809,86.7058823529412,31.1428571428571,67.4,71,1084810,90.8,69789,1,35689,8.7,11.7639157894737,"3","3","2","3","3","3","0","2","3","0","0","0","3","non-elderly",1.15057773903366,"general"
"366","NCT02881112",431,"Interventional",NA,2016-03-31,2017-12-14,"An Open-Label, Non-Controlled Study to Evaluate Outcomes of Pulsed Electromagnetic Field (PEMF) Therapy in Subjects With Various Pain Etiologies",180,"Industry","United States",83,8,9,17,69,180,2016,2017,1,"North America",0,"United States","Industry","After 2013",4840824,"Provant Therapy System",0,"Non-opioids",180,149,15,16,31,NA,"chronic",NA,8.33333333333333,"yes",0.10915,1107242.16666667,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.0369777554465,3678.375,23.217382724399,88.4604128050583,22.6737819909328,92.6393898322437,85.8529959798301,90.0625,9.9375,"0",43066.75,"Alabama,Arizona,Arizona,Florida,Idaho,Idaho,Michigan,Washington","278,60,60,620,1,1,277,79",172,37.9875,17.7666666666667,9.16666666666667,3429664.5,68.290625,12.7875,"After",NA,0.54625,"Mixed","small",29.4974512511607,"non-acute","chronic","non-cancer","2","3","1","1","1","2","2","1","2","2","1","1","0","0","1","3","2","1",89.4535107743738,81.5166276886136,89.117499095493,22.2210437551007,59.5125,66.665625,3320962.625,90.85,56640.75,12.6666666666667,831035.625,13.2125,8.82503291891892,"3","3","3","2","3","2","1","2","2","1","0","1","1","non-elderly",8.55567795637627,"general"
"367","NCT02887989",432,"Interventional",NA,2016-11-16,2017-08-17,"Immersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled Trial",140,"Other","United States",64,26,10,36,50,240,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4840297,"Virtual Reality, Health and Wellness Channel",0,"Non-opioids",120,77,31,12,43,NA,"acute",NA,25.8333333333333,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","2","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",92.1200891643829,85.6062206171081,89.2399791068873,24.3115108840907,54.4,53.825,14075264,92.7,66637,37,2160958,13.9,12.8882948837209,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.50562309310592,"general"
"368","NCT02901054",433,"Interventional",NA,2016-08-25,2016-11-17,"Investigation of Cerebrospinal Fluid (CSF) Pharmacokinetics of Ondansetron",19,"Other","United States",93,7,0,7,53,15,2016,2016,0,"North America",0,"United States","Non-Industry","After 2013",4839294,"Ondansetron",1,"Non-opioids",15,14,1,0,1,NA,"acute",NA,6.66666666666667,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"0",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"acute","non-chronic","non-cancer","0","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",88.2844244648746,79.9296096747282,86.9730248232065,18.1836912700975,63.8,66.7,2774831,91.1,55016,13,698734,13,6.22706666666667,"2","2","2","1","3","2","1","3","2","1","0","1","0","non-elderly",11.4678155260135,"general"
"369","NCT02913222",435,"Interventional",NA,2017-02-04,2021-01-21,"Movement Pattern Training in People With Intra-articular, Prearthritic Hip Disorders",46,"Other","United States",83,10,7,17,60,42,2017,2021,4,"North America",0,"United States","Non-Industry","After 2013",4838363,"Rehabilitation",0,"Non-opioids",42,35,4,3,7,NA,"chronic",NA,9.52380952380952,"yes",0.11335,1065997,"GOVERNMENT","non-kids","Government","non-female","non-veterans",20.719969690542,4884,17.6926198263889,87.1067024317173,19.4792672638108,90.0462724426177,83.9402258804049,92.1,7.9,"0",37869.5,"Missouri,Pennsylvania","318,308",313,39.3,19.3,8.85,4276005.5,69.1375,11.7,"After","0",0.565,"R","small",30.7037928555975,"non-acute","chronic","non-cancer","1","3","1","2","1","0","2","0","0","0","1","0","2","0","1","3","1","2",88.8779795304977,82.0391688115717,86.1164707584564,18.7978072855501,58.65,68.1375,4241941.5,92.7,58907.5,16,1031042.5,11.15,9.05949891384391,"2","3","2","1","2","2","1","3","2","1","1","0","1","non-elderly",11.0188586055051,"general"
"370","NCT02915978",NA,"Interventional","Phase 2",2016-12-31,2017-02-10,"A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain",45,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4838154,NA,NA,"Opioids",45,29,14,2,16,"Early Phase","acute",NA,31.1111111111111,"yes",0.05145,1295786,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",22.7159824838658,13410,22.7823554274395,90.4231241430209,25.9946994366044,93.8475935748419,87.7883976792873,90.5,9.5,"1",49611.5,"Arizona,California","60,808",434,38.45,17.25,9.45,8721158.5,60.325,13.45,"After",NA,0.51,"Mixed","small",31.9883121053621,"acute","non-chronic","non-cancer","1","3","0","2","3","2","3","3","3","3","1","3","3","0","3","0","3","1",91.5824871518566,84.7053219341973,89.5022420364781,23.603274654665,58.85,57.875,8520903,91.35,61868.5,21,1222718,15,9.30887544186045,"3","3","3","3","2","0","3","3","3","2","1","2","2","non-elderly",4.80500521186096,"general"
"371","NCT02917603",436,"Interventional",NA,2016-09-01,2018-03-31,"Shared Decision Making to Improve Palliative Care in the Nursing Home",40,"Other","United States",98,2,0,2,72,40,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4838031,"Web Conferencing",0,"Non-opioids",40,39,1,0,1,NA,"pallative",NA,2.5,"no",0.1149,701334,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"0",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"non-acute","non-chronic","non-cancer","1","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",88.2844244648746,79.9296096747282,86.9730248232065,18.1836912700975,63.8,66.7,2774831,91.1,55016,13,698734,13,6.22706666666667,"2","2","2","1","3","2","1","3","2","1","0","1","0","non-elderly",11.4678155260135,"general"
"372","NCT02922985",437,"Interventional","Phase 4",2016-10-31,2017-07-31,"Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial",120,"Other","United States",21,13,66,79,100,120,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4837620,"Intravenous acetominophen, Ketorolac, intramuscular, Bupivacaine, subcutaneous, Normal saline",1,"Non-opioids",120,25,16,79,95,"Late Phase","acute","female",13.3333333333333,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After",NA,0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","2","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",89.9858058298346,80.9542341571405,89.356833684308,23.2421281509342,60.6,61.45,10769844,83.4,58146,37,3270776,13.8,8.16322738853503,"3","3","3","3","3","0","3","0","2","3","3","2","1","non-elderly",11.7389492350246,"female"
"373","NCT02923245",438,"Interventional",NA,2015-09-30,2016-11-05,"Point-of-Care-Ultrasound Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound: A Randomized Controlled Trial",120,"Other","United States",57,8,35,43,100,240,2015,2016,1,"North America",0,"United States","Non-Industry","After 2013",4837600,"point-of-care ultrasound",0,"Non-opioids",120,68,10,42,52,NA,"acute","kids",8.33333333333333,"no",0.0677,71561,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",15.5824957672408,334,20.73832,87.74185136897,23.5593220338983,89.3463952618945,85.5670280587147,95.9,4.1,"1",45727,"Rhode Island","7",7,38.3,20.9,12.2,470168,63.825,10.3,"After",NA,0.49,"D","small",34.5314266746905,"acute","non-chronic","non-cancer","2","3","0","1","0","1","2","2","0","2","3","2","0","0","0","1","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",5.43066445264499,"kids"
"374","NCT02944656",440,"Interventional","Phase 4",2016-12-08,2018-06-26,"Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial",114,"Other","United States",24,68,8,76,100,111,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4835962,"Gabapentin, Placebo",1,"Non-opioids",111,27,76,8,84,"Late Phase","acute","female",68.4684684684685,"no",0.3161,3289020,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",13.6741976969953,2746,24.2397516666667,87.617356953251,24.5959842592997,91.5827047750272,83.9380333761502,86.6,13.4,"1",44670,"Georgia","542",542,39.2,24.3,11.9,4378391,64.425,14.7,"After","0",0.66,"R","small",32.0235221190875,"acute","non-chronic","non-cancer","2","3","3","1","0","3","2","2","1","0","0","2","3","2","1","1","3","3",89.4458130851821,81.1154164289518,86.4777323916399,23.4371975521265,57.8,62.325,4235301,87.1,53527,23,3205543,15.4,6.5360347107438,"3","3","2","3","2","1","1","1","2","2","3","3","0","non-elderly",31.0904719141532,"female"
"375","NCT02948634",NA,"Interventional","N/A",2016-10-31,2019-06-30,"A Prospective, Randomized, Double-blind, Sham-controlled Study of the Low-level Phoenix Thera-lase 42 Watt Laser in Patients With Chronic Fibromyalgia",28,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4835657,NA,NA,"Non-opioids",28,21,7,NA,7,NA,"chronic",NA,25,"no",0.1213,3428210,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","0","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",89.9858058298346,80.9542341571405,89.356833684308,23.2421281509342,60.6,61.45,10769844,83.4,58146,37,3270776,13.8,8.16322738853503,"3","3","3","3","3","0","3","0","2","3","3","2","1","non-elderly",11.7389492350246,"general"
"376","NCT02949271",441,"Interventional","Phase 4",2016-11-08,2017-11-01,"Comparison of Programmed Intermittent Epidural Boluses With Continuous Epidural Infusion for Maintenance of Labor Analgesia",179,"Other","United States",62,32,6,38,100,120,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4835610,"Programmed Intermittent Epidural Bolus, Continuous Epidural Infusion, Ropivacaine, Fentanyl",1,"Non-opioids",120,75,38,7,45,"Late Phase","acute","female",31.6666666666667,"no",0.2144,2200760,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"1",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","2","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",88.0370717328552,79.5037835947125,84.6947733059304,20.3862351851095,56.1,65.75,4567285,89.6,53764,17,2144650,13.6,8.17658750000001,"2","2","1","2","2","1","2","2","2","2","2","1","1","non-elderly",21.1362452827437,"female"
"377","NCT02959996",443,"Interventional","Phase 2/Phase 3",2017-03-08,2017-11-03,"Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain",80,"Other",NA,78,12,10,22,100,NA,2017,2017,0,"North America",0,"United States","Non-Industry","After 2013",4834788,"Liposomal bupivacaine, Placebo",1,"Non-opioids",79,64,6,9,15,"Early Phase","acute","female",7.59493670886076,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","1","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",91.4197815933238,87.1566785939269,86.4760527953532,27.681257131003,63.7,59.975,2896402,97.2,76243,3,477846,11.2,9.27905357142857,"3","3","2","3","3","0","1","3","3","0","0","0","2","non-elderly",6.96586892452993,"female"
"378","NCT02961062",NA,"Interventional","Phase 2",2016-12-01,2018-02-21,"A Randomized, Vehicle-controlled, Subject and Investigator-masked, Proof-of-concept Study to Evaluate the Use of Topical Ocular SAF312 in the Treatment of Postoperative Ocular Pain in Patients Undergoing Photorefractive Keratectomy (PRK) Surgery",40,"Industry",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Industry",NA,4834707,NA,NA,"Non-opioids",40,35,1,4,5,"Early Phase","acute",NA,2.5,"yes",0.130675,868765,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",11.9962923090464,2256.75,19.5616927424713,85.1640958506668,22.2792616302192,92.8764181710102,86.8555590728934,91.55,8.45,"0",49923.75,"Maryland,South Dakota,Utah,Virginia","269,1,14,249",133.25,39.475,23.4,11.1,1891960.5,69.41875,9.375,"After",NA,0.595,"Mixed","small",36.0318220383632,"acute","non-chronic","non-cancer","1","3","2","1","0","0","0","1","3","2","1","3","0","1","0","3","0","2",91.0966262940949,83.9583164147647,83.7660188449831,25.1333508086825,63.55,68.4125,1844036,91.925,66285.5,14.5,846591.5,10.4,8.4624780113519,"3","3","0","3","3","2","0","3","3","1","1","0","1","non-elderly",12.686369826422,"general"
"379","NCT02978833",446,"Interventional","Phase 4",2013-10-01,2017-06-30,"Ultrasound-Guided Platelet Rich Plasma Versus Whole Blood Injection for the Treatment of Gluteus Medius Tendinopathy: A Double-Blind Randomized Controlled Study",2,"Other","United States",100,0,0,0,50,2,2013,2017,4,"North America",0,"United States","Non-Industry","Earlier 2013",4833346,"PRP, Whole Blood, Ultrasound",0,"Non-opioids",2,2,0,0,0,"Late Phase","chronic",NA,0,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"non-acute","chronic","non-cancer","0","2","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",86.4281733903204,78.0899267054675,82.6101,22.0535,51.9,53.025,8193686,89.3,49966,25,2831270,17.3,6.33298278377812,"2","2","0","2","0","0","3","2","1","2","3","3","0","non-elderly",14.4076723945655,"general"
"380","NCT02996591",447,"Interventional","Phase 4",2017-01-31,2017-05-31,"Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery: A Double-Blinded Randomized Controlled Trial.",36,"Other","United States",92,0,8,8,72,36,2017,2017,0,"North America",0,"United States","Non-Industry","After 2013",4831985,"25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block, 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block, Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed, 45-60 mg of 1.5% mepivacaine for spinal anesthesia, LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia",1,"Non-opioids",36,33,0,3,3,"Late Phase","acute",NA,0,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","1","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",90.0628038953365,83.8139983932805,84.3725777818524,24.6411470791695,54.5,51.075,8321682,94.3,61543,13,2846481,12.7,5.36598139534884,"3","3","1","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3403888450225,"general"
"381","NCT03040011",448,"Interventional","Phase 1/Phase 2",2017-06-01,2019-08-05,"Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block With Bupivacaine and Dexamethasone for Improved Pain Control After Vaginal Reconstructive Surgery: A Three-Arm Randomized Controlled Trial",79,"Other","United States",89,8,3,11,100,75,2017,2019,2,"North America",0,"United States","Non-Industry","After 2013",4828659,"Dexamethasone, Bupivacaine, Bilateral Pudendal Nerve Block, Bilateral Levator Ani Muscle Injection, Saline",1,"Non-opioids",75,67,6,2,8,"Early Phase","acute","female",8,"no",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","1","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",87.9909781899719,82.1347078343483,87.818656826198,20.0291245639583,55.5,68.625,5693469,94.5,61285,14,1367815,10.9,12.0080371134021,"2","3","2","2","2","2","2","3","3","1","1","0","3","non-elderly",10.6814341327505,"female"
"382","NCT03044106",NA,"Interventional","N/A",2017-03-04,2017-07-31,"The Effects of Cranial Laser Reflex Technique on Hamstring Flexibility, Strength, and Pain Pressure Threshold: a Pilot Study",44,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4828344,NA,NA,"Non-opioids",44,38,3,3,6,NA,"acute",NA,6.81818181818182,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After",NA,0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",89.5402104134693,82.3287577716703,86.0635959899996,21.447032058202,57,66.325,4621314,89.3,49547,25,2175617,15.2,7.4349275,"3","3","2","2","2","1","2","2","1","2","3","2","1","non-elderly",21.1771465760328,"general"
"383","NCT03045081",449,"Interventional",NA,2016-04-30,2017-09-30,"PainTracker Self-Manager: Development and Testing of a Web-based Platform to Promote and Track Chronic Pain Self-management and Other Treatment Outcomes",99,"Other","United States",70,3,27,30,78,99,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4828269,"PainTracker Self-Manager",0,"Non-opioids",99,69,3,27,30,NA,"chronic",NA,3.03030303030303,"no",0.038,281683,"GOVERNMENT","non-kids","Government","non-female","non-veterans",36.3274444869134,9176,31.6889445945946,89.9549312007655,27.2652644054344,94.6878709316023,90.128095190568,93.4,6.6,"0",52742,"Washington","79",79,40.1,19.5,7.1,3195004,63.75,10.3,"After","0",0.45,"D","small",36.6505101649993,"non-acute","chronic","non-cancer","2","3","0","3","2","3","3","3","3","3","2","3","0","0","1","1","0","0",92.9679936071027,87.8103965503787,85.512298012298,26.3733972067305,65.7,61.575,3061095,94,70310,6,254841,11,13.1492662162162,"3","3","1","3","3","0","1","3","3","0","0","0","3","non-elderly",3.49672063666301,"general"
"384","NCT03052426",NA,"Interventional","N/A",2017-02-27,2017-08-27,"Occupational Therapy's Role in Promoting Community Wellness: A Multi-modal Approach to Combat Sedentary Behavior in the Workplace Utilizing Sit-Stand Workstations",18,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4827704,NA,NA,"Non-opioids",18,15,1,2,3,NA,"acute",NA,5.55555555555556,"no",0.0369,66990,"GOVERNMENT","non-kids","Government","non-female","non-veterans",3.97535739833819,621,22.3954142857143,91.4019199799218,13.4126701942986,86.6114242392484,79.424146693689,93.3,6.7,"1",33133,"West Virginia","18",18,41.2,17.4,14.3,894956,75.6,17.2,"After",NA,0.69,"R","small",21.3697857860109,"acute","non-chronic","non-cancer","0","3","0","0","0","1","3","0","0","0","2","0","0","0","0","3","3","3",84.7494093469964,75.6170052145224,91.1471986019649,17.967734373335,52.6,75.05,892048,93.9,46957,1,71358,17.1,5.95896330275229,"1","2","3","1","1","3","0","3","0","0","0","3","0","non-elderly",3.92971472973918,"general"
"385","NCT03054844",NA,"Interventional","Phase 2",2017-04-03,2017-10-10,"Comparison of Two Methods Using Intranasal Lidocaine to Alleviate Discomfort Associated With Administration of Intranasal Midazolam in Children.",55,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4827518,NA,NA,"Non-opioids",51,4,4,43,47,"Early Phase","acute","kids",7.84313725490196,"no",0.1566,3065470,"NON-PROFIT","kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","1",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","1","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",90.0628038953365,83.8139983932805,84.3725777818524,24.6411470791695,54.5,51.075,8321682,94.3,61543,13,2846481,12.7,5.36598139534884,"3","3","1","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3403888450225,"kids"
"386","NCT03080493",453,"Interventional","Phase 4",2017-03-20,2018-11-05,"Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial",121,"Other","United States",48,19,33,52,100,118,2017,2018,1,"North America",0,"United States","Non-Industry","After 2013",4825552,"Gabapentin 600mg, Placebo oral capsule, acetaminophen/codeine and ibuprofen",1,"Non-opioids",118,57,22,39,57,"Late Phase","acute","female",18.6440677966102,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","2","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",93.5058032671521,87.9388282493744,89.8348984561285,25.6915278397978,56.8,54.375,14172348,92.8,70038,32,2164239,12.1,11.9825938823529,"3","3","3","3","2","0","3","3","3","3","3","1","3","non-elderly",5.47400661355932,"female"
"387","NCT03102710",454,"Interventional",NA,2016-05-31,2019-03-31,"Neuromodulation of Placebo and Nocebo Effects",103,"Other","United States",64,7,29,36,46,81,2016,2019,3,"North America",0,"United States","Non-Industry","After 2013",4823848,"transcranial direct current stimulation (tDCS), Lidocaine cream, Capsaicin cream, Control cream",0,"Non-opioids",81,52,6,23,29,NA,"acute","healthy",7.40740740740741,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","1",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","1","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",90.5497018166255,85.5727163859935,85.7289189931723,25.3752200442972,63.2,59.775,2881140,97.5,72266,7,456681,9.6,9.66208148148148,"3","3","2","3","3","0","1","3","3","0","0","0","2","non-elderly",6.7042838588862,"general"
"388","NCT03105518",NA,"Interventional","Phase 4",2011-03-01,2020-08-30,"Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction",100,"Other",NA,NA,NA,NA,NA,NA,NA,2011,NA,NA,"North America",NA,"United States","Non-Industry",NA,4823634,NA,NA,"Non-opioids",100,90,5,5,10,"Late Phase","acute","female",5,"no",0.0763,522357,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","1",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","2","2","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",89.3267181077153,83.5,89.054,22.2431,55.3,65.3,2817715,96.63637334,63313,4,406157,10.6,9.2587366295912,"3","3","3","2","1","1","1","3","3","0","0","0","2","non-elderly",6.16553746347648,"female"
"389","NCT03107481",455,"Interventional","Phase 4",2017-06-04,2017-11-14,"Acetaminophen 1g IV vs Hydromorphone 1mg IV for the Treatment of Acute Pain in the Emergency Department",220,"Other",NA,4,24,72,96,59,NA,2017,2017,0,"North America",0,"United States","Non-Industry","After 2013",4823483,"Acetaminophen, Hydromorphone",1,"Opioids",220,10,48,162,210,"Late Phase","acute",NA,21.8181818181818,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"1",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After",NA,0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","3","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",90.0628038953365,83.8139983932805,84.3725777818524,24.6411470791695,54.5,51.075,8321682,94.3,61543,13,2846481,12.7,5.36598139534884,"3","3","1","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3403888450225,"general"
"390","NCT03107754",NA,"Interventional","Phase 4",2017-05-15,2018-10-25,"Buffered Lidocaine for Paracervical Block to Decrease Injection Pain During First Trimester Uterine Aspirations",98,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4823462,NA,NA,"Non-opioids",98,35,5,58,63,"Late Phase","acute","female",5.10204081632653,"no",0.0183,26025,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",47.5183694421591,1309,18.6575083333333,95.7649796393252,30.8376963350785,91.7915446804492,85.8786631555135,95.8,4.2,"1",69678,"Hawaii","2",2,36.3,NA,NA,550273,60,9.5,"After",NA,0.47,"D","small",33.2159905191544,"acute","non-chronic","non-cancer","2","3","0","3","0","0","3","3","1","2","3","3","0",NA,"0","0","0","0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"non-elderly",1.58517671683696,"female"
"391","NCT03192137",NA,"Interventional","Phase 3",2018-01-30,2019-11-22,"A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery",260,"Industry",NA,NA,NA,NA,NA,NA,NA,2018,NA,NA,"North America",NA,"United States","Industry",NA,4817027,NA,NA,"Non-opioids",238,213,15,10,25,"Late Phase","acute",NA,6.30252100840336,"no",0.1676,1124470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",4.52218646785983,2324,20.9540659574468,85.8662841877553,19.9805891026834,89.389189315855,82.3504396793573,89.9,10.1,"0",38791,"Tennessee","201",201,40,13.9,8.6,3028213,68.775,12.6,"After",NA,0.73,"R","small",27.3673170485781,"acute","non-chronic","non-cancer","3","3","3","0","0","1","1","0","0","0","1","1","0","0","1","3","2","3",89.389189315855,82.3504396793573,85.8662841877553,19.9805891026834,58.9,68.05,2995928,89.9,56060,15,1123551,12,10.4053854166667,"3","3","2","2","3","2","1","2","2","1","1","1","2","non-elderly",16.5960020738522,"general"
"392","NCT03193593",457,"Interventional","Phase 2",2017-08-29,2018-08-07,"Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)",66,"Industry","United States",64,32,4,36,100,66,2017,2018,1,"North America",0,"United States","Industry","After 2013",4816915,"Placebo, EB-001",1,"Non-opioids",66,42,21,3,24,"Early Phase","acute","female",31.8181818181818,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After",NA,0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","1","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",93.5058032671521,87.9388282493744,89.8348984561285,25.6915278397978,56.8,54.375,14172348,92.8,70038,32,2164239,12.1,11.9825938823529,"3","3","3","3","2","0","3","3","3","3","3","1","3","non-elderly",5.47400661355932,"female"
"393","NCT03194490",458,"Interventional",NA,2016-08-24,2018-01-08,"Benefit of Adding Stretching to Standard Intervention For Patients With Nonspecific Mechanical Neck Pain",43,"Other","United States",0,0,100,100,63,38,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4816846,"combined intervention group, The standard intervention",0,"Non-opioids",38,0,0,0,38,NA,"chronic",NA,0,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After",NA,0.49,"D","small",34.3650287791398,"non-acute","chronic","non-cancer","1","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",92.1200891643829,85.6062206171081,89.2399791068873,24.3115108840907,54.4,53.825,14075264,92.7,66637,37,2160958,13.9,12.8882948837209,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.50562309310592,"general"
"394","NCT03202550",459,"Interventional","Phase 4",2017-06-28,2019-05-28,"Oral Sedation During Cervical Dilator Placement: A Randomized Controlled Trial",27,"Other","United States",4,88,8,96,100,24,2017,2019,2,"North America",0,"United States","Non-Industry","After 2013",4816227,"Oxycodone and Lorazepam (Active Comparator), Placebo Comparator",1,"Opioids",24,1,21,2,23,"Late Phase","acute","female",87.5,"no",0.2989,1799090,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",21.0582330511643,3310,23.724418,89.9765779286483,30.0221976041811,93.2427230557547,88.3305797953642,94,6,"1",67583,"Maryland","269",269,38.9,24.4,12.4,2470316,68.775,7.1,"After","1",0.54,"D","small",40.7376904453232,"acute","non-chronic","non-cancer","0","3","3","2","0","2","3","3","3","3","2","3","1","2","0","3","0","1",93.0834725660253,88.0487157369789,89.952498527329,29.1994100960474,65.3,66.925,2448604,93.9,82093,11,1776692,7.6,10.979062,"3","3","3","3","3","2","1","3","3","1","2","0","3","non-elderly",29.35624652088,"female"
"395","NCT03206216",460,"Interventional",NA,2017-08-04,2017-10-30,"Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN",1,"Other","United States",100,0,0,0,100,2,2017,2017,0,"North America",0,"United States","Non-Industry","After 2013",4815947,"Diode Laser fiber type Selective Stimulator (DLss)",0,"Non-opioids",1,1,0,0,0,NA,"cancer","female",0,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","1",0.49,"D","small",34.3650287791398,"non-acute","non-chronic","cancer","0","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",93.5058032671521,87.9388282493744,89.8348984561285,25.6915278397978,56.8,54.375,14172348,92.8,70038,32,2164239,12.1,11.9825938823529,"3","3","3","3","2","0","3","3","3","3","3","1","3","non-elderly",5.47400661355932,"female"
"396","NCT03243084",461,"Interventional",NA,2017-09-07,2018-01-10,"Effect of Transcranial Alternating Current Stimulation in Chronic Low Back Pain: A Pilot Study",21,"Other","United States",90,10,0,10,57,21,2017,2018,1,"North America",0,"United States","Non-Industry","After 2013",4813128,"XCSITE100 Stimulator Sham, XCSITE100 Stimulator tACS",0,"Non-opioids",21,19,2,0,2,NA,"chronic",NA,9.52380952380952,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",89.5402104134693,82.3287577716703,86.0635959899996,21.447032058202,57,66.325,4621314,89.3,49547,25,2175617,15.2,7.4349275,"3","3","2","2","2","1","2","2","1","2","3","2","1","non-elderly",21.1771465760328,"general"
"397","NCT03251937",NA,"Interventional","N/A",2018-01-09,2020-06-30,"VERITAS - A Study to Demonstrate the Value of Multiple Modalities Using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain",97,"Industry",NA,NA,NA,NA,NA,NA,NA,2018,NA,NA,"North America",NA,"United States","Industry",NA,4812449,NA,NA,"Non-opioids",40,0,0,0,40,NA,"chronic",NA,0,"yes",0.109909090909091,1689179.63636364,"Mixed","non-kids","Non-Government","non-female","non-veterans",26.691971441913,7638.26666666667,22.9552079278043,86.5107756870368,21.1023058182833,91.9343458996038,85.6168186719507,91.2866666666667,8.71333333333333,"0",40031.8,"California,Florida,Florida,Michigan,Missouri,New York,North Carolina,Ohio,Ohio,Ohio,Ohio,Oregon,Texas,Washington,Wisconsin","808,620,620,277,318,292,264,368,368,368,368,18,624,79,96",365.866666666667,38.9533333333333,22.7285714285714,9.63571428571429,6283907.46666667,64.89,12.2533333333333,"After",NA,0.543333333333333,"Mixed","small",31.354868973736,"non-acute","chronic","non-cancer","1","3","1","2","2","2","1","1","2","2","1","1","2","1","2","1","2","1",91.9343458996038,85.6168186719507,86.5107756870368,21.1023058182833,57.8,64.8033333333333,6229892.6,91.5466666666667,62695.4666666667,20.2666666666667,1703754.06666667,11.64,8.13655412994745,"3","3","2","2","2","1","2","3","3","2","2","0","1","non-elderly",11.2619916694832,"general"
"398","NCT03254459",NA,"Interventional","Phase 2",2017-09-12,2017-11-13,"A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain",100,"Industry",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Industry",NA,4812255,NA,NA,"Opioids",100,60,33,7,40,"Early Phase","acute",NA,33,"yes",0.0349,1155479.5,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",24.0710774672127,12888,23.3384503078223,89.7598153316434,24.7171962425501,95.3310771198275,89.5994912286776,91.3,8.7,"1",46794.5,"California,Utah","808,14",411,39.15,24.2,11.1,7749928.5,63.325,10.2,"After",NA,0.565,"Mixed","small",34.7049596634527,"acute","non-chronic","non-cancer","2","3","0","2","3","2","3","2","3","3","1","2","2","2","2","1","0","2",94.5404287877936,88.0147594894276,88.2703904045349,28.4171924913274,62.1,62.6875,7628579,91.8,69913.5,16.5,1099964,10.4,11.8732548359133,"3","3","2","3","3","1","3","3","3","1","1","0","3","non-elderly",3.31229217629649,"general"
"399","NCT03272139",NA,"Interventional","Phase 4",2017-09-28,2019-07-09,"Interscalene Block Versus Superior Trunk Block: A Randomized Controlled Clinical Trial",126,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4810902,NA,NA,"Non-opioids",126,106,8,12,20,"Late Phase","acute",NA,6.34920634920635,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","2","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",90.0628038953365,83.8139983932805,84.3725777818524,24.6411470791695,54.5,51.075,8321682,94.3,61543,13,2846481,12.7,5.36598139534884,"3","3","1","3","1","0","3","3","3","1","3","1","0","non-elderly",14.3403888450225,"general"
"400","NCT03284411",462,"Interventional","Phase 4",2017-11-01,2019-03-15,"Spinal Cord Stimulation (SCS) Dosing Study",30,"Industry","United States",100,0,0,0,77,60,2017,2019,2,"North America",0,"United States","Industry","After 2013",4809964,"Spinal Cord Stimulation",0,"Non-opioids",30,30,0,0,0,"Late Phase","chronic",NA,0,"yes",0.1092625,1171803,"Mixed","non-kids","Non-Government","non-female","non-veterans",11.2572164517117,3881.9,21.3163927943904,87.5148841432921,20.8069957274064,91.1722258881327,84.3720603967754,90.44,9.56,"0",40253.8,"Arizona,Georgia,Indiana,Indiana,Kentucky,Kentucky,Missouri,Texas,Washington,Wisconsin","60,542,144,144,76,76,318,624,79,96",215.9,39.39,18.49,8.98,3733218.8,66.9675,12.87,"After",NA,0.567,"Mixed","small",29.2449018733954,"non-acute","chronic","non-cancer","0","3","1","1","1","1","2","1","1","0","1","1","1","0","1","2","3","2",89.8406525847869,82.9715378452799,87.2662279662147,20.7169030233704,60.3,66.8325,3653409.8,91.14,58620.7,14.5,1012256.7,12.18,6.94045809255337,"3","3","2","2","3","2","1","3","2","1","1","1","0","non-elderly",10.2539678675286,"general"
"401","NCT03290378",464,"Interventional","Phase 3",2017-09-19,2018-04-23,"A Phase 3, Multicenter, Randomized, Double Blind, Three-Arm Study to Evaluate the Efficacy and Safety of Tramadol Infusion (AVE-901) Versus Placebo in the Management of Postoperative Pain Following Bunionectomy",409,"Industry","United States",68,25,7,32,85,409,2017,2018,1,"North America",0,"United States","Industry","After 2013",4809505,"Tramadol, Placebo",1,"Non-opioids",409,280,104,25,129,"Late Phase","acute",NA,25.4278728606357,"yes",0.159366666666667,2500470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",21.1293376619641,14492.8,24.4460065440202,90.3855556332951,26.8372289484204,93.392508589152,87.1252008370232,88.36,11.64,"1",52880.2,"California,California,Maryland,Texas,Texas","808,808,269,624,624",626.6,39.3,25.16,10.64,10753938.8,60.655,11.9,"After",NA,0.56,"Mixed","large",34.0044748446606,"acute","non-chronic","non-cancer","3","3","3","2","3","3","3","3","3","2","0","3","3","2","3","0","2","2",92.7239207025042,86.2083886173139,89.879021419585,26.0040675322643,60.54,59.835,10529737.2,88.98,68470.6,25.4,2553115.6,11.64,10.1977401968436,"3","3","3","3","3","0","3","2","3","3","3","0","2","non-elderly",12.7670897634162,"general"
"402","NCT03302793",465,"Interventional",NA,2015-04-30,2017-12-31,"Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management",12,"Other","United States",58,17,25,42,42,12,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4808553,"BreEStim, tDCS, tDCS sham",0,"Non-opioids",12,7,2,3,5,NA,"chronic",NA,16.6666666666667,"no",0.1213,3428210,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","0",0.64,"R","small",30.2773131098502,"non-acute","chronic","non-cancer","0","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,88.5072,21.9744,59.7,61.875,10604257,82.9,56473,38,3209454,14.7,9.43231929885351,"2","1","2","2","3","0","3","0","2","3","3","2","2","non-elderly",11.6838642848109,"general"
"403","NCT03307174",NA,"Interventional","Phase 4",2016-04-14,2019-02-28,"A Prospective, Randomized Analysis of Epidural Anesthesia Using Programmed Intermittent Epidural Boluses Versus Continuous Epidural Infusion in Patients Undergoing Abdominal Surgery.",120,"Other",NA,NA,NA,NA,NA,NA,NA,2016,NA,NA,"North America",NA,"United States","Non-Industry",NA,4808218,NA,NA,"Opioids",120,82,1,37,38,"Late Phase","acute",NA,0.833333333333333,"no",0.0579,2274110,"GOVERNMENT","non-kids","Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"0",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After","0",0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","2","3","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",92.1200891643829,85.6062206171081,89.2399791068873,24.3115108840907,54.4,53.825,14075264,92.7,66637,37,2160958,13.9,12.8882948837209,"3","3","3","3","1","0","3","3","3","3","3","2","3","non-elderly",5.50562309310592,"general"
"404","NCT03316378",467,"Interventional","Phase 2/Phase 3",2016-01-28,2018-05-10,"Impact of Peripheral Pain Perception on Central Sensitization and Movement Strategies in Patients With Chronic Achilles Tendinopathy",46,"Other","United States",80,7,13,20,65,46,2016,2018,2,"North America",0,"United States","Non-Industry","After 2013",4807514,"Ropivacaine injection",1,"Non-opioids",46,37,3,6,9,"Early Phase","chronic",NA,6.52173913043478,"no",0.0371,116359,"GOVERNMENT","non-kids","Government","non-female","non-veterans",7.53602122624231,1756,15.11095,81.5007807726254,12.0289904270487,90.1524048544294,84.0797146086398,95,5,"1",32139,"Iowa","34",34,38.1,NA,NA,NA,69.525,9.2,"After","0",0.55,"R","small",28.6266618238787,"non-acute","chronic","non-cancer","1","3","0","0","0","0","0","0","0","0","3","0","0",NA,NA,"3","0","2",87.8993723190539,80.9536134725829,81.6609464554415,23.6326440901483,67.2,69.975,1385453,95.7,59094,6,108502,9.8,6.28039120879121,"2","3","0","3","3","3","0","3","2","0","0","0","0","non-elderly",3.46132779190817,"general"
"405","NCT03319277",468,"Interventional",NA,2017-10-13,2019-06-25,"A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery",118,"Other","United States",90,4,6,10,100,118,2017,2019,2,"North America",0,"United States","Non-Industry","After 2013",4807291,"Decreased opiate prescription, Routine opiate prescription",0,"Non-opioids",118,106,5,7,12,NA,"acute","female",4.23728813559322,"no",0.1241,1446190,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",7.98407802392024,4507,25.7839386792453,85.3764780439716,17.5875722433769,90.5656773262732,84.8145907165702,93.4,6.6,"0",33158,"Ohio","368",368,38.6,19.3,7.3,5232869,68.175,12.8,"After","0",0.58,"R","small",28.8464382806458,"acute","non-chronic","non-cancer","2","3","2","0","1","3","0","0","0","1","2","0","2","0","1","2","2","2",89.6127036311485,83.6284745396652,85.4093262644292,17.3289893634669,54.2,65.975,5201015,94,60688,20,1421030,12.9,6.929292,"3","3","1","0","1","1","2","3","3","2","1","1","0","non-elderly",12.1886753385417,"female"
"406","NCT03328208",469,"Interventional",NA,2017-11-22,2018-12-31,"Nonpharmacologic Reduction of Periprocedural Pain, Anxiety, and Prescription Drug Use",72,"Industry","United States",85,3,12,15,69,72,2017,2018,1,"North America",0,"United States","Industry","After 2013",4806606,"Comfort TalkÂ® app, White Noise app",0,"Non-opioids",72,61,2,9,11,NA,"acute",NA,2.77777777777778,"yes",0.0763,522357,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"0",51842,"Massachusetts,Massachusetts","45,45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"acute","non-chronic","non-cancer","1","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",91.4197815933238,87.1566785939269,86.4760527953532,27.681257131003,63.7,59.975,2896402,97.2,76243,3,477846,11.2,9.27905357142857,"3","3","2","3","3","0","1","3","3","0","0","0","2","non-elderly",6.96586892452993,"general"
"407","NCT03344510",NA,"Interventional","N/A",2017-01-23,2018-05-30,"Kinetic Anesthesia Device for Lidocaine Injection: a Randomized Split-body Study of the Effects of Kinetic Anesthesia Devices on Pain of Lidocaine Injection in Healthy Volunteers",47,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4805360,NA,NA,"Non-opioids",47,20,5,22,27,NA,"acute",NA,10.6382978723404,"no",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","1","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",87.9909781899719,82.1347078343483,87.818656826198,20.0291245639583,55.5,68.625,5693469,94.5,61285,14,1367815,10.9,12.0080371134021,"2","3","2","2","2","2","2","3","3","1","1","0","3","non-elderly",10.6814341327505,"general"
"408","NCT03345472",470,"Interventional",NA,2017-11-30,2019-10-21,"Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation (SCS) With High Dose (HD) Stimulation Parameters",175,"Industry","United States",89,10,1,11,54,103,2017,2019,2,"North America",0,"United States","Industry","After 2013",4805288,"Spinal Cord Stimulation System",0,"Non-opioids",103,92,10,1,11,NA,"chronic",NA,9.70873786407767,"yes",0.165606666666667,1682228,"Mixed","non-kids","Non-Government","non-female","non-veterans",29.6209406977443,7633.1,24.0617815795467,87.6085907227695,22.1134880787712,91.7535392711566,85.7347655169863,91.635,8.365,"0",44605.3,"California,California,Delaware,Georgia,Maryland,Michigan,Nevada,New Jersey,New York,North Carolina,Ohio,Pennsylvania,Pennsylvania,Pennsylvania,Pennsylvania,South Carolina,South Carolina,Texas,Virginia,Washington","808,808,31,542,269,277,80,243,292,264,368,308,308,308,308,229,229,624,249,79",331.2,38.865,22.91,10.325,5482052.2,65.65875,11.815,"After",NA,0.559,"Mixed","small",32.7912827963962,"non-acute","chronic","non-cancer","2","3","3","2","2","3","2","1","1","2","1","2","2","1","2","2","2","2",90.8022810862212,84.1224406600528,87.361190167863,21.7793862708154,57.58,64.83875,5399808.05,91.9,62961.8,17.15,1606080.6,11.885,9.5966424002422,"3","3","2","2","2","1","2","3","3","2","1","1","2","non-elderly",15.3128610710705,"general"
"409","NCT03350724",471,"Interventional",NA,2015-10-29,2017-05-19,"Randomized Controlled Clinical Trial Pilot Study: Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites",34,"Other","United States",88,6,6,12,65,34,2015,2017,2,"North America",0,"United States","Non-Industry","After 2013",4804884,"episil wound dressing, PeriAcryl90 wound dressing",0,"Non-opioids",34,30,2,2,4,NA,"acute",NA,5.88235294117647,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","non-female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"0",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After",NA,0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","0","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",86.6667409655243,74.7460411976551,88.5072,21.9744,59.7,61.875,10604257,82.9,56473,38,3209454,14.7,9.43231929885351,"2","1","2","2","3","0","3","0","2","3","3","2","2","non-elderly",11.6838642848109,"general"
"410","NCT03372382",NA,"Interventional","Phase 4",2017-12-13,2018-04-10,"Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section: A Prospective, Randomized Control Trial",170,"Other",NA,NA,NA,NA,NA,NA,NA,2017,NA,NA,"North America",NA,"United States","Non-Industry",NA,4803227,NA,NA,"Opioids",170,16,85,69,154,"Late Phase","acute","female",50,"no",0.1213,3428210,"GOVERNMENT","non-kids","Government","female","non-veterans",10.0313270985708,10375,25.6830383233533,89.9678371268443,25.1026878645774,92.4704183608953,84.7096193249626,81.6,18.4,"1",46572,"Texas","624",624,40.1,26.5,9.3,11283353,62.425,13.7,"After","1",0.64,"R","small",30.2773131098502,"acute","non-chronic","non-cancer","2","3","1","1","2","3","3","2","2","0","0","2","3","3","3","0","3","3",91.7622622060957,83.5577854254209,89.8864058291696,24.7189359428392,61.9,61.75,10927693,82.7,60092,26,3330204,13.2,8.0222256097561,"3","3","3","3","3","0","3","0","3","3","3","1","1","non-elderly",11.7655945345413,"female"
"411","NCT03383588",472,"Interventional","Phase 2",2018-07-19,2018-12-31,"Efficacy of Subcutaneous Infiltration With Local Anesthetic During Elective Cesarean Delivery for Postoperative Pain Control: a Randomized Controlled Trial",26,"Other","United States",8,15,77,92,100,26,2018,2018,0,"North America",0,"United States","Non-Industry","After 2013",4802367,"Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution",1,"Non-opioids",26,2,4,20,24,"Early Phase","acute","female",15.3846153846154,"no",0.1566,3065470,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",202.884364842149,20351,24.2147890625,84.6531632829577,24.9827276206052,91.0321739581328,85.5337589965215,94.8,5.2,"0",48557,"New York","292",292,38.4,37,17.8,8404381,52,11.8,"After","0",0.46,"D","small",37.275328091991,"acute","non-chronic","non-cancer","0","3","2","3","3","3","0","2","0","1","3","2","1","3","2","0","1","0",91.0321739581328,85.5337589965215,84.6531632829577,24.9827276206052,53.2,50.975,8362686,94.6,67274,12,2789585,11.1,5.36349534883721,"3","3","1","3","1","0","3","3","3","1","3","0","0","non-elderly",14.2746656736708,"female"
"412","NCT03384953",473,"Interventional",NA,2017-06-22,2020-03-13,"Chronic Pain Skills Study - Vanderbilt University Medical Center",103,"Other","United States",83,5,12,17,72,103,2017,2020,3,"North America",0,"United States","Non-Industry","After 2013",4802263,"Clinical Hypnosis - Group Treatment, Clinical Hypnosis - Individual Treatment",0,"Non-opioids",103,85,5,13,18,NA,"chronic",NA,4.85436893203883,"no",0.1676,1124470,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",4.52218646785983,2324,20.9540659574468,85.8662841877553,19.9805891026834,89.389189315855,82.3504396793573,89.9,10.1,"0",38791,"Tennessee","201",201,40,13.9,8.6,3028213,68.775,12.6,"After","0",0.73,"R","small",27.3673170485781,"non-acute","chronic","non-cancer","2","3","3","0","0","1","1","0","0","0","1","1","0","0","1","3","2","3",87.6009404107769,79.8000197786033,87.2633538311865,20.3962074753899,59.1,67.2,2960881,90.5,55306,4,1115187,11.3,9.32470612244898,"2","2","2","2","3","2","1","2","2","0","1","0","2","non-elderly",16.6049680880717,"general"
"413","NCT03392675",474,"Interventional",NA,2017-04-24,2017-11-07,"Promoting Self-Management of Breast and Nipple Pain in Breastfeeding Women",65,"NIH",NA,77,11,12,23,100,NA,2017,2017,0,"North America",0,"United States","Non-Industry","After 2013",4801671,"Self-monitoring of BF and intervention",0,"Non-opioids",56,43,6,7,13,NA,"acute","female",10.7142857142857,"yes",0.1072,383416,"Mixed","non-kids","Non-Government","female","non-veterans",11.3292436232018,1475,22.4784368421053,88.0308410862301,22.9153127921748,92.3056381781412,87.3243851803261,94.1,5.9,"0",49000,"Connecticut,Connecticut","41,41",41,37.4,38.1,43.2,1524992,64.25,9.9,"After","0",0.43,"D","small",39.6963200211786,"acute","non-chronic","non-cancer","1","3","1","1","0","1","2","2","2","2","2","3","0","3","0","1","0","0",91.2128830543965,86.0782939342949,87.5626242884089,20.0534280130071,60.8,66.125,1517251,94.5,74304,6,354320,10.6,9.97751794871795,"3","3","2","2","3","1","0","3","3","0","0","0","2","non-elderly",9.87463296196628,"female"
"414","NCT03404206",NA,"Interventional","Phase 4",2018-02-12,2018-07-10,"A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain",387,"Industry",NA,NA,NA,NA,NA,NA,NA,2018,NA,NA,"North America",NA,"United States","Industry",NA,4800786,NA,NA,"Non-opioids",387,344,7,36,43,"Late Phase","acute",NA,1.80878552971576,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","large",35.0448905477656,"acute","non-chronic","non-cancer","3","3","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",96.2726626555477,90.2608895874421,88.5118676712174,22.4551067807172,65.3,72.125,1108655,90.6,77067,3,37546,6.9,11.2520315789474,"3","3","3","2","3","3","0","2","3","0","0","0","3","non-elderly",1.18774922060482,"general"
"415","NCT03407430",475,"Interventional","Phase 2",2016-01-27,2017-07-20,"A Phase II, Placebo-controlled, Double-blind, Randomized Crossover Trial of Pregabalin for the Prophylaxis of Pegfilgrastim-induced Bone Pain",11,"Other","United States",75,12,13,25,75,8,2016,2017,1,"North America",0,"United States","Non-Industry","After 2013",4800541,"Pregabalin, Placebo",1,"Non-opioids",8,6,1,1,2,"Early Phase","cancer",NA,12.5,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"non-acute","non-chronic","cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",88.0370717328552,79.5037835947125,84.6947733059304,20.3862351851095,56.1,65.75,4567285,89.6,53764,17,2144650,13.6,8.17658750000001,"2","2","1","2","2","1","2","2","2","2","2","1","1","non-elderly",21.1362452827437,"general"
"416","NCT03445390",476,"Interventional","Phase 4",2014-05-01,2017-11-01,"The Effect of Intravenous Acetaminophen on Post-Operative Pain After Craniotomy: A Randomized Control Trial",27,"Other","United States",60,10,30,40,80,20,2014,2017,3,"North America",0,"United States","Non-Industry","After 2013",4797643,"Acetaminophen, Placebo",1,"Non-opioids",20,12,2,6,8,"Late Phase","acute",NA,10,"no",0.0579,2274110,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",32.2629005307572,24202,23.5697690366972,91.0077629920693,26.9792857043831,94.3894915841073,88.9380928699132,92.3,7.7,"1",51837,"California","808",808,38.7,24.2,11.1,14366336,54.825,12.5,"After",NA,0.49,"D","small",34.3650287791398,"acute","non-chronic","non-cancer","0","2","0","2","3","2","3","3","3","3","2","3","3","2","3","0","2","0",89.7698557762244,81.7837732046313,89.7711,22.752,50.5,54.225,13906691,87.6,60487,40,2155733,15.8,14.2617707647834,"3","3","3","2","0","0","3","2","3","3","3","3","3","non-elderly",5.55565491914181,"general"
"417","NCT03495856",477,"Interventional",NA,2018-04-23,2018-10-26,"Feasibility of a 4-week, Adapted Mindfulness Program for Adults With Chronic Pain",23,"Other","United States",83,17,0,17,74,23,2018,2018,0,"North America",0,"United States","Non-Industry","After 2013",4793781,"Mindfulness Training For Chronic Pain",0,"Non-opioids",23,19,4,0,4,NA,"chronic",NA,17.3913043478261,"no",0.2144,2200760,"GOVERNMENT","non-kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"non-acute","chronic","non-cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",91.1145518013476,83.7164639686858,86.6484511796544,21.4244776562496,59.7,65.2,4683620,89.3,53369,20,2184448,13.1,6.03664210526316,"3","3","2","2","3","1","2","2","2","2","3","1","0","non-elderly",21.0374416629268,"general"
"418","NCT03528369",479,"Interventional","Phase 2",2018-05-14,2018-12-30,"A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)",122,"Industry","United States",68,30,2,32,63,122,2018,2018,0,"North America",0,"United States","Industry","After 2013",4791292,"CGS-200-1, CGS-200-5, CGS-200 Vehicle",1,"Non-opioids",122,83,37,2,39,"Early Phase","chronic",NA,30.327868852459,"yes",0.135366666666667,2744476.66666667,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",10.1004613697177,8041.5,24.063303595992,86.0524447348355,21.3200812996977,92.5175317599161,85.0887512208183,86.1666666666667,13.8333333333333,"1",41901.3333333333,"Florida,Florida,Florida,Ohio,Texas,Texas","620,620,620,368,624,624",579.333333333333,39.5,23.35,9.71666666666667,9470103.5,65.1833333333333,13.5,"After",NA,0.58,"R","small",30.1260053719568,"non-acute","chronic","non-cancer","2","3","2","1","2","3","1","1","2","1","0","1","3","1","3","2","3","2",92.5175317599161,85.0887512208183,86.0524447348355,21.3200812996977,60.2666666666667,64.9041666666667,9341896.16666667,86.5166666666667,57522.5,33.3333333333333,3000294.33333333,13.4,8.49424586080586,"3","3","2","2","3","1","3","1","2","3","3","1","1","non-elderly",13.6276177406376,"general"
"419","NCT03562481",480,"Interventional","Phase 4",2018-07-24,2019-06-30,"Pilot Study: Comparison of Buffered 1% vs. Unbuffered 2% Lidocaine in Pediatric Subjects; Clinical Outcomes",26,"Other","United States",73,19,8,27,50,26,2018,2019,1,"North America",0,"United States","Non-Industry","After 2013",4788679,"1% Buffered Lidocaine 1:100,000 Epinephrine, 2% Unbuffered Lidocaine 1:100,000 Epinephrine",1,"Non-opioids",26,19,5,2,7,"Late Phase","acute","kids",19.2307692307692,"no",0.2144,2200760,"GOVERNMENT","kids","Government","non-female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","1",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","0","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",91.1145518013476,83.7164639686858,86.6484511796544,21.4244776562496,59.7,65.2,4683620,89.3,53369,20,2184448,13.1,6.03664210526316,"3","3","2","2","3","1","2","2","2","2","3","1","0","non-elderly",21.0374416629268,"kids"
"420","NCT03566979",481,"Interventional","Phase 3",2018-08-13,2019-04-15,"A Randomized, Double-Blind, Placebo- and Active- Controlled, Efficacy and Safety Study of a Test Naproxen Sodium 220 mg Tablet in Postoperative Dental Pain",501,"Industry","United States",90,2,8,10,52,501,2018,2019,1,"North America",0,"United States","Industry","After 2013",4788336,"Test naproxen sodium tablet, Commercial naproxen sodium tablet, Commercial naproxen sodium liquid gels capsule, Placebo tablet",1,"Non-opioids",501,451,8,42,50,"Late Phase","acute",NA,1.59680638722555,"no",0.0119,36849,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",15.8792544036682,1574,23.1071315789474,88.5118676712174,22.4551067807172,96.2726626555477,90.2608895874421,90.3,9.7,"1",41752,"Utah","14",14,39.6,NA,NA,1133521,71.825,7.9,"After",NA,0.64,"R","large",35.0448905477656,"acute","non-chronic","non-cancer","3","3","0","1","0","2","2","1","3","3","1","1","0",NA,"0","3","0","3",96.2726626555477,90.2608895874421,88.5118676712174,22.4551067807172,65.3,72.125,1108655,90.6,77067,3,37546,6.9,11.2520315789474,"3","3","3","2","3","3","0","2","3","0","0","0","3","non-elderly",1.18774922060482,"general"
"421","NCT03588806",483,"Interventional","Phase 4",2018-05-01,2019-10-31,"Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills",11,"Other","United States",73,27,0,27,64,11,2018,2019,1,"North America",0,"United States","Non-Industry","After 2013",4786661,"Xtampza ER (oxycodone)",1,"Opioids",11,8,3,0,3,"Late Phase","chronic",NA,27.2727272727273,"no",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"1",38560,"Pennsylvania","308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","1",0.53,"R","small",31.8196178223866,"non-acute","chronic","non-cancer","0","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",89.5830868305181,84.6781146518118,87.6412767997808,19.7744137726328,57.6,69.875,5712698,94.5,64524,17,1352804,11.8,11.6936530612245,"3","3","2","2","2","3","2","3","3","2","1","1","3","non-elderly",10.5629551200666,"general"
"422","NCT03603028",484,"Interventional",NA,2018-08-17,2018-09-30,"Mixed Reality Gaming for Chronic Low Back Pain",13,"Other","United States",0,100,0,100,62,13,2018,2018,0,"North America",0,"United States","Non-Industry","After 2013",4785571,"Exergaming",0,"Non-opioids",13,0,13,0,13,NA,"chronic",NA,100,"no",0.2664,1299050,"GOVERNMENT","non-kids","Government","non-female","non-veterans",1.62507069982056,900,22.6392183673469,83.3613868714217,17.195147573548,87.6352559797239,80.1686731141783,90.3,9.7,"1",33928,"Alabama","278",278,39.1,20.7,12.4,2284847,70.725,16,"After","0",0.77,"R","small",25.3013815767412,"non-acute","chronic","non-cancer","0","3","3","0","0","1","0","0","0","0","1","0","1","0","0","3","3","3",87.6352559797239,80.1686731141783,83.3613868714217,17.195147573548,52,70.275,2270705,90,49936,9,1298603,16,6.46823611111111,"2","3","0","0","0","3","0","2","1","1","1","3","0","non-elderly",26.5678656412986,"general"
"423","NCT03634306",485,"Interventional",NA,2018-10-11,2019-01-22,"A Randomized, Controlled Study Evaluating The Effectiveness Of The Ultravision Visual Field Clearing System in Laparoscopic Hysterectomy and Myomectomy",35,"Other","United States",71,26,3,29,100,35,2018,2019,1,"North America",0,"United States","Non-Industry","After 2013",4783181,"Ultravision System, Laparoscopic Hysterectomy",0,"Non-opioids",35,25,9,1,10,NA,"acute","female",25.7142857142857,"no",0.1149,701334,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",9.34495529008618,2240,16.3708844444444,86.5721280636538,19.1841207549887,90.5094580547174,83.2023371089981,90,10,"1",37179,"Missouri","318",318,40.3,20.9,8.9,2819383,69.05,11.9,"After","0",0.6,"R","small",29.5879678888084,"acute","non-chronic","non-cancer","0","3","1","0","0","0","1","0","0","0","1","0","2","0","0","3","2","3",90.5094580547174,83.2023371089981,86.5721280636538,19.1841207549887,61.1,69.675,2806113,90.6,61726,18,698641,12.4,5.67790714285714,"3","3","2","1","3","3","1","2","3","2","0","1","0","non-elderly",11.4036803030531,"female"
"424","NCT03638635",487,"Interventional","Phase 4",2018-05-14,2019-01-16,"TAP Blocks Performed With Bupivacaine Versus Liposomal Bupivacaine in Colorectal Surgery Patients: A Prospective, Cluster Randomized Trial",63,"Other","United States",79,8,13,21,56,63,2018,2019,1,"North America",0,"United States","Non-Industry","After 2013",4782849,"Bupivacaine, Bupivacaine liposome",1,"Non-opioids",63,50,5,8,13,"Late Phase","acute",NA,7.93650793650794,"yes",0.1918,1621590,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",7.90867222743972,3685,15.3311136986301,86.1120794921748,24.5399464956516,91.8161068524883,85.8209274833271,92.1,7.9,"0",51654,"Virginia,Virginia,Virginia,Virginia,Virginia,Virginia","249,249,249,249,249,249",249,39.7,22.4,9.8,3562143,67.55,10.7,"After","0",0.61,"D","small",39.4719593291509,"acute","non-chronic","non-cancer","1","3","3","0","1","0","1","2","1","2","1","3","1","1","1","2","0","3",91.8161068524883,85.8209274833271,86.1120794921748,24.5399464956516,64.9,66,3538415,91.2,77151,11,1597761,9.8,6.558525,"3","3","2","3","3","1","1","3","3","1","1","0","0","non-elderly",18.7581602278084,"general"
"425","NCT03756038",490,"Interventional","Phase 2",2019-01-25,2019-03-27,"Single Dose Administration of Benzodiazepines to Reduce Distress, Pain Severity, and the Need for Opiates Both During and After Emergency Department Care",1,"Other","United States",0,0,100,100,100,1,2019,2019,0,"North America",0,"United States","Non-Industry","After 2013",4773857,"Placebos, Lorazepam",1,"Non-opioids",1,0,0,1,1,"Early Phase","acute",NA,0,"yes",0.1118,1430660,"NON-PROFIT","non-kids","Non-Government","non-female","non-veterans",32.0949840909979,7528,19.0143552083333,87.6412767997808,19.7744137726328,89.5830868305181,84.6781146518118,94.2,5.8,"0",38560,"Pennsylvania,Pennsylvania","308,308",308,38.3,17.7,8.8,5732628,69.225,11.5,"After","0",0.53,"R","small",31.8196178223866,"acute","non-chronic","non-cancer","0","3","1","2","2","0","2","0","0","0","3","0","2","0","2","3","1","1",89.5830868305181,84.6781146518118,88.526703,21.165448,58.1,69.225,5732628,94.2,70582,10,1374488,8.7,11.6123947916667,"3","3","3","2","2","2","2","3","3","1","1","0","3","non-elderly",10.7365191455796,"general"
"426","NCT03786055",491,"Interventional",NA,2018-06-04,2019-07-31,"Impact of Somatic Yoga and Meditation on Fall Risk, Function, and Quality of Life for Chemotherapy-Induced Peripheral Neuropathy Syndrome in Cancer Survivors",18,"Other",NA,70,10,20,30,90,NA,2018,2019,1,"North America",0,"United States","Non-Industry","After 2013",4771555,"Somatic Yoga and Meditation (SYM)",0,"Non-opioids",10,7,1,2,3,NA,"cancer",NA,10,"yes",0.1346,1194880,"Mixed","non-kids","Non-Government","non-female","non-veterans",45.8441178126936,7207,19.0587173913044,87.9523561065641,25.3564725763369,93.0681905605973,88.3455657210031,92.1,7.9,"0",53247,"New Jersey,New Jersey","243,243",243,39.2,26.2,9.6,3641812,65.025,9.1,"After","0",0.55,"D","small",40.5519319574834,"non-acute","non-chronic","cancer","0","3","2","3","2","0","2","3","3","3","1","3","1","2","1","1","0","2",93.0681905605973,88.3455657210031,87.9523561065641,25.3564725763369,59.4,65.025,3628032,92.6,74176,13,1137645,8.2,6.92540476190476,"3","3","2","3","3","1","1","3","3","1","1","0","0","non-elderly",12.7703030357456,"general"
"427","NCT03875664",NA,"Interventional","Phase 4",2018-07-23,2019-03-31,"Extended Release Local Anesthetic for Postsurgical Pain After Posterior Colporrhaphy and Perineorrhaphy: A Randomized Controlled Study",72,"Other",NA,NA,NA,NA,NA,NA,NA,2018,NA,NA,"North America",NA,"United States","Non-Industry",NA,4764687,NA,NA,"Non-opioids",72,69,2,1,3,"Late Phase","acute","female",2.77777777777778,"no",0.2144,2200760,"NON-PROFIT","non-kids","Non-Government","female","non-veterans",6.85852263538856,3932,19.626534375,86.6484511796544,21.4244776562496,91.1145518013476,83.7164639686858,88.7,11.3,"0",39108,"North Carolina","264",264,38.5,25.5,12.6,4747943,65.05,14.1,"After","0",0.65,"R","small",31.8954262899941,"acute","non-chronic","non-cancer","1","3","3","0","1","0","1","1","1","0","0","1","1","2","1","1","3","3",91.1145518013476,83.7164639686858,86.6484511796544,21.4244776562496,59.7,65.2,4683620,89.3,53369,20,2184448,13.1,6.03664210526316,"3","3","2","2","3","1","2","2","2","2","3","1","0","non-elderly",21.0374416629268,"female"
"428","NCT03982433",493,"Interventional",NA,2019-03-01,2019-06-27,"Internet-based Video-conferencing to Address Alcohol Use and Pain Among Heavy Drinkers in HIV-care",8,"Other","United States",25,75,0,75,12,8,2019,2019,0,"North America",0,"United States","Non-Industry","After 2013",4756518,"Motivation and Cognitive Behavioral Management for Alcohol and Pain",0,"Non-opioids",8,6,2,0,2,NA,"chronic",NA,25,"no",0.0763,522357,"PROPRIETARY","non-kids","Non-Government","non-female","non-veterans",58.5333760063061,4954,20.3650436363636,86.6488909743447,30.2046212572762,92.5748748513401,88.2491152808066,97,3,"1",51842,"Massachusetts","45",45,39.3,23.6,13.5,2928732,61.325,9.8,"After","0",0.33,"D","small",44.4377437165865,"non-acute","chronic","non-cancer","0","3","0","3","1","0","1","3","2","3","3","3","0","1","0","0","0","0",92.5748748513401,88.2491152808066,87.229234,28.603983,67.5,61.325,2928732,97,87707,1,489592,7.5,8.944521875,"3","3","2","3","3","0","1","3","3","0","0","0","1","non-elderly",7.10325407185169,"general"
